]> Junguk Hur Abra Guo Jane Bane 2016-05-16 An ontology for the annotation of the adverse event domain. ODNAE is an extension of OAE with a focus on drug-associated neuropathy adverse events. ODNAE: Ontology of Drug Neuropathy Adverse Events Vision Release; 1.0.13 Yu Lin Guoqian Jiang OWL-DL Product version Rebecca Racz Yongqun "Oliver" He (YH) BFO OWL specification label BFO OWL specification label Really of interest to developers only Relates an entity in the ontology to the name of the variable that is used to represent it in the code that generates the BFO OWL file from the lispy specification. BFO CLIF specification label BFO CLIF specification label Person:Alan Ruttenberg Really of interest to developers only Relates an entity in the ontology to the term that is used to represent it in the the CLIF specification of BFO2 editor preferred term editor preferred label editor preferred term GROUP:OBI:<http://purl.obolibrary.org/obo/obi> PERSON:Daniel Schober The concise, meaningful, and human-friendly name for a class or property preferred by the ontology developers. (US-English) editor preferred label editor preferred term example of usage example of usage A phrase describing how a class name should be used. May also include other kinds of examples that facilitate immediate understanding of a class semantics, such as widely known prototypical subclasses or instances of the class. Although essential for high level terms, examples for low level terms (e.g., Affymetrix HU133 array) are not GROUP:OBI:<http://purl.obolibrary.org/obo/obi> PERSON:Daniel Schober example example of usage has curation status has curation status OBI_0000281 PERSON:Alan Ruttenberg PERSON:Bill Bug PERSON:Melanie Courtot has curation status definition textual definition definition definition definition GROUP:OBI:<http://purl.obolibrary.org/obo/obi> PERSON:Daniel Schober The official OBI definition, explaining the meaning of a class or property. Shall be Aristotelian, formalized and normalized. Can be augmented with colloquial definitions. The official definition, explaining the meaning of a class or property. Shall be Aristotelian, formalized and normalized. Can be augmented with colloquial definitions. definition editor note editor note editor note 1 IAO:0000116 editor_note editor_note uberon An administrative note intended for its editor. It may not be included in the publication version of the ontology, so it should contain nothing necessary for end users to understand the ontology. GROUP:OBI:<http://purl.obfoundry.org/obo/obi> PERSON:Daniel Schober editor note term editor definition editor definition editor term editor 20110707, MC: label update to term editor and definition modified accordingly. See http://code.google.com/p/information-artifact-ontology/issues/detail?id=115. GROUP:OBI:<http://purl.obolibrary.org/obo/obi> Name of editor entering the definition in the file. The definition editor is a point of contact for information regarding the term. The definition editor may be, but is not always, the author of the definition, which may have been worked upon by several people Name of editor entering the term in the file. The term editor is a point of contact for information regarding the term. The term editor may be, but is not always, the author of the definition, which may have been worked upon by several people PERSON:Daniel Schober definition editor term editor alternative term alternative term An alternative name for a class or property which means the same thing as the preferred name (semantically equivalent) GROUP:OBI:<http://purl.obolibrary.org/obo/obi> PERSON:Daniel Schober alternative term definition source definition source Discussion on obo-discuss mailing-list, see http://bit.ly/hgm99w GROUP:OBI:<http://purl.obolibrary.org/obo/obi> PERSON:Daniel Schober definition source formal citation, e.g. identifier in external database to indicate / attribute source(s) for the definition. Free text indicate / attribute source(s) for the definition. EXAMPLE: Author Name, URI, MeSH Term C04, PUBMED ID, Wiki uri on 31.01.2007 curator notes curator note curator note 1 IAO:0000232 curator_notes curator_notes uberon An administrative note of use for a curator but of no use for a user PERSON:Alan Ruttenberg curator note imported from imported from For external terms/classes, the ontology from which the term was imported GROUP:OBI:<http://purl.obolibrary.org/obo/obi> PERSON:Alan Ruttenberg PERSON:Melanie Courtot imported from expand expression to elucidation elucidation has associated axiom(nl) has associated axiom(nl) has associated axiom(fol) has associated axiom(fol) Chinese translation YH, JX a chinese translation represents a chinese translation of the existing term. temporal interpretation https://code.google.com/p/obo-relations/wiki/ROAndTime An assertion that holds between an OWL Object Property and a temporal interpretation that elucidates how OWL Class Axioms that use this property are to be interpreted in a temporal context. logical macro assertion on an object property external_definition 1 An alternate textual definition for a class taken unmodified from an external source. This definition may have been used to derive a generalized definition for the new class. This annotation property may be replaced with an annotation property from an external ontology such as IAO UBPROP:0000001 external_definition external_definition uberon axiom_lost_from_external_ontology 1 A textual description of an axiom loss in this ontology compared to an external ontology. This annotation property may be replaced with an annotation property from an external ontology such as IAO UBPROP:0000002 axiom_lost_from_external_ontology axiom_lost_from_external_ontology uberon homology_notes 1 Notes on the homology status of this class. This annotation property may be replaced with an annotation property from an external ontology such as IAO UBPROP:0000003 homology_notes homology_notes uberon has_relational_adjective 1 UBPROP:0000007 Used to connect a class to an adjectival form of its label. For example, a class with label 'intestine' may have a relational adjective 'intestinal'. has_relational_adjective has_relational_adjective uberon taxon_notes 1 Notes on the how instances of this class vary across species. UBPROP:0000008 taxon_notes taxon_notes uberon structure_notes 1 Notes on the structure, composition or histology of instances of this class. This annotation property may be replaced with an annotation property from an external ontology such as IAO UBPROP:0000010 structure_notes structure_notes uberon external_ontology_notes 1 Notes on how similar or equivalent classes are represented in other ontologies. This annotation property may be replaced with an annotation property from an external ontology such as IAO UBPROP:0000012 external_ontology_notes external_ontology_notes uberon has_RxCUI CUMBO A class which has a weakened disjointness axiom, to avoid inconsistency. These are kept separately in the uberon_disjoint_from_strict ontology. A class that represents an early developmental structure, like a blastocyst. This part of the ontology is undergoing review to remove inappropriate grouping classes. EFO slim functional_classification Subset consisting of classes creating for grouping purposes classes that have some inconsistency with FMA somewhat fuzzy grouping for analysis purposes, currently composed of something like: liver, heart, skeletal, kidney, bladder, brain, skin, mouth, esophagus, stomach, small intestine, large intestines, trachea nose, lungs, brain, spinal cord, peripheral nerves, kidneys, ureters, bladder, urethra, gonads organs, excluding individual muscles and skeletal elements Uberon slim - somewhat arbitrary subset that excludes obscure terms and deep compositional terms abstract upper-level terms not directly useful for analysis core classes typically found across vertebrates. one purpose is to create a rough set of terms that could be used to start a new vertebrate AO abstract upper-level terms not directly useful for analysis subset_property has_alternative_id has_alternative_id has_broad_synonym database_cross_reference database_cross_reference has_exact_synonym has_exact_synonym has_narrow_synonym has_narrow_synonym has_obo_namespace has_related_synonym has_related_synonym in_subset in_subset shorthand label depicted_by 1 foaf-depicted_by foaf-depicted_by uberon part_of part of BFO:0000050 part_of part_of uberon has_part has part BFO:0000051 has_part has_part uberon realized in realizedIn realized-in [copied from inverse property 'realizes'] to say that b realizes c at t is to assert that there is some material entity d & b is a process which has participant d at t & c is a disposition or role of which d is bearer_of at t& the type instantiated by b is correlated with the type instantiated by c. (axiom label in BFO2 Reference: [059-003]) (forall (x y z t) (if (and (RealizableEntity x) (Process y) (realizesAt y x t) (bearerOfAt z x t)) (hasParticipantAt y z t))) // axiom label in BFO2 CLIF: [106-002] if a realizable entity b is realized in a process p, then p stands in the has_participant relation to the bearer of b. (axiom label in BFO2 Reference: [106-002]) has participant has participant has_participant preceded_by is preceded by preceded by BFO:0000062 X preceded_by Y iff: end(Y) before_or_simultaneous_with start(X) is preceded by preceded_by preceded_by takes place after uberon X preceded_by Y iff: end(Y) before_or_simultaneous_with start(X) preceded by preceded_by proceeds starts_after precedes precedes BFO:0000063 precedes precedes uberon occurs in occurs in BFO:0000066 occurs_in occurs-in occursIn b occurs_in c =def b is a process and c is a material entity or immaterial entity& there exists a spatiotemporal region r and b occupies_spatiotemporal_region r.& forall(t) if b exists_at t then c exists_at t & there exist spatial regions s and s’ where & b spatially_projects_onto s at t& c is occupies_spatial_region s’ at t& s is a proper_continuant_part_of s’ at t [XXX-001 contains process contains process BFO:0000067 contains_process contains_process uberon has quality at some time has-q_st has specific dependent at some time [copied from inverse property 'specifically depends on at some time'] a shape s-depends_on the shaped object has-s-dep_st [copied from inverse property 'specifically depends on at some time'] To say that b s-depends_on a at t is to say that b and c do not share common parts & b is of its nature such that it cannot exist unless c exists & b is not a boundary of c and b is not a site of which c is the host [64 [copied from inverse property 'specifically depends on at some time'] one-sided s-dependence of a process on something: an instance of seeing (a relational process) s-depends_on some organism and on some seen entity, which may be an occurrent or a continuant [copied from inverse property 'specifically depends on at some time'] the one-sided dependence of an occurrent on an independent continuant: football match on the players, the ground, the ball [copied from inverse property 'specifically depends on at some time'] a gait s-depends_on the walking object. (All at some specific time.) [copied from inverse property 'specifically depends on at some time'] A pain s-depends_on the organism that is experiencing the pain [copied from inverse property 'specifically depends on at some time'] BFO 2 Reference: the relation of s-depends_on does not in every case require simultaneous existence of its relata. Note the difference between such cases and the cases of continuant universals defined historically: the act of answering depends existentially on the prior act of questioning; the human being who was baptized or who answered a question does not himself depend existentially on the prior act of baptism or answering. He would still exist even if these acts had never taken place. [copied from inverse property 'specifically depends on at some time'] one-sided s-dependence of one occurrent on multiple independent continuants: a relational process of paying cash to a merchant in exchange for a bag of figs [copied from inverse property 'specifically depends on at some time'] Alan Ruttenberg: This is a binary version of a ternary time-indexed, instance level, relation. The BFO reading of the binary relation 'specifically depends on at some time@en' is: exists t, exists_at(x,t) & exists_at(y,t) & 'specifically depends on@en'(x,y,t) [copied from inverse property 'specifically depends on at some time'] one-sided s-dependence of one occurrent on multiple independent continuants: a relational process of hitting a ball with a cricket bat [copied from inverse property 'specifically depends on at some time'] the one-sided dependence of an occurrent on an independent continuant: handwave on a hand [copied from inverse property 'specifically depends on at some time'] reciprocal s-dependence between occurrents: in a game of chess the process of playing with the white pieces is mutually dependent on the process of playing with the black pieces [copied from inverse property 'specifically depends on at some time'] the two-sided reciprocal s-dependence of the roles of husband and wife [20 [copied from inverse property 'specifically depends on at some time'] BFO2 Reference: specifically dependent continuant\; process; process boundary [copied from inverse property 'specifically depends on at some time'] the three-sided reciprocal s-dependence of the hue, saturation and brightness of a color [45 [copied from inverse property 'specifically depends on at some time'] reciprocal s-dependence between occurrents: a process of buying and the associated process of selling [copied from inverse property 'specifically depends on at some time'] the three-sided reciprocal s-dependence of the pitch, timbre and volume of a tone [45 [copied from inverse property 'specifically depends on at some time'] reciprocal s-dependence between occurrents: a process of increasing the volume of a portion of gas while temperature remains constant and the associated process of decreasing the pressure exerted by the gas [copied from inverse property 'specifically depends on at some time'] one-sided s-dependence of a dependent continuant on an independent continuant: an instance of temperature s-depends_on some organism [copied from inverse property 'specifically depends on at some time'] one-sided s-dependence of one occurrent on another: a process of obeying a command is dependent on a prior process of issuing a command [copied from inverse property 'specifically depends on at some time'] one-sided s-dependence of a process on something: a process of cell death s-depends_on a cell [copied from inverse property 'specifically depends on at some time'] BFO 2 Reference: S-dependence is just one type of dependence among many; it is what, in the literature, is referred to as ‘existential dependence’ [87, 46, 65, 20 [copied from inverse property 'specifically depends on at some time'] BFO 2 Reference: An entity – for example an act of communication or a game of football – can s-depends_on more than one entity. Complex phenomena for example in the psychological and social realms (such as inferring, commanding and requesting) or in the realm of multi-organismal biological processes (such as infection and resistance), will involve multiple families of dependence relations, involving both continuants and occurrents [1, 4, 28 [copied from inverse property 'specifically depends on at some time'] one-sided s-dependence of a dependent continuant on an independent continuant: an instance of headache s-depends_on some head [copied from inverse property 'specifically depends on at some time'] one-sided s-dependence of one occurrent on another: a process of answering a question is dependent on a prior process of asking a question adverse event occurs in a 'occurs in' relation that is applied at the adverse event setting and indicates where an adverse event occurs in. Yongqun He has_specified_input 8/17/09: specified inputs of one process are not necessarily specified inputs of a larger process that it is part of. This is in contrast to how 'has participant' works. PERSON: Bjoern Peters PERSON: Larry Hunter PERSON: Melanie Coutot A relation between a planned process and a continuant participating in that process that is not created during the process. The presence of the continuant during the process is explicitly specified in the plan specification which the process realizes the concretization of. PERSON: Alan Ruttenberg has_specified_input see is_input_of example_of_usage has_specified_output PERSON: Bjoern Peters PERSON: Larry Hunter PERSON: Melanie Courtot A relation between a planned process and a continuant participating in that process. The presence of the continuant at the end of the process is explicitly specified in the objective specification which the process realizes the concretization of. PERSON: Alan Ruttenberg has_specified_output inheres in RO:0000052 inheres_in bearer of bearer of RO:0000053 bearer_of bearer_of uberon A bearer can have many dependents, and its dependents can exist for different periods of time, but none of its dependents can exist when the bearer does not exist. a relation between an independent continuant (the bearer) and a specifically dependent continuant (the dependent), in which the dependent specifically depends on the bearer for its existence bearer of bearer_of is bearer of this apple is bearer of this red color this vase is bearer of this fragility role of has quality has quality RO:0000086 has_quality has_quality uberon has role A bearer can have many roles, and its roles can exist for different periods of time, but none of its roles can exist when the bearer does not exist. A role need not be realized at all the times that the role exists. a relation between an independent continuant (the bearer) and a role, in which the role specifically depends on the bearer for its existence has_role this person has role this investigator role (more colloquially: this person has this role of investigator) location_of location of RO:0001015 location_of location_of uberon located_in located in RO:0001025 located_in located_in uberon boundary of RO:0002000 The relationships between a boundary (a 2D immaterial entity) and the material entity that it delimits. boundary_of has boundary has boundary RO:0002002 The relationship between a material entity and the boundary (2D immaterial entity) that delimits it. has_boundary has_boundary uberon innervated_by innervated_by FMA:85999 RO:0002005 dbprop:nerve http://code.google.com/p/obo-relations/issues/detail?id=6 innervated_by innervated_by nerve supply uberon before_or_simultaneous_with RO:0002081 before_or_simultaneous_with simultaneous_with simultaneous_with RO:0002082 Relation between occurrents, shares start and end boundaries. coincides_with is_equal_to simultaneous_with simultaneous_with uberon ends_after RO:0002086 ends_after immediately_preceded_by immediately_preceded_by A non-transitive temporal relation in which one process immediately precedes another process, such that there is no interval of time between the two processes[SIO:000251]. RO:0002087 X immediately_preceded_by Y iff: end(X) simultaneous_with start(Y) directly preceded by immediately_preceded_by immediately_preceded_by is directly preceded by is immediately preceded by starts_at_end_of uberon immediately_precedes RO:0002090 immediately_precedes starts_during happens_during overlaps overlaps A overlaps B if they share some part in common. BFO_0000051 some (BFO_0000050 some ?Y) RO:0002131 overlaps overlaps uberon x overlaps y iff they have some part in common. x overlaps y if and only if there exists some z such that x has part z and z part of y innervates innervates RO:0002134 http://code.google.com/p/obo-relations/issues/detail?id=6 innervates innervates uberon continuous_with continuous with RO:0002150 X continuous_with Y if and only if X and Y share a fiat boundary. continuous_with continuous_with uberon only in taxon only_in_taxon RO:0002160 S only_in_taxon T iff: S SubClassOf in_taxon only T only_in_taxon only_in_taxon uberon x only in taxon y if and only if x is in taxon y, and there is no other organism z such that y!=z a and x is in taxon z. in taxon RO:0002162 in_taxon in_taxon uberon x is in taxon y if an only if y is an organism, and the relationship between x and y is one of: part of (reflexive), developmentally preceded by, derives from, secreted by, expressed. connected to connected to Binary relationship: x connected_to y if and only if there exists some z such that z connects x and y in a ternary connected_to(x,y,z) relationship. Connection does not imply overlaps. RO:0002170 connected_to connected_to uberon connects connects Binary relationship: z connects x if and only if there exists some y such that z connects x and y in a ternary connected_to(x,y,z) relationship. RO:0002176 connects connects this is currently used for both structural relationships (such as between a valve and the chamber it connects) and abstract relationships (anatomical lines and the entities they connect) uberon Binary relationship: z connects x if and only if there exists some y such that z connects x and y in a ternary connected_to(x,y,z) relationship. attaches_to_part_of attached to part of RO:0002177 attached_to_part_of attaches_to_part_of attaches_to_part_of uberon a is attached to part of b if a is attached to b, or a is attached to some p, where p is part of b. supplies supplies FMA:86003 RO:0002178 arterial supply of relation between an artery and the structure is supplies with blood. source: FMA supplies supplies uberon Relation between an arterial structure and another structure, where the arterial structure acts as a conduit channeling fluid, substance or energy. develops_from develops from RO:0002202 develops_from develops_from uberon x develops from y if and only if either (a) x directly develops from y or (b) there exists some z such that x directly develops from z and z develops from y directly_develops_from directly develops from RO:0002207 directly_develops_from directly_develops_from uberon Candidate definition: x directly_develops from y if and only if there exists some developmental process (GO:0032502) p such that x and y both participates in p, and x is the output of p and y is the input of p, and a substantial portion of the matter of y comes from x, and the start of x is coincident with or after the end of y capable_of capable of RO:0002215 capable_of capable_of uberon A relation between a material entity (such as a cell) and a process, in which the material entity has the ability to carry out the process. capable_of_part_of capable of part of RO:0002216 capable_of_part_of capable_of_part_of uberon c stands in this relationship to p if and only if there exists some p' such that c is capable_of p', and p' is part_of p. temporally related to RO:0002222 temporally_related_to starts starts RO:0002223 Relation between occurrents, shares a start boundary with. starts starts uberon inverse of starts with ends ends RO:0002229 Relation between occurrents, shares an end boundary with. ends ends finishes uberon inverse of ends with ends with RO:0002230 ends_with x ends with y if and only if x has part y and the time point at which x ends is equivalent to the time point at which y ends. Formally: α(y) > α(x) ∧ ω(y) = ω(x), where α is a function that maps a process to a start point, and ω is a function that maps a process to an end point. has developmental contribution from has developmental contribution from RO:0002254 has_developmental_contribution_from has_developmental_contribution_from uberon x has developmental contribution from y iff x has some part z such that z develops from y developmentally_induced_by developmentally induced by RO:0002256 developmentally_induced_by developmentally_induced_by sources for developmentally_induced_by relationships in Uberon: Developmental Biology, Gilbert, 8th edition, figure 6.5(F) t1 developmentally_induced_by t2 if there is a process of organ induction (GO:0001759) with t1 and t2 as interacting participants. t2 causes t1 to change its fate from a precursor tissue type T to T', where T' develops_from T. uberon t1 induced_by t2 if there is a process of developmental induction (GO:0031128) with t1 and t2 as interacting participants. t2 causes t1 to change its fate from a precursor anatomical structure type T to T', where T' develops_from T developmentally preceded by developmentally preceded by RO:0002258 developmentally_preceded_by developmentally_preceded_by uberon Candidate definition: x developmentally related to y if and only if there exists some developmental process (GO:0032502) p such that x and y both participates in p, and x is the output of p and y is the input of p inheres in part of RO:0002314 inheres_in_part_of q inheres in part of w if and only if there exists some p such that q inheres in p and p part of w. evolutionarily related to RO:0002320 evolutionarily_related_to A relationship that holds via some environmental process mereotopologically related to RO:0002323 mereotopologically_related_to A mereological relationship or a topological relationship developmentally related to RO:0002324 developmentally_related_to A relationship that holds via some developmental process (GO:0032502) functionally related to functionally related to RO:0002328 functionally_related_to functionally_related_to uberon attaches_to attached to FMA:85990 RO:0002371 attached_to attaches_to attaches_to uberon in branching relationship with RO:0002375 in_branching_relationship_with branching_part_of branching part of FMA:85994 RO:0002380 branching_part_of branching_part_of uberon we need to check if FMA branch_of implies part_of. the relation we intend to use here should - for example, see vestibulocochlear nerve x is a branching part of y if and only if x is part of y and x is a branch_of the main stem of y has developmental potential involving RO:0002384 has_developmental_potential_involving x has developmental potential involving y iff x is capable of a developmental process with output y. y may be the successor of x, or may be a different structure in the vicinity (as for example in the case of developmental induction). has potential to develop into has potential to develop into RO:0002387 has_potential_to_develop_into has_potential_to_develop_into uberon x has the potential to develop into y iff x develops into y or if x is capable of developing into y x has the potential to develop into y iff x develops into y or if x is capable of developing into y composed_primarily_of composed primarily of RO:0002473 UBREL:0000002 composed_primarily_of composed_primarily_of uberon x composed_primarily_of y iff: more than half of the mass of x is made from parts of y x composed_primarily_of y if and only if more than half of the mass of x is made from y or units of the same type as y. relation between structure and stage RO:0002487 relation_between_structure_and_stage existence starts during existence starts during BFO:0000068 RO:0002488 Relation between continuant c and occurrent s, such that every instance of c comes into existing during some s. begins_to_exist_during existence_starts_during existence_starts_during uberon c existence starts during s iff start_of(c) part_of s existence starts with existence starts with RO:0002489 Relation between continuant and occurrent, such that c comes into existence at the start of p. existence_starts_with existence_starts_with uberon c existence starts during s iff start_of(c) = start_of(s) existence overlaps RO:0002490 existence_overlaps existence ends during existence ends during BFO:0000069 RO:0002492 Relation between continuant c and occurrent s, such that every instance of c ceases to exist during some s, if it does not die prematurely. ceases_to_exist_during existence_ends_during existence_ends_during uberon existence ends with existence ends with RO:0002493 Relation between continuant and occurrent, such that c ceases to exist at the end of p. existence_ends_with existence_ends_with uberon transformation of transformation of RO:0002494 transformation_of transformation_of transforms from uberon x transformation of y if x is the immediate transformation of y, or is linked to y through a chain of transformation relationships immediate transformation of immediate transformation of RO:0002495 direct_transformation_of immediate_transformation_of immediate_transformation_of immediately transforms from uberon x immediate transformation of y iff x immediately succeeds y temporally at a time boundary t, and all of the matter present in x at t is present in y at t, and all the matter in y at t is present in x at t existence starts during or after existence starts during or after RO:0002496 existence_starts_during_or_after existence_starts_during_or_after uberon existence ends during or before existence ends during or before RO:0002497 existence_ends_during_or_before existence_ends_during_or_before uberon depends on RO:0002502 depends_on has material contribution from RO:0002507 has_material_contribution_from has_material_contribution_from uberon produces produces RO:0003000 a produces b if some process that occurs_in a has_output b, where a and b are material entities. Examples: hybridoma cell line produces monoclonal antibody reagent; chondroblast produces avascular GAG-rich matrix. produces produces uberon produced_by produced by RO:0003001 produced_by produced_by uberon existence starts and ends during existence_starts_and_ends_during uberon transitively_connected to transitively_connected_to uberon has_proper_part has_proper_part http://purl.org/obo/owl/relationship relationship OBO_REL:0000007 Physiochemical Activity [MoA] Physiochemical Activity N0000000065 989958 C308 C1372991 Small Ion Transport Pump Interactions [MoA] 986087 N0000000066 C310 Small Ion Transport Pump Interactions C1373107 HER Receptor Family Interactions [MoA] EGFR Family Interactions C312 Human Epidermal Growth Factor Receptor Family Interactions N0000000067 HER Receptor Family Interactions 986672 Epidermal Growth Factor Receptor Family Interactions C2916814 HER Family Interactions Calcium Channel Antagonists [MoA] 986242 D002121 Calcium Channel Blockers C2757014 N0000000069 Calcium Channel Antagonists C316 Calcium Channel Blocker Angiotensin 2 Receptor Antagonists [MoA] 984935 C318 N0000000070 Angiotensin II Receptor Blockers C2757003 Angiotensin II Receptor Antagonists Angiotensin 2 Receptor Antagonists Active Transporter Interactions [MoA] Active Transporter Interactions 1031287 C322 N0000000072 C1373104 Protease Inhibitors [MoA] Protease Inhibitors N0000000076 992709 Protease Inhibitors C330 C2756997 D011480 Immunologic Factors [MoA] C342 Immunologic Factors Immunologic Factors C2757006 993127 D007155 N0000000082 Leukotriene Receptor Antagonists [MoA] C2757015 992724 C344 N0000000083 Leukotriene Receptor Antagonists Sex Hormone Receptor Antagonists [MoA] C1373000 N0000000084 Sex Hormone Receptor Antagonists 985639 C346 Receptor Interactions [MoA] C1372999 C348 Receptor Interactions 988560 N0000000085 Chelating Activity [MoA] N0000000087 Chelating Activity Chelating Activity C352 1025213 D002614 C1527256 Adrenergic Antagonists [MoA] C2757018 993129 Adrenergic Antagonists Adrenergic Antagonists N0000000092 D018674 C362 Cholinergic Muscarinic Receptor Interactions [MoA] C372 986244 N0000000097 C1373009 Cholinergic Muscarinic Receptor Interactions Thymidylate Synthetase Inhibitors [MoA] N0000000098 993154 C374 Thymidylate Synthetase Inhibitors C2756988 Adrenergic alpha-Antagonists [MoA] 1023426 N0000000099 alpha-Adrenergic Antagonists Adrenergic alpha-Antagonists C2756989 Adrenergic alpha-Antagonists Alpha-adrenergic Blocker D000317 C376 Norepinephrine Uptake Inhibitors [MoA] 989028 Norepinephrine Uptake Inhibitors C2757023 C382 D018759 Adrenergic Uptake Inhibitors N0000000102 Reverse Transcriptase Inhibitors [MoA] N0000000103 C2757067 993157 Reverse Transcriptase Inhibitors C384 D018894 Reverse Transcriptase Inhibitors Cholinergic Muscarinic Agonists [MoA] C386 Cholinergic Muscarinic Agonists 990721 N0000000104 C2757026 Neurotransmitter Transporter Interactions [MoA] Neurotransmitter Transporter Interactions C1373006 N0000000105 C388 985066 Serotonin Uptake Inhibitors [MoA] C2757053 Serotonin Uptake Inhibitors Serotonin Uptake Inhibitors C396 D017367 N0000000109 992711 Folic Acid Metabolism Inhibitors [MoA] C2916820 Folic Acid Antagonists 1029786 C400 Folic Acid Metabolic Inhibitors N0000000111 Folic Acid Metabolism Inhibitors Folic Acid Antagonists D005493 Dopamine Uptake Inhibitors [MoA] C406 N0000000114 C2757017 Dopamine Uptake Inhibitors 1028789 D018765 Dopamine Uptake Inhibitors Dopamine Agonists [MoA] D018491 N0000000117 C2757007 992714 C412 Dopaminergic Agonist Dopamine Agonists Dopamine Agonists GABA A Modulators [MoA] C1373017 C414 N0000000118 GABA A Receptor Modulators GABA A Modulators 990722 Hydroxymethylglutaryl-CoA Reductase Inhibitors [MoA] D019161 993150 C2756999 Hydroxymethylglutaryl-CoA Reductase Inhibitors C420 HMG-CoA Reductase Inhibitor HMG-CoA Reductase Inhibitors N0000000121 Hydroxymethylglutaryl-CoA Reductase Inhibitors Adrenergic Agonists [MoA] 1029285 C422 Adrenergic Agonists C2757025 N0000000122 Adrenergic Agonists D000322 Leukotriene Receptor Interactions [MoA] C1373014 N0000000124 Leukotriene Receptor Interactions C426 987670 Phosphodiesterase Inhibitors [MoA] N0000000128 D010726 C1656262 Phosphodiesterase Inhibitors 993167 C434 Phosphodiesterase Inhibitors Serotonin Antagonists [MoA] D012702 N0000000130 C2757052 C438 993156 Serotonin Antagonists Serotonin Antagonists Organic Anion Transporter Interactions [MoA] C1373100 987411 N0000000132 Organic Anion Transporter Interactions C442 Enzyme Inhibitors [MoA] C444 D004791 N0000000133 Enzyme Inhibitors C2756995 Enzyme Inhibitors 1032544 Lipoxygenase Inhibitors [MoA] D016859 C446 1031400 C2757064 Lipoxygenase Inhibitors Lipoxygenase Inhibitors N0000000134 Immunologic Adjuvants [MoA] Adjuvants, Immunologic Immunologic Adjuvants 989878 N0000000135 Adjuvants, Immunologic D000276 C448 C1383096 GABA A Receptor Interactions [MoA] C454 N0000000138 GABA A Receptor Interactions C1373022 988922 Calcium Channel Interactions [MoA] C458 C1373020 990245 N0000000140 Calcium Channel Interactions Iron Chelating Activity [MoA] C466 985781 N0000000144 Iron Chelating Activity Iron Chelating Activity D007502 C2757050 Estrogen Receptor Antagonists [MoA] 984514 N0000000145 C1373098 C468 Estrogen Receptor Antagonists Estrogen Receptor Inhibitor Proton Pump Inhibitors [MoA] 986356 Proton Pump Inhibitors C1384478 N0000000147 C472 Hormone Receptor Agonists [MoA] 985200 Hormone Receptor Agonists C476 C1373095 N0000000149 Protein Synthesis Inhibitors [MoA] C2757051 993158 Protein Synthesis Inhibitors C478 N0000000150 Protein Synthesis Inhibitors D011500 G-Protein-linked Receptor Interactions [MoA] 984725 C482 G-Protein-linked Receptor Interactions C2916797 G-Protein-linked Receptor-Effector Interactions N0000000152 Adrenergic Receptor Interactions [MoA] 987972 Adrenergic Receptor Interactions C1373072 C484 N0000000153 Uncouplers [MoA] Uncouplers C488 C1373071 N0000000155 986674 Chloride Channel Interactions [MoA] C1373070 N0000000156 C490 987326 Chloride Channel Interactions Glucocorticoid Receptor Agonists [MoA] Glucocorticoid Receptor Agonists C496 N0000000159 989879 C1373068 Cyclooxygenase Inhibitors [MoA] C2756982 D016861 992710 Cyclooxygenase Inhibitors N0000000160 Cyclooxygenase Inhibitors C498 Adrenergic beta-Antagonists [MoA] D000319 993131 Adrenergic beta-Antagonists Beta-adrenergic Receptor Inhibitor C500 beta-Adrenergic Antagonists N0000000161 C2757061 beta-Adrenergic Receptor Inhibitor beta-Adrenergic Blocker Beta-adrenergic Blocker Adrenergic beta-Antagonists Steroid Receptor Antagonists [MoA] N0000000162 987973 C1373067 C502 Steroid Receptor Antagonists Serotonin Transporter Interactions [MoA] N0000000167 987204 C512 Serotonin Transporter Interactions C1373063 Selective Estrogen Receptor Modulators [MoA] D020845 993164 Selective Estrogen Receptor Modulators N0000000168 C2757056 C514 Selective Estrogen Receptor Modulators Steroid Receptor Modulators [MoA] C1373061 C522 Steroid Receptor Modulators N0000000172 987671 Opioid Agonists [MoA] 985466 C1373059 N0000000174 Opioid Agonists C526 Cytokine Receptor Superfamily Interactions [MoA] Cytokine Receptor Superfamily Interactions C1373058 984937 C528 N0000000175 Topoisomerase Inhibitors [MoA] DNA Gyrase Inhibitors 989757 Topoisomerase Inhibitors N0000000176 C1384454 Topoisomerase Inhibitor C530 Cholinesterase Inhibitors [MoA] 992680 Cholinesterase Inhibitors D002800 C532 Cholinesterase Inhibitors N0000000177 C2757012 Sodium Channel Interactions [MoA] Sodium Channel Interactions C538 987802 C1373055 N0000000180 Angiotensin-converting Enzyme Inhibitors [MoA] C540 N0000000181 Angiotensin Converting Enzyme Inhibitor 992731 D000806 C2757044 Angiotensin-Converting Enzyme Inhibitors Angiotensin-converting Enzyme Inhibitors Steroid Hormone Receptor Agonists [MoA] N0000000182 C1373054 C542 Steroid Hormone Receptor Agonists 990907 Acetyl Aldehyde Dehydrogenase Inhibitors [MoA] C1373053 986817 Acetyl Aldehyde Dehydrogenase Inhibitors C544 N0000000183 Monoamine Oxidase Inhibitors [MoA] N0000000184 992698 D008996 Monoamine Oxidase Inhibitors C2756978 C546 Monoamine Oxidase Inhibitors MAOI Progestational Hormone Receptor Agonists [MoA] Progestational Hormone Receptor Agonists C1373052 N0000000185 C548 986818 Histamine H1 Receptor Antagonists [MoA] C2757048 C558 992695 H1 Receptor Blockers Histamine H1 Antagonists Histamine H1 Blockers N0000000190 Histamine H1 Receptor Antagonists Histamine H1 Antagonists H1 Receptor Antagonists D006634 Dihydrofolate Reductase Inhibitors [MoA] C1373048 N0000000191 C560 441741 Dihydrofolate Reductase Inhibitors Ion Channel Interactions [MoA] N0000000193 C1373047 988382 Ion Channel Interactions C564 Serotonin Receptor Interactions [MoA] Serotonin Receptor Interactions N0000000198 988082 C574 C1373043 Opioid Receptor Interactions [MoA] N0000000200 989758 C578 Opioid Receptor Interactions C1373041 Dopamine Receptor Interactions [MoA] N0000000203 C584 C1373039 985948 Dopamine Receptor Interactions Radiopharmaceutical Activity [MoA] Radiopharmaceutical Activity C2757000 987975 Radiopharmaceuticals N0000000205 D019275 C588 Xanthine Oxidase Inhibitors [MoA] 984728 N0000000206 Xanthine Oxidase Inhibitors C1384464 C590 Histamine Receptor Antagonists [MoA] D006633 Histamine Receptor Antagonists Histamine Antagonists C592 989667 N0000000207 C1383092 Histamine Antagonists Adrenergic alpha-Agonists [MoA] Adrenergic alpha-Agonists Adrenergic alpha-Agonists alpha-Adrenergic Agonists C2757042 1029039 N0000000209 D000316 C596 Potassium Channel Interactions [MoA] C600 N0000000211 C1373036 989960 Potassium Channel Interactions Ribonucleotide Reductase Inhibitors [MoA] Ribonucleotide Reductase Inhibitors N0000000212 C602 441728 C1373035 Receptor Protein Kinase Interactions [MoA] C604 Receptor Protein Kinase Interactions C1373034 986538 N0000000213 Sex Hormone Receptor Agonists [MoA] 990080 N0000000214 C606 Sex Hormone Receptor Agonists C1373033 Histamine Receptor Interactions [MoA] Histamine Receptor Interactions 989394 N0000000216 C610 C1373031 Dopamine Transporter Interactions [MoA] N0000000219 984515 C1373028 Dopamine Transporter Interactions C616 Hormone Receptor Antagonists [MoA] 990790 C620 Hormone Receptor Antagonists N0000000221 C1373026 Insulin Receptor Agonists [MoA] N0000000225 C628 C1373092 Insulin Receptor Agonists 986676 Dopamine Antagonists [MoA] Dopamine Antagonists Dopamine Antagonists D018492 C2757008 C638 N0000000230 1032050 Nucleic Acid Synthesis Inhibitors [MoA] C644 N0000000233 993166 Nucleic Acid Synthesis Inhibitors C2757009 Nucleic Acid Synthesis Inhibitors D019384 Norepinephrine Transporter Interactions [MoA] N0000000234 988817 C2267223 C646 Norepinephrine Transporter Interactions Alkylating Activity [MoA] D000477 N0000000236 C650 Alkylating Activity 1031878 C2756975 Alkylating Activity Insulin Receptor Interactions [MoA] C1373083 987414 N0000000240 C658 Insulin Receptor Interactions Transcription Factor Activity [MoA] Transcription Factor Activity N0000000242 C1148759 1028825 C662 Androgen Receptor Antagonists [MoA] Androgen Receptor Antagonists C664 989356 C1373082 Androgen Receptor Inhibitor N0000000243 HIV Protease Inhibitors [MoA] D017320 HIV Protease Inhibitors Human Immunodeficiency Virus Protease Inhibitors N0000000246 C670 HIV Protease Inhibitors C2756991 993149 Biological Response Modifiers [MoA] Biological Response Modifiers C672 D015545 N0000000247 993132 Biological Response Modifiers C2757019 Immunologic and Biological Factors [MoA] Immunologic and Biological Factors 1032698 D007151 C686 C0021048 Immunologic and Biological Factors N0000000254 Hormone Receptor Modulators [MoA] 989214 C688 N0000000255 C1373075 Hormone Receptor Modulators Serotonin Agonists [MoA] 1022850 C690 C2756998 N0000000256 Serotonin Agonists Serotonin Agonists D017366 Hormone Receptor Interactions [MoA] N0000000257 C692 986361 C1373074 Hormone Receptor Interactions Cyclooxygenase 2 Inhibitors [MoA] C2757001 Cyclooxygenase II Inhibitors COX-2 Inhibitors C26942 Cyclooxygenase 2 Inhibitors N0000008288 993136 Adrenergic alpha2-Agonists [MoA] C1373110 C30202 Adrenergic alpha-2 Agonists Adrenergic alpha2-Agonists alpha-2 Adrenergic Agonists N0000009918 1035126 Adrenergic beta1-Antagonists [MoA] beta-1 Adrenergic Antagonists Adrenergic beta1-Antagonists C30212 Adrenergic beta-1 Antagonists 986189 N0000009923 C1373134 Adrenergic beta2-Antagonists [MoA] Adrenergic beta2-Antagonists N0000009924 beta-2 Adrenergic Antagonists C1373133 Adrenergic beta-2 Antagonists C30214 987660 Para-Aminobenzoic Acid Inhibitors [MoA] C2916799 C30260 PABA Inhibitor N0000009946 984916 Para-Aminobenzoic Acid Inhibitors Non-Nucleoside Reverse Transcriptase Inhibitors [MoA] 989597 C30264 N0000009948 Non-Nucleoside Reverse Transcriptase Inhibitors C1373120 Antibody-Receptor Interactions [MoA] C2267208 985716 C30266 N0000009949 Antibody-Receptor Interactions Tumor Necrosis Factor Receptor Interactions [MoA] N0000009950 C1373118 TNF Receptor Interactions C30268 984657 Tumor Necrosis Factor Receptor Interactions Sterol Synthesis Inhibitors [MoA] Sterol Synthesis Inhibitors C1373112 988794 C30280 N0000009956 Bone Surface Interactions [MoA] 985507 N0000009958 C1373129 Bone Surface Interactions C30284 Transpeptidase Inhibitors [MoA] Transpepsidase Inhibitors PBP inhibitors N0000010215 Transpeptidase Inhibitors penicillin binding protein Inhibitors C1373138 C31788 984931 Antibody Interactions [MoA] C2916825 N0000010226 Antibody Interactions C31810 987958 Cellular Structure Molecule Interactions [MoA] 989808 C1373148 C31868 N0000010255 Cellular Structure Molecule Interactions Tubulin Interactions [MoA] Tubulin Interactions N0000010256 C31870 C1373147 1023254 beta Tubulin Interactions [MoA] 986466 C31878 beta Tubulin Interactions C1373143 N0000010260 Neurokinin 1 Receptor Interactions [MoA] C31880 NK 1 Receptor Interactions Neurokinin 1 Receptor Interactions N0000010261 Substance P Receptor Interactions C1373142 984193 Neurokinin 1 Antagonists [MoA] N0000010262 C2916827 Substance P Receptor Antagonists Neurokinin 1 Antagonists C31882 988216 NK 1 Receptor Antagonists Interleukin 2 Receptor Interactions [MoA] N0000010278 C31914 C1373153 Interleukin 2 Receptor Interactions 984934 IL2 Receptor Interactions Interleukin 2 Receptor Antagonists [MoA] IL2 Receptor Antagonists Interleukin 2 Receptor Blockers 986467 C31916 Interleukin 2 Receptor Antagonists C1373152 IL2 Receptor Inhibitors N0000010279 Interleukin 2 Receptor Inhibitors IL2 Receptor Blockers Hypothalmic Hormone Interactions [MoA] N0000019992 985094 C300377 Hypothalmic Hormone Interactions C2267109 Hypothalamic Hormone Receptor Agonists [MoA] 989569 Hypothalamic Hormone Receptor Agonists C300378 N0000019993 C2916835 Receptor Tyrosine Kinase Inhibitors [MoA] Receptor Tyrosine Kinase Inhibitors C2267115 987029 C300385 N0000020000 Tyrosine Kinase Inhibitors [MoA] 1028392 C2757011 C300386 Tyrosine Kinase Inhibitors N0000020001 HER Receptor Family Antagonists [MoA] EGFR Family Inhibitors EGFR Family Antagonists Epidermal Growth Factor Receptor Family Antagonists HER Inhibitors 990667 N0000020006 HER Receptor Family Antagonists Epidermal Growth Factor Receptor Family Inhibitors Human Epidermal Growth Factor Receptor Family Inhibitors C2916840 Human Epidermal Growth Factor Receptor Family Antagonists HER Receptor Family Inhibitors C300391 HER Family Inhibitors HER Antagonists HER Family Antagonists HER2/Neu/cerbB2 Antagonists [MoA] HER2/Neu/cerbB2 Antagonists HER2 Antagonists HER-2 Inhibitors C300393 HER2 Inhibitors HER2/Neu/cerbB2 Inhibitors 984590 C2916795 HER-2 Antagonists HER-2/Neu/cerbB2 Antagonists N0000020008 HER-2/Neu/cerbB2 Inhibitors Bcr-Abl Tyrosine Kinase Inhibitors [MoA] 984994 C300394 Bcr-Abl Tyrosine Kinase Inhibitor N0000020009 Bcr-Abl Tyrosine Kinase Inhibitors C2267122 HER1 Antagonists [MoA] HER1 Inhibitors HER-1 Antagonists HER1 Antagonists C300395 Epidermal Growth Factor Receptor Antagonists 989266 N0000020010 Epidermal Growth Factor Receptor Inhibitors EGFR Inhibitors HER-1 Inhibitors C2916831 EGFR Antagonists Glucosyl Transferase Inhibitors [MoA] 988136 N0000020018 C2267130 C300403 Glucosyl Transferase Inhibitors Glucosylceramide Synthase Inhibitors [MoA] 989376 C300404 C2267131 Glucosylceramide Synthase Inhibitors N0000020019 14-alpha Demethylase Inhibitors [MoA] C300411 C2267137 N0000020025 989952 14-alpha Demethylase Inhibitors Phosphodiesterase 5 Inhibitors [MoA] C2267138 Phosphodiesterase V Inhibitor N0000020026 985515 C300412 Phosphodiesterase V Inhibitors Phosphodiesterase 5 Inhibitors L-Calcium Channel Receptor Antagonists [MoA] L-Calcium Channel Receptor Antagonists C300455 989377 N0000020065 C2916833 Ubiquitin Ligase Inhibitors [MoA] C300474 C1661195 N0000020084 986156 Ubiquitin Ligase Inhibitors Viral Envelope Interactions [MoA] C2267190 989812 Viral Envelope Interactions N0000020089 C300479 Nucleoside Synthesis Inhibitors [MoA] C2266855 N0000175074 C634436 987332 Nucleoside Synthesis Inhibitors Proteasome Inhibitors [MoA] C634437 N0000175075 988088 Proteasome Inhibitors Proteosome Inhibitors C2266856 Proteasome Inhibitor Protein Kinase Inhibitors [MoA] C634438 Protein Kinase Inhibitors 993161 N0000175076 C2757016 Kinase Inhibitors [MoA] 1025684 Kinase Inhibitors N0000175082 C634444 C1152564 Binding Activity [MoA] C2266866 Binding Activity N0000175355 C634738 990338 Cholinergic Interactions [MoA] C634751 Cholinergic Interactions C2266879 N0000175368 987379 Cholinergic Agonists [MoA] C634752 N0000175369 C2757066 Cholinergic Agonists 1033063 Tumor Necrosis Factor alpha Receptor Blocking Activity [MoA] C2267209 TNF-a Receptor Blocking Activity 988325 N0000175446 Tumor Necrosis Factor alpha Receptor Blocking Activity C30270 TNF-alpha Receptor Blocking Activity Corticosteroid Hormone Receptor Agonists [MoA] C634830 C2266939 Corticosteroid Hormone Receptor Agonists 988660 N0000175450 Tumor Necrosis Factor Receptor Blocking Activity [MoA] N0000175451 C634831 TNF Blocker TNF Receptor Blocking Activity Tumor Necrosis Factor Receptor Blocking Activity 984952 C2266940 Metal Chelating Activity [MoA] C634853 N0000175472 C1154714 Metal Chelating Activity 986481 Cholesterol Synthesis Inhibitors [MoA] C2917205 991925 N0000175919 Cholesterol Synthesis Inhibitors C635357 entity entity BFO 2 Reference: In all areas of empirical inquiry we encounter general terms of two sorts. First are general terms which refer to universals or types:animaltuberculosissurgical procedurediseaseSecond, are general terms used to refer to groups of entities which instantiate a given universal but do not correspond to the extension of any subuniversal of that universal because there is nothing intrinsic to the entities in question by virtue of which they – and only they – are counted as belonging to the given group. Examples are: animal purchased by the Emperortuberculosis diagnosed on a Wednesdaysurgical procedure performed on a patient from Stockholmperson identified as candidate for clinical trial #2056-555person who is signatory of Form 656-PPVpainting by Leonardo da VinciSuch terms, which represent what are called ‘specializations’ in [81 Entity An entity is anything that exists or has existed or will exist. (axiom label in BFO2 Reference: [001-001]) Entity doesn't have a closure axiom because the subclasses don't necessarily exhaust all possibilites. For example Werner Ceusters 'portions of reality' include 4 sorts, entities (as BFO construes them), universals, configurations, and relations. It is an open question as to whether entities as construed in BFO will at some point also include these other portions of reality. See, for example, 'How to track absolutely everything' at http://www.referent-tracking.com/_RTU/papers/CeustersICbookRevised.pdf Julius Caesar Verdi’s Requiem the Second World War your body mass index continuant continuant Continuant (forall (x) (if (Continuant x) (Entity x))) // axiom label in BFO2 CLIF: [008-002] (forall (x y) (if (and (Continuant x) (exists (t) (continuantPartOfAt y x t))) (Continuant y))) // axiom label in BFO2 CLIF: [009-002] (forall (x) (if (Material Entity x) (exists (t) (and (TemporalRegion t) (existsAt x t))))) // axiom label in BFO2 CLIF: [011-002] (forall (x y) (if (and (Continuant x) (exists (t) (hasContinuantPartOfAt y x t))) (Continuant y))) // axiom label in BFO2 CLIF: [126-001] A continuant is an entity that persists, endures, or continues to exist through time while maintaining its identity. (axiom label in BFO2 Reference: [008-002]) BFO 2 Reference: Continuant entities are entities which can be sliced to yield parts only along the spatial dimension, yielding for example the parts of your table which we call its legs, its top, its nails. ‘My desk stretches from the window to the door. It has spatial parts, and can be sliced (in space) in two. With respect to time, however, a thing is a continuant.’ [60, p. 240 Continuant doesn't have a closure axiom because the subclasses don't necessarily exhaust all possibilites. For example, in an expansion involving bringing in some of Ceuster's other portions of reality, questions are raised as to whether universals are continuants if b is a continuant and if, for some t, c has_continuant_part b at t, then c is a continuant. (axiom label in BFO2 Reference: [126-001]) if b is a continuant and if, for some t, cis continuant_part of b at t, then c is a continuant. (axiom label in BFO2 Reference: [009-002]) if b is a material entity, then there is some temporal interval (referred to below as a one-dimensional temporal region) during which b exists. (axiom label in BFO2 Reference: [011-002]) occurrent (forall (x) (iff (Occurrent x) (and (Entity x) (exists (y) (temporalPartOf y x))))) // axiom label in BFO2 CLIF: [079-001] Simons uses different terminology for relations of occurrents to regions: Denote the spatio-temporal location of a given occurrent e by 'spn[e]' and call this region its span. We may say an occurrent is at its span, in any larger region, and covers any smaller region. Now suppose we have fixed a frame of reference so that we can speak not merely of spatio-temporal but also of spatial regions (places) and temporal regions (times). The spread of an occurrent, (relative to a frame of reference) is the space it exactly occupies, and its spell is likewise the time it exactly occupies. We write 'spr[e]' and `spl[e]' respectively for the spread and spell of e, omitting mention of the frame. (forall (x) (if (Occurrent x) (exists (r) (and (SpatioTemporalRegion r) (occupiesSpatioTemporalRegion x r))))) // axiom label in BFO2 CLIF: [108-001] An occurrent is an entity that unfolds itself in time or it is the instantaneous boundary of such an entity (for example a beginning or an ending) or it is a temporal or spatiotemporal region which such an entity occupies_temporal_region or occupies_spatiotemporal_region. (axiom label in BFO2 Reference: [077-002]) BFO 2 Reference: every occurrent that is not a temporal or spatiotemporal region is s-dependent on some independent continuant that is not a spatial region BFO 2 Reference: s-dependence obtains between every process and its participants in the sense that, as a matter of necessity, this process could not have existed unless these or those participants existed also. A process may have a succession of participants at different phases of its unfolding. Thus there may be different players on the field at different times during the course of a football game; but the process which is the entire game s-depends_on all of these players nonetheless. Some temporal parts of this process will s-depend_on on only some of the players. Occurrent Occurrent doesn't have a closure axiom because the subclasses don't necessarily exhaust all possibilites. An example would be the sum of a process and the process boundary of another process. b is an occurrent entity iff b is an entity that has temporal parts. (axiom label in BFO2 Reference: [079-001]) occurrent Every occurrent occupies_spatiotemporal_region some spatiotemporal region. (axiom label in BFO2 Reference: [108-001]) independent continuant IndependentContinuant (forall (x t) (if (and (IndependentContinuant x) (existsAt x t)) (exists (y) (and (Entity y) (specificallyDependsOnAt y x t))))) // axiom label in BFO2 CLIF: [018-002] (iff (IndependentContinuant a) (and (Continuant a) (not (exists (b t) (specificallyDependsOnAt a b t))))) // axiom label in BFO2 CLIF: [017-002] (forall (x t) (if (IndependentContinuant x) (exists (r) (and (SpatialRegion r) (locatedInAt x r t))))) // axiom label in BFO2 CLIF: [134-001] For any independent continuant b and any time t there is some spatial region r such that b is located_in r at t. (axiom label in BFO2 Reference: [134-001]) For every independent continuant b and time t during the region of time spanned by its life, there are entities which s-depends_on b during t. (axiom label in BFO2 Reference: [018-002]) a heart a molecule ic a chair a leg a spatial region an atom an orchestra. an organism b is an independent continuant = Def. b is a continuant which is such that there is no c and no t such that b s-depends_on c at t. (axiom label in BFO2 Reference: [017-002]) the bottom right portion of a human torso the interior of your mouth process Process (iff (Process a) (and (Occurrent a) (exists (b) (properTemporalPartOf b a)) (exists (c t) (and (MaterialEntity c) (specificallyDependsOnAt a c t))))) // axiom label in BFO2 CLIF: [083-003] BFO 2 Reference: The realm of occurrents is less pervasively marked by the presence of natural units than is the case in the realm of independent continuants. Thus there is here no counterpart of ‘object’. In BFO 1.0 ‘process’ served as such a counterpart. In BFO 2.0 ‘process’ is, rather, the occurrent counterpart of ‘material entity’. Those natural – as contrasted with engineered, which here means: deliberately executed – units which do exist in the realm of occurrents are typically either parasitic on the existence of natural units on the continuant side, or they are fiat in nature. Thus we can count lives; we can count football games; we can count chemical reactions performed in experiments or in chemical manufacturing. We cannot count the processes taking place, for instance, in an episode of insect mating behavior.Even where natural units are identifiable, for example cycles in a cyclical process such as the beating of a heart or an organism’s sleep/wake cycle, the processes in question form a sequence with no discontinuities (temporal gaps) of the sort that we find for instance where billiard balls or zebrafish or planets are separated by clear spatial gaps. Lives of organisms are process units, but they too unfold in a continuous series from other, prior processes such as fertilization, and they unfold in turn in continuous series of post-life processes such as post-mortem decay. Clear examples of boundaries of processes are almost always of the fiat sort (midnight, a time of death as declared in an operating theater or on a death certificate, the initiation of a state of war) a process of cell-division, \ a beating of the heart a process of meiosis a process of sleeping p is a process = Def. p is an occurrent that has temporal proper parts and for some time t, p s-depends_on some material entity at t. (axiom label in BFO2 Reference: [083-003]) process the course of a disease the flight of a bird the life of an organism your process of aging. disposition (forall (x) (if (Disposition x) (and (RealizableEntity x) (exists (y) (and (MaterialEntity y) (bearerOfAt x y t)))))) // axiom label in BFO2 CLIF: [062-002] BFO 2 Reference: Dispositions exist along a strength continuum. Weaker forms of disposition are realized in only a fraction of triggering cases. These forms occur in a significant number of cases of a similar type. Disposition (forall (x t) (if (and (RealizableEntity x) (existsAt x t)) (exists (y) (and (MaterialEntity y) (specificallyDepends x y t))))) // axiom label in BFO2 CLIF: [063-002] disposition If b is a realizable entity then for all t at which b exists, b s-depends_on some material entity at t. (axiom label in BFO2 Reference: [063-002]) an atom of element X has the disposition to decay to an atom of element Y b is a disposition means: b is a realizable entity & b’s bearer is some material entity & b is such that if it ceases to exist, then its bearer is physically changed, & b’s realization occurs when and because this bearer is in some special physical circumstances, & this realization occurs in virtue of the bearer’s physical make-up. (axiom label in BFO2 Reference: [062-002]) certain people have a predisposition to colon cancer children are innately disposed to categorize objects in certain ways. the cell wall is disposed to filter chemicals in endocytosis and exocytosis realizable entity (forall (x) (if (RealizableEntity x) (and (SpecificallyDependentContinuant x) (exists (y) (and (IndependentContinuant y) (not (SpatialRegion y)) (inheresIn x y)))))) // axiom label in BFO2 CLIF: [058-002] (forall (x t) (if (RealizableEntity x) (exists (y) (and (IndependentContinuant y) (not (SpatialRegion y)) (bearerOfAt y x t))))) // axiom label in BFO2 CLIF: [060-002] All realizable dependent continuants have independent continuants that are not spatial regions as their bearers. (axiom label in BFO2 Reference: [060-002]) RealizableEntity To say that b is a realizable entity is to say that b is a specifically dependent continuant that inheres in some independent continuant which is not a spatial region and is of a type instances of which are realized in processes of a correlated type. (axiom label in BFO2 Reference: [058-002]) realizable the disposition of this piece of metal to conduct electricity. the disposition of your blood to coagulate the function of your reproductive organs the role of being a doctor the role of this boundary to delineate where Utah and Colorado meet quality (forall (x) (if (Quality x) (SpecificallyDependentContinuant x))) // axiom label in BFO2 CLIF: [055-001] quality Quality (forall (x) (if (exists (t) (and (existsAt x t) (Quality x))) (forall (t_1) (if (existsAt x t_1) (Quality x))))) // axiom label in BFO2 CLIF: [105-001] If an entity is a quality at any time that it exists, then it is a quality at every time that it exists. (axiom label in BFO2 Reference: [105-001]) a quality is a specifically dependent continuant that, in contrast to roles and dispositions, does not require any further process in order to be realized. (axiom label in BFO2 Reference: [055-001]) the ambient temperature of this portion of air the color of a tomato the length of the circumference of your waist the mass of this piece of gold. the shape of your nose the shape of your nostril specifically dependent continuant (iff (SpecificallyDependentContinuant a) (and (Continuant a) (forall (t) (if (existsAt a t) (exists (b) (and (IndependentContinuant b) (not (SpatialRegion b)) (specificallyDependsOnAt a b t))))))) // axiom label in BFO2 CLIF: [050-003] (iff (RelationalSpecificallyDependentContinuant a) (and (SpecificallyDependentContinuant a) (forall (t) (exists (b c) (and (not (SpatialRegion b)) (not (SpatialRegion c)) (not (= b c)) (not (exists (d) (and (continuantPartOfAt d b t) (continuantPartOfAt d c t)))) (specificallyDependsOnAt a b t) (specificallyDependsOnAt a c t)))))) // axiom label in BFO2 CLIF: [131-004] SpecificallyDependentContinuant Reciprocal specifically dependent continuants: the function of this key to open this lock and the mutually dependent disposition of this lock: to be opened by this key Specifically dependent continuant doesn't have a closure axiom because the subclasses don't necessarily exhaust all possibilites. We're not sure what else will develop here, but for example there are questions such as what are promises, obligation, etc. b is a relational specifically dependent continuant = Def. b is a specifically dependent continuant and there are n &gt; 1 independent continuants c1, … cn which are not spatial regions are such that for all 1 i &lt; j n, ci and cj share no common parts, are such that for each 1 i n, b s-depends_on ci at every time t during the course of b’s existence (axiom label in BFO2 Reference: [131-004]) b is a specifically dependent continuant = Def. b is a continuant & there is some independent continuant c which is not a spatial region and which is such that b s-depends_on c at every time t during the course of b’s existence. (axiom label in BFO2 Reference: [050-003]) of one-sided specifically dependent continuants: the mass of this tomato of relational dependent continuants (multiple bearers): John’s love for Mary, the ownership relation between John and this statue, the relation of authority between John and his subordinates. sdc the disposition of this fish to decay the function of this heart: to pump blood the mutual dependence of proton donors and acceptors in chemical reactions [79 the mutual dependence of the role predator and the role prey as played by two organisms in a given interaction the pink color of a medium rare piece of grilled filet mignon at its center the role of being a doctor the shape of this hole. the smell of this portion of mozzarella role Role role (forall (x) (if (Role x) (RealizableEntity x))) // axiom label in BFO2 CLIF: [061-001] BFO 2 Reference: One major family of examples of non-rigid universals involves roles, and ontologies developed for corresponding administrative purposes may consist entirely of representatives of entities of this sort. Thus ‘professor’, defined as follows,b instance_of professor at t =Def. there is some c, c instance_of professor role & c inheres_in b at t.denotes a non-rigid universal and so also do ‘nurse’, ‘student’, ‘colonel’, ‘taxpayer’, and so forth. (These terms are all, in the jargon of philosophy, phase sortals.) By using role terms in definitions, we can create a BFO conformant treatment of such entities drawing on the fact that, while an instance of professor may be simultaneously an instance of trade union member, no instance of the type professor role is also (at any time) an instance of the type trade union member role (any more than any instance of the type color is at any time an instance of the type length).If an ontology of employment positions should be defined in terms of roles following the above pattern, this enables the ontology to do justice to the fact that individuals instantiate the corresponding universals – professor, sergeant, nurse – only during certain phases in their lives. John’s role of husband to Mary is dependent on Mary’s role of wife to John, and both are dependent on the object aggregate comprising John and Mary as member parts joined together through the relational quality of being married. b is a role means: b is a realizable entity & b exists because there is some single bearer that is in some special physical, social, or institutional set of circumstances in which this bearer does not have to be& b is not such that, if it ceases to exist, then the physical make-up of the bearer is thereby changed. (axiom label in BFO2 Reference: [061-001]) the priest role the role of a boundary to demarcate two neighboring administrative territories the role of a building in serving as a military target the role of a stone in marking a property boundary the role of subject in a clinical trial the student role object object object Object BFO 2 Reference: BFO rests on the presupposition that at multiple micro-, meso- and macroscopic scales reality exhibits certain stable, spatially separated or separable material units, combined or combinable into aggregates of various sorts (for example organisms into what are called ‘populations’). Such units play a central role in almost all domains of natural science from particle physics to cosmology. Many scientific laws govern the units in question, employing general terms (such as ‘molecule’ or ‘planet’) referring to the types and subtypes of units, and also to the types and subtypes of the processes through which such units develop and interact. The division of reality into such natural units is at the heart of biological science, as also is the fact that these units may form higher-level units (as cells form multicellular organisms) and that they may also form aggregates of units, for example as cells form portions of tissue and organs form families, herds, breeds, species, and so on. At the same time, the division of certain portions of reality into engineered units (manufactured artifacts) is the basis of modern industrial technology, which rests on the distributed mass production of engineered parts through division of labor and on their assembly into larger, compound units such as cars and laptops. The division of portions of reality into units is one starting point for the phenomenon of counting. BFO 2 Reference: Each object is such that there are entities of which we can assert unproblematically that they lie in its interior, and other entities of which we can assert unproblematically that they lie in its exterior. This may not be so for entities lying at or near the boundary between the interior and exterior. This means that two objects – for example the two cells depicted in Figure 3 – may be such that there are material entities crossing their boundaries which belong determinately to neither cell. Something similar obtains in certain cases of conjoined twins (see below). BFO 2 Reference: To say that b is causally unified means: b is a material entity which is such that its material parts are tied together in such a way that, in environments typical for entities of the type in question,if c, a continuant part of b that is in the interior of b at t, is larger than a certain threshold size (which will be determined differently from case to case, depending on factors such as porosity of external cover) and is moved in space to be at t at a location on the exterior of the spatial region that had been occupied by b at t, then either b’s other parts will be moved in coordinated fashion or b will be damaged (be affected, for example, by breakage or tearing) in the interval between t and t.causal changes in one part of b can have consequences for other parts of b without the mediation of any entity that lies on the exterior of b. Material entities with no proper material parts would satisfy these conditions trivially. Candidate examples of types of causal unity for material entities of more complex sorts are as follows (this is not intended to be an exhaustive list):CU1: Causal unity via physical coveringHere the parts in the interior of the unified entity are combined together causally through a common membrane or other physical covering\. The latter points outwards toward and may serve a protective function in relation to what lies on the exterior of the entity [13, 47 BFO 2 Reference: an object is a maximal causally unified material entity BFO 2 Reference: ‘objects’ are sometimes referred to as ‘grains’ [74 atom b is an object means: b is a material entity which manifests causal unity of one or other of the types CUn listed above & is of a type (a material universal) instances of which are maximal relative to this criterion of causal unity. (axiom label in BFO2 Reference: [024-001]) cell cells and organisms engineered artifacts grain of sand molecule organelle organism planet solid portions of matter star generically dependent continuant gdc (iff (GenericallyDependentContinuant a) (and (Continuant a) (exists (b t) (genericallyDependsOnAt a b t)))) // axiom label in BFO2 CLIF: [074-001] GenericallyDependentContinuant The entries in your database are patterns instantiated as quality instances in your hard drive. The database itself is an aggregate of such patterns. When you create the database you create a particular instance of the generically dependent continuant type database. Each entry in the database is an instance of the generically dependent continuant type IAO: information content entity. b is a generically dependent continuant = Def. b is a continuant that g-depends_on one or more other entities. (axiom label in BFO2 Reference: [074-001]) the pdf file on your laptop, the pdf file that is a copy thereof on my laptop the sequence of this protein molecule; the sequence that is a copy thereof in that protein molecule. material entity material entity material (forall (x) (if (MaterialEntity x) (IndependentContinuant x))) // axiom label in BFO2 CLIF: [019-002] (forall (x) (if (and (Entity x) (exists (y t) (and (MaterialEntity y) (continuantPartOfAt y x t)))) (MaterialEntity x))) // axiom label in BFO2 CLIF: [020-002] (forall (x) (if (and (Entity x) (exists (y t) (and (MaterialEntity y) (continuantPartOfAt x y t)))) (MaterialEntity x))) // axiom label in BFO2 CLIF: [021-002] A material entity is an independent continuant that has some portion of matter as proper or improper continuant part. (axiom label in BFO2 Reference: [019-002]) BFO 2 Reference: Material entities (continuants) can preserve their identity even while gaining and losing material parts. Continuants are contrasted with occurrents, which unfold themselves in successive temporal parts or phases [60 BFO 2 Reference: Object, Fiat Object Part and Object Aggregate are not intended to be exhaustive of Material Entity. Users are invited to propose new subcategories of Material Entity. BFO 2 Reference: ‘Matter’ is intended to encompass both mass and energy (we will address the ontological treatment of portions of energy in a later version of BFO). A portion of matter is anything that includes elementary particles among its proper or improper parts: quarks and leptons, including electrons, as the smallest particles thus far discovered; baryons (including protons and neutrons) at a higher level of granularity; atoms and molecules at still higher levels, forming the cells, organs, organisms and other material entities studied by biologists, the portions of rock studied by geologists, the fossils studied by paleontologists, and so on.Material entities are three-dimensional entities (entities extended in three spatial dimensions), as contrasted with the processes in which they participate, which are four-dimensional entities (entities extended also along the dimension of time).According to the FMA, material entities may have immaterial entities as parts – including the entities identified below as sites; for example the interior (or ‘lumen’) of your small intestine is a part of your body. BFO 2.0 embodies a decision to follow the FMA here. Every entity which has a material entity as continuant part is a material entity. (axiom label in BFO2 Reference: [020-002]) MaterialEntity a flame a forest fire a human being a hurricane a photon a puff of smoke a sea wave a tornado an aggregate of human beings. an energy wave an epidemic every entity of which a material entity is continuant part is also a material entity. (axiom label in BFO2 Reference: [021-002]) the undetached arm of a human being voriconazole (2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol (R-(R*,S*))-alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha-(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol (alphaR,betaS)-alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol 121243 A triazole-based antifungal agent used for the treatment of esophageal candidiasis, invasive pulmonary aspergillosis, and serious fungal infections caused by Scedosporium apiospermum and Fusarium spp. Beilstein:7694998 C16H14F3N5O CHEBI:10023 CHEBI:127308 C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F ChEMBL:127308 ChemIDplus:137234-62-9 DrugBank:137234-62-9 DrugBank:DB00582 InChI=1S/C16H14F3N5O/c1-10(15-14(19)5-20-7-22-15)16(25,6-24-9-21-8-23-24)12-3-2-11(17)4-13(12)18/h2-5,7-10,25H,6H2,1H3/t10-,16+/m0/s1 InChIKey=BCEHBSKCWLPMDN-MGPLVRAMSA-N KEGG COMPOUND:137234-62-9 KEGG COMPOUND:C07622 KEGG DRUG:137234-62-9 KEGG DRUG:D00578 Patent:EP440372 Patent:US5278175 VCZ Vfend Wikipedia:Voriconazole voriconazole Ciprofloxacin ciprofloxacin 1-CYCLOPROPYL-6-FLUORO-4-OXO-7-PIPERAZIN-1-YL-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID 1-Cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-quinoline-3-carboxylic acid 1-Cyclopropyl-6-fluoro-7-(4-methyl-piperazin-1-yl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid 1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid 1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid 1-cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydroquinoline-3-carboxylic acid 1-cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid 1-cyclopropyl-6-fluoro-7-hexahydro-1-pyrazinyl-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid 2551 Beilstein:3568352 C17H18FN3O3 CHEBI:100241 CHEBI:102718 CHEBI:3717 CHEBI:41638 ChEMBL:100241 ChEMBL:102718 ChEMBL:10397494 ChEMBL:10737746 ChemIDplus:85721-33-1 Ciprofloxacin DrugBank:DB00537 InChI=1S/C17H18FN3O3/c18-13-7-11-14(8-15(13)20-5-3-19-4-6-20)21(10-1-2-10)9-12(16(11)22)17(23)24/h7-10,19H,1-6H2,(H,23,24) InChIKey=MYSWGUAQZAJSOK-UHFFFAOYSA-N KEGG COMPOUND:85721-33-1 KEGG DRUG:D00186 OC(=O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O Patent:DE3142854 Patent:US4670444 Quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively. Wikipedia:Ciprofloxacin ciprofloxacin ciprofloxacin ciprofloxacine ciprofloxacino ciprofloxacinum Norfloxacin norfloxacin 1,4-Dihydro-1-ethyl-6-fluoro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid 1-Ethyl-6-fluor-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-chinolincarbonsaeure 1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid 1-ethyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid 7517 A synthetic fluoroquinolone with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase. Beilstein:567897 C16H18FN3O3 CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCNCC1 CHEBI:100246 CHEBI:7629 ChEMBL:100246 ChemIDplus:70458-96-7 CiteXplore:3317294 CiteXplore:3908074 CiteXplore:6211142 CiteXplore:6224685 CiteXplore:6234465 CiteXplore:6454381 CiteXplore:6461606 DrugBank:DB01059 Gmelin:1576626 InChI=1S/C16H18FN3O3/c1-2-19-9-11(16(22)23)15(21)10-7-12(17)14(8-13(10)19)20-5-3-18-4-6-20/h7-9,18H,2-6H2,1H3,(H,22,23) InChIKey=OGJPXUAPXNRGGI-UHFFFAOYSA-N KEGG COMPOUND:70458-96-7 KEGG COMPOUND:C06687 KEGG DRUG:D00210 NFLX Patent:BE863429 Patent:DE2840910 Patent:US4146719 Patent:US4292317 Wikipedia:Norfloxacin norfloxacin norfloxacine norfloxacino norfloxacinum zafirlukast 114970 4-(5-cyclopentyloxycarbonylamino-1-methyl-1H-indol-3-ylmethyl)-3-methoxy-N-o-tolylsulfonylbenzamide Accolate An indole that has formula C31H33N3O6S. Beilstein:3641829 C31H33N3O6S CHEBI:10100 COc1cc(ccc1Cc1cn(C)c2ccc(NC(=O)OC3CCCC3)cc12)C(=O)NS(=O)(=O)c1ccccc1C ChemIDplus:107753-78-6 DrugBank:DB00549 InChI=1S/C31H33N3O6S/c1-20-8-4-7-11-29(20)41(37,38)33-30(35)22-13-12-21(28(17-22)39-3)16-23-19-34(2)27-15-14-24(18-26(23)27)32-31(36)40-25-9-5-6-10-25/h4,7-8,11-15,17-19,25H,5-6,9-10,16H2,1-3H3,(H,32,36)(H,33,35) InChIKey=YEEZWCHGZNKEEK-UHFFFAOYSA-N KEGG COMPOUND:107753-78-6 KEGG COMPOUND:C07206 KEGG DRUG:D00411 Wikipedia:Zafirlukast cyclopentyl 3-(2-methoxy-4-((o-tolylsulfonyl)carbamoyl)benzyl)-1-methylindole-5-carbamate cyclopentyl 3-[2-methoxy-4-(2-methylphenylsulfonylcarbamoyl)benzyl]-1-methyl-1H-indol-5-ylcarbamate zafirlukast zaleplon 3'-(3-Cyanopyrazolo(1,5-a)pyrimidin-7-yl)-N-ethylacetanilide 74667 A pyrazolo[1,5-a]pyrimidine having a nitrile group at position 3 and a 3-(N-ethylacetamido)phenyl substituent at the 7-position. Beilstein:8153844 C17H15N5O CCN(C(C)=O)c1cccc(c1)-c1ccnc2c(cnn12)C#N CHEBI:10102 ChemIDplus:151319-34-5 DrugBank:151319-34-5 DrugBank:DB00962 InChI=1S/C17H15N5O/c1-3-21(12(2)23)15-6-4-5-13(9-15)16-7-8-19-17-14(10-18)11-20-22(16)17/h4-9,11H,3H2,1-2H3 InChIKey=HUNXMJYCHXQEGX-UHFFFAOYSA-N KEGG COMPOUND:151319-34-5 KEGG COMPOUND:C07484 KEGG DRUG:151319-34-5 KEGG DRUG:D00530 N-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-ethylacetamide NIST Chemistry WebBook:151319-34-5 Patent:US4626538 Wikipedia:Zaleplon zaleplon Zidovudine zidovudine 11413 3'-azido-3'-deoxythymidine A pyrimidine 2',3'-dideoxyribonucleoside compound having a 3'-azido substituent and thymine as the nucleobase. AZT Azidothymidine Beilstein:763034 C10H13N5O4 CHEBI:10110 CHEBI:619601 Cc1cn([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)c(=O)[nH]c1=O ChEMBL:19112024 ChEMBL:619601 ChemIDplus:30516-87-1 DrugBank:30516-87-1 DrugBank:DB00495 InChI=1S/C10H13N5O4/c1-5-3-15(10(18)12-9(5)17)8-2-6(13-14-11)7(4-16)19-8/h3,6-8,16H,2,4H2,1H3,(H,12,17,18)/t6-,7+,8+/m0/s1 InChIKey=HBOMLICNUCNMMY-XLPZGREQSA-N KEGG COMPOUND:30516-87-1 KEGG COMPOUND:C07210 KEGG DRUG:30516-87-1 KEGG DRUG:D00413 Patent:US4724232 Wikipedia:Zidovudine Zidovudin Zidovudinum zidovudine ziprasidone 115698 5-{2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl}-6-chloro-1,3-dihydro-2H-indol-2-one A piperazine compound having 1,2-benzothiazol-3-yl- and 2-(6-chloro-1,3-dihydro-2-oxindol-5-yl)ethyl substituents attached to the nitrogen atoms. Beilstein:6669199 C21H21ClN4OS CHEBI:10119 ChemIDplus:146939-27-7 Clc1cc2NC(=O)Cc2cc1CCN1CCN(CC1)c1nsc2ccccc12 DrugBank:146939-27-7 DrugBank:DB00246 InChI=1S/C21H21ClN4OS/c22-17-13-18-15(12-20(27)23-18)11-14(17)5-6-25-7-9-26(10-8-25)21-16-3-1-2-4-19(16)28-24-21/h1-4,11,13H,5-10,12H2,(H,23,27) InChIKey=MVWVFYHBGMAFLY-UHFFFAOYSA-N KEGG COMPOUND:C07568 KEGG DRUG:146939-27-7 KEGG DRUG:D08687 Patent:EP281309 Patent:US4831031 Wikipedia:Ziprasidone Ziprasidone ziprasidona ziprasidone ziprasidonum zolpidem 39993 An imidazo[1,2-a]pyridine compound having a 4-tolyl group at the 2-position, an N,N-dimethylcarbamoylmethyl group at the 3-position and a methyl substituent at the 6-position. Beilstein:4355785 C19H21N3O CHEBI:10125 CN(C)C(=O)Cc1c(nc2ccc(C)cn12)-c1ccc(C)cc1 ChemIDplus:82626-48-0 DrugBank:82626-48-0 DrugBank:DB00425 InChI=1S/C19H21N3O/c1-13-5-8-15(9-6-13)19-16(11-18(23)21(3)4)22-12-14(2)7-10-17(22)20-19/h5-10,12H,11H2,1-4H3 InChIKey=ZAFYATHCZYHLPB-UHFFFAOYSA-N KEGG COMPOUND:82626-48-0 KEGG COMPOUND:C07219 KEGG DRUG:82626-48-0 KEGG DRUG:D08690 N,N,6-Trimethyl-2-(4-methylphenyl)imidazo(1,2-a)pyridine-3-acetamide N,N-dimethyl-2-[6-methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridin-3-yl]acetamide NIST Chemistry WebBook:82626-48-0 Patent:EP50563 Patent:US4382938 Wikipedia:Zolpidem zolpidem zolpidemum zonisamide 1,2-Benzisoxazole-3-methanesulfonamide 1-(1,2-benzisoxazol-3-yl)methanesulfonamide 3-(Sulfamoylmethyl)-1,2-benzisoxazole 39998 A 1,2-benzoxazole compound having a sulfamoylmethyl substituent at the 3-position. Beilstein:1077076 Benzo[d]isoxazol-3-yl-methanesulfonamide C8H8N2O3S CHEBI:10127 CHEBI:139857 ChEMBL:139857 ChemIDplus:68291-97-4 DrugBank:68291-97-4 DrugBank:DB00909 InChI=1S/C8H8N2O3S/c9-14(11,12)5-7-6-3-1-2-4-8(6)13-10-7/h1-4H,5H2,(H2,9,11,12) InChIKey=UBQNRHZMVUUOMG-UHFFFAOYSA-N KEGG COMPOUND:68291-97-4 KEGG COMPOUND:C07504 KEGG DRUG:68291-97-4 KEGG DRUG:D00538 NS(=O)(=O)Cc1noc2ccccc12 Patent:JP7877057 Patent:US4172896 Wikipedia:Zonisamide zonisamida zonisamide zonisamidum Diltiazem diltiazem (+)-cis-5-[2-(dimethylamino)ethyl]-2,3-dihydro-3-hydroxy-2-(p-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one acetate ester (2S,3S)-5-(2-(dimethylamino)ethyl)-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepin-3-yl acetate (2S,3S)-5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate (2S-cis)-3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one 3443 Acetic acid (2S,3S)-5-(2-dimethylamino-ethyl)-2-(4-methoxy-phenyl)-4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]thiazepin-3-yl ester Beilstein:3573079 C22H26N2O4S CHEBI:101278 CHEBI:4602 COc1ccc(cc1)[C@@H]1Sc2ccccc2N(CCN(C)C)C(=O)[C@@H]1OC(C)=O ChEMBL:101278 ChemIDplus:42399-41-7 DILTIAZEM Diltiazem DrugBank:DB00343 InChI=1S/C22H26N2O4S/c1-15(25)28-20-21(16-9-11-17(27-4)12-10-16)29-19-8-6-5-7-18(19)24(22(20)26)14-13-23(2)3/h5-12,20-21H,13-14H2,1-4H3/t20-,21+/m1/s1 InChIKey=HSUGRBWQSSZJOP-RTWAWAEBSA-N KEGG COMPOUND:42399-41-7 KEGG COMPOUND:C06958 KEGG DRUG:D07845 NIST Chemistry WebBook:42399-41-7 Patent:DE1805714 Patent:DE3415035 Patent:US3562257 Patent:US4552695 The (S,S)-diastereoisomer of 2,3-dihydro-1,5-benzothiazepin-4(5H)-one in which positions 2 and 3 are substituted by 4-methoxyphenyl and acetoxy, respectively, while the hydrogen attached to the nitrogen is substituted by a 2-(dimethylamino)ethyl group. A calcium-channel blocker and vasodilator, it is used as the hydrochloride in the management of angina pectoris and hypertension. Wikipedia:Diltiazem diltiazem diltiazemum butalbital 19860 5-(2-methylpropyl)-5-(prop-2-en-1-yl)pyrimidine-2,4,6(1H,3H,5H)-trione 5-(2-methylpropyl)-5-prop-2-enyl-1,3-diazinane-2,4,6-trione 5-Allyl-5-isobutyl-pyrimidine-2,4,6-trione 5-allyl-5-(2'-methyl-n-propyl) barbituric acid 5-allyl-5-(2-methylpropyl)barbituric acid 5-allyl-5-isobutyl-2,4,6(1H,3H,5H)-pyrimidinetrione 5-allyl-5-isobutylbarbituric acid 5-isobutyl-5-allylbarbituric acid Barbituric acid in which the hydrogens at position 5 are substituted by an allyl group and an isobutyl group. Frequently combined with other medicines, such as aspirin, paracetamol and codeine, it is used for treatment of pain and headache. Beilstein:202119 C11H16N2O3 CC(C)CC1(CC=C)C(=O)NC(=O)NC1=O CHEBI:102524 ChEMBL:102524 ChEMBL:6864729 ChemIDplus:77-26-9 DrugBank:DB00241 InChI=1S/C11H16N2O3/c1-4-5-11(6-7(2)3)8(14)12-10(16)13-9(11)15/h4,7H,1,5-6H2,2-3H3,(H2,12,13,14,15,16) InChIKey=UZVHFVZFNXBMQJ-UHFFFAOYSA-N KEGG DRUG:D03182 NIST Chemistry WebBook:77-26-9 Wikipedia:Butalbital allylbarbital allylbarbitone allylbarbituric acid butalbarbital butalbital butalbitalum iso-butylallylbarbituric acid itobarbital tetrallobarbital Sumatriptan sumatriptan (3-[2-(dimethylamino)ethyl]-1H-indol-5-yl)-N-methylmethanesulfonamide 1-[3-(2-dimethylaminoethyl)-1H-indol-5-yl]-N-methyl-methanesulfonamide 1-{3-[2-(dimethylamino)ethyl]-1H-indol-5-yl}-N-methylmethanesulfonamide 3-(2-(dimethylamino)ethyl)-N-methyl-1H-indole-5-methanesulfonamide 3-[2-(dimethylamino)ethyl]-N-methylindole-5-methanesulfonamide 37418 A sulfonamide that consists of N,N-dimethyltryptamine bearing an additional (N-methylsulfamoyl)methyl substituent at position 5. Selective agonist for a vascular 5-HT1 receptor subtype (probably a member of the 5-HT1D family). Beilstein:5346011 C14H21N3O2S CHEBI:10650 CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1 ChemIDplus:103628-46-2 CiteXplore:11045888 CiteXplore:11401410 CiteXplore:12172708 CiteXplore:12856385 CiteXplore:12917936 CiteXplore:15652399 CiteXplore:16120224 CiteXplore:16142613 CiteXplore:17557349 CiteXplore:18442019 CiteXplore:19619527 CiteXplore:19825906 CiteXplore:22106962 CiteXplore:22150557 CiteXplore:22272067 CiteXplore:22302025 CiteXplore:22336849 CiteXplore:22336867 CiteXplore:22336868 CiteXplore:22435741 DrugBank:DB00669 HMDB:HMDB05037 Imigran Imitrex InChI=1S/C14H21N3O2S/c1-15-20(18,19)10-11-4-5-14-13(8-11)12(9-16-14)6-7-17(2)3/h4-5,8-9,15-16H,6-7,10H2,1-3H3 InChIKey=KQKPFRSPSRPDEB-UHFFFAOYSA-N KEGG COMPOUND:103628-46-2 KEGG COMPOUND:C07319 KEGG DRUG:D00451 NIST Chemistry WebBook:103628-46-2 Reaxys:5346011 Sumatran Sumax Wikipedia:Sumatriptan sumatriptan sumatriptanum Fentanyl fentanyl 1-phenethyl-4-(N-phenylpropionamido)piperidine 1-phenethyl-4-N-propionylanilinopiperidine 4337 C22H28N2O CCC(=O)N(C1CCN(CC1)CCc1ccccc1)c1ccccc1 CHEBI:119915 CHEBI:310077 CHEBI:5012 ChEMBL:10669565 ChEMBL:10987438 ChEMBL:11585443 ChEMBL:119915 ChEMBL:14698188 ChEMBL:310077 ChemIDplus:437-38-7 CiteXplore:16621415 DrugBank:DB00813 FENTANYL InChI=1S/C22H28N2O/c1-2-22(25)24(20-11-7-4-8-12-20)21-14-17-23(18-15-21)16-13-19-9-5-3-6-10-19/h3-12,21H,2,13-18H2,1H3 InChIKey=PJMPHNIQZUBGLI-UHFFFAOYSA-N KEGG DRUG:437-38-7 KEGG DRUG:D00320 N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide N-(1-phenethyl-4-piperidinyl)-N-phenylpropionamide N-(1-phenethyl-4-piperidyl)propionanilide N-(1-phenethylpiperidin-4-yl)-N-phenylpropionamide N-phenethyl-4-(N-propionylanilino)piperidine N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide Patent:FR1344366 Patent:US3164600 Reaxys:494484 The carboxamide resulting from the formal condensation of the aryl amino group of N-phenyl-1-(2-phenylethyl)piperidin-4-amine with propanoic acid. Wikipedia:Fentanyl fentanila fentanyl fentanylum Foscarnet phosphonoformic acid 33562 CH3O5P CHEBI:127780 CHEBI:45085 CHEBI:8158 ChEMBL:127780 ChemIDplus:4428-95-9 CiteXplore:11576919 CiteXplore:15182735 CiteXplore:16858125 CiteXplore:19213941 CiteXplore:19288498 CiteXplore:21056575 CiteXplore:21566148 DrugBank:DB00529 FOSCARNET Foscarmet InChI=1S/CH3O5P/c2-1(3)7(4,5)6/h(H,2,3)(H2,4,5,6) InChIKey=ZJAOAACCNHFJAH-UHFFFAOYSA-N KEGG COMPOUND:4428-95-9 KEGG COMPOUND:C06456 OC(=O)P(O)(O)=O PDBeChem:PPF PHOSPHONOFORMIC ACID Phosphoric acid in which one of the hydroxy groups is replaced by a carboxylic acid group. It is used as the trisodium salt as an antiviral agent in the treatment of cytomegalovirus retinitis (CMV retinitis, an inflamation of the retina that can lead to blindness) and as an alternative to ganciclovir for AIDS patients who require concurrent antiretroviral therapy but are unable to tolerate ganciclovir due to haematological toxicity. Reaxys:1756501 Wikipedia:Foscarnet carboxyphosphonic acid dihydroxyphosphanecarboxylic acid oxide foscarnet phosphonomethanoic acid anilide Any amide of aniline. C7H6NOR CHEBI:13248 CiteXplore:6205897 KEGG COMPOUND:C01402 N-phenyl amide N-phenyl amides [*]C(=O)Nc1ccccc1 anilide Aspirin acetylsalicylic acid 1191 2-(ACETYLOXY)BENZOIC ACID 2-(acetyloxy)benzoic acid 2-Acetoxybenzenecarboxylic acid 2-acetoxybenzoic acid ASA Acetylsalicylate Acetylsalicylic acid Acetylsalicylsaeure Aspirin Azetylsalizylsaeure Beilstein:779271 Benzoic acid carrying an acetoxy group at the 2-position. C9H8O4 CC(=O)Oc1ccccc1C(O)=O CHEBI:15365 CHEBI:22188 CHEBI:22203 CHEBI:2890 CHEBI:40705 ChemIDplus:50-78-2 CiteXplore:11402787 CiteXplore:11597554 CiteXplore:11733186 CiteXplore:12852484 CiteXplore:14753751 CiteXplore:15542410 CiteXplore:15590729 CiteXplore:1650428 CiteXplore:18226435 CiteXplore:18335236 CiteXplore:19386367 CiteXplore:19706045 CiteXplore:21699808 CiteXplore:445303 DrugBank:DB00945 Easprin Gmelin:218864 InChI=1S/C9H8O4/c1-6(10)13-8-5-3-2-4-7(8)9(11)12/h2-5H,1H3,(H,11,12) InChIKey=BSYNRYMUTXBXSQ-UHFFFAOYSA-N KEGG COMPOUND:50-78-2 KEGG COMPOUND:C01405 KEGG DRUG:D00109 NIST Chemistry WebBook:50-78-2 O-acetylsalicylic acid PDBeChem:AIN Reaxys:779271 Wikipedia:Aspirin acide 2-(acetyloxy)benzoique acide acetylsalicylique acido acetilsalicilico acidum acetylsalicylicum o-acetoxybenzoic acid o-carboxyphenyl acetate salicylic acid acetate L-dopa Levodopa (-)-3-(3,4-dihydroxyphenyl)-L-alanine (-)-dopa (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid 3,4-DIHYDROXYPHENYLALANINE 3,4-Dihydroxy-L-phenylalanine 3-Hydroxy-L-tyrosine 6375 An optically active form of dopa having L-configuration. Beilstein:2215169 Beilstein:6060047 C9H11NO4 CHEBI:11693 CHEBI:13098 CHEBI:1377 CHEBI:15765 CHEBI:19825 CHEBI:41871 CHEBI:49933 COMe:MOL000169 ChemIDplus:59-92-7 CiteXplore:8301021 Dihydroxy-L-phenylalanine Dopar DrugBank:DB01235 Gmelin:365846 InChI=1S/C9H11NO4/c10-6(9(13)14)3-5-1-2-7(11)8(12)4-5/h1-2,4,6,11-12H,3,10H2,(H,13,14)/t6-/m0/s1 InChIKey=WTDRDQBEARUVNC-LURJTMIESA-N KEGG COMPOUND:59-92-7 KEGG COMPOUND:C00355 KEGG DRUG:D00059 L-DOPA L-Dopa L-beta-(3,4-Dihydroxyphenyl)alanine L-dopa NIST Chemistry WebBook:59-92-7 N[C@@H](Cc1ccc(O)c(O)c1)C(O)=O PDBeChem:DAH_LFOH Reaxys:2215169 Wikipedia:Levodopa beta-(3,4-dihydroxyphenyl)-L-alanine beta-(3,4-dihydroxyphenyl)alanine levodopa levodopum organic sulfide CHEBI:13694 CHEBI:16385 CHEBI:26960 CHEBI:9340 Compounds having the structure RSR (R =/= H). Such compounds were once called thioethers. KEGG COMPOUND:C00297 RSR SR2 Sulfide Thioether organic sulfides sulfides thioether thioethers peptide Amide derived from two or more amino carboxylic acid molecules (the same or different) by formation of a covalent bond from the carbonyl carbon of one to the nitrogen atom of another with formal loss of water. The term is usually applied to structures formed from alpha-amino acids, but it includes those derived from any amino carboxylic acid. C2H4NO2R(C2H2NOR)n CHEBI:14753 CHEBI:16670 CHEBI:25906 CHEBI:7990 KEGG COMPOUND:C00012 Peptid Peptide peptides peptido peptidos Codeine codeine (5alpha,6alpha)-7,8-Didehydro-4,5-epoxy-3-methoxy-17-methylmorphinan-6-ol 2670 3-methoxy-17-methyl-7,8-didehydro-4,5alpha-epoxymorphinan-6alpha-ol 7,8-didehydro-4,5alpha-epoxy-3-methoxy-17-methylmorphinan-6alpha-ol Beilstein:5303198 Beilstein:5768734 Beilstein:94996 C18H21NO3 CHEBI:14006 CHEBI:16714 CHEBI:23348 CHEBI:3803 ChemIDplus:76-57-3 CiteXplore:2215478 Codein Codeine Codeine is an alkaloid found in the opium poppy, Papaver somniferum var. album; has analgesic, anti-tussive and anti-diarrhoeal properties. Codicept Coducept DrugBank:DB00318 Gmelin:232454 InChI=1S/C18H21NO3/c1-19-8-7-18-11-4-5-13(20)17(18)22-16-14(21-2)6-3-10(15(16)18)9-12(11)19/h3-6,11-13,17,20H,7-9H2,1-2H3/t11-,12+,13-,17-,18-/m0/s1 InChIKey=OROGSEYTTFOCAN-DNJOTXNNSA-N KEGG COMPOUND:76-57-3 KEGG COMPOUND:C06174 NIST Chemistry WebBook:76-57-3 O(3)-methylmorphine Wikipedia:Codeine [H][C@]12C=C[C@H](O)[C@@H]3Oc4c(OC)ccc5C[C@H]1N(C)CC[C@@]23c45 codeina codeine codeine anhydrous l-codeine methylmorphine morphine 3-methyl ether morphine monomethyl ether morphine-3-methyl ether primary aliphatic amine CH4NR CHEBI:13431 CHEBI:17062 CHEBI:8749 KEGG COMPOUND:C00375 NC[*] RCH2NH2 primary aliphatic amines Streptomycin streptomycin 10109 2,4-Diguanidino-3,5,6-trihydroxycyclohexyl 5-deoxy-2-O-(2-deoxy-2-methylamino-alpha-L-glucopyranosyl)-3-C-formyl-beta-L-lyxopentanofuranoside A amino cyclitol glycoside that consists of streptidine having a disaccharyl moiety attached at the 4-position. The parent of the streptomycin class Beilstein:74498 C21H39N7O12 CHEBI:15119 CHEBI:17076 CHEBI:26784 CHEBI:45745 CHEBI:9284 CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@H]1[C@@H](O[C@@H](C)[C@]1(O)C=O)O[C@H]1[C@H](O)[C@@H](O)[C@H](NC(N)=N)[C@@H](O)[C@@H]1NC(N)=N ChemIDplus:57-92-1 CiteXplore:11228320 CiteXplore:11905029 CiteXplore:12118520 CiteXplore:13030054 CiteXplore:13116094 CiteXplore:13136149 CiteXplore:13596285 CiteXplore:13691614 CiteXplore:13985260 CiteXplore:13990247 CiteXplore:14623118 CiteXplore:14828344 CiteXplore:14852338 CiteXplore:14939639 CiteXplore:15081082 CiteXplore:15137533 CiteXplore:15207172 CiteXplore:15686853 CiteXplore:15736038 CiteXplore:16904706 CiteXplore:17105735 CiteXplore:17238915 CiteXplore:17429930 CiteXplore:18173084 CiteXplore:18916143 CiteXplore:19052412 CiteXplore:19335957 CiteXplore:21350946 CiteXplore:21362244 CiteXplore:21593257 CiteXplore:21937264 DrugBank:DB01082 InChI=1S/C21H39N7O12/c1-5-21(36,4-30)16(40-17-9(26-2)13(34)10(31)6(3-29)38-17)18(37-5)39-15-8(28-20(24)25)11(32)7(27-19(22)23)12(33)14(15)35/h4-18,26,29,31-36H,3H2,1-2H3,(H4,22,23,27)(H4,24,25,28)/t5-,6-,7+,8-,9-,10-,11+,12-,13-,14+,15+,16-,17-,18-,21+/m0/s1 InChIKey=UCSJYZPVAKXKNQ-HZYVHMACSA-N KEGG COMPOUND:57-92-1 KEGG COMPOUND:C00413 KEGG DRUG:D08531 Kantrex N,N'''-[(1R,2R,3S,4R,5R,6S)-4-{5-deoxy-2-O-[2-deoxy-2-(methylamino)-alpha-L-glucopyranosyl]-3-C-formyl-alpha-L-lyxofuranosyloxy}-2,5,6-trihydroxycyclohexane-1,3-diyl]diguanidine PDBeChem:SRY Reaxys:74498 SM STREPTOMYCIN Wikipedia:Streptomycin [2-deoxy-2-(dimethylamino)-alpha-L-glucopyranosyl]-(1->2)-[5-deoxy-3-C-formyl-alpha-L-lyxofuranosyl]-(1->4)-{N',N'''-[(1,3,5/2,4,6)-2,4,5,6-tetrahydroxycyclohexane-1,3-diyl]diguanidine} streptomycin ketone A compound in which a carbonyl group is bonded to two carbon atoms: R2C=O (neither R may be H). CHEBI:13427 CHEBI:17087 CHEBI:24974 CHEBI:6127 CHEBI:8742 COR2 KEGG COMPOUND:C00709 KEGG COMPOUND:C01450 Keton Ketone R-CO-R' [*]C([*])=O cetone ketones ketones penicillin Any member of the group of substituted penams containing two methyl substituents at position 2, a carboxylate substituent at position 3 and a carboxamido group at position 6. C9H11N2O4SR CHEBI:14742 CHEBI:17334 CHEBI:25869 CHEBI:7961 CiteXplore:12833570 CiteXplore:1502708 CiteXplore:16033609 CiteXplore:7798534 KEGG COMPOUND:C00395 Penicillin [H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC([*])=O)C(O)=O penicillin penicillins penicillins gemcitabine 12574 2',2'-Difluorodeoxycytidine 2'-Deoxy-2',2'-difluorocytidine 2'-deoxy-2',2'-difluorocytidine 4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one A 2'-deoxycytidine having geminal fluoro substituents in the 2'-position. Gemcitabine is used in various carcinomas: non-small cell lung cancer, pancreatic cancer, bladder cancer and breast cancer. Beilstein:5382060 C9H11F2N3O4 CHEBI:175901 CHEBI:42752 CHEBI:5295 ChEMBL:11356111 ChEMBL:17101674 ChEMBL:175901 ChEMBL:17602464 ChEMBL:17887663 ChEMBL:17939651 ChEMBL:18186604 ChEMBL:18257544 ChemIDplus:95058-81-4 CiteXplore:11034044 CiteXplore:11061612 CiteXplore:11088063 CiteXplore:11122828 CiteXplore:11132538 CiteXplore:11142482 CiteXplore:11221019 CiteXplore:11374818 CiteXplore:11489002 CiteXplore:11504793 CiteXplore:11510027 CiteXplore:11585734 CiteXplore:11595724 CiteXplore:11807603 CiteXplore:11859947 CiteXplore:11901308 CiteXplore:12057041 CiteXplore:12057046 CiteXplore:12057157 CiteXplore:12115355 CiteXplore:12142097 CiteXplore:12571808 CiteXplore:12722678 CiteXplore:12722691 CiteXplore:12743987 CiteXplore:12761494 CiteXplore:12798170 CiteXplore:12917815 CiteXplore:12954073 CiteXplore:14606642 CiteXplore:14653877 CiteXplore:14720338 CiteXplore:15131028 CiteXplore:15160243 CiteXplore:15221904 CiteXplore:15282439 CiteXplore:15297392 CiteXplore:15542781 CiteXplore:15637766 CiteXplore:15744590 CiteXplore:16001951 CiteXplore:16041610 CiteXplore:16080557 CiteXplore:16143373 CiteXplore:16149285 CiteXplore:16317298 CiteXplore:16500746 CiteXplore:16555971 CiteXplore:16584929 CiteXplore:16807461 CiteXplore:16807463 CiteXplore:16894289 CiteXplore:16905983 CiteXplore:17296311 CiteXplore:17296587 CiteXplore:17347561 CiteXplore:17429628 CiteXplore:17460420 CiteXplore:17639396 CiteXplore:17941128 CiteXplore:17987263 CiteXplore:18035967 CiteXplore:18050344 CiteXplore:18086345 CiteXplore:18166944 CiteXplore:18348652 CiteXplore:18773046 CiteXplore:18789834 CiteXplore:18819792 CiteXplore:18981552 CiteXplore:19034448 CiteXplore:19177022 CiteXplore:19399788 CiteXplore:19839926 CiteXplore:19879060 DrugBank:95058-81-4 DrugBank:DB00441 InChI=1S/C9H11F2N3O4/c10-9(11)6(16)4(3-15)18-7(9)14-2-1-5(12)13-8(14)17/h1-2,4,6-7,15-16H,3H2,(H2,12,13,17)/t4-,6-,7-/m1/s1 InChIKey=SDUQYLNIPVEERB-QPPQHZFASA-N KEGG COMPOUND:95058-81-4 KEGG COMPOUND:C07650 KEGG DRUG:95058-81-4 KEGG DRUG:D02368 Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1 PDBeChem:GEO Patent:EP1939198 Patent:EP2108368 Patent:EP2275135 Patent:GB2136425 Patent:US2009124797 Patent:US2010111852 Patent:US4808614 Reaxys:5382060 Wikipedia:Gemcitabine gemcitabina gemcitabine gemcitabinum Hydrocortisone cortisol (11beta)-11,17,21-trihydroxypregn-4-ene-3,20-dione 11beta,17,21-trihydroxypregn-4-ene-3,20-dione 11beta,17alpha,21-Trihydroxy-4-pregnene-3,20-dione 11beta,17alpha,21-trihydroxy-4-pregnene-3,20-dione 11beta-hydrocortisone 17-hydroxycorticosterone 4-pregnen-11beta,17alpha,21-triol-3,20-dione 5492 Beilstein:1354819 C21H30O5 CHEBI:14023 CHEBI:17650 CHEBI:24633 CHEBI:3893 CHEBI:58221 ChemIDplus:50-23-7 CiteXplore:10438974 Cortisol Cortisol is a corticosteroid hormone or glucocorticoid produced by zona fasciculata of the adrenal cortex, which is a part of the adrenal gland. It is usually referred to as the "stress hormone" as it is involved in response to stress and anxiety, controlled by corticotropin-releasing hormone (CRH). It increases blood pressure and blood sugar, and reduces immune responses DrugBank:DB00741 Hydrocortisone InChI=1S/C21H30O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h9,14-16,18,22,24,26H,3-8,10-11H2,1-2H3/t14-,15-,16-,18+,19-,20-,21-/m0/s1 InChIKey=JYGXADMDTFJGBT-VWUMJDOOSA-N KEGG COMPOUND:50-23-7 KEGG COMPOUND:C00735 KEGG DRUG:D00088 Kendall's compound F LIPID MAPS:LMST02030001 NIST Chemistry WebBook:50-23-7 Patent:US2602769 Reichstein's substance M Wikipedia:Hydrocortisone [H][C@@]12CCC3=CC(=O)CC[C@]3(C)[C@@]1([H])[C@@H](O)C[C@@]1(C)[C@@]2([H])CC[C@]1(O)C(=O)CO cortisol hidrocortisona hydrocortisone hydrocortisonum Gentamicin Sulfate (USP) gentamycin 142438 4,6-diamino-3-[3-deoxy-4-C-methyl-3-(methylamino)pentopyranosyloxy]-2-hydroxycyclohexyl 2-amino-2,3,4,6,7-pentadeoxy-6-(methylamino)heptopyranoside Any of a group of aminoglycoside antibiotics produced by fermentation of some Micromonospora spp. CHEBI:14293 CHEBI:17833 CHEBI:24206 CHEBI:24212 CHEBI:5306 Gentamicin KEGG COMPOUND:1403-66-3 KEGG COMPOUND:C00505 gentamicin gentamycins lipid 'Lipids' is a loosely defined term for substances of biological origin that are soluble in nonpolar solvents. They consist of saponifiable lipids, such as glycerides (fats and oils) and phospholipids, as well as nonsaponifiable lipids, principally steroids. CHEBI:14517 CHEBI:18059 CHEBI:25054 CHEBI:6486 KEGG COMPOUND:C01356 Lipid lipid lipids Penicillin G benzylpenicillin (2S,5R,6R)-3,3-dimethyl-7-oxo-6-(phenylacetamido)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid 2,2-dimethyl-6beta-(phenylacetamido)penam-3alpha-carboxylic acid 6-(2-phenylacetamido)penicillanic acid 7980 A penicillin in which the substituent at position 6 of the penam ring is a phenylacetamido group. Beilstein:44740 Benzylpenicillin C16H18N2O4S CHEBI:14743 CHEBI:18208 CHEBI:25866 CHEBI:45073 CHEBI:7962 ChemIDplus:61-33-6 CiteXplore:10930630 CiteXplore:11431418 CiteXplore:11906332 CiteXplore:12569987 CiteXplore:12850488 CiteXplore:1384868 CiteXplore:16033609 CiteXplore:1709917 CiteXplore:2083978 CiteXplore:6161899 CiteXplore:7602118 CiteXplore:7716788 DrugBank:DB01053 Gmelin:781913 InChI=1S/C16H18N2O4S/c1-16(2)12(15(21)22)18-13(20)11(14(18)23-16)17-10(19)8-9-6-4-3-5-7-9/h3-7,11-12,14H,8H2,1-2H3,(H,17,19)(H,21,22)/t11-,12+,14-/m1/s1 InChIKey=JGSARLDLIJGVTE-MBNYWOFBSA-N KEGG COMPOUND:61-33-6 KEGG COMPOUND:C05551 KEGG DRUG:D02336 PDBeChem:PNN PENICILLIN G PG Patent:US3024169 Penicillin G Reaxys:44740 Wikipedia:Penicillin_G [H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)Cc1ccccc1)C(O)=O bencilpenicilina benzylpenicillin benzylpenicilline benzylpenicillinic acid benzylpenicillinum free penicillin II 2'-deoxyribonucleoside 2'-Deoxynucleoside 2'-deoxynucleoside 2'-deoxyribonucleosides 2-Deoxy-D-ribosyl-base CHEBI:1083 CHEBI:11394 CHEBI:11567 CHEBI:11568 CHEBI:18274 CHEBI:19259 CHEBI:19560 CHEBI:4421 Deoxynucleoside KEGG COMPOUND:C02269 KEGG COMPOUND:C03216 nitrile A compound having the structure RC#N; thus a C-substituted derivative of hydrocyanic acid, HC#N. In systematic nomenclature, the suffix nitrile denotes the triply bound #N atom, not the carbon atom attached to it. CHEBI:13212 CHEBI:13426 CHEBI:13660 CHEBI:18379 CHEBI:25547 CHEBI:7584 CNR KEGG COMPOUND:C00726 Nitril Nitrile R-CN [*]C#N nitrile nitriles nitrilos delta-lactone 1,5-lactone 1,5-lactones CHEBI:18946 delta-lactona delta-lactonas delta-lactone delta-lactones 17-oxo steroid 17-keto steroids 17-ketosteroids 17-oxo steroids CHEBI:19168 purine 2'-deoxyribonucleoside CHEBI:19254 purine 2'-deoxyribonucleosides pyrimidine 2'-deoxyribonucleoside CHEBI:19255 pyrimidine 2'-deoxyribonucleosides 2-aminopurines 2-aminopurines Any aminopurine having the amino substituent at the 2-position. CHEBI:20702 N-glycosyl compound A glycosyl compound arising formally from the elimination of water from a glycosidic hydroxy group and an H atom bound to a nitrogen atom, thus creating a C-N bond. CHEBI:21731 N-glycoside N-glycosides N-glycosyl compounds glycosylamine glycosylamines alkaloid Alkaloid Alkaloide Any of basic nitrogen compounds (mostly heterocyclic) occurring mostly in the plant kingdom (but not excluding those of animal origin). Amino acids, peptides, proteins, nucleotides, nucleic acids, amino sugars and antibiotics are not normally regarded as alkaloids. By extension, certain neutral compounds biogenetically related to basic alkaloids are included. CHEBI:22315 alcaloide alcaloides alkaloids alkyl sulfide CHEBI:22327 amino alcohol An alcohol containing an amino functional group in addition to the alcohol-defining hydroxy group. CHEBI:22478 amino alcohols aminoalcohol aminoalcohols amino cyclitol glycoside CHEBI:22479 amino cyclitol glycoside amino cyclitol glycosides aminoglycoside antibiotic CHEBI:22507 aminoglycoside antibiotics aminopurine Any purine having at least one amino substituent. CHEBI:22527 aminopurines anthraquinone CHEBI:22580 anthracenequinones anthraquinones azides CHEBI:22680 Compounds containing the group -N3, and salts of hydrazoic acid, HN3. azides azobenzenes Any member of the wide class of molecules that share the core azobenzene structure, comprising two phenyl rings linked by a N=N double bond, which may have different functional groups extending from the rings. CHEBI:22682 azobenzenes barbiturates CHEBI:22693 Pyrimidine-2,4,6(1H,3H,5H)-trione (barbituric acid) and derivatives. Largest group of the synthetic sedative/hypnotics, sharing a characteristic six-membered ring structure. barbiturates barbituric acids benzenes CHEBI:22712 benzimidazoles An organic heterocyclic compound containing a benzene ring fused to an imidazole ring. CHEBI:22715 benzoic acids CHEBI:22723 benzopyrrole CHEBI:22728 benzopyrroles beta-D-glucoside CHEBI:22798 beta-D-glucoside beta-D-glucosides biphenyls Benzenoid aromatic compounds containing two phenyl or substituted-phenyl groups which are joined together by a single bond. CHEBI:22888 carbamate ester An ester of carbamic acid. CHEBI:23003 carbamate esters carbamates carbohydrate-containing antibiotic CHEBI:23007 cephalosporin A class of beta-lactam antibiotics differing from the penicillins in having a 6-membered, rather than a 5-membered, side ring. C7H5NO3SR2 CHEBI:23066 CHEBI:3538 Cephalosporin CiteXplore:12833570 CiteXplore:6762896 KEGG COMPOUND:C00875 [H][C@]12SCC([*])=C(N1C(=O)[C@H]2[*])C(O)=O cephalosporins chlorine molecular entity CHEBI:23117 Colchicine colchicine 2683 A carbotricyclic compound comprising 5,6,7,9-tetrahydrobenzo[a]heptalene having four methoxy substituents at the 1-, 2-, 3- and 10-positions as well as an oxo group at the 9-position and an acetamido group at the 7-position. Beilstein:2228812 C22H25NO6 CHEBI:23359 COc1cc2CCC(NC(C)=O)c3cc(=O)c(OC)ccc3-c2c(OC)c1OC CiteXplore:9819133 InChI=1S/C22H25NO6/c1-12(24)23-16-8-6-13-10-19(27-3)21(28-4)22(29-5)20(13)14-7-9-18(26-2)17(25)11-15(14)16/h7,9-11,16H,6,8H2,1-5H3,(H,23,24) InChIKey=IAKHMKGGTNLKSZ-UHFFFAOYSA-N N-(1,2,3,10-tetramethoxy-9-oxo-5,6,7,9-tetrahydrobenzo[a]heptalen-7-yl)acetamide NIST Chemistry WebBook:54192-66-4 Reaxys:2228812 molecular entity Any constitutionally or isotopically distinct atom, molecule, ion, ion pair, radical, radical ion, complex, conformer etc., identifiable as a separately distinguishable entity. CHEBI:23367 entidad molecular entidades moleculares entite moleculaire molecular entities molecular entity molekulare Entitaet cyanides CHEBI:23424 Salts and C-organyl derivatives of hydrogen cyanide, HC#N. cyanides cyclic amide CHEBI:23443 cyclic amide cyclic amides cyclic peptide CHEBI:23449 Cyclopeptid Zyklopeptid cyclic peptides peptide cyclique peptido ciclico cyclitol A polyol consisting of a cycloalkane containing at least three hydroxy groups, each attached to a different ring carbon atom. CHEBI:23451 cyclitols cyclohexanols CHEBI:23480 deoxyribonucleoside CHEBI:23636 deoxyribonucleosides diamine CHEBI:23666 diamines diazole CHEBI:23677 Either one of a pair of heterocyclic organic compounds comprising three carbon atoms and two nitrogen atoms arranged in a ring. diazoles quinolone CHEBI:23765 quinolones diterpenoid Any terpenoid having a C20 skeleton, derived from geranylgeranyl phosphate. C20 isoprenoids CHEBI:23849 LIPID MAPS:LMPR0104 diterpenoides diterpenoids ethanolamines CHEBI:23981 ethanolamine fluorine molecular entity CHEBI:24062 fluorine compounds fluorine molecular entities fluorine molecular entity furans CHEBI:24129 Compounds containing at least one furan ring. oxacyclopenta-2,4-dienes glucocorticoid CHEBI:24261 Glucocorticoids are a class of steroid hormones that regulate a variety of physiological processes, in particular control of the concentration of glucose in blood. glucocorticoids glucoside CHEBI:24278 glucosides glycoside A glycosyl compound resulting from the attachment of a glycosyl group to a non-acyl group RO-, which itself may be derived from a saccharide and chalcogen replacements thereof (RS-, RSe-). The bond between the glycosyl group and the OR group is called a glycosidic bond. By extension, the terms N-glycosides and C-glycosides are used as class names for glycosylamines and for compounds having a glycosyl group attached to a hydrocarbyl group respectively. These terms are misnomers and should not be used. The preferred terms are glycosylamines and C-glycosyl compounds, respectively. CHEBI:24400 O-glycoside O-glycosides glycosides glycosides chemical entity A chemical entity is a physical entity of interest in chemistry including molecular entities, parts thereof, and chemical substances. CHEBI:24431 guanidines CHEBI:24436 halogen molecular entity CHEBI:24471 halogen compounds halogen molecular entities halogen molecular entity heterocyclic antibiotic CHEBI:24531 organic heterocyclic compound A cyclic compound having as ring members atoms of carbon and at least of one other element. CHEBI:24532 organic heterocycle organic heterocyclic compounds homodetic cyclic peptide A homodetic cyclic peptide is a cyclic peptide in which the ring consists solely of amino-acid residues in peptide linkages. CHEBI:24613 homodetic cyclic peptide homodetic cyclic peptides peptide cyclique homodetique peptido ciclico homodetico imidazolidine-2,4-dione CHEBI:24628 hydroxides CHEBI:24651 Hydroxides are chemical compounds containing a hydroxy group or salts containing hydroxide (OH(-)). hydroxy-amino acid CHEBI:24662 hydroxy carboxylic acid CHEBI:24669 hydroxy carboxylic acids hydroxyphenylalanine CHEBI:24734 imidazoles A five-membered organic heterocycle containing two nitrogen atoms at positions 1 and 3, or any of its derivatives; compounds containing an imidazole skeleton. CHEBI:24780 indole-3-acetic acids CHEBI:24803 indol-3-yl carboxylic acid CHEBI:24810 indol-3-yl carboxylic acids indoles Any compound containing an indole skeleton. CHEBI:24828 indolones CHEBI:24829 oxoacid A compound which contains oxygen, at least one other element, and at least one hydrogen bound to oxygen, and which produces a conjugate base by loss of positive hydrogen ion(s) (hydrons). CHEBI:24833 oxacids oxiacids oxo acid oxoacid oxoacids oxy-acids oxyacids iodine molecular entity CHEBI:24860 iodine compounds iodine molecular entities iodine molecular entity isoprenoid Any lipid formally derived from isoprene (2-methylbuta-1,3-diene), the skeleton of which can generally be discerned in repeated occurrence in the molecule. The skeleton of isoprenoids may differ from strict additivity of isoprene units by loss or shift of a fragment, commonly a methyl group. The class includes both hydrocarbons and oxygenated derivatives. CHEBI:24913 CiteXplore:12769708 CiteXplore:19219049 LIPID MAPS:LMPR01 isoprenoid isoprenoids isoprenoids isoquinoline alkaloid CHEBI:24921 isoquinoline alkaloids isoquinolines A benzopyridine with the nitrogen of the pyridine moiety in position 2. CHEBI:24922 lactam CHEBI:24995 Cyclic amides of amino carboxylic acids, having a 1-azacycloalkan-2-one structure, or analogues having unsaturation or heteroatoms replacing one or more carbon atoms of the ring. Laktam Laktame lactam lactams lactams lactone Any cyclic carboxylic ester containing a 1-oxacycloalkan-2-one structure, or an analogue having unsaturation or heteroatoms replacing one or more carbon atoms of the ring. CHEBI:25000 Lacton Lakton Laktone lactona lactonas lactone lactones methylxanthine CHEBI:25348 methylxanthines modified amino acid CHEBI:25359 monocarboxylic acid An oxoacid containing a single carboxy group. CHEBI:25384 monocarboxylic acid monocarboxylic acids morphinane alkaloid CHEBI:25418 organonitrogen heterocyclic antibiotic CHEBI:25558 organonitrogen heterocyclic antibiotics oligopeptide Any molecule that contains a small number (usually 2 to 10) amino-acid residues connected by peptide linkages. CHEBI:25676 Oligopeptid oligopeptides oligopeptido organic heteromonocyclic compound CHEBI:25693 organic heteromonocyclic compounds ether A compound ROR (where R is not H). CHEBI:25698 OR2 [*]O[*] ether ethers ethers oxo carboxylic acid Any compound that has an aldehydic or ketonic group as well as a carboxylic acid group in the same molecule. CHEBI:25754 oxo acids oxo carboxylic acids oxo carboxylic acids oxygen molecular entity CHEBI:25806 oxygen molecular entities oxygen molecular entity oxopurine CHEBI:25810 oxopurines penicillanic acids CHEBI:25865 phenylalanine derivative CHEBI:25985 phosphonic acids CHEBI:26069 HP(=O)(OH)2 (phosphonic acid) and its P-substituted derivatives. phosphonic acids phosphorus molecular entity CHEBI:26082 phosphorus molecular entities piperazines CHEBI:26144 piperidines CHEBI:26151 Amantadine amantadine 1-adamantanamine 1-adamantylamine 1-aminoadamantane 620 Amantadine Amantidine Aminoadamantane An adamantane that has formula C10H17N. Beilstein:2204333 C10H17N CHEBI:2618 ChemIDplus:768-94-5 DrugBank:DB00915 Gmelin:27066 InChI=1S/C10H17N/c11-10-4-7-1-8(5-10)3-9(2-7)6-10/h7-9H,1-6,11H2 InChIKey=DKNWSYNQZKUICI-UHFFFAOYSA-N KEGG COMPOUND:768-94-5 KEGG COMPOUND:C06818 KEGG DRUG:D07441 NC12CC3CC(CC(C3)C1)C2 NIST Chemistry WebBook:768-94-5 Viregyt Virosol Wikipedia:Amantadine adamantan-1-ylamine amantadina amantadine amantadinum tricyclo[3.3.1.1(3,7)]decan-1-amine tricyclo[3.3.1.1(3,7)]decan-1-ylamine tricyclo[3.3.1.1(3,7)]decane-1-amine polyol A compound that contains three or more hydroxyl groups. CHEBI:26191 polyols propanone CHEBI:26292 amidine Amidines CHEBI:2634 Derivatives of oxoacids RnE(=O)OH in which the hydroxy group is replaced by an amino group and the oxo group is replaced by =NR. In organic chemistry an unspecified amidine is commonly a carboxamidine. amidine amidines amidines pteridines CHEBI:26373 purine alkaloid CHEBI:26385 purine alkaloids purine nucleoside CHEBI:26394 purine nucleoside purine nucleosides purines Any compound containing purine as part of its structure. CHEBI:13678 CHEBI:26401 pyridinemonocarboxylic acid CHEBI:26420 pyridinemonocarboxylic acids pyridines CHEBI:26421 pyrimidine nucleoside CHEBI:26440 pyrimidine nucleosides pyrroles CHEBI:26455 quinolinemonocarboxylic acid CHEBI:26512 quinolinemonocarboxylic acids quinolines A class of aromatic heterocyclic compounds each of which contains a benzene ring ortho fused to carbons 2 and 3 of a pyridine ring. CHEBI:26513 Amiodarone amiodarone (2-butyl-1-benzofuran-3-yl){4-[2-(diethylamino)ethoxy]-3,5-diiodophenyl}methanone 2-Butyl-3-(3,5-diiodo-4-(2-diethylaminoethoxy)benzoyl)benzofuran 2-Butyl-3-benzofuranyl 4-(2-(diethylamino)ethoxy)-3,5-diiodophenyl ketone 2-n-Butyl-3',5'-diiodo-4'-N-diethylaminoethoxy-3-benzoylbenzofuran 703 A 1-benzofuran that has formula C25H29I2NO3. Amiodarone Beilstein:1271711 C25H29I2NO3 CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1 CHEBI:2663 ChemIDplus:1951-25-3 InChI=1S/C25H29I2NO3/c1-4-7-11-22-23(18-10-8-9-12-21(18)31-22)24(29)17-15-19(26)25(20(27)16-17)30-14-13-28(5-2)6-3/h8-10,12,15-16H,4-7,11,13-14H2,1-3H3 InChIKey=IYIKLHRQXLHMJQ-UHFFFAOYSA-N KEGG COMPOUND:1951-25-3 KEGG COMPOUND:C06823 Wikipedia:Amiodarone Amitriptyline amitriptyline 10,11-dihydro-5-(gamma-dimethylaminopropylidene)-5H-dibenzo(a,d)cycloheptene 10,11-dihydro-N,N-dimethyl-5H-dibenzo(a,d)heptalene-Delta(5),gamma-propylamine 3-(10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5-ylidene)-N,N-dimethyl-1-propanamine 3-(10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-ylidene)-N,N-dimethylpropan-1-amine 3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N,N-dimethylpropan-1-amine 5-(3-dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,d)cycloheptatriene 5-(3-dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,d)cycloheptene 5-(gamma-dimethylaminopropylidene)-5H-dibenzo[a,d][1,4]cycloheptadiene 704 A tricyclic antidepressant that has formula C20H23N. Amitriptylin Amitriptyline Beilstein:2217885 C20H23N CHEBI:2666 CN(C)CCC=C1c2ccccc2CCc2ccccc12 ChemIDplus:50-48-6 InChI=1S/C20H23N/c1-21(2)15-7-12-20-18-10-5-3-8-16(18)13-14-17-9-4-6-11-19(17)20/h3-6,8-12H,7,13-15H2,1-2H3 InChIKey=KRMDCWKBEZIMAB-UHFFFAOYSA-N KEGG COMPOUND:50-48-6 KEGG COMPOUND:C06824 NIST Chemistry WebBook:50-48-6 Wikipedia:Amitriptyline Amlodipine amlodipine 17767 3-Ethyl-5-methyl (+-)-2-(2-aminoethoxymethyl)-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate 3-ethyl 5-methyl 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina. Amlodipine Free Base Beilstein:3570229 C20H25ClN2O5 CCOC(=O)C1=C(COCCN)NC(C)=C(C1c1ccccc1Cl)C(=O)OC CHEBI:2668 ChemIDplus:88150-42-9 DrugBank:88150-42-9 DrugBank:DB00381 InChI=1S/C20H25ClN2O5/c1-4-28-20(25)18-15(11-27-10-9-22)23-12(2)16(19(24)26-3)17(18)13-7-5-6-8-14(13)21/h5-8,17,23H,4,9-11,22H2,1-3H3 InChIKey=HTIQEAQVCYTUBX-UHFFFAOYSA-N KEGG COMPOUND:88150-42-9 KEGG COMPOUND:C06825 KEGG DRUG:88150-42-9 KEGG DRUG:D07450 Patent:EP89167 Patent:US4572909 Wikipedia:Amlodipine amlodipine amlodipino amlodipinum steroid hormone Any steroid that act as hormone. CHEBI:26764 Steroidhormon Steroidhormone hormona esteroide hormonas esteroideas hormone steroide hormones steroides steroid hormones streptomycins CHEBI:26788 sulfide CHEBI:26822 sulfur molecular entity CHEBI:26835 sulfur molecular entities sulfur molecular entity terpenoid Any natural product or related compound formally derived from isoprene units. Terpenoids may contain oxygen in various functional groups. This class is subdivided according to the number of carbon atoms in the same manner as are terpenes. The skeleton of terpenoids may differ from strict additivity of isoprene units by the loss or shift of a fragment, generally a methyl group. CHEBI:26873 Terpenoid terpenoide terpenoides terpenoids tertiary alcohol A tertiary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has three other carbon atoms attached to it. C4H7OR3 CHEBI:26878 OC(C[*])(C[*])C[*] tertiary alcohol tertiary alcohols oxolanes Any oxacycle having an oxolane (tetrahydrofuran) skeleton. CHEBI:26912 organic heterotricyclic compound CHEBI:26979 heterotricyclic compounds organic heterotricyclic compounds anastrozole 2,2'-[5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene]bis(2-methylpropanenitrile) 84857 A 1,2,4-triazole compound having a 3,5-bis(2-cyano-2-propyl)benzyl group at the 1-position. Anastrozol Beilstein:8005958 C17H19N5 CC(C)(C#N)c1cc(Cn2cncn2)cc(c1)C(C)(C)C#N CHEBI:2704 ChemIDplus:120511-73-1 DrugBank:120511-73-1 DrugBank:DB01217 InChI=1S/C17H19N5/c1-16(2,9-18)14-5-13(8-22-12-20-11-21-22)6-15(7-14)17(3,4)10-19/h5-7,11-12H,8H2,1-4H3 InChIKey=YBBLVLTVTVSKRW-UHFFFAOYSA-N KEGG COMPOUND:120511-73-1 KEGG COMPOUND:C08159 KEGG DRUG:120511-73-1 KEGG DRUG:D00960 Patent:EP296749 Patent:US4935437 Wikipedia:Anastrozole alpha,alpha,alpha',alpha'-Tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile anastrozole trimethylxanthine CHEBI:27134 trimethylxanthines tryptamines CHEBI:27162 Tryptamine and its substitution derivatives. organic heterobicyclic compound CHEBI:27171 heterobicyclic compounds organic heterobicyclic compounds valine derivative CHEBI:27267 vinca alkaloid A group of indole-indoline dimers which are alkaloids obtained from the Vinca genus of plants. CHEBI:27288 vinca alkaloid vinca alkaloids vincaleukoblastines Penicillin V phenoxymethylpenicillin (2S,5R,6R)-3,3-DIMETHYL-7-OXO-6-(2-PHENOXYACETAMIDO)-4-THIA-1- AZABICYCLO(3.2.0)HEPTANE-2-CARBOXYLIC ACID (2S,5R,6R)-3,3-dimethyl-7-oxo-6-[(phenoxyacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid 2,2-dimethyl-6beta-[(phenoxyacetyl)amino]penam-3alpha-carboxylic acid 3,3-dimethyl-6beta-[(phenoxyacetyl)amino]penam-2alpha-carboxylic acid (PIN) 6-phenoxyacetamidopenicillanic acid 7984 A penicillin compound having a 6beta-(phenoxyacetyl)amino side chain. Beilstein:96259 C16H18N2O5S CHEBI:25868 CHEBI:27446 CHEBI:44947 CHEBI:7966 ChemIDplus:87-08-1 CiteXplore:10930630 CiteXplore:12569987 CiteXplore:14687482 CiteXplore:16033609 CiteXplore:8566082 Fenospen InChI=1S/C16H18N2O5S/c1-16(2)12(15(21)22)18-13(20)11(14(18)24-16)17-10(19)8-23-9-6-4-3-5-7-9/h3-7,11-12,14H,8H2,1-2H3,(H,17,19)(H,21,22)/t11-,12+,14-/m1/s1 InChIKey=BPLBGHOLXOTWMN-MBNYWOFBSA-N KEGG COMPOUND:87-08-1 KEGG COMPOUND:C08126 KEGG DRUG:D05411 Oracillin PDBeChem:PNV PV Penicillin V Reaxys:96259 V-Cillin Wikipedia:Phenoxymethylpenicillin [H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)COc1ccccc1)C(O)=O fenoximetilpenicilina penicillin phenoxymethyl phenoxomethylpenicillin phenoxymethylenepenicillinic acid phenoxymethylpenicillin phenoxymethylpenicilline phenoxymethylpenicillinum Caffeine caffeine 1,3,7-trimethyl-2,6-dioxopurine 1,3,7-trimethyl-3,7-dihydro-1H-purine-2,6-dione 1,3,7-trimethylpurine-2,6-dione 1,3,7-trimethylxanthine 1-methyltheobromine 1886 3,7-Dihydro-1,3,7-trimethyl-1H-purin-2,6-dion 7-methyltheophylline A trimethylxanthine that has formula C8H10N4O2. Beilstein:17705 C8H10N4O2 CAFFEINE CHEBI:22982 CHEBI:27732 CHEBI:3295 CHEBI:41472 Caffeine ChemIDplus:58-08-2 Cn1cnc2n(C)c(=O)n(C)c(=O)c12 Coffein DrugBank:DB00201 Gmelin:103040 InChI=1S/C8H10N4O2/c1-10-4-9-6-5(10)7(13)12(3)8(14)11(6)2/h4H,1-3H3 InChIKey=RYYVLZVUVIJVGH-UHFFFAOYSA-N KEGG COMPOUND:58-08-2 KEGG COMPOUND:C07481 KEGG DRUG:D00528 Koffein NIST Chemistry WebBook:58-08-2 PDBeChem:CFF Thein Wikipedia:Caffeine anhydrous caffeine cafeina cafeine guaranine mateina methyltheobromine teina theine Cisplatin cisplatin (SP-4-2)-diamminedichloridoplatinum (SP-4-2)-diamminedichloroplatinum 2555 A platinum-containing anticancer drug that interacts with, and forms cross-links between, DNA and proteins. It is used as a neoplasm inhibitor to treat solid tumours, primarily of the testis and ovary. Briplatin CHEBI:23314 CHEBI:27899 CHEBI:3722 ChemIDplus:15663-27-1 Cismaplat Cisplatin Cl2H6N2Pt DrugBank:DB00515 Gmelin:2519 H6Cl2N2Pt InChI=1S/2ClH.2H3N.Pt/h2*1H;2*1H3;/q;;;;+2/p-2 InChIKey=LXZZYRPGZAFOLE-UHFFFAOYSA-L KEGG COMPOUND:15663-27-1 KEGG COMPOUND:C06911 KEGG DRUG:D00275 Lederplatin MolBase:25 Neoplatin Patent:DE2318020 Patent:DE2329485 Peyrone's chloride Peyrone's salt Platamine Platinex Platinol Randa [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] cis-DDP cis-[PtCl2(NH3)2] cis-diamminedichloridoplatinum(II) cis-diamminedichloroplatinum cis-diamminedichloroplatinum(II) cis-diammineplatinum(II) dichloride cis-dichlorodiammineplatinum(II) cisplatin cisplatine cisplatino cisplatinum beta-lactam antibiotic CHEBI:10427 CHEBI:22844 CHEBI:27933 Tobramycin tobramycin (1S,2S,3R,4S,6R)-4,6-diamino-3-(2,6-diamino-2,3,6-trideoxy-alpha-D-ribo-hexopyranosyloxy)-2-hydroxycyclohexyl 3-amino-3-deoxy-alpha-D-glucopyranoside 10627 3'-Deoxykanamycin B A amino cyclitol glycoside that is kanamycin B lacking the 3-hydroxy substituent from the 2,6-diaminoglucose ring. C18H37N5O9 CHEBI:19849 CHEBI:28864 CHEBI:45933 CHEBI:9610 ChemIDplus:32986-56-4 CiteXplore:11000679 CiteXplore:11072877 CiteXplore:11459219 CiteXplore:11478352 CiteXplore:14961139 CiteXplore:15813341 CiteXplore:16205136 CiteXplore:16239129 CiteXplore:16478137 CiteXplore:16650821 CiteXplore:17150225 CiteXplore:18331849 CiteXplore:19072156 CiteXplore:19220547 CiteXplore:19340717 CiteXplore:19465435 CiteXplore:20000576 CiteXplore:20884302 CiteXplore:20938669 CiteXplore:21275493 CiteXplore:21343445 CiteXplore:21357290 CiteXplore:21396748 CiteXplore:21414310 CiteXplore:21429824 CiteXplore:21438171 CiteXplore:21530479 CiteXplore:21592592 CiteXplore:21726492 CiteXplore:21756818 CiteXplore:21796931 CiteXplore:21815282 InChI=1S/C18H37N5O9/c19-3-9-8(25)2-7(22)17(29-9)31-15-5(20)1-6(21)16(14(15)28)32-18-13(27)11(23)12(26)10(4-24)30-18/h5-18,24-28H,1-4,19-23H2/t5-,6+,7+,8-,9+,10+,11-,12+,13+,14-,15+,16-,17+,18+/m0/s1 InChIKey=NLVFBUXFDBBNBW-PBSUHMDJSA-N KEGG COMPOUND:32986-56-4 KEGG COMPOUND:C00397 KEGG DRUG:D00063 NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)C[C@@H]1O Nebramycin 6 Nebramycin factir 6 O-3-Amino-3-deoxy-alpha-D-glucopyranosyl-(1-4)-O-(2,6-diamino-2,3,6-trideoxy-alpha-D-ribohexopyranosyl-(1-4))-2-deoxy-D-streptamine PDBeChem:TOY Reaxys:1357507 Tobracin (TN) Tobramycin Tobrex (TN) Wikipedia:Tobramycin monocarboxylic acid amide CHEBI:13211 CHEBI:22207 CHEBI:25383 CHEBI:29347 CHEBI:6977 monocarboxylic acid amide monocarboxylic acid amides fatty amide A monocarboxylic acid amide derived from a fatty acid. Aliphatic amide CHEBI:13247 CHEBI:22310 CHEBI:22330 CHEBI:2572 CHEBI:29348 CHEBI:35749 CHEBI:38838 CHNOR2 KEGG COMPOUND:C02244 LIPID MAPS:LMFA08 an aliphatic amide fatty amide fatty amides Betaxolol betaxolol 1-(4-(2-(cyclopropylmethoxy)ethyl)phenoxy)-3-((1-methylethyl)amino)-2-propanol 1-(isopropylamino)-3-[p-(cyclopropylmethoxyethyl)phenoxy]-2-propanol 1-{4-[2-(cyclopropylmethoxy)ethyl]phenoxy}-3-(propan-2-ylamino)propan-2-ol 1520 3-Aminopropane-1,2-diol in which the hydrogen of the primary hydoxy is substituted by a 4-[2-(cyclopropylmethoxy)ethyl]phenyl group and one of the hydrogens attached to the amino group is substituted by isopropyl. It is a selective beta1-receptor blocker and is used in the treatment of glaucoma as well as hypertension, arrhythmias, and coronary heart disease. It is also used to reduce non-fatal cardiac events in patients with heart failure. Beilstein:1991268 C18H29NO3 CC(C)NCC(O)COc1ccc(CCOCC2CC2)cc1 CHEBI:101354 CHEBI:3082 ChEMBL:101354 ChEMBL:10891117 ChEMBL:1361581 ChEMBL:14971904 ChEMBL:15993593 ChemIDplus:63659-18-7 DrugBank:DB00195 InChI=1S/C18H29NO3/c1-14(2)19-11-17(20)13-22-18-7-5-15(6-8-18)9-10-21-12-16-3-4-16/h5-8,14,16-17,19-20H,3-4,9-13H2,1-2H3 InChIKey=NWIUTZDMDHAVTP-UHFFFAOYSA-N KEGG COMPOUND:63659-18-7 KEGG COMPOUND:C06849 KEGG DRUG:D07526 Patent:DE2649605 Patent:US4252984 Wikipedia:Betaxolol betaxolol betaxololum alcohol A compound in which a hydroxy group, -OH, is attached to a saturated carbon atom. Alcohol CHEBI:13804 CHEBI:22288 CHEBI:2553 CHEBI:30879 CHOR3 HOR KEGG COMPOUND:C00069 OC([*])([*])[*] alcohols bicalutamide (2R)-N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide 83008 A carboxamide that has formula C18H14F4N2O4S. Beilstein:5364666 C18H14F4N2O4S CHEBI:3090 C[C@](O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(c1)C(F)(F)F Casodex ChemIDplus:90357-06-5 DrugBank:DB01128 InChI=1S/C18H14F4N2O4S/c1-17(26,10-29(27,28)14-6-3-12(19)4-7-14)16(25)24-13-5-2-11(9-23)15(8-13)18(20,21)22/h2-8,26H,10H2,1H3,(H,24,25)/t17-/m0/s1 InChIKey=LKJPYSCBVHEWIU-KRWDZBQOSA-N KEGG COMPOUND:C08160 KEGG DRUG:D00961 Patent:EP100172 Patent:US4636505 Wikipedia:Bicalutamide bicalutamida bicalutamide bicalutamidum Carboplatin carboplatin (SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum 40048 A platinum coordination entity that has formula C6H12N2O4Pt. C6H12N2O4Pt C6H6O4Pt.2H3N CHEBI:31355 Carboplatin ChemIDplus:41575-94-4 Gmelin:1044703 Gmelin:51428 InChI=1S/C6H8O4.2H3N.Pt/c7-4(8)6(5(9)10)2-1-3-6;;;/h1-3H2,(H,7,8)(H,9,10);2*1H3;/q;;;+2/p-2 InChIKey=OLESAACUTLOWQZ-UHFFFAOYSA-L KEGG DRUG:41575-94-4 KEGG DRUG:D01363 Paraplatin [H][N]([H])([H])[Pt]1(OC(=O)C2(CCC2)C(=O)O1)[N]([H])([H])[H] cbdca cis-(1,1-cyclobutanedicarboxylato)diammineplatinum(II) cis-diammine(1,1-cyclobutanedicarboxylato)platinum cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II) ethylenediamine derivatives CHEBI:31577 Bromocriptine bromocriptine (5'alpha)-2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-3',6',18-trioxoergotaman (5'alpha)-2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)ergotaman-3',6',18-trione (5'alpha)-2-bromo-12'-hydroxy-5'-(2-methylpropyl)-2'-(propan-2-yl)-3',6',18-trioxoergotaman (5'alpha)-2-bromo-12'-hydroxy-5'-isobutyl-2'-isopropyl-3',6',18-trioxoergotaman 1760 2-bromo-alpha-ergocryptine 2-bromo-alpha-ergokryptin 2-bromo-alpha-ergokryptine An indole alkaloid that has formula C32H40BrN5O5. Beilstein:741357 Bromocriptine C32H40BrN5O5 CHEBI:3181 ChemIDplus:25614-03-3 DrugBank:DB01200 InChI=1S/C32H40BrN5O5/c1-16(2)12-24-29(40)37-11-7-10-25(37)32(42)38(24)30(41)31(43-32,17(3)4)35-28(39)18-13-20-19-8-6-9-22-26(19)21(27(33)34-22)14-23(20)36(5)15-18/h6,8-9,13,16-18,23-25,34,42H,7,10-12,14-15H2,1-5H3,(H,35,39)/t18-,23-,24+,25+,31-,32+/m1/s1 InChIKey=OZVBMTJYIDMWIL-AYFBDAFISA-N KEGG COMPOUND:25614-03-3 KEGG COMPOUND:C06856 KEGG DRUG:D03165 Patent:DE1926045 Patent:US3752814 Wikipedia:Bromocriptine [H][C@@]12Cc3c(Br)[nH]c4cccc(C1=C[C@H](CN2C)C(=O)N[C@@]1(O[C@]2(O)N([C@@H](CC(C)C)C(=O)N5CCC[C@@]25[H])C1=O)C(C)C)c34 bromocriptine bromocriptinum bromocryptine bromoergocriptine oxaliplatin (SP-4-2)[(1R,2R)-cyclohexane-1,2-diamine-kappa(2)N,N'][ethanedioato(2-)-kappa(2)O(1),O(2)]platinum (SP-4-2-(1R-trans))-(1,2-cyclohexanediamine-N,N')(ethanedioato(2-)-O,O')platinum 32592 A platinum coordination entity that has formula C6H14N2.C2O4.Pt. C6H14N2.C2O4.Pt C8H14N2O4Pt CHEBI:31941 ChemIDplus:63121-00-6 DrugBank:DB00526 Eloxatin Gmelin:1046012 Gmelin:28892 InChI=1S/C6H14N2.C2H2O4.Pt/c7-5-3-1-2-4-6(5)8;3-1(4)2(5)6;/h5-6H,1-4,7-8H2;(H,3,4)(H,5,6);/q;;+2/p-2/t5-,6-;;/m1../s1 InChIKey=ZROHGHOFXNOHSO-BNTLRKBRSA-L KEGG COMPOUND:61825-94-3 KEGG COMPOUND:C13258 KEGG DRUG:D01790 Oxaliplatin [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1 oxalato(1,2-diaminocyclohexane)platinum(II) oxaliplatin oxaliplatine oxaliplatino oxaliplatinum Bupropion bupropion 2-(tert-butylamino)-1-(3-chlorophenyl)propan-1-one 42347 A propanone that has formula C13H18ClNO. Bupropion C13H18ClNO CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1 CHEBI:3219 ChemIDplus:2101062 ChemIDplus:34911-55-2 InChI=1S/C13H18ClNO/c1-9(15-13(2,3)4)12(16)10-6-5-7-11(14)8-10/h5-9,15H,1-4H3 InChIKey=SNPPWIUOZRMYNY-UHFFFAOYSA-N KEGG COMPOUND:34841-39-9 KEGG COMPOUND:C06860 Wikipedia:Bupropion Buspirone buspirone 1827 8-(4-(4-(2-Pyrimidinyl)-1-piperizinyl)butyl)-8-azaspiro(4,5)decane-7,9-dione 8-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]-8-azaspiro[4.5]decane-7,9-dione An azaspiro compound that has formula C21H31N5O2. Beilstein:964904 Buspirone C21H31N5O2 CHEBI:3223 ChemIDplus:36505-84-7 DrugBank:DB00490 InChI=1S/C21H31N5O2/c27-18-16-21(6-1-2-7-21)17-19(28)26(18)11-4-3-10-24-12-14-25(15-13-24)20-22-8-5-9-23-20/h5,8-9H,1-4,6-7,10-17H2 InChIKey=QWCRAEMEVRGPNT-UHFFFAOYSA-N KEGG COMPOUND:36505-84-7 KEGG COMPOUND:C06861 KEGG DRUG:D07593 O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)c1ncccn1 Patent:DE2057845 Patent:US3717634 Wikipedia:Buspirone buspirona buspirone buspironum tertiary amine A compound formally derived from ammonia by replacing three hydrogen atoms by hydrocarbyl groups. CHEBI:26879 CHEBI:32876 CHEBI:9458 KEGG COMPOUND:C02196 NR3 R3N Tertiary amine [*]N([*])[*] tertiaeres Amin tertiary amines primary amine A compound formally derived from ammonia by replacing one hydrogen atom by a hydrocarbyl group. CHEBI:26263 CHEBI:26265 CHEBI:32877 CHEBI:8407 CHEBI:8409 H2NR KEGG COMPOUND:C00893 KEGG COMPOUND:C02580 N[*] Primary amine Primary monoamine R-NH2 primaeres Amin primary amines amine A compound formally derived from ammonia by replacing one, two or three hydrogen atoms by hydrocarbyl groups. Amin Amine CHEBI:13814 CHEBI:22474 CHEBI:2641 CHEBI:32952 KEGG COMPOUND:C00706 amines an amine amide Amide An amide is a derivative of an oxoacid RkE(=O)l(OH)m (l =/= 0) in which an acidic hydroxy group has been replaced by an amino or substituted amino group. CHEBI:22473 CHEBI:2633 CHEBI:32988 KEGG COMPOUND:C00241 amides coordination entity An assembly consisting of a central atom (usually metallic) to which is attached a surrounding array of other groups of atoms (ligands). CHEBI:33240 coordination compounds coordination entities coordination entity oxoacid derivative CHEBI:33241 oxoacid derivatives primary amide A derivative of an oxoacid RkE(=O)l(OH)m (l =/= 0) in which an acidic hydroxy group has been replaced by an amino or substituted amino group. CHEBI:33256 primary amide primary amides organosulfur compound An organosulfur compound is a compound containing at least one carbon-sulfur bond. CHEBI:23010 CHEBI:25714 CHEBI:33261 Wikipedia:Organosulfur_compounds organosulfur compound organosulfur compounds heteroorganic entity A heteroorganic entity is an organic molecular entity in which carbon atoms or organic groups are bonded directly to one or more heteroatoms. CHEBI:33285 heteroorganic entities organoelement compounds pnictogen molecular entity CHEBI:33302 pnictogen molecular entities pnictogen molecular entity chalcogen molecular entity Any p-block molecular entity containing a chalcogen. CHEBI:33304 chalcogen compounds chalcogen molecular entities chalcogen molecular entity carboxylic ester An ester of a carboxylic acid. CHEBI:13204 CHEBI:23028 CHEBI:33308 CHEBI:3408 CO2R2 Carboxylic ester KEGG COMPOUND:C02391 carboxylic acid esters carboxylic ester carboxylic esters sulfur oxoacid derivative CHEBI:33424 sulfur oxoacid derivative sulfur oxoacid derivatives transition element molecular entity A molecular entity containing one or more atoms of a transition element. CHEBI:33497 transition element molecular entities transition metal molecular entity sulfonic acid derivative CHEBI:33552 derivatives of sulfonic acid sulfonic acid derivative sulfonic acid derivatives carboxylic acid An oxoacid acid carrying at least one -C(=O)OH group and having the structure RC(=O)OH, where R is any any monovalent functional group. Carboxylic acids are the most common type of organic acid. CHEBI:13428 CHEBI:13627 CHEBI:23027 CHEBI:33575 CHO2R Carbonsaeure Carbonsaeuren CiteXplore:17147560 CiteXplore:18433345 Karbonsaeure OC([*])=O RC(=O)OH acide carboxylique acides carboxyliques acido carboxilico acidos carboxilicos carboxylic acid carboxylic acids main group molecular entity A molecular entity containing one or more atoms from any of groups 1, 2, 13, 14, 15, 16, 17, and 18 of the periodic table. CHEBI:33579 main group compounds main group molecular entities carbon group molecular entity CHEBI:33582 carbon group molecular entities carbon group molecular entity cyclic compound CHEBI:33595 cyclic compounds homocyclic compound A cyclic compound having as ring members atoms of the same element only. CHEBI:33597 homocyclic compound homocyclic compounds isocyclic compounds carbocyclic compound A cyclic compound in which all of the ring members are carbon atoms. CHEBI:33598 carbocycle carbocyclic compound carbocyclic compounds spiro compound A compound having one atom as the only common member of two rings. CHEBI:33599 spiro compound spiro compounds spiro-fused compounds spirofused compounds hydrogen molecular entity CHEBI:33608 hydrogen compounds hydrogen molecular entities polycyclic compound CHEBI:33635 polycyclic compounds bicyclic compound A molecule that features two fused rings. CHEBI:33636 bicyclic compounds aliphatic compound Any acyclic or cyclic, saturated or unsaturated carbon compound, excluding aromatic compounds. CHEBI:33653 aliphatic compounds alicyclic compound An aliphatic compound having a carbocyclic ring structure which may be saturated or unsaturated, but may not be a benzenoid or other aromatic system. CHEBI:33654 alicyclic compounds aromatic compound A cyclically conjugated molecular entity with a stability (due to delocalization) significantly greater than that of a hypothetical localized structure (e.g. Kekule structure) is said to possess aromatic character. CHEBI:33655 aromatic compounds aromatic molecular entity aromatics aromatische Verbindungen organic aromatic compound CHEBI:33659 organic aromatic compounds monocyclic compound CHEBI:33661 monocyclic compounds heteromonocyclic compound CHEBI:33670 heteromonocyclic compound heteromonocyclic compounds heteropolycyclic compound CHEBI:33671 heteropolycyclic compounds polyheterocyclic compounds heterobicyclic compound A bicyclic compound in which at least one of the rings contains at least one skeletal heteroatom. CHEBI:33672 heterobicyclic compounds s-block molecular entity An s-block molecular entity is a molecular entity containing one or more atoms of an s-block element. CHEBI:33674 s-block compounds s-block molecular entities s-block molecular entity p-block molecular entity A p-block molecular entity is a molecular entity containing one or more atoms of a p-block element. CHEBI:33675 p-block compounds p-block molecular entities p-block molecular entitiy d-block molecular entity A d-block molecular entity is a molecular entity containing one or more atoms of a d-block element. CHEBI:33676 d-block compounds d-block molecular entities d-block molecular entity amino acid A carboxylic acid containing one or more amino groups. Aminocarbonsaeure Aminokarbonsaeure Aminosaeure CHEBI:13815 CHEBI:22477 CHEBI:33709 amino acids Capsaicin capsaicin (6E)-N-(4-hydroxy-3-methoxybenzyl)-8-methylnon-6-enamide (E)-8-Methyl-N-vanillyl-6-nonenamide 1992 A capsaicinoid that has formula C18H27NO3. Beilstein:2816484 C18H27NO3 CHEBI:3374 COc1cc(CNC(=O)CCCC\C=C\C(C)C)ccc1O Capsaicin ChemIDplus:404-86-4 InChI=1S/C18H27NO3/c1-14(2)8-6-4-5-7-9-18(21)19-13-15-10-11-16(20)17(12-15)22-3/h6,8,10-12,14,20H,4-5,7,9,13H2,1-3H3,(H,19,21)/b8-6+ InChIKey=YKPUWZUDDOIDPM-SOFGYWHQSA-N Isodecenoic acid vanillylamide KEGG COMPOUND:404-86-4 KEGG COMPOUND:C06866 KEGG DRUG:D00250 Wikipedia:Capsaicin Zostrix trans-8-Methyl-N-vanillyl-6-nonenamide copper group molecular entity CHEBI:33745 copper group molecular entities copper group molecular entity nickel group molecular entity CHEBI:33747 nickel group molecular entities nickel group molecular entity platinum molecular entity CHEBI:33749 platinum compounds platinum molecular entities platinum molecular entity organic hydroxy compound An organic compound having at least one hydroxy group attached to a carbon atom. CHEBI:33822 hydroxy compounds organic hydroxy compounds organic cyclic compound CHEBI:33832 organic cyclic compounds heteroarene A heterocyclic compound formally derived from an arene by replacement of one or more methine (-C=) and/or vinylene (-CH=CH-) groups by trivalent or divalent heteroatoms, respectively, in such a way as to maintain the continuous pi-electron system characteristic of aromatic systems and a number of out-of-plane pi-electrons corresponding to the Hueckel rule (4n+2). CHEBI:33833 hetarenes heteroarenes benzenoid aromatic compound CHEBI:33836 benzenoid aromatic compounds benzenoid compound nucleoside C5H9O4R CHEBI:13661 CHEBI:25611 CHEBI:33838 CHEBI:7647 KEGG COMPOUND:C00801 Nucleoside Nucleosides are ribosyl or deoxyribosyl derivatives of the pyrimidine or purine bases adenine, guanine, xanthine, thymine, cytosine, and uracil. nucleoside nucleosides nucleosides phenols Aryl alcohol CHEBI:13664 CHEBI:13825 CHEBI:25969 CHEBI:2857 CHEBI:33853 Compounds having one or more hydroxy groups attached to a benzene or other arene ring. KEGG COMPOUND:C15584 MetaCyc:Aryl-Alcohol arenols aryl alcohol phenols aromatic amine An amine in which the amino group is linked directly to an aromatic system. CHEBI:22622 CHEBI:2834 CHEBI:33860 aromatic amines transition element coordination entity CHEBI:33861 transition element coordination entities transition metal coordination compounds transition metal coordination entities platinum coordination entity CHEBI:33862 platinum coordination compounds platinum coordination entities platinum coordination entity gold molecular entity CHEBI:33969 gold compounds gold molecular entities gold molecular entity gold coordination entity CHEBI:33971 gold coordination compounds gold coordination entities benzofurans CHEBI:22721 CHEBI:35259 carbopolycyclic compound A polyclic compound in which all of the ring members are carbon atoms. CHEBI:35294 carbopolycyclic compounds homopolycyclic compound CHEBI:35295 homopolycyclic compounds hexoside CHEBI:35313 hexoside hexosides steroid Any of naturally occurring compounds and synthetic analogues, based on the cyclopenta[a]phenanthrene carbon skeleton, partially or completely hydrogenated; there are usually methyl groups at C-10 and C-13, and often an alkyl group at C-17. By extension, one or more bond scissions, ring expansions and/or ring contractions of the skeleton may have occurred. Natural steroids are derived biogenetically from triterpenoids. CHEBI:13687 CHEBI:26768 CHEBI:35341 CHEBI:9263 KEGG COMPOUND:C00377 Steroid a steroid steroids 17alpha-hydroxy steroid 17-alpha-Hydroxysteroid 17alpha-hydroxy steroids CHEBI:13585 CHEBI:19174 CHEBI:35342 CHEBI:782 KEGG COMPOUND:C03336 a 17alpha-hydroxysteroid 21-hydroxy steroid 21-Hydroxysteroid 21-hydroxy steroids 21-hydroxysteroids CHEBI:1300 CHEBI:13596 CHEBI:19803 CHEBI:35344 KEGG COMPOUND:C02506 a 21-hydroxysteroid 11beta-hydroxy steroid 11beta-Hydroxysteroid 11beta-hydroxy steroids 11beta-hydroxysteroids CHEBI:13774 CHEBI:19134 CHEBI:35346 CHEBI:738 KEGG COMPOUND:C01058 an 11beta-hydroxysteroid hydroxy steroid CHEBI:24748 CHEBI:35350 CHEBI:5814 Hydroxysteroid KEGG COMPOUND:C02159 hydroxy steroids hydroxysteroids organonitrogen compound Any heteroorganic entity containing at least one carbon-nitrogen bond. CHEBI:35352 organonitrogen compounds organonitrogens sulfonamide An amide of a sulfonic acid RS(=O)2NR'2. CHEBI:35358 CiteXplore:2434548 NO2SR3 [*]S(=O)(=O)N([*])[*] sulfonamides sulfonamides carboxamidine Amidines CHEBI:35359 Compounds having the structure RC(=NR)NR2. The term is used as a suffix in systematic nomenclature to denote the -C(=NH)NH2 group including its carbon atom. KEGG COMPOUND:C06060 carboxamidines carboxamidines hydrazide CHEBI:35362 Compounds derived from oxoacids RkE(=O)l(OH)m (l =/= 0) by replacing -OH by -NRNR2 (R groups are commonly H). (IUPAC). hydrazides hydrazides carbohydrazide A hydrazide consisting of hydrazine carrying one or more carboacyl groups. CHEBI:35363 carbohydrazides carbohydrazides D-glucoside C6H11O6R CHEBI:21009 CHEBI:35436 CHEBI:4173 D-Glucoside D-glucosides KEGG COMPOUND:C01798 organic disulfide CHEBI:35489 Compounds of structure RSSR in which R and R' are organic groups. S2R2 [*]SS[*] disulfides organic disulfides addition compound An addition compound contains two or more simpler compounds that can be packed in a definite ratio into a crystal. The term covers donor-acceptor complexes (adducts) and a variety of lattice compounds. CHEBI:35504 addition compounds hydrate An addition compound that contains water in weak chemical combination with another compound. CHEBI:35505 Hydrat hidrato hidratos hydrates propanolamine CHEBI:35533 propanolamine propanolamines aromatic ether CHEBI:35618 azaspiro compound An azaspiro compound is a spiro compound in which at least one of the cyclic components is a nitrogen heterocyle. CHEBI:35624 azaspiro compound azaspiro compounds beta-lactam A beta-lactam is a lactam in which the amide bond is contained within a four-membered ring, which includes the amide nitrogen and the carbonyl carbon. CHEBI:10426 CHEBI:22845 CHEBI:35627 KEGG COMPOUND:C01866 beta-Lactam beta-lactam beta-lactams secondary alcohol A secondary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has two other carbon atoms attached to it. C3H6OR2 CHEBI:13425 CHEBI:13686 CHEBI:26617 CHEBI:35681 CHEBI:58662 CHEBI:8741 CHEBI:9077 KEGG COMPOUND:C00432 KEGG COMPOUND:C01612 R-CHOH-R' Secondary alcohol [H]C(O)(C[*])C[*] secondary alcohol secondary alcohols tetrazoles CHEBI:35689 dicarboxylic acid An oxoacid containing two carboxy groups. C2H2O4R CHEBI:23692 CHEBI:35692 CHEBI:4501 Dicarboxylic acid KEGG COMPOUND:C02028 dicarboxylic acids ester A compound formally derived from an oxoacid RkE(=O)l(OH)m (l > 0) and an alcohol, phenol, heteroarenol, or enol by linking with formal loss of water from an acidic hydroxy group of the former and a hydroxy group of the latter. CHEBI:23960 CHEBI:35701 CHEBI:4859 Ester KEGG COMPOUND:C00287 esters nitro compound A compound having the nitro group, -NO2 (free valence on nitrogen), which may be attached to carbon, nitrogen (as in nitramines), or oxygen (as in nitrates), among other elements (in the absence of specification, C-nitro compounds are usually implied). CHEBI:35715 nitro compounds C-nitro compound A compound having the nitro group (-NO2) attached to carbon atom. C-nitro compounds CHEBI:35716 triazoles CHEBI:35727 triazole compounds fatty acid ester CHEBI:27315 CHEBI:35747 CHEBI:35748 fatty acid esters oxo steroid CHEBI:24979 CHEBI:25804 CHEBI:35789 keto steroids ketosteroids oxo steroids oxosteroids oxazole A compound based on a five-membered heterocyclic aromatic skeleton containing one N and one O atom. CHEBI:35790 oxazole oxazoles sulfoxide CHEBI:35813 Compounds having the structure R2S=O (R =/= H). sulfoxide sulfoxides sulfone CHEBI:35850 Compounds having the structure RS(=O)2R (R =/= H). sulfone sulfones hydroxy monocarboxylic acid CHEBI:35868 hydroxy acid hydroxy monocarboxylic acids oxo monocarboxylic acid Any monocarboxylic acid having at least one additional oxo functional group. CHEBI:35871 oxo monocarboxylic acids imidazopyrimidine CHEBI:35875 imidazopyrimidines dihydroxy monocarboxylic acid CHEBI:35972 dihydroxy monocarboxylic acids penams CHEBI:35992 Natural and synthetic antibiotics containing the 4-thia-1-azabicyclo[3.2.0]heptan-7-one structure, generally assumed to have the 5R configuration unless otherwise specified. penams quinone CHEBI:13684 CHEBI:26517 CHEBI:36141 Chinon Compounds having a fully conjugated cyclic dione structure, such as that of benzoquinones, derived from aromatic compounds by conversion of an even number of -CH= groups into -C(=O)- groups with any necessary rearrangement of double bonds (polycyclic and heterocyclic analogues are included). Wikipedia:Quinone a quinone quinone quinones quinones dicarboxylic acid monoester A monoester of a dicarboxylic acid. CHEBI:36244 dicarboxylic acid monoesters polyatomic entity Any molecular entity consisting of more than one atom. CHEBI:36357 polyatomic entities phosphorus oxoacids and derivatives CHEBI:36360 pseudoketone CHEBI:36585 pseudoketone pseudoketones pseudoketones carbonyl compound Any compound containing the carbonyl group, C=O. The term is commonly used in the restricted sense of aldehydes and ketones, although it actually includes carboxylic acids and derivatives. CHEBI:36586 carbonyl compounds organic oxo compound CHEBI:36587 Organic compounds containing an oxygen atom, =O, doubly bonded to carbon or another element. organic oxo compounds oxo compounds cyclic pseudoketone A cyclic compound in which a carbonyl group in a ring is bonded to one or two skeletal heteroatoms. CHEBI:36588 cyclic pseudoketones acyclic pseudoketone CHEBI:36589 Compounds in which an acyclic carbonyl group is bonded to one or two acyclic skeletal heteroatoms, except nitrogen, halogen, or halogenoid atoms, or to a heteroatom of a ring or ring system. acyclic pseudoketone acyclic pseudoketones acyclic pseudoketones organochlorine compound An organochlorine compound is a compound containing at least one carbon-chlorine bond. CHEBI:36683 chloroorganic compounds chlororganische Verbindungen organochlorine compound organochlorine compounds organohalogen compound A compound containing at least one carbon-halogen bond. CHEBI:36684 organohalogen compounds heterotricyclic compound CHEBI:36688 heterotricyclic compound heterotricyclic compounds heterotricyclic compounds corticosteroid hormone Any of a class of steroid hormones that are produced in the adrenal cortex. CHEBI:36699 adrenal cortex hormones corticosteroid hormones aminoquinoline CHEBI:36709 aminoquinoline aminoquinolines carbobicyclic compound A bicyclic compound in which all the ring atoms are carbon. CHEBI:36785 carbobicyclic compounds tricyclic antidepressant CHEBI:36809 antidepresivo triciclico antidepresivos triciclicos tricyclic antidepressant drugs tricyclic antidepressants tricyclic antidepressive agents 5-methoxyvalerophenone O-(2-aminoethyl)oxime CHEBI:36815 oxime O-ether CHEBI:36816 CNOR3 O-organyl oximes R2C=NOR' (R' =/= H). O-substituted oximes [*]O\N=C(/[*])[*] oxime O-ether oxime O-ethers oxime O-ethers ring assembly CHEBI:36820 Two or more cyclic systems (single rings or fused systems) which are directly joined to each other by double or single bonds are named ring assemblies when the number of such direct ring junctions is one less than the number of cyclic systems involved. ring assemblies ring assembly 17-hydroxy steroid 17-hydroxy steroids CHEBI:36838 11-hydroxy steroid 11-hydroxy steroids CHEBI:36841 20-oxo steroid 20-oxo steroids CHEBI:36885 organochalcogen compound An organochalcogen compound is a compound containing at least one carbon-chalcogen bond. CHEBI:36962 organochalcogen compound organochalcogen compounds organooxygen compound An organochalcogen compound containing at least one carbon-oxygen bond. CHEBI:36963 CiteXplore:17586126 organooxygen compound organooxygen compounds organoiodine compound An organoiodine compound is a compound containing at least one carbon-iodine bond. CHEBI:37142 organoiodine compound organoiodine compounds organofluorine compound An organofluorine compound is a compound containing at least one carbon-fluorine bond. CHEBI:37143 fluoroorganic compound fluoroorganic compounds fluoroorganics fluororganische Verbindungen organofluorine compound organofluorine compounds hydroxyanthraquinones An anthraquinone substituted with one or more hydroxy groups. CHEBI:13829 CHEBI:24672 CHEBI:37485 an hydroxyanthraquinone azo compound CHEBI:37533 Derivatives of diazene with the general structure R-N=N-R'. azo compounds azo compounds heteroatomic molecular entity A molecular entity consisting of two or more chemical elements. CHEBI:37577 chemical compound heteroatomic molecular entities halide CHEBI:37578 nitrogen mustard CHEBI:37598 Compounds having two beta-haloalkyl groups bound to a nitrogen atom, as in (X-C2H2-C2H2)2NR. nitrogen mustards nitrogen mustards carboxamide An amide of a carboxylic acid, having the structure RC(=O)NR2. The term is used as a suffix in systematic name formation to denote the -C(=O)NH2 group including its carbon atom. CHEBI:35354 CHEBI:35355 CHEBI:37622 CNOR3 [*]C(=O)N([*])[*] carboxamides carboxamides primary carboxamide clopidogrel (+)-Clopidogrel 32968 A thienopyridine that has formula C16H16ClNO2S. Beilstein:8151914 C16H16ClNO2S CHEBI:37941 COC(=O)[C@@H](N1CCc2sccc2C1)c1ccccc1Cl ChemIDplus:113665-84-2 DrugBank:DB00758 InChI=1S/C16H16ClNO2S/c1-20-16(19)15(12-4-2-3-5-13(12)17)18-8-6-14-11(10-18)7-9-21-14/h2-5,7,9,15H,6,8,10H2,1H3/t15-/m0/s1 InChIKey=GKTWGGQPFAXNFI-HNNXBMFYSA-N Patent:EP281459 Patent:EP99802 Patent:US4529596 Patent:US4847265 Wikipedia:Clopidogrel clopidogrel clopidogrelum methyl (2S)-(2-chlorophenyl)(6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)acetate thienopyridine CHEBI:37942 thienopyridines benzothiazoles CHEBI:37947 carbotricyclic compound CHEBI:38032 carbotricyclic compounds organonitrogen heterocyclic compound Any organonitrogen compound containing a cyclic component with nitrogen and at least one other element as ring member atoms. CHEBI:38101 heterocyclic organonitrogen compounds organonitrogen heterocyclic compounds oxacycle Any organic heterocyclic compound containing at least one ring oxygen atom. CHEBI:38104 CiteXplore:17134300 heterocyclic organooxygen compounds organooxygen heterocyclic compounds oxacycles organosulfur heterocyclic compound CHEBI:38106 heterocyclic organosulfur compounds organosulfur heterocyclic compounds organic heteropentacyclic compound CHEBI:38164 organic heteropentacyclic compounds organic heteropolycyclic compound CHEBI:25429 CHEBI:38075 CHEBI:38166 organic heteropolycyclic compounds monocyclic heteroarene CHEBI:38179 monocyclic heteroarenes polycyclic heteroarene CHEBI:38180 polycyclic heteroarenes imidazolidines CHEBI:38261 azabicycloalkane CHEBI:38295 azabicycloalkanes cyclopentapyrrole CHEBI:38296 cyclopentapyrroles benzodioxoles CHEBI:38298 diazolidine CHEBI:38304 diazolidines cephem CHEBI:38311 cephems diazines Any organic heterocyclic compound containing a benzene ring in which two of the C-H fragments have been replaced by isolobal nitrogens (the diazine parent structure). CHEBI:38313 pyrimidone CHEBI:38337 pyrimidones 1,3-thiazole 1,3-thiazoles CHEBI:26949 CHEBI:38417 CHEBI:38418 phenethylamine alkaloid CHEBI:38605 phenethylamine alkaloids pyrazolopyrimidine CHEBI:38669 pyrazolopyrimidines Aurothiomalate aurothiomalic acid (1,2-dicarboxyethylthio)gold 1,2-dicarboxyethanethiolatogold(I) 1,2-dicarboxyethylsulfanylgold 42547 A gold coordination entity that has formula C4H5AuO4S. Beilstein:4030297 C4H5AuO4S CHEBI:38722 ChemIDplus:4846-27-9 Gmelin:1043252 Gmelin:1288314 InChI=1S/C4H6O4S.Au/c5-3(6)1-2(9)4(7)8;/h2,9H,1H2,(H,5,6)(H,7,8);/q;+1/p-1 InChIKey=XJHSMFDIQHVMCY-UHFFFAOYSA-M OC(=O)CC(S[Au])C(O)=O aurothiomalate gold(1+) 1,2-dicarboxyethanethiolate mercaptobutanedioic acid, monogold(1+) salt 1-benzofurans CHEBI:38830 indole alkaloid An alkaloid containing an indole skeleton. CHEBI:24795 CHEBI:38958 CHEBI:5901 Indole alkaloid KEGG COMPOUND:C06073 indole alkaloids dioxolane CHEBI:39430 dioxolanes pyrimidines Any compound having a pyrimidine as part of its structure. CHEBI:13681 CHEBI:26448 CHEBI:39447 atorvastatin (3R,5R)-7-[3-(anilinocarbonyl)-5-(4-fluorophenyl)-4-phenyl-2-(propan-2-yl)-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid (R-(R*,R*))-2-(4-Fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid 7-[2-(4-FLUORO-PHENYL)-5-ISOPROPYL-3-PHENYL-4-PHENYLCARBAMOYL-PYRROL-1-YL]-3,5-DIHYDROXY-HEPTANOIC ACID 83367 A dihydroxy monocarboxylic acid that has formula C33H35FN2O5. Atorlip Atorvastatin Beilstein:8373630 C33H35FN2O5 CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O CHEBI:2910 CHEBI:39538 CHEBI:39548 ChemIDplus:134523-00-5 DrugBank:DB01076 InChI=1S/C33H35FN2O5/c1-21(2)31-30(33(41)35-25-11-7-4-8-12-25)29(22-9-5-3-6-10-22)32(23-13-15-24(34)16-14-23)36(31)18-17-26(37)19-27(38)20-28(39)40/h3-16,21,26-27,37-38H,17-20H2,1-2H3,(H,35,41)(H,39,40)/t26-,27-/m1/s1 InChIKey=XUKUURHRXDUEBC-KAYWLYCHSA-N KEGG COMPOUND:134523-00-5 KEGG COMPOUND:C06834 KEGG DRUG:D07474 PDBeChem:117 Patent:EP409281 Patent:US5273995 Wikipedia:Atorvastatin atorvastatin atorvastatina atorvastatine atorvastatinum cyclic ketone CHEBI:3992 Cyclic ketone KEGG COMPOUND:C02019 cyclic ketones cyclobenzaprine (3-Dibenzo[a,d]cyclohepten-5-ylidene-propyl)-dimethyl-amine 21949 3-(5H-dibenzo[a,d][7]annulen-5-ylidene)-N,N-dimethylpropan-1-amine 3-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-N,N-dimethylpropan-1-amine 5-Methylidene-5H-dibenzo[a,d]cycloheptene in which one of the hydrogens of the methylidene group is substituted by a 2-(dimethylamino)ethyl group. A centrally acting skeletal muscle relaxant, it is used as its hydrochloride salt in the symptomatic treatment of painful muscle spasm. Beilstein:2126383 C20H21N CHEBI:128119 CHEBI:3996 CN(C)CCC=C1c2ccccc2C=Cc2ccccc12 ChEMBL:128119 ChEMBL:17725338 ChEMBL:18027916 Cyclobenzaprine DrugBank:DB00924 InChI=1S/C20H21N/c1-21(2)15-7-12-20-18-10-5-3-8-16(18)13-14-17-9-4-6-11-19(17)20/h3-6,8-14H,7,15H2,1-2H3 InChIKey=JURKNVYFZMSNLP-UHFFFAOYSA-N KEGG COMPOUND:303-53-7 KEGG COMPOUND:C06931 KEGG DRUG:D07758 N,N-dimethyl-5H-dibenzo(a,d)cycloheptene-Delta(5,gamma)-propylamine NIST Chemistry WebBook:303-53-7 Patent:GB858187 Wikipedia:Cyclobenzaprine ciclobenzaprina cyclobenzaprine cyclobenzaprinum Allopurinol allopurinol 1,5-Dihydro-4H-pyrazolo(3,4-d)pyrimidin-4-one 1,5-Dihydro-4H-pyrazolo(3,4-d)pyrimidine-4-one 1H-Pyrazolo(3,4-d)pyrimidin-4-ol 1H-pyrazolo[3,4-d]pyrimidin-4-ol 4'-Hydroxypyrazolol(3,4-d)pyrimidine 4-HPP 4-Hydroxy-1H-pyrazolo(3,4-d)pyrimidine 4-Hydroxy-3,4-pyrazolopyrimidine 4-Hydroxypyrazolo(3,4-d)pyrimidine 4-Hydroxypyrazolopyrimidine 4-Hydroxypyrazolyl(3,4-d)pyrimidine 4H-Pyrazolo(3,4-d)pyrimidin-4-one 519 A bicyclic structure comprising a pyrazole ring fused to a hydroxy-substituted pyrimidine ring. AL-100 Allopurinol Allopurinolum Alopurinol Beilstein:608611 C5H4N4O CHEBI:2601 CHEBI:40276 CHEBI:40279 ChemIDplus:315-30-0 CiteXplore:7602118 DrugBank:DB00437 InChI=1S/C5H4N4O/c10-5-3-1-8-9-4(3)6-2-7-5/h1-2H,(H2,6,7,8,9,10) InChIKey=OFCNXPDARWKPPY-UHFFFAOYSA-N KEGG DRUG:315-30-0 KEGG DRUG:D00224 NIST Chemistry WebBook:315-30-0 Oc1ncnc2[nH]ncc12 Wikipedia:Allopurinol Zyloprim (TN) Lovastatin lovastatin (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-(2R,4R)-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl (S)-2-methyl-butyrate (1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl (2S)-2-methylbutanoate 2beta,6alpha-dimethyl-8alpha-(2-methyl-1-oxobutoxy)-mevinic acid lactone 6472 6alpha-methylcompactin A delta-lactone that has formula C24H36O5. C24H36O5 CHEBI:40299 CHEBI:40303 CHEBI:6544 ChemIDplus:3631989 ChemIDplus:75330-75-5 InChI=1S/C24H36O5/c1-5-15(3)24(27)29-21-11-14(2)10-17-7-6-16(4)20(23(17)21)9-8-19-12-18(25)13-22(26)28-19/h6-7,10,14-16,18-21,23,25H,5,8-9,11-13H2,1-4H3/t14-,15-,16-,18+,19+,20-,21-,23-/m0/s1 InChIKey=PCZOHLXUXFIOCF-BXMDZJJMSA-N KEGG COMPOUND:C07074 KEGG DRUG:75330-75-5 KEGG DRUG:D00359 LOVASTATIN Lovastatin MK-803 ML-530B Mevacor Mevinolin PDBeChem:803 Wikipedia:Lovastatin [H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC Cyclosporine cyclosporin A (R-[R*,R*-(E)])-Cyclic(L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl-3-hydroxy-N,4-dimethyl-L-2-amino-6-octenoyl-L-alpha-aminobutyryl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl) 1,11-cyclo[L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl-(E)-(2S,3R,4R)-2-amino-3-hydroxy-N,4-dimethyloct-6-enoyl-L-2-aminobutanoyl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucine] 30-ethyl-33-[(4E)-1-hydroxy-2-methylhex-4-en-1-yl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-bis(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone 30-ethyl-33-[(4E)-1-hydroxy-2-methylhex-4-en-1-yl]-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone 3008 A cyclic nonribosomal peptide of eleven amino acids; an immunosuppressant drug widely used in post-allogeneic organ transplant to reduce the activity of the patient's immune system, and therefore the risk of organ rejection. Also causes reversible inhibition of immunocompetent lymphocytes in the G0- and G1-phase of the cell cycle. Antibiotic S 7481F1 Beilstein:3647785 C62H111N11O12 CC[C@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C CHEBI:4031 CHEBI:63586 ChemIDplus:59865-13-3 Ciclosporin CiteXplore:11058832 CiteXplore:11069928 CiteXplore:11079273 CiteXplore:11080188 CiteXplore:11238591 CiteXplore:11256490 CiteXplore:11278005 CiteXplore:11315347 CiteXplore:11370709 CiteXplore:11406057 CiteXplore:11426833 CiteXplore:11442023 CiteXplore:11481617 CiteXplore:11493684 CiteXplore:11529914 CiteXplore:11557554 CiteXplore:11564166 CiteXplore:11676831 CiteXplore:11870366 CiteXplore:12021257 CiteXplore:12050171 CiteXplore:12603598 CiteXplore:12761440 CiteXplore:12929192 CiteXplore:12950728 CiteXplore:14521916 CiteXplore:14621732 CiteXplore:14638917 CiteXplore:14672695 CiteXplore:14682659 CiteXplore:14743390 CiteXplore:15030555 CiteXplore:15175101 CiteXplore:15210365 CiteXplore:15306697 CiteXplore:15383526 CiteXplore:15541012 CiteXplore:15613074 CiteXplore:15626898 CiteXplore:15657176 CiteXplore:1566062 CiteXplore:15711594 CiteXplore:15811524 CiteXplore:15962181 CiteXplore:16372476 CiteXplore:16404634 CiteXplore:16724420 CiteXplore:16801218 CiteXplore:16898534 CiteXplore:17032751 CiteXplore:17083576 CiteXplore:17117422 CiteXplore:17192032 CiteXplore:17220244 CiteXplore:17229932 CiteXplore:17265451 CiteXplore:17446460 CiteXplore:17603747 CiteXplore:18076075 CiteXplore:18171316 CiteXplore:18191430 CiteXplore:18217899 CiteXplore:18259730 CiteXplore:18299432 CiteXplore:18359899 CiteXplore:18583716 CiteXplore:18597363 CiteXplore:18790203 CiteXplore:18818682 CiteXplore:18931077 CiteXplore:18975184 CiteXplore:19282398 CiteXplore:19589783 Cyclo(L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl-((3R,4R,6E)-6,7-didehydro-3-hydroxy-N,4-dimethyl-L-2-aminooctanoyl)-L-2-aminobutanoyl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methylleucyl) Cyclosporin A Cyclosporine DrugBank:DB00091 Gengraf InChI=1S/C62H111N11O12/c1-25-27-28-40(15)52(75)51-56(79)65-43(26-2)58(81)67(18)33-48(74)68(19)44(29-34(3)4)55(78)66-49(38(11)12)61(84)69(20)45(30-35(5)6)54(77)63-41(16)53(76)64-42(17)57(80)70(21)46(31-36(7)8)59(82)71(22)47(32-37(9)10)60(83)72(23)50(39(13)14)62(85)73(51)24/h25,27,34-47,49-52,75H,26,28-33H2,1-24H3,(H,63,77)(H,64,76)(H,65,79)(H,66,78)/b27-25+/t40-,41+,42+,43-,44+,45-,46+,47+,49+,50-,51+,52-/m1/s1 InChIKey=PMATZTZNYRCHOR-VJRYSDSKSA-N KEGG COMPOUND:59865-13-3 KEGG COMPOUND:C05086 KEGG DRUG:D00184 Neoral Patent:US4117118 Reaxys:3647785 Sandimmune Wikipedia:Ciclosporin ciclosporin ciclosporina ciclosporine ciclosporinum Tamoxifen tamoxifen (Z)-2-(4-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine (Z)-2-(para-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine 1-p-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene 1-para-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene 10324 2-{4-[(1Z)-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine A tertiary amino compound that has formula C26H29NO. Apo-Tamox Beilstein:2062020 C26H29NO CC\C(c1ccccc1)=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1 CHEBI:41767 CHEBI:41774 CHEBI:9396 ChemIDplus:10540-29-1 Crisafeno Diemon DrugBank:DB00675 InChI=1S/C26H29NO/c1-4-25(21-11-7-5-8-12-21)26(22-13-9-6-10-14-22)23-15-17-24(18-16-23)28-20-19-27(2)3/h5-18H,4,19-20H2,1-3H3/b26-25- InChIKey=NKANXQFJJICGDU-QPLCGJKRSA-N KEGG COMPOUND:10540-29-1 KEGG COMPOUND:C07108 Patent:BE637389 Patent:BE678807 Patent:US4536516 Tamoxifen Wikipedia:Tamoxifen tamoxifen tamoxifene tamoxifeno tamoxifenum trans-Tamoxifen Dexamethasone dexamethasone 1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone 16alpha-Methyl-9alpha-fluoro-1-dehydrocortisol 3264 9-fluoro-11beta,17,21-trihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione 9alpha-Fluoro-16alpha-methylprednisolone A fluorinated steroid that has formula C22H29FO5. Beilstein:2066652 C22H29FO5 CHEBI:41873 CHEBI:41879 CHEBI:4461 ChemIDplus:50-02-2 Decadron Dexamethasone DrugBank:DB01234 InChI=1S/C22H29FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,17+,19+,20+,21+,22+/m1/s1 InChIKey=UREBDLICKHMUKA-CXSFZGCWSA-N KEGG DRUG:D00292 Patent:DE1113690 Patent:GB869511 Patent:US3007923 Wikipedia:Dexamethasone [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C dexametasona dexamethasone dexamethasonum Dapsone dapsone 1,1'-sulfonylbis(4-aminobenzene) 3108 4,4'-Sulfonylbisbenzenamine 4,4'-dapsone 4,4'-diaminodiphenyl sulfone 4,4'-sulfonylbisaniline 4,4'-sulfonyldianiline 4-(4-amino-benzenesulfonyl)-phenylamine 4-(4-aminophenylsulfonyl)aniline 4-(4-aminophenylsulfonyl)benzenamine 4-aminophenyl sulfone Beilstein:788055 Bis(p-aminophenyl) sulfone C12H12N2O2S CHEBI:226356 CHEBI:4325 ChEMBL:226356 ChemIDplus:80-08-0 DADPS DAPSONE DDS DIAPHENYLSULFONE Dapsone Diaphenylsulfone Diphenylsulfone in which the hydrogen atom at the 4 position of each of the phenyl groups is substituted by an amino group. It is active against a wide range of bacteria, but is mainly employed for its actions against Mycobacterium leprae, being used as part of multidrug regimens in the treatment of all forms of leprosy. DrugBank:DB00250 InChI=1S/C12H12N2O2S/c13-9-1-5-11(6-2-9)17(15,16)12-7-3-10(14)4-8-12/h1-8H,13-14H2 InChIKey=MQJKPEGWNLWLTK-UHFFFAOYSA-N KEGG COMPOUND:80-08-0 KEGG COMPOUND:C07666 KEGG DRUG:D00592 NIST Chemistry WebBook:80-08-0 Nc1ccc(cc1)S(=O)(=O)c1ccc(N)cc1 Patent:FR829926 Wikipedia:Dapsone bis(4-aminophenyl)sulfone dapsona dapsone dapsonum p,p'-diaminodiphenyl sulfone p,p-sulphonylbisbenzamine p,p-sulphonylbisbenzenamine p-aminophenyl sulfone Deferoxamine desferrioxamine B 3131 An acyclic desferrioxamine that has formula C25H48N6O8. Beilstein:2514118 C25H48N6O8 CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN CHEBI:4356 ChemIDplus:70-51-9 DFO Deferoxamin Deferrioxamine Desferrioxamine DrugBank:DB00746 InChI=1S/C25H48N6O8/c1-21(32)29(37)18-9-3-6-16-27-22(33)12-14-25(36)31(39)20-10-4-7-17-28-23(34)11-13-24(35)30(38)19-8-2-5-15-26/h37-39H,2-20,26H2,1H3,(H,27,33)(H,28,34) InChIKey=UBQYURCVBFRUQT-UHFFFAOYSA-N KEGG COMPOUND:C06940 KEGG DRUG:D03670 N'-{5-[acetyl(hydroxy)amino]pentyl}-N-(5-{4-[(5-aminopentyl)(hydroxy)amino]-4-oxobutanamido}pentyl)-N-hydroxybutanediamide Patent:BE609053 Wikipedia:Deferoxamine deferoxamina deferoxamine deferoxaminum deferrioxamine B Lisinopril lisinopril (S)-1-(N(2)-(1-carboxy-3-phenylpropyl)-L-lysyl)-L-proline 29046 A dipeptide that has formula C21H31N3O5. Beilstein:4276619 C21H31N3O5 CHEBI:43750 CHEBI:43755 ChemIDplus:76547-98-3 InChI=1S/C21H31N3O5/c22-13-5-4-9-16(19(25)24-14-6-10-18(24)21(28)29)23-17(20(26)27)12-11-15-7-2-1-3-8-15/h1-3,7-8,16-18,23H,4-6,9-14,22H2,(H,26,27)(H,28,29)/t16-,17-,18-/m0/s1 InChIKey=RLAWWYSOJDYHDC-BZSNNMDCSA-N N(2)-[(1S)-1-carboxy-3-phenylpropyl]-L-lysyl-L-proline NCCCC[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O PDBeChem:LPR Wikipedia:Lisinopril [N2-[(S)-1-CARBOXY-3-PHENYLPROPYL]-L-LYSYL-L-PROLINE lisinopril anhydrous Methotrexate methotrexate 4-amino-10-methylfolic acid 4-amino-N(10)-methylpteroylglutamic acid 6851 A pteridine that has formula C20H22N8O5. Beilstein:70669 C20H22N8O5 CHEBI:44183 CHEBI:44185 CHEBI:6837 CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O ChemIDplus:59-05-2 DrugBank:DB00563 Emtexate InChI=1S/C20H22N8O5/c1-28(9-11-8-23-17-15(24-11)16(21)26-20(22)27-17)12-4-2-10(3-5-12)18(31)25-13(19(32)33)6-7-14(29)30/h2-5,8,13H,6-7,9H2,1H3,(H,25,31)(H,29,30)(H,32,33)(H4,21,22,23,26,27)/t13-/m0/s1 InChIKey=FBOZXECLQNJBKD-ZDUSSCGKSA-N KEGG COMPOUND:59-05-2 KEGG COMPOUND:C01937 KEGG DRUG:D00142 Ledertrexate METHOTREXATE MTX Methotrexate N-(4-{[(2,4-diaminopteridin-6-yl)methyl](methyl)amino}benzoyl)-L-glutamic acid N-[(4-{[(2,4-diaminopteridin-6-yl)methyl](methyl)amino}phenyl)carbonyl]-L-glutamic acid N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid NIST Chemistry WebBook:59-05-2 PDBeChem:MTX Patent:US2512572 Rheumatrex Trexall Wikipedia:Methotrexate methotrexate methotrexatum metotrexato hydroxyurea 5552 An urea that has formula CH4N2O2. CH4N2O2 CHEBI:44420 CHEBI:44423 CHEBI:5816 ChemIDplus:127-07-1 ChemIDplus:1741548 Gmelin:130423 Hydroxycarbamid Hydroxycarbamide Hydroxyharnstoff Hydroxyurea InChI=1S/CH4N2O2/c2-1(4)3-5/h5H,(H3,2,3,4) InChIKey=VSNHCAURESNICA-UHFFFAOYSA-N KEGG COMPOUND:127-07-1 KEGG COMPOUND:C07044 N-HYDROXYUREA N-carbamoylhydroxylamine N-hydroxyurea NC(=O)NO PDBeChem:NHY Wikipedia:Hydroxyurea carbamohydroxamic acid carbamohydroximic acid carbamoyl oxime carbamyl hydroxamate hydrea hydroxycarbamide oxyurea Propofol propofol 2,6-BIS(1-METHYLETHYL)PHENOL 2,6-Diisopropylphenol 2,6-bis(1-methylethyl)phenol 2,6-bis(propan-2-yl)phenol 8782 A phenol resulting from the formal substitution of the hydrogen at the 2 position of 1,3-diisopropylbenzene by a hydroxy group. C12H18O CC(C)c1cccc(C(C)C)c1O CHEBI:44914 CHEBI:44915 CHEBI:8495 ChemIDplus:1866484 ChemIDplus:2078-54-8 Diprivan Disoprivan Disoprofol DrugBank:DB00818 InChI=1S/C12H18O/c1-8(2)10-6-5-7-11(9(3)4)12(10)13/h5-9,13H,1-4H3 InChIKey=OLBCVFGFOZPWHH-UHFFFAOYSA-N KEGG COMPOUND:2078-54-8 KEGG COMPOUND:C07523 KEGG DRUG:D00549 NIST Chemistry WebBook:2078-54-8 PDBeChem:PFL Propofol Rapinovet Wikipedia:Propofol propofol propofolum Pentamidine pentamidine 1,5-bis(4-amidinophenoxy)pentane 4,4'-(1,5-pentanediylbis(oxy))bis-benzenecarboximidamide 4,4'-(pentamethylenedioxy)dibenzamidine 4,4'-Diamidinodiphenoxypentane 4,4'-[pentane-1,5-diylbis(oxy)]dibenzenecarboximidamide 7994 A diether compound consisting of pentane-1,5-diol with both hydroxyls bearing 4-amidinophenyl groups. C19H24N4O2 CHEBI:45077 CHEBI:45081 CHEBI:7976 ChemIDplus:100-33-4 ChemIDplus:3159790 CiteXplore:11438428 CiteXplore:14603035 CiteXplore:15711592 CiteXplore:18971316 CiteXplore:19966562 CiteXplore:22046004 CiteXplore:22093811 CiteXplore:22200378 CiteXplore:22327112 DrugBank:DB00738 InChI=1S/C19H24N4O2/c20-18(21)14-4-8-16(9-5-14)24-12-2-1-3-13-25-17-10-6-15(7-11-17)19(22)23/h4-11H,1-3,12-13H2,(H3,20,21)(H3,22,23) InChIKey=XDRYMKDFEDOLFX-UHFFFAOYSA-N KEGG COMPOUND:100-33-4 KEGG COMPOUND:C07420 KEGG DRUG:D08333 NC(=N)c1ccc(OCCCCCOc2ccc(cc2)C(N)=N)cc1 PDBeChem:PNT Patent:EP975608 Patent:GB507565 Patent:US2006235001 Patent:US2008167296 Patent:US2008214569 Patent:US2394003 Patent:US7115665 Pentamidine Reaxys:3159790 Wikipedia:Pentamidine p,p'-(pentamethylenedioxy)dibenzamidine pentamidine Ritonavir ritonavir 85762 CHEBI:45409 Paclitaxel paclitaxel (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R*,betaS*),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester 4alpha,10beta-bis(acetyloxy)-13alpha-[(2S,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyloxy]-1,7beta-dihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate 56946 5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine A tetracyclic diterpenoid isolated originally from the bark of the Pacific yew tree, Taxus brevifolia. It is a mitotic inhibitor used in cancer chemotherapy. Note that the use of the former generic name 'taxol' is now limited, as Taxol is a registered trade mark. C47H51NO14 CHEBI:45862 CHEBI:45863 CHEBI:7887 ChemIDplus:33069-62-4 InChI=1S/C47H51NO14/c1-25-31(60-43(56)36(52)35(28-16-10-7-11-17-28)48-41(54)29-18-12-8-13-19-29)23-47(57)40(61-42(55)30-20-14-9-15-21-30)38-45(6,32(51)22-33-46(38,24-58-33)62-27(3)50)39(53)37(59-26(2)49)34(25)44(47,4)5/h7-21,31-33,35-38,40,51-52,57H,22-24H2,1-6H3,(H,48,54)/t31-,32-,33+,35-,36+,37+,38-,40-,45+,46-,47+/m0/s1 InChIKey=RCINICONZNJXQF-MZXODVADSA-N KEGG COMPOUND:33069-62-4 KEGG COMPOUND:C07394 KEGG DRUG:D00491 PDBeChem:TA1 Paclitaxel TAXOL Taxol A Wikipedia:Paclitaxel [H][C@]12[C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C Fluconazole fluconazole 2,4-difluoro-alpha,alpha-bis(1H-1,2,4-triazol-1-ylmethyl)benzyl alcohol 2-(2,4-DIFLUOROPHENYL)-1,3-DI(1H-1,2,4-TRIAZOL-1-YL)PROPAN-2-OL 2-(2,4-difluorophenyl)-1,3-bis-(1H-1,2,4-triazol-1-yl)propan-2-ol 4450 A triazole that has formula C13H12F2N6O. Beilstein:4269710 Biozolene C13H12F2N6O CHEBI:46079 CHEBI:46081 CHEBI:5099 ChemIDplus:86386-73-4 Diflucan Elazor Fluconazole InChI=1S/C13H12F2N6O/c14-10-1-2-11(12(15)3-10)13(22,4-20-8-16-6-18-20)5-21-9-17-7-19-21/h1-3,6-9,22H,4-5H2 InChIKey=RFHAOTPXVQNOHP-UHFFFAOYSA-N KEGG DRUG:D00322 OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F PDBeChem:TPF Triflucan Wikipedia:Fluconazole vardenafil 2-{2-ETHOXY-5-[(4-ETHYLPIPERAZIN-1-YL)SULFONYL]PHENYL}-5-METHYL-7-PROPYLIMIDAZO[5,1-F][1,2,4]TRIAZIN-4(1H)-ONE 2-{2-ethoxy-5-[(4-ethylpiperazin-1-yl)sulfonyl]phenyl}-5-methyl-7-propylimidazo[5,1-f][1,2,4]triazin-4(1H)-one 306674 Beilstein:9967331 C23H32N6O4S CCCc1nc(C)c2n1[nH]c(nc2=O)-c1cc(ccc1OCC)S(=O)(=O)N1CCN(CC)CC1 CHEBI:46295 ChemIDplus:224785-90-4 CiteXplore:19949666 CiteXplore:19959201 CiteXplore:20859794 CiteXplore:20925442 CiteXplore:21209618 CiteXplore:21235726 CiteXplore:21290241 CiteXplore:21427994 CiteXplore:21496853 CiteXplore:21548209 CiteXplore:21552528 CiteXplore:21771280 CiteXplore:21883954 CiteXplore:21943935 CiteXplore:21950284 DrugBank:DB00862 InChI=1S/C23H32N6O4S/c1-5-8-20-24-16(4)21-23(30)25-22(26-29(20)21)18-15-17(9-10-19(18)33-7-3)34(31,32)28-13-11-27(6-2)12-14-28/h9-10,15H,5-8,11-14H2,1-4H3,(H,25,26,30) InChIKey=SECKRCOLJRRGGV-UHFFFAOYSA-N KEGG DRUG:D08668 Levitra PDBeChem:VDN Reaxys:9967331 The sulfonamide resulting from formal condensation of the sulfo group of 4-ethoxy-3-(5-methyl-7-propylimidazo[5,1-f][1,2,4]triazin-4(1H)-one-2-yl)benzenesulfonic acid and the secondary amino group of 4-ethylpiperazine. Wikipedia:Vardenafil 5-fluorouracil Fluorouracil 4492 5-FU 5-Fluoropyrimidine-2,4-dione 5-Fluorouracil 5-fluoropyrimidine-2,4(1H,3H)-dione 5-fluorouracil An organofluorine compound that has formula C4H3FN2O2. Beilstein:127172 C4H3FN2O2 CHEBI:2054 CHEBI:46343 CHEBI:46345 ChemIDplus:51-21-8 Fc1c[nH]c(=O)[nH]c1=O Fluorouracil InChI=1S/C4H3FN2O2/c5-2-1-6-4(9)7-3(2)8/h1H,(H2,6,7,8,9) InChIKey=GHASVSINZRGABV-UHFFFAOYSA-N KEGG COMPOUND:51-21-8 KEGG COMPOUND:C07649 Wikipedia:Fluorouracil Ganciclovir ganciclovir 2-(6-Amino-purin-9-ylmethoxy)-propane-1,3-diol 2-Amino-9-(2-hydroxy-1-hydroxymethyl-ethoxymethyl)-1,9-dihydro-purin-6-one 2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-1H-purin-6(9H)-one 2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-3H-purin-6(9H)-one 2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-9H-purin-6-ol 2-amino-9-(2-hydroxy-1-hydroxymethylethoxymethyl)-6,9-dihydro-1H-6-purinone 2-amino-9-{[(1,3-dihydroxypropan-2-yl)oxy]methyl}-1,9-dihydro-6H-purin-6-one 4678 9-((2-Hydroxy-1-(hydroxymethyl)ethoxy)methyl)guanine 9-[(1,3-dihydroxy-2-propoxy)methyl]guanine Beilstein:3654487 C9H13N5O4 CHEBI:465284 CHEBI:5273 ChEMBL:10197958 ChEMBL:10377226 ChEMBL:10411487 ChEMBL:10447945 ChEMBL:10560739 ChEMBL:10691698 ChEMBL:10882370 ChEMBL:10882372 ChEMBL:10882374 ChEMBL:10882375 ChEMBL:10888336 ChEMBL:10966740 ChEMBL:10966745 ChEMBL:10999475 ChEMBL:11229780 ChEMBL:11262090 ChEMBL:11412988 ChEMBL:11454465 ChEMBL:11472207 ChEMBL:11495586 ChEMBL:11585457 ChEMBL:11677126 ChEMBL:11708924 ChEMBL:11708929 ChEMBL:11754587 ChEMBL:11814776 ChEMBL:11858989 ChEMBL:11985471 ChEMBL:12408716 ChEMBL:12459010 ChEMBL:12723951 ChEMBL:1310744 ChEMBL:1319491 ChEMBL:1323678 ChEMBL:14521407 ChEMBL:14584954 ChEMBL:14643328 ChEMBL:14643358 ChEMBL:14736238 ChEMBL:15027877 ChEMBL:15081019 ChEMBL:15481985 ChEMBL:15509173 ChEMBL:15509174 ChEMBL:15509175 ChEMBL:15509176 ChEMBL:15615545 ChEMBL:15634003 ChEMBL:15658858 ChEMBL:15658861 ChEMBL:15658873 ChEMBL:15689173 ChEMBL:15745823 ChEMBL:15801851 ChEMBL:16134946 ChEMBL:16392791 ChEMBL:16392824 ChEMBL:16420056 ChEMBL:16480257 ChEMBL:1652016 ChEMBL:16759112 ChEMBL:16814545 ChEMBL:17004726 ChEMBL:17043128 ChEMBL:17092728 ChEMBL:17161946 ChEMBL:17181158 ChEMBL:17181162 ChEMBL:17188402 ChEMBL:17239594 ChEMBL:17298047 ChEMBL:17329103 ChEMBL:17402726 ChEMBL:17434304 ChEMBL:17438061 ChEMBL:17513108 ChEMBL:17518459 ChEMBL:17539622 ChEMBL:17622128 ChEMBL:17672445 ChEMBL:17869124 ChEMBL:17948980 ChEMBL:17960926 ChEMBL:18082410 ChEMBL:1849998 ChEMBL:2157013 ChEMBL:2160539 ChEMBL:2163453 ChEMBL:2163454 ChEMBL:2165163 ChEMBL:2175356 ChEMBL:2329551 ChEMBL:2329561 ChEMBL:2391689 ChEMBL:2500527 ChEMBL:2544723 ChEMBL:2822928 ChEMBL:2826784 ChEMBL:2840500 ChEMBL:2842505 ChEMBL:2846837 ChEMBL:2848125 ChEMBL:2913300 ChEMBL:2989523 ChEMBL:2993615 ChEMBL:3009811 ChEMBL:3016263 ChEMBL:3871860 ChEMBL:465284 ChEMBL:7562929 ChEMBL:7562946 ChEMBL:7562947 ChEMBL:7752205 ChEMBL:7877148 ChEMBL:7932543 ChEMBL:8071942 ChEMBL:8176714 ChEMBL:8254613 ChEMBL:8394933 ChEMBL:8632412 ChEMBL:8709116 ChEMBL:8765514 ChEMBL:8784444 ChEMBL:8784445 ChEMBL:8941388 ChEMBL:9046339 ChEMBL:9057866 ChEMBL:9057867 ChEMBL:9057868 ChEMBL:9216836 ChEMBL:9438017 ChEMBL:9548814 ChEMBL:9575044 ChEMBL:9836613 ChEMBL:9836626 ChEMBL:9871553 ChEMBL:9925738 ChEMBL:9934470 ChEMBL:9934471 ChemIDplus:82410-32-0 DrugBank:82410-32-0 DrugBank:DB01004 GA2 Ganciclovir Ganciclovir is an antiviral drug used to treat or prevent AIDS-related cytomegalovirus infections. InChI=1S/C9H13N5O4/c10-9-12-7-6(8(17)13-9)11-3-14(7)4-18-5(1-15)2-16/h3,5,15-16H,1-2,4H2,(H3,10,12,13,17) InChIKey=IRSCQMHQWWYFCW-UHFFFAOYSA-N KEGG COMPOUND:82410-32-0 KEGG COMPOUND:C07019 KEGG DRUG:82410-32-0 KEGG DRUG:D00333 Nc1nc2n(COC(CO)CO)cnc2c(=O)[nH]1 Patent:US4355032 Wikipedia:Ganciclovir ganciclovir ganciclovirum gancyclovir Disulfiram disulfiram 1,1',1'',1'''-[disulfanediylbis(carbonothioylnitrilo)]tetraethane 1,1'-dithiobis(N,N-diethylthioformamide) 3554 An organic disulfide that has formula C10H20N2S4. Antabuse (TN) C10H20N2S4 CCN(CC)C(=S)SSC(=S)N(CC)CC CHEBI:4659 ChemIDplus:97-77-8 Disulfiram InChI=1S/C10H20N2S4/c1-5-11(6-2)9(13)15-16-10(14)12(7-3)8-4/h5-8H2,1-4H3 InChIKey=AUZONCFQVSMFAP-UHFFFAOYSA-N KEGG COMPOUND:97-77-8 KEGG COMPOUND:C01692 KEGG DRUG:D00131 N,N,N',N'-tetraethylthiuram disulfide NIST Chemistry WebBook:97-77-8 Wikipedia:Disulfiram bis(diethylthiocarbamoyl) disulfide tetraethylthioperoxydicarbonic diamide tetraethylthiuram disulfide tetraethylthiuram disulphide benzoxazole CHEBI:46700 Compounds based on a fused 1,2- or 1,3-oxazole and benzene bicyclic ring skeleton. benzoxazoles hidden amide CHEBI:46754 Compounds in which an acyclic carbonyl group is bonded to one or two nitrogen atoms of a ring or ring system. hidden amides dipeptide Any molecule that contains two amino-acid residues connected by peptide linkages. C4H6N2O3R2 CHEBI:23835 CHEBI:4634 CHEBI:46761 Dipeptid Dipeptide KEGG COMPOUND:C00107 dipeptides diether CHEBI:46786 Organic compounds having two ether functional groups. diether diethers N-acylpiperazine CHEBI:46844 N-acylpiperazines N-alkylpiperazine CHEBI:46845 N-alkylpiperazines N-arylpiperazine CHEBI:46848 N-arylpiperazines indolyl carboxylic acid CHEBI:46867 indolyl carboxylic acids imidazotriazine CHEBI:46906 imidazotriazines imidazopyridine CHEBI:46908 imidazopyridines N-sulfonylpiperazine CHEBI:46918 N-sulfonylpiperazines capsaicinoid A family of aromatic fatty amides produced as secondary metabolites by chilli peppers. CHEBI:46931 capsaicinoids anthracenes CHEBI:46955 Compounds containing an anthracene skeleton. tetrahydrofuranol CHEBI:47017 tetrahydrofuranols monohydroxytetrahydrofuran CHEBI:47018 monohydroxytetrahydrofurans Imipramine imipramine 10,11-dihydro-N,N-dimethyl-5H-dibenz[b,f]azepine-5-propanamine 3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethylpropan-1-amine 3-(5H-DIBENZO[B,F]AZEPIN-5-YL)-N,N-DIMETHYLPROPAN-1-AMINE 5-[3-(dimethylamino)propyl]-10,11-dihydro-5H-dibenz[b,f]azepine 5691 A dibenzoazepine that has formula C19H24N2. Antideprin Beilstein:256892 C19H24N2 CHEBI:47498 CHEBI:47499 CHEBI:5881 CN(C)CCCN1c2ccccc2CCc2ccccc12 ChemIDplus:50-49-7 DrugBank:DB00458 Gmelin:1572523 Imipramin Imipramine InChI=1S/C19H24N2/c1-20(2)14-7-15-21-18-10-5-3-8-16(18)12-13-17-9-4-6-11-19(17)21/h3-6,8-11H,7,12-15H2,1-2H3 InChIKey=BCGWQEUPMDMJNV-UHFFFAOYSA-N Irmin KEGG COMPOUND:50-49-7 KEGG COMPOUND:C07049 Melipramine N-(gamma-dimethylaminopropyl)iminodibenzyl NIST Chemistry WebBook:50-49-7 PDBeChem:IXX Patent:US2554736 Wikipedia:Imipramine imipramine imipraminum imizine acetate ester Acetic ester Acetyl ester Any carboxylic ester where the carboxylic acid component is acetic acid. C2H3O2R CHEBI:13244 CHEBI:13799 CHEBI:22189 CHEBI:2406 CHEBI:47622 KEGG COMPOUND:C01883 acetate acetate esters acetates acetyl ester acetyl esters aminoglycoside CHEBI:47779 aminoglycosides Clomipramine clomipramine 2597 3-(3-CHLORO-5H-DIBENZO[B,F]AZEPIN-5-YL)-N,N-DIMETHYLPROPAN-1-AMINE 3-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethyl-1-propanamine 3-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethylpropan-1-amine 3-chloroimipramine A dibenzoazepine that is 10,11-dihydro-5H-dibenzo[b,f]azepine which is substituted by chlorine at position 3 and in which the hydrogen attached to the nitrogen is replaced by a 3-(dimethylamino)propyl group. One of the more sedating tricyclic antidepressants, it is used as the hydrochloride salt for the treatment of depression as well as obsessive-compulsive disorder and phobias. C19H23ClN2 CHEBI:3754 CHEBI:47359 CHEBI:47780 CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc12 ChemIDplus:1323477 ChemIDplus:303-49-1 CiteXplore:12007764 CiteXplore:12084414 CiteXplore:16085036 CiteXplore:17471183 CiteXplore:19810911 Clomipramine DrugBank:DB01242 G 34586 InChI=1S/C19H23ClN2/c1-21(2)12-5-13-22-18-7-4-3-6-15(18)8-9-16-10-11-17(20)14-19(16)22/h3-4,6-7,10-11,14H,5,8-9,12-13H2,1-2H3 InChIKey=GDLIGKIOYRNHDA-UHFFFAOYSA-N KEGG COMPOUND:303-49-1 KEGG COMPOUND:C06918 NIST Chemistry WebBook:303-49-1 PDBeChem:CXX Patent:CH371799 Patent:US3467650 Reaxys:1323477 Wikipedia:Clomipramine chlorimipramine monochlorimipramine Desipramine desipramine 3-(10,11-DIHYDRO-5H-DIBENZO[B,F]AZEPIN-5-YL)-N-METHYLPROPAN-1-AMINE 3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N-methylpropan-1-amine 3247 5-(gamma-methylaminopropyl)iminodibenzyl A dibenzoazepine that has formula C18H22N2. C18H22N2 CHEBI:4448 CHEBI:47393 CHEBI:47781 CNCCCN1c2ccccc2CCc2ccccc12 ChemIDplus:1432747 ChemIDplus:50-47-5 DMI Desipramin Desipramine DrugBank:DB01151 InChI=1S/C18H22N2/c1-19-13-6-14-20-17-9-4-2-7-15(17)11-12-16-8-3-5-10-18(16)20/h2-5,7-10,19H,6,11-14H2,1H3 InChIKey=HCYAFALTSJYZDH-UHFFFAOYSA-N KEGG COMPOUND:50-47-5 KEGG COMPOUND:C06943 KEGG DRUG:D07791 N-(3-methylaminopropyl)iminobibenzyl NIST Chemistry WebBook:50-47-5 PDBeChem:DSM Wikipedia:Desipramine demethylimipramine desipramina desipramine desipraminum desmethylimipramine monodemethylimipramine norimipramine 3-oxo steroid 3-Oxosteroid 3-oxo steroids 3-oxosteroid 3-oxosteroids CHEBI:13607 CHEBI:1653 CHEBI:20182 CHEBI:47788 KEGG COMPOUND:C01876 dibenzoazepine CHEBI:47804 dibenzazepine dibenzoazepine dibenzoazepines cefepime (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-[(1-methylpyrrolidinium-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate 20481 7beta-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido]-3-[(1-methylpyrrolidinium-1-yl)methyl]-3,4-didehydrocepham-4-carboxylate A cephalosporin bearing (1-methylpyrrolidinium-1-yl)methyl and (2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido groups at positions 3 and 7, respectively, of the cephem skeleton. Beilstein:7453587 C19H24N6O5S2 CHEBI:3486 CHEBI:473919 CHEBI:478164 Cefepime ChEMBL:473919 ChEMBL:478164 CiteXplore:11084674 CiteXplore:11179650 CiteXplore:11191931 CiteXplore:11260566 CiteXplore:11280610 CiteXplore:11303846 CiteXplore:11306793 CiteXplore:11328792 CiteXplore:11431192 CiteXplore:11442796 CiteXplore:11864944 CiteXplore:11910959 CiteXplore:11964152 CiteXplore:12848746 CiteXplore:14628573 CiteXplore:14642333 CiteXplore:15303411 CiteXplore:15494381 CiteXplore:15830071 CiteXplore:15978309 CiteXplore:15980347 CiteXplore:16207962 CiteXplore:16650951 CiteXplore:16705389 CiteXplore:16930923 CiteXplore:17042189 CiteXplore:17214092 CiteXplore:17323865 CiteXplore:17448937 CiteXplore:17625777 CiteXplore:18025111 CiteXplore:18154532 CiteXplore:18651542 CiteXplore:18673128 CiteXplore:18717040 CiteXplore:19053894 CiteXplore:19304881 CiteXplore:21425867 DrugBank:DB01413 InChI=1S/C19H24N6O5S2/c1-25(5-3-4-6-25)7-10-8-31-17-13(16(27)24(17)14(10)18(28)29)22-15(26)12(23-30-2)11-9-32-19(20)21-11/h9,13,17H,3-8H2,1-2H3,(H3-,20,21,22,26,28,29)/b23-12-/t13-,17-/m1/s1 InChIKey=HVFLCNVBZFFHBT-ZKDACBOMSA-N KEGG COMPOUND:88040-23-7 KEGG COMPOUND:C08111 KEGG DRUG:D02376 Patent:DE3307550 Patent:US4406899 Reaxys:7453587 Wikipedia:Cefepime [H][C@]12SCC(C[N+]3(C)CCCC3)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\c1csc(N)n1)C([O-])=O cefepima cefepime cefepime cefepimum Enalapril enalapril (S)-1-(N-(1-(ethoxycarbonyl)-3-phenylpropyl)-L-alanyl)-L-proline (S)-1-{(S)-2-[1-((S)-Ethoxycarbonyl)-3-phenyl-propylamino]-propionyl}-pyrrolidine-2-carboxylic acid 1-(N-((S)-1-carboxy-3-phenylpropyl)-L-alanyl)-L-proline 1'-ethyl ester 3827 A dicarboxylic acid monoester that is ethyl 4-phenylbutanoate in which a hydrogen alpha to the carboxy group is substituted by the amino group of L-alanyl-L-proline (S-configuration). Beilstein:3657467 C20H28N2O5 CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O CHEBI:116847 CHEBI:4784 ChEMBL:10669559 ChEMBL:116847 ChemIDplus:75847-73-3 DrugBank:DB00584 ENALAPRIL Enalapril InChI=1S/C20H28N2O5/c1-3-27-20(26)16(12-11-15-8-5-4-6-9-15)21-14(2)18(23)22-13-7-10-17(22)19(24)25/h4-6,8-9,14,16-17,21H,3,7,10-13H2,1-2H3,(H,24,25)/t14-,16-,17-/m0/s1 InChIKey=GBXSMTUPTTWBMN-XIRDDKMYSA-N KEGG COMPOUND:75847-73-3 KEGG COMPOUND:C06977 KEGG DRUG:D07892 N-[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]-L-alanyl-L-proline Patent:EP12401 Patent:US4374829 Wikipedia:Enalapril enalapril enalaprila enalaprilum ureas CHEBI:27220 CHEBI:36947 CHEBI:47857 urea derivatives 3-oxo monocarboxylic acid 3-Oxo acid 3-oxo monocarboxylic acids C3H2O3R2 CHEBI:13600 CHEBI:1619 CHEBI:35949 CHEBI:47881 KEGG COMPOUND:C01656 3-oxo Delta(4)-steroid 3-Oxo-delta4-steroid 3-oxo Delta(4)-steroids 3-oxo-Delta(4)-steroid CHEBI:13604 CHEBI:1626 CHEBI:20157 CHEBI:47909 KEGG COMPOUND:C00619 2',3'-dideoxyribonucleoside 2',3'-dideoxyribonucleosides CHEBI:47945 vinorelbine 39541 A vinca alkaloid with a norvinblastine skeleton. Beilstein:9035861 C45H54N4O8 CHEBI:480999 ChEMBL:480999 ChemIDplus:71486-22-1 DrugBank:71486-22-1 DrugBank:DB00361 InChI=1S/C45H54N4O8/c1-8-27-19-28-22-44(40(51)55-6,36-30(25-48(23-27)24-28)29-13-10-11-14-33(29)46-36)32-20-31-34(21-35(32)54-5)47(4)38-43(31)16-18-49-17-12-15-42(9-2,37(43)49)39(57-26(3)50)45(38,53)41(52)56-7/h10-15,19-21,28,37-39,46,53H,8-9,16-18,22-25H2,1-7H3/t28-,37-,38+,39+,42+,43+,44-,45+/m0/s1 InChIKey=GBABOYUKABKIAF-GHYRFKGUSA-N KEGG DRUG:71486-22-1 KEGG DRUG:D08680 Nor-5'-anhydrovinblastine Patent:JP8031096 Patent:US4307100 [H][C@]12CN(CC(CC)=C1)Cc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@]1([H])[C@@](O)([C@H](OC(C)=O)[C@]3(CC)C=CCN4CC[C@]21[C@]34[H])C(=O)OC methyl (2beta,3beta,4beta,5alpha,12beta,19alpha)-4-acetoxy-15-[(6R,8S)-4-ethyl-8-(methoxycarbonyl)-1,3,6,7,8,9-hexahydro-2,6-methanoazecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidine-3-carboxylate vinorelbina vinorelbine vinorelbinum sulfamate ester CHEBI:48199 sulfamate esters disulfide CHEBI:48343 Compounds of structure RSSR'. disulfides biphenylyltetrazole CHEBI:48420 pyrimidine 2',3'-dideoxyribonucleoside CHEBI:48441 pyrimidine 2',3'-dideoxyribonucleosides purine 2',3'-dideoxyribonucleoside CHEBI:48442 purine 2',3'-dideoxyribonucleosides pyrimidinethione CHEBI:48546 pyrimidinethiones hydroxypiperidine CHEBI:48590 hydroxypiperidines piperidinecarboxamide CHEBI:48592 piperidinecarboxamides pyranoindolizinoquinoline CHEBI:48626 pyranoindolizinoquinolines benzothiazepine CHEBI:48684 benzothiazepines Ethambutol ethambutol (+)-2,2'-(ethylenediimino)di-1-butanol (+)-N,N'-bis(1-(hydroxymethyl)propyl)ethylenediamine (+)-S,S-ethambutol (+)-ethambutol (2S,2'S)-2,2'-(ethane-1,2-diyldiimino)dibutan-1-ol (2S,7S)-2,7-diethyl-3,6-diazaoctane-1,8-diol (S,S)-ethambutol 4110 Beilstein:6312870 C10H24N2O2 CC[C@@H](CO)NCCN[C@@H](CC)CO CHEBI:133410 CHEBI:4877 CHEBI:659237 CHEBI:678172 ChEMBL:10649975 ChEMBL:10891117 ChEMBL:10966749 ChEMBL:12182855 ChEMBL:133410 ChEMBL:14695841 ChEMBL:14698152 ChEMBL:15225698 ChEMBL:16005211 ChEMBL:16759086 ChEMBL:16870429 ChEMBL:17210775 ChEMBL:17239593 ChEMBL:17276683 ChEMBL:17315960 ChEMBL:17331717 ChEMBL:17562368 ChEMBL:17851083 ChEMBL:17888665 ChEMBL:19524332 ChEMBL:19648006 ChEMBL:3934384 ChEMBL:659237 ChEMBL:678172 ChemIDplus:74-55-5 DrugBank:DB00330 EMB Ethambutol Ethane-1,2-diamine in which one hydrogen attached to each of the nitrogens is sutstituted by a 1-hydroxybutan-2-yl group (S,S-configuration). It is a bacteriostatic antimycobacterial drug, effective against Mycobacterium tuberculosis and some other mycobacteria. It is used (as the dihydrochloride salt) in combination with other antituberculous drugs in the treatment of pulmonary and extrapulmonary tuberculosis; resistant strains of M. tuberculosis are readily produced if ethambutol is used alone. InChI=1S/C10H24N2O2/c1-3-9(7-13)11-5-6-12-10(4-2)8-14/h9-14H,3-8H2,1-2H3/t9-,10-/m0/s1 InChIKey=AEUTYOVWOVBAKS-UWVGGRQHSA-N KEGG COMPOUND:74-55-5 KEGG COMPOUND:C06984 KEGG DRUG:D07925 S,S-Ethambutol Wikipedia:Ethambutol etambutol ethambutol ethambutolum benzothiadiazole CHEBI:48864 benzothiadiazoles thiadiazolidine CHEBI:48865 thiadiazolidines thiazoles CHEBI:48901 1,2-thiazole 1,2-thiazoles CHEBI:48902 isothiazoles Etidronate etidronic acid (1-Hydroxyethylene)diphosphonic acid (1-Hydroxyethylidene)bis(phosphonic acid) (1-Hydroxyethylidene)bisphosphonic acid (1-Hydroxyethylidene)diphosphonic acid (1-hydroxyethane-1,1-diyl)bis(phosphonic acid) (Hydroxyethylidene)diphosphonic acid 1,1,1-Ethanetriol diphosphonate 1-Hydroxy-1,1-diphosphonoethane 1-Hydroxyethane-1,1-bisphosphonic acid 1-Hydroxyethane-1,1-diphosphonate 1-Hydroxyethane-1,1-diphosphonic acid 1-Hydroxyethanediphosphonic acid 1-Hydroxyethylidene-1,1-bisphosphonate 1-Hydroxyethylidene-1,1-diphosphonic acid 42682 A phosphonic acid consisting of (ethane-1,1-diyl)bis(phosphonic acid) having a hydroxy substituent at the 1-position. Inhibits formation, growth, and dissolution of hydroxyapatite crystals by chemisorption to calcium phosphate surfaces Acetodiphosphonic acid C2H8O7P2 CC(O)(P(O)(O)=O)P(O)(O)=O CHEBI:4907 CHEBI:63588 ChemIDplus:2809-21-4 CiteXplore:10385693 CiteXplore:17157266 CiteXplore:17214981 CiteXplore:18313802 DrugBank:DB01077 EHDP Ethane-1-hydroxy-1,1-diphosphonate Ethane-1-hydroxy-1,1-diphosphonic acid Etidronsaeure HEDP Hydroxyethanediphosphonic acid InChI=1S/C2H8O7P2/c1-2(3,10(4,5)6)11(7,8)9/h3H,1H3,(H2,4,5,6)(H2,7,8,9) InChIKey=DBVJJBKOTRCVKF-UHFFFAOYSA-N KEGG COMPOUND:2809-21-4 KEGG COMPOUND:C07736 KEGG DRUG:D02373 Oxyethylidenediphosphonic acid Patent:US3159581 Reaxys:1789291 Wikipedia:Etidronate acide etidronique acido etidronico acidum etidronicum ethane-1-hydroxy-1,1-bisphosphonic acid etidronate etidronic acid Didanosine didanosine 2',3'-dideoxyinosine 2,3-dideoxyinosine 3364 9-((2R,5S)-5-(hydroxymethyl)-tetrahydrofuran-2-yl)-1H-purin-6(9H)-one 9-((2R,5S)-5-Hydroxymethyl-tetrahydro-furan-2-yl)-1,9-dihydro-purin-6-one 9-((2S,5R)-5-Hydroxymethyl-tetrahydro-furan-2-yl)-9H-purin-6-ol 9-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1,9-dihydro-6H-purin-6-one A purine 2',3'-dideoxyribonucleoside that is inosine in which the hydroxy groups at both the 2' and the 3' positions on the sugar moiety have been replaced by hydrogen. Beilstein:3619529 C10H12N4O3 CHEBI:158219 CHEBI:39738 CHEBI:4516 CHEBI:475381 CHEBI:490877 CHEBI:668806 ChEMBL:10386939 ChEMBL:158219 ChEMBL:1619614 ChEMBL:17046264 ChEMBL:475381 ChEMBL:490877 ChEMBL:668806 ChemIDplus:69655-05-6 CiteXplore:18549801 DDI Didanosine DrugBank:DB00900 InChI=1S/C10H12N4O3/c15-3-6-1-2-7(17-6)14-5-13-8-9(14)11-4-12-10(8)16/h4-7,15H,1-3H2,(H,11,12,16)/t6-,7+/m0/s1 InChIKey=BXZVVICBKDXVGW-NKWVEPMBSA-N KEGG COMPOUND:69655-05-6 KEGG COMPOUND:C06953 KEGG DRUG:D00296 OC[C@@H]1CC[C@@H](O1)n1cnc2c1nc[nH]c2=O PDBeChem:2DI Patent:EP206497 Wikipedia:Didanosine ddI ddIno didanosina didanosine didanosinum dideoxyinosine Etoposide etoposide (-)-etoposide (5S,5aR,8aR,9R)-9-(4-hydroxy-3,5-dimethoxyphenyl)-8-oxo-5,5a,6,8,8a,9-hexahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxol-5-yl 4,6-O-[(1R)-ethylidene]-beta-D-glucopyranoside 4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside) 4-demethylepipodophyllotoxin beta-D-ethylideneglucoside 4179 9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-d)-1,3-dioxol-6(5aH)-one A beta-D-glucoside that has formula C29H32O13. C29H32O13 CHEBI:4911 ChemIDplus:33419-42-0 DrugBank:DB00773 Eposin Etopophos Etoposide Etoposido InChI=1S/C29H32O13/c1-11-36-9-20-27(40-11)24(31)25(32)29(41-20)42-26-14-7-17-16(38-10-39-17)6-13(14)21(22-15(26)8-37-28(22)33)12-4-18(34-2)23(30)19(5-12)35-3/h4-7,11,15,20-22,24-27,29-32H,8-10H2,1-3H3/t11-,15+,20-,21-,22+,24-,25-,26-,27-,29+/m1/s1 InChIKey=VJJPUSNTGOMMGY-MRVIYFEKSA-N KEGG COMPOUND:33419-42-0 KEGG COMPOUND:C01576 KEGG DRUG:D00125 Lastet Patent:US3524844 Toposar VP-16 Vepesid Wikipedia:Etoposide [H][C@]12COC(=O)[C@]1([H])[C@H](c1cc(OC)c(O)c(OC)c1)c1cc3OCOc3cc1[C@H]2O[C@@H]1O[C@@H]2CO[C@@H](C)O[C@H]2[C@H](O)[C@H]1O etoposide etoposidum trans-Etoposide dopa (+-)-3-(3,4-dihydroxyphenyl)alanine (+-)-dopa (R,S)-dopa 2-amino-3-(3,4-dihydroxyphenyl)propanoic acid 3',4'-dihydroxyphenylalanine 3-hydroxy-DL-tyrosine 3-hydroxytyrosine A hydroxyphenylalanine that has formula C9H11NO4. Beilstein:1462084 C9H11NO4 CHEBI:49168 ChemIDplus:63-84-3 DL-3,4-dopa DL-beta-(3,4-dihydroxyphenyl)alanine DL-dihydroxyphenylalanine DL-dioxyphenylalanine Gmelin:51382 InChI=1S/C9H11NO4/c10-6(9(13)14)3-5-1-2-7(11)8(12)4-5/h1-2,4,6,11-12H,3,10H2,(H,13,14) InChIKey=WTDRDQBEARUVNC-UHFFFAOYSA-N NC(Cc1ccc(O)c(O)c1)C(O)=O NIST Chemistry WebBook:63-84-3 beta-(3,4-dihydroxyphenyl)-DL-alpha-alanine dl-beta-(3,4-dihydroxyphenyl)-alpha-alanine dopa exemestane 258494 6-methyleneandrosta-1,4-diene-3,17-dione 6-methylideneandrosta-1,4-diene-3,17-dione Androsta-1,4-diene-3,17-dione in which the hydrogens at position 6 are replaced by a double bond to a methylene group.a selective inhibitor of the aromatase (oestrogen synthase) system, it is used in the treatment of advanced breast cancer. C20H24O2 CHEBI:4953 ChemIDplus:107868-30-4 CiteXplore:10882163 DrugBank:DB00990 Exemestane InChI=1S/C20H24O2/c1-12-10-14-15-4-5-18(22)20(15,3)9-7-16(14)19(2)8-6-13(21)11-17(12)19/h6,8,11,14-16H,1,4-5,7,9-10H2,2-3H3/t14-,15-,16-,19+,20-/m0/s1 InChIKey=BFYIZQONLCFLEV-DAELLWKTSA-N KEGG COMPOUND:107868-30-4 KEGG COMPOUND:C08162 KEGG DRUG:D00963 Wikipedia:Exemestane [H][C@@]12CC(=C)C3=CC(=O)C=C[C@]3(C)[C@@]1([H])CC[C@]1(C)C(=O)CC[C@@]21[H] exemestane exemestano exemestanum Indomethacin indomethacin 1-(p-chlorobenzoyl)-5-methoxy-2-methylindole-3-acetic acid 5781 An indole-3-acetic acid that has formula C19H16ClNO4. Beilstein:497341 C19H16ClNO4 CHEBI:49660 CHEBI:49662 CHEBI:5918 COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(O)=O)c2c1 ChemIDplus:53-86-1 Gmelin:1446006 INDOMETHACIN InChI=1S/C19H16ClNO4/c1-11-15(10-18(22)23)16-9-14(25-2)7-8-17(16)21(11)19(24)12-3-5-13(20)6-4-12/h3-9H,10H2,1-2H3,(H,22,23) InChIKey=CGIGDMFJXJATDK-UHFFFAOYSA-N Indocin Indometacin Indomethacin KEGG COMPOUND:53-86-1 KEGG COMPOUND:C01926 KEGG DRUG:D00141 NIST Chemistry WebBook:53-86-1 PDBeChem:IMN Wikipedia:Indomethacin [1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]acetic acid organic amino compound A compound formally derived from ammonia by replacing one, two or three hydrogen atoms by organyl groups. CHEBI:50047 organic amino compounds dihydropyridine CHEBI:50075 dihydropyridine dihydropyridines Selegiline selegiline 9639 A phenethylamine alkaloid that has formula C13H17N. Beilstein:2092580 C13H17N CC(Cc1ccccc1)N(C)CC#C CHEBI:50217 InChI=1S/C13H17N/c1-4-10-14(3)12(2)11-13-8-6-5-7-9-13/h1,5-9,12H,10-11H2,2-3H3 InChIKey=MEZLKOACVSPNER-UHFFFAOYSA-N N-methyl-N-(1-methyl-2-phenylethyl)prop-2-yn-1-amine selegilina selegiline selegilinum 6-methylprednisolone (11beta)-11,17,21-trihydroxy-6-methylpregna-1,4-diene-3,20-dione 11beta,17,21-trihydroxy-6-methylpregna-1,4-diene-3,20-dione A 3-oxo steroid that has formula C22H30O5. Beilstein:7113955 C22H30O5 CHEBI:50366 InChI=1S/C22H30O5/c1-12-8-14-15-5-7-22(27,18(26)11-23)21(15,3)10-17(25)19(14)20(2)6-4-13(24)9-16(12)20/h4,6,9,12,14-15,17,19,23,25,27H,5,7-8,10-11H2,1-3H3/t12?,14-,15-,17-,19+,20-,21-,22-/m0/s1 InChIKey=VHRSUDSXCMQTMA-UWKORSIYSA-N [H][C@@]12CC(C)C3=CC(=O)C=C[C@]3(C)[C@@]1([H])[C@@H](O)C[C@@]1(C)[C@@]2([H])CC[C@]1(O)C(=O)CO taxane diterpenoid CHEBI:50367 taxane diterpenoid taxane diterpenoids desferrioxamine CHEBI:50453 acyclic desferrioxamine CHEBI:50454 thiocarbonyl compound Any compound containing the thiocarbonyl group, C=S. CHEBI:50492 thiocarbonyl compounds Methimazole methimazole 1-METHYL-1,3-DIHYDRO-2H-IMIDAZOLE-2-THIONE 1-Methylimidazole-2(3H)-thione 1-methyl-1,3-dihydro-2H-imidazole-2-thione 6835 A thiocarbonyl compound that has formula C4H6N2S. Beilstein:108646 C4H6N2S CHEBI:44168 CHEBI:50673 CHEBI:6828 ChemIDplus:60-56-0 Cn1cc[nH]c1=S Danantizol DrugBank:DB00763 Favistan InChI=1S/C4H6N2S/c1-6-3-2-5-4(6)7/h2-3H,1H3,(H,5,7) InChIKey=PMRYVIKBURPHAH-UHFFFAOYSA-N KEGG DRUG:D00401 NIST Chemistry WebBook:60-56-0 PDBeChem:MMZ Strumazol Tapazole Thacapzol USAF el-30 Wikipedia:Methimazole thiamazol thiamazole thiamazolum tiamazol Mitoxantrone mitoxantrone 1,4-DIHYDROXY-5,8-BIS({2-[(2-HYDROXYETHYL)AMINO]ETHYL}AMINO)-9,10-ANTHRACENEDIONE 1,4-dihydroxy-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)anthracene-9,10-dione 7005 A hydroxyanthraquinone that has formula C22H28N4O6. Beilstein:2795126 C22H28N4O6 CHEBI:43919 CHEBI:50729 CHEBI:6955 ChemIDplus:65271-80-9 DrugBank:DB01204 InChI=1S/C22H28N4O6/c27-11-9-23-5-7-25-13-1-2-14(26-8-6-24-10-12-28)18-17(13)21(31)19-15(29)3-4-16(30)20(19)22(18)32/h1-4,23-30H,5-12H2 InChIKey=KKZJGLLVHKMTCM-UHFFFAOYSA-N KEGG COMPOUND:65271-80-9 KEGG COMPOUND:C11195 Mitoxantrone OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3c(O)ccc(O)c3C(=O)c12 PDBeChem:MIX Patent:DE2835661 Patent:US4197249 Wikipedia:Mitoxantrone mitoxantrona mitoxantrone mitoxantronum montelukast (R-(E))-1-(((1-(3-(2-(7-Chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropaneacetic acid 1-[[[(1 R)-1-[3-[(1E)-2-(7-chloro-2-quinolinyl)ethenyl] phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]sulfanyl]methyl]cyclopropaneacetic acid 88249 An alkyl sulfide that has formula C35H36ClNO3S. Beilstein:7896575 C35H36ClNO3S CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC1)CC(O)=O)c1cccc(\C=C\c2ccc3ccc(Cl)cc3n2)c1 CHEBI:49756 CHEBI:50730 CHEBI:6992 ChemIDplus:158966-92-8 DrugBank:DB00471 InChI=1S/C35H36ClNO3S/c1-34(2,40)30-9-4-3-7-25(30)13-17-32(41-23-35(18-19-35)22-33(38)39)27-8-5-6-24(20-27)10-15-29-16-12-26-11-14-28(36)21-31(26)37-29/h3-12,14-16,20-21,32,40H,13,17-19,22-23H2,1-2H3,(H,38,39)/b15-10+/t32-/m1/s1 InChIKey=UCHDWCPVSPXUMX-TZIWLTJVSA-N KEGG COMPOUND:158966-92-8 KEGG COMPOUND:C07482 MONTELUKAST Montelukast PDBeChem:MTK Patent:EP1886997 Wikipedia:Montelukast montelukast {1-[({(1R)-1-{3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl}-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl}sulfanyl)methyl]cyclopropyl}acetic acid fluorinated steroid A steroid which is substituted with one or more fluorine atoms in any position. CHEBI:50830 corticosteroid A natural or synthetic analogue of the hormones secreted by the adrenal gland. CHEBI:50858 corticoides corticosteroides corticosteroids organic molecular entity Any molecular entity that contains carbon. CHEBI:25700 CHEBI:33244 CHEBI:50860 organic compounds organic entity organic molecular entities thiazolidenediones CHEBI:50990 primary amino compound A compound formally derived from ammonia by replacing one hydrogen atom by an organyl group. CHEBI:50994 primary amino compounds secondary amino compound A compound formally derived from ammonia by replacing two hydrogen atoms by organyl groups. CHEBI:50995 secondary amino compounds tertiary amino compound A compound formally derived from ammonia by replacing three hydrogen atoms by organyl groups. CHEBI:50996 tertiary amino compounds Flucytosine flucytosine 4-amino-5-fluoropyrimidin-2(1H)-one 4451 5-FC 5-Fluorocystosine 5-Fluorocytosine An organofluorine compound that has formula C4H4FN3O. Ancobon (TN) C4H4FN3O CHEBI:5100 ChemIDplus:2022-85-7 Flucytosine InChI=1S/C4H4FN3O/c5-2-1-7-4(9)8-3(2)6/h1H,(H3,6,7,8,9) InChIKey=XRECTZIEBJDKEO-UHFFFAOYSA-N KEGG DRUG:2022-85-7 KEGG DRUG:D00323 Nc1nc(=O)[nH]cc1F Wikipedia:Flucytosine nitrogen molecular entity CHEBI:25556 CHEBI:51143 CHEBI:7594 KEGG COMPOUND:C06061 Nitrogenous compounds nitrogen compounds nitrogen molecular entities Fluoxetine fluoxetine (+-)-N-methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-p-tolyl)oxy)propylamine (+-)-N-methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine 4493 A benzenoid aromatic compound that has formula C17H18F3NO. Beilstein:39914106 C17H18F3NO CHEBI:5118 CNCCC(Oc1ccc(cc1)C(F)(F)F)c1ccccc1 ChemIDplus:54910-89-3 DrugBank:DB00472 InChI=1S/C17H18F3NO/c1-21-12-11-16(13-5-3-2-4-6-13)22-15-9-7-14(8-10-15)17(18,19)20/h2-10,16,21H,11-12H2,1H3 InChIKey=RTHCYVBBDHJXIQ-UHFFFAOYSA-N KEGG DRUG:54910-89-3 KEGG DRUG:D00326 N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine Patent:DE2500110 Patent:US4314081 Prozac Wikipedia:Fluoxetine fluoxetina fluoxetine fluoxetinum diamminedichloroplatinum CHEBI:51214 Cl2H6N2Pt Gmelin:101110 NIST Chemistry WebBook:14913-33-8 diammine(dichloro)platinum diamminedichloridoplatinum diamminedichloridoplatinum(II) diamminedichloroplatinum diamminedichloroplatinum(II) diammineplatinum dichloride acenes CHEBI:51269 Polycyclic aromatic hydrocarbons consisting of fused benzene rings in a rectilinear arrangement and their substitution derivatives. acenoquinone CHEBI:51285 Quinones containing an acene fused ring system. acenoquinone acenoquinones adamantanes CHEBI:51339 Compounds containing an adamantane skeleton. Fluvoxamine fluvoxamine (1E)-5-methoxy-1-[4-(trifluoromethyl)phenyl]pentan-1-one O-(2-aminoethyl)oxime 42355 A 5-methoxyvalerophenone O-(2-aminoethyl)oxime that has formula C15H21F3N2O2. Beilstein:5583954 C15H21F3N2O2 CHEBI:5138 COCCCC\C(c1ccc(cc1)C(F)(F)F)=N/OCCN ChemIDplus:54739-18-3 DrugBank:DB00176 Fluvoxamine InChI=1S/C15H21F3N2O2/c1-21-10-3-2-4-14(20-22-11-9-19)12-5-7-13(8-6-12)15(16,17)18/h5-8H,2-4,9-11,19H2,1H3/b20-14+ InChIKey=CJOFXWAVKWHTFT-XSFVSMFZSA-N KEGG COMPOUND:54739-18-3 KEGG COMPOUND:C07571 Patent:NL7503310 Patent:US4085225 Wikipedia:Fluvoxamine fluvoxamina fluvoxamine fluvoxaminum cyclopropanes CHEBI:51454 Cyclopropane and its derivatives formed by substitution. 1,2-benzoxazoles CHEBI:51545 Compounds based on a fused 1,2-oxazole and benzene bicyclic ring skeleton, with the O atom positioned adjacent to one of the positions of ring fusion. benzisoxazole CHEBI:51549 Compounds based on a fused 1,2-oxazole and benzene bicyclic ring skeleton. benzisoxazoles dihydrofuran CHEBI:51659 Compounds containing a mono-unsaturated furan ring skeleton. dihydrofurans enone An alpha,beta-unsaturated ketone of general formula R(1)R(2)C=CR(3)-C(=O)R(4) (R(4) =/= H) in which the C=O function is conjugated to a C=C double bond at the alpha,beta position. C3OR4 CHEBI:51689 [*]\C([*])=C(\[*])C([*])=O enones alpha,beta-unsaturated ketone A ketone of general formula R(1)R(2)C=CR(3)-C(=O)R(4) (R(4) =/= H) or R(1)C#C-C(=O)R(2) (R(2) =/= H) in which the ketonic C=O function is conjugated to an unsaturated C-C bond at the alpha,beta position. CHEBI:51721 alpha,beta-unsaturated ketones organic polycyclic compound CHEBI:51958 organic polycyclic compounds organic tricyclic compound CHEBI:51959 organic tricyclic compounds tetracyclic diterpenoid A terpenoid having a C20 tetracyclic skeleton. CHEBI:52557 tetracyclic diterpenoids oxazinoquinoline Any organic heterotricyclic compound based on a skeleton comprised of an oxazine ring fused onto a quinoline system. CHEBI:53665 oxazinoquinolines ifosfamides CHEBI:55369 Compounds containing an ifosfamide skeleton. isosfamides imidazolidinone An imidazolidine containing one or more oxo groups. CHEBI:55370 imidazolidinones isoxazoles 1,2-oxazoles CHEBI:46813 CHEBI:55373 Oxazoles in which the N and O atoms are adjacent. isoxazoles Haloperidol haloperidol 1-(3-p-fluorobenzoylpropyl)-4-p-chlorophenyl-4-hydroxypiperidine 4'-fluoro-4-(4-(p-chlorophenyl)-4-hydroxypiperidinyl)butyrophenone 4'-fluoro-4-(4-hydroxy-4-(4'-chlorophenyl)piperidino)butyrophenone 4-(4-(para-chlorophenyl)-4-hydroxypiperidino)-4'-fluorobutyrophenone 4-[4-(4-chlorophenyl)-4-hydroxy-1-piperidyl]-1-(4-fluorophenyl)-butan-1-one 4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-1-(4-fluorophenyl)butan-1-one 5093 A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4; and an N-linked p-fluorobutyrophenone moiety. Beilstein:331267 C21H23ClFNO2 CHEBI:5613 ChemIDplus:52-86-8 CiteXplore:7602118 DrugBank:DB00502 Haldol InChI=1S/C21H23ClFNO2/c22-18-7-5-17(6-8-18)21(26)11-14-24(15-12-21)13-1-2-20(25)16-3-9-19(23)10-4-16/h3-10,26H,1-2,11-15H2 InChIKey=LNEPOXFFQSENCJ-UHFFFAOYSA-N KEGG COMPOUND:52-86-8 KEGG COMPOUND:C01814 KEGG DRUG:D00136 NIST Chemistry WebBook:52-86-8 OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c1ccc(Cl)cc1 Patent:BE577977 Patent:GB895309 Patent:US3438991 Wikipedia:Haloperidol gamma-(4-(p-chlorophenyl)-4-hydroxpiperidino)-p-fluorbutyrophenone haloperidol haloperidolum Cladribine cladribine (2R,3S,5R)-5-(6-amino-2-chloropurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol 2'-Deoxyadenosine in which the hydrogen at position 2 on the purine ring has been substituted by chlorine. It inhibits the synthesis and repair of DNA, particularly in lymphocytes and monocytes, and is used as an antimetabolite antineoplastic drug for the treatment of lymphoid malignancies including hairy-cell leukaemia and chronic lymphocytic leukaemia. 2-CdA 2-chloro-2'-deoxy-beta-adenosine 2-chloro-2'-deoxyadenosine 2-chloro-6-amino-9-(2-deoxy-beta-D-erythro-pentofuranosyl)purine 2-chloro-deoxyadenosine 2-chlorodeoxyadenosine 2ClAdo 44157 Beilstein:624220 C10H12ClN5O3 CHEBI:31407 CHEBI:567361 CHEBI:568373 ChEMBL:17526755 ChEMBL:18570408 ChEMBL:567361 ChEMBL:568373 ChemIDplus:4291-63-8 Cladribine CldAdo DrugBank:DB00242 InChI=1S/C10H12ClN5O3/c11-10-14-8(12)7-9(15-10)16(3-13-7)6-1-4(18)5(2-17)19-6/h3-6,17-18H,1-2H2,(H2,12,14,15)/t4-,5+,6+/m0/s1 InChIKey=PTOAARAWEBMLNO-KVQBGUIXSA-N KEGG DRUG:4291-63-8 KEGG DRUG:D01370 Nc1nc(Cl)nc2n(cnc12)[C@H]1C[C@H](O)[C@@H](CO)O1 Patent:EP173059 Patent:US4760137 Wikipedia:Cladribine cladribina cladribine cladribinum heterocyclic compound A cyclic compound having as ring members atoms of at least two different elements. CHEBI:5686 Heterocyclic compound compuesto heterociclico compuestos heterociclicos heterocycle heterocyclic compounds Ifosfamide ifosfamide 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide 5657 A nitrogen mustard alkylating agent used in the treatment of cancer Beilstein:611835 C7H15Cl2N2O2P CHEBI:219640 CHEBI:5864 ChEMBL:219640 ChemIDplus:3778-73-2 ClCCNP1(=O)OCCCN1CCCl DrugBank:DB01181 InChI=1S/C7H15Cl2N2O2P/c8-2-4-10-14(12)11(6-3-9)5-1-7-13-14/h1-7H2,(H,10,12) InChIKey=HOMGKSMUEGBAAB-UHFFFAOYSA-N Iphosphamide Isofosfamide Isophosphamide KEGG COMPOUND:3778-73-2 KEGG COMPOUND:C07047 KEGG DRUG:D00343 N,3-bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide Wikipedia:Ifosfamide ifosfamida ifosfamide ifosfamidum isosfamide acetal A compound having the structure RR'C(OR'')(OR''') (R'', R''' =/= H) and thus diethers of geminal diols. Originally, the term was confined by IUPAC to derivatives of aldehydes (R = H), but it now applies equally to derivatives of ketones (neither R nor R' = H ). Mixed acetals have R'' and R''' groups which differ. CHEBI:59769 acetals ketal An acetal of formula R2C(OR)2 (R =/= H) derived from a ketone by replacement of the oxo group by two hydrocarbyloxy groups. The class name 'ketals', once abandoned by IUPAC, has been reinstated as a subclass of acetals. CHEBI:59777 ketals cyclic ketal A ketal in the molecule of which the ketal carbon and one or both oxygen atoms thereon are members of a ring. CHEBI:59779 cyclic ketals docetaxel docetaxel trihydrate 4-(acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate--water (1/3) 72962 Beilstein:10054412 C43H59NO17 CHEBI:59809 ChemIDplus:148408-66-6 DrugBank:DB01248 InChI=1S/C43H53NO14.3H2O/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45;;;/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,52);3*1H2/t26-,27-,28+,30-,31+,32+,33-,35-,41+,42-,43+;;;/m0.../s1 InChIKey=XCDIRYDKECHIPE-QHEQPUDQSA-N KEGG DRUG:148408-66-6 KEGG DRUG:D02165 N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel trihydrate N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol trihydrate O.O.O.[H][C@@]1(C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@]3([H])[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](O)C(=C1C)C2(C)C)OC(C)=O)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c1ccccc1 Patent:EP253738 Patent:US4814470 The trihydrate form of docetaxel. It is used for the treatment of breast, ovarian, and non-small cell lung cancer, and with prednisone or prednisolone in hormone-refractory metastatic prostate cancer. docetaxel chemical substance A chemical substance is a portion of matter of constant composition, composed of molecular entities of the same type or of different types. CHEBI:59999 Chemische Substanz mixture A mixture is a chemical substance composed of multiple molecules, at least two of which are of a different kind. CHEBI:60004 Mischung purine deoxyribonucleoside A nucleoside having a purine base covalently bonded to a deoxyribose. CHEBI:60173 purine deoxyribonucleosides isoniazid isoniazide 4-pyridinecarbohydrazide 6038 A carbohydrazide obtained by formal condensation between pyridine-4-carboxylic acid and hydrazine. Beilstein:119374 C6H7N3O CHEBI:6030 ChemIDplus:54-85-3 CiteXplore:18220565 CiteXplore:19183459 CiteXplore:445303 Gmelin:82804 InChI=1S/C6H7N3O/c7-9-6(10)5-1-3-8-4-2-5/h1-4H,7H2,(H,9,10) InChIKey=QRXWMOHMRWLFEY-UHFFFAOYSA-N Isoniazid Isonicotinsaeurehydrazid KEGG COMPOUND:54-85-3 KEGG COMPOUND:C07054 NIST Chemistry WebBook:54-85-3 NNC(=O)c1ccncc1 Reaxys:119374 Wikipedia:Isoniazid isonicotinic acid hydrazide isonicotinic hydrazide isonicotinohydrazide isonicotinoylhydrazide pyridine-4-carbohydrazide pyridine-4-carboxylic acid hydrazide isonicotinic acid 4-carboxypyridine 4-pyridinecarboxylic acid A pyridinemonocarboxylic acid that has formula C6H5NO2. Beilstein:109599 C6H5NO2 CHEBI:6032 ChemIDplus:55-22-1 Gmelin:68876 InChI=1S/C6H5NO2/c8-6(9)5-1-3-7-4-2-5/h1-4H,(H,8,9) InChIKey=TWBYWOBDOCUKOW-UHFFFAOYSA-N Isonicotinic acid KEGG COMPOUND:55-22-1 KEGG COMPOUND:C07446 NIST Chemistry WebBook:55-22-1 OC(=O)c1ccncc1 Wikipedia:Isonicotinic_Acid gamma-picolinic acid gamma-pyridinecarboxylic acid isonicotinic acid p-pyridinecarboxylic acid pyridine-4-carboxylic acid Itraconazole itraconazole 2-(butan-2-yl)-4-{4-[4-(4-{[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-2,4-dihydro-3H-1,2,4-triazol-3-one 28031 A dioxolane that has formula C35H38Cl2N8O4. C35H38Cl2N8O4 CCC(C)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@H]3CO[C@@](Cn4cncn4)(O3)c3ccc(Cl)cc3Cl)cc2)c1=O CHEBI:6076 ChemIDplus:84625-61-6 InChI=1S/C35H38Cl2N8O4/c1-3-25(2)45-34(46)44(24-40-45)29-7-5-27(6-8-29)41-14-16-42(17-15-41)28-9-11-30(12-10-28)47-19-31-20-48-35(49-31,21-43-23-38-22-39-43)32-13-4-26(36)18-33(32)37/h4-13,18,22-25,31H,3,14-17,19-21H2,1-2H3/t25?,31-,35-/m0/s1 InChIKey=VHVPQPYKVGDNFY-ZPGVKDDISA-N Itraconazole Itrizole (TN) KEGG DRUG:84625-61-6 KEGG DRUG:D00350 Oriconazole Sporanox (TN) Wikipedia:Itraconazole nucleoside analogue An analogue of a nucleoside, being an N-glycosyl compound in which the nitrogen-containing moiety is a modified nucleotide base. They are commonly used as antiviral products to prevent viral replication in infected cells. CHEBI:60783 nucleoside analogues ropivacaine (+-)-ropivacaine 1-propyl-2',6'-dimethyl-2-piperidylcarboxyanilide 1-propyl-2',6'-pipecoloxylidide 35780 C17H26N2O CCCN1CCCCC1C(=O)Nc1c(C)cccc1C CHEBI:60802 DL-ropivacaine InChI=1S/C17H26N2O/c1-4-11-19-12-6-5-10-15(19)17(20)18-16-13(2)8-7-9-14(16)3/h7-9,15H,4-6,10-12H2,1-3H3,(H,18,20) InChIKey=ZKMNUMMKYBVTFN-UHFFFAOYSA-N N-(2,6-dimethylphenyl)-1-propylpiperidine-2-carboxamide N-n-propylpipecolic acid-2,6-xylidide Reaxys:253266 The piperidinecarboxamide obtained by the formal condensation of N-propylpipecolic acid and 2,6-dimethylaniline. rac-ropivacaine racemic ropivacaine racemate A racemate is an equimolar mixture of a pair of enantiomers. CHEBI:60911 melange racemique racemic mixture diastereoisomeric mixture A mixture composed of two or more diastereoisomers (stereoisomers not related as mirror images). CHEBI:60915 diastereomeric mixture beta-glucoside A glucoside in which the anomeric carbon of the glycosidic bond is in a beta configuration CHEBI:60980 beta-glucosides Tacrolimus tacrolimus hydrate (-)-(3S,4R,5S,8R,9E,12S,14S,15R,16S,18R,19R,26aS)-5,19-dihydroxy-3-{(1E)-1-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl}-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(prop-2-en-1-yl)-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-3H-15,19-epoxypyrido[2,1-c][1,4]oxazacyclotricosine-1,7,20,21(4H,23H)-tetrone monohydrate (3S,4R,5S,8R,9E,12S,14S,15R,16S,18R,19R,26aS)-5,19-dihydroxy-3-{(1E)-1-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl}-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(prop-2-en-1-yl)-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-3H-15,19-epoxypyrido[2,1-c][1,4]oxazacyclotricosine-1,7,20,21(4H,23H)-tetrone--water (1/1) 42316 A hydrate that is the monohydrate form of tacrolimus. C44H71NO13 CHEBI:61057 ChemIDplus:109581-93-3 DrugBank:DB00864 InChI=1S/C44H69NO12.H2O/c1-10-13-31-19-25(2)18-26(3)20-37(54-8)40-38(55-9)22-28(5)44(52,57-40)41(49)42(50)45-17-12-11-14-32(45)43(51)56-39(29(6)34(47)24-35(31)48)27(4)21-30-15-16-33(46)36(23-30)53-7;/h10,19,21,26,28-34,36-40,46-47,52H,1,11-18,20,22-24H2,2-9H3;1H2/b25-19+,27-21+;/t26-,28+,29+,30-,31+,32-,33+,34-,36+,37-,38-,39+,40+,44+;/m0./s1 InChIKey=NWJQLQGQZSIBAF-MLAUYUEBSA-N KEGG DRUG:109581-93-3 KEGG DRUG:D00107 O.CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@H]([C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC)[C@H](C[C@H]2C)OC Prograf Protopic Reaxys:6265275 tacrolimus tacrolimus monohydrate tsukubaenolide hydrate nucleobase-containing molecular entity Any compound that has a nucleobase as a part. CHEBI:61120 nucleobase-containing compound nucleobase-containing compounds nucleobase-containing molecular entities C21-steroid A steroid compound with a structure based on a 21-carbon (pregnane) skeleton. CHEBI:61313 3-hydroxy carboxylic acid 3-hydroxy carboxylic acids Any hydroxy carboxylic acid which contains a hydroxy group located beta- to the carboxylic acid group. CHEBI:61355 beta-hydroxy carboxylic acid beta-hydroxy carboxylic acids glycosyl compound A carbohydrate derivative arising formally from the elimination of water from a glycosidic hydroxy group and an H atom bound to an oxygen, carbon, nitrogen or sulfur atom of a separate entity. CHEBI:63161 glycosyl compounds carbohydrate derivative Any organooxygen compound derived from a carbohydrate by replacement of one or more hydroxy group(s) by an amino group, a thiol group or similar heteroatomic groups. The term also includes derivatives of these compounds. CHEBI:63299 carbohydrate derivatives derivatised carbohydrate derivatised carbohydrates derivatized carbohydrate derivatized carbohydrates monosaccharide derivative A carbohydrate derivative that is formally obtained from a monosaccharide. CHEBI:63367 monosaccharide derivatives hexose derivative A monosaccharide derivative that is formally obtained from a hexose. CHEBI:63385 hexose derivatives ketohexose derivative A hexose derivative that is formally obtained from a ketohexose. CHEBI:63391 ketohexose derivatives Ribavirin ribavirin 1-(beta-D-ribofuranosyl)-1H-1,2,4-triazole-3-carboxamide 1-beta-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide 1-beta-D-Ribofuranosyl-1H-1,2,4-triazole-3-carboxamide 9344 A 1-ribosyltriazole that is the 1-ribofuranosyl derivative of 1,2,4-triazole-3-carboxamide. An inhibitor of HCV polymerase. C8H12N4O5 CHEBI:63580 CHEBI:8840 ChemIDplus:36791-04-5 ChemIDplus:892462 CiteXplore:21827730 CiteXplore:22052088 CiteXplore:22052220 CiteXplore:22156853 CiteXplore:22158703 CiteXplore:22212566 CiteXplore:22212568 CiteXplore:22212569 CiteXplore:22212572 CiteXplore:22212576 CiteXplore:22212579 CiteXplore:22220723 CiteXplore:22239498 CiteXplore:22239511 DrugBank:DB00811 InChI=1S/C8H12N4O5/c9-6(16)7-10-2-12(11-7)8-5(15)4(14)3(1-13)17-8/h2-5,8,13-15H,1H2,(H2,9,16)/t3-,4-,5-,8-/m1/s1 InChIKey=IWUCXVSUMQZMFG-AFCXAGJDSA-N KEGG DRUG:36791-04-5 KEGG DRUG:D00423 NC(=O)c1ncn(n1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O RBV Reaxys:892462 Wikipedia:Ribavirin ribavirin ribavirina ribavirine ribavirinum Stavudine stavudine 1-(2,3-Dideoxy-beta-D-glycero-pent-2-enofuranosyl)thymine 1-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methylpyrimidine-2,4(1H,3H)-dione 2',3'-Didehydro-3'-deoxythimidine 3'-Deoxy-2'-thymidinene 59763 A nucleoside analogue obtained by formal dehydration across positions 2 and 3 of thymidine. An inhibitor of HIV-1 reverse transcriptase C10H12N2O4 CHEBI:63581 CHEBI:9253 Cc1cn([C@@H]2O[C@H](CO)C=C2)c(=O)[nH]c1=O ChemIDplus:3056-17-5 DrugBank:DB00649 InChI=1S/C10H12N2O4/c1-6-4-12(10(15)11-9(6)14)8-3-2-7(5-13)16-8/h2-4,7-8,13H,5H2,1H3,(H,11,14,15)/t7-,8+/m0/s1 InChIKey=XNKLLVCARDGLGL-JGVFFNPUSA-N KEGG COMPOUND:3056-17-5 KEGG COMPOUND:C07312 KEGG DRUG:D00445 Patent:EP334368 Patent:US5130421 Reaxys:618327 STV Sanilvudine Stavudine Wikipedia:Stavudine d4T estavudina stavudine stavudinum 1-glycosyltriazole 1-glycosyltriazoles An N-glycosyl compound that consists of any triazole having a glycosyl residue attached at position 1. CHEBI:63593 1-ribosyltriazole CHEBI:63594 Levofloxacin levofloxacin (-)-Ofloxacin (3S)-(-)-9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid (3S)-9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid (S)-(-)-9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzooxazine-6-carboxylic acid (S)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid (S)-Ofloxacin 82122 An optically active form of ofloxacin having (S)-configuration; an inhibitor of bacterial topoisomerase IV and DNA gyrase C18H20FN3O4 CHEBI:63598 CHEBI:6440 C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c2n1cc(C(O)=O)c3=O ChemIDplus:100986-85-4 CiteXplore:21075586 CiteXplore:21965436 CiteXplore:21974858 CiteXplore:22088660 CiteXplore:22221614 DrugBank:DB01137 HMDB:HMDB01929 InChI=1S/C18H20FN3O4/c1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21/h7-8,10H,3-6,9H2,1-2H3,(H,24,25)/t10-/m0/s1 InChIKey=GSDSWSVVBLHKDQ-JTQLQIEISA-N KEGG COMPOUND:100986-85-4 KEGG COMPOUND:C07660 KEGG DRUG:D08120 L-Ofloxacin Ofloxacin S-(-)-form Reaxys:5385660 Wikipedia:Levofloxacin levofloxacin levofloxacine levofloxacino levofloxacinum Mefloquine mefloquine 6694 A racemate composed of (+)-(11R,2'S)- and (-)-(11S,2'R)-enantiomers of mefloquine. An antimalarial agent which acts as a blood schizonticide; its mechanism of action is unknown. CHEBI:63609 CHEBI:6718 ChemIDplus:53230-10-7 CiteXplore:21118921 CiteXplore:21853223 CiteXplore:21861987 CiteXplore:22006004 CiteXplore:22217970 CiteXplore:22223333 CiteXplore:22232280 CiteXplore:22233563 CiteXplore:22236373 CiteXplore:22245668 CiteXplore:22246492 DrugBank:DB00358 KEGG COMPOUND:53230-10-7 KEGG COMPOUND:C07633 KEGG DRUG:D04895 Racemic mefloquine Reaxys:5306591 Wikipedia:Mefloquine [(R*,S*)-2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanol [DL-erythro-alpha-2-Piperidyl-2,8-bis(trifluoromethyl)]-4-quinolinemethanol mefloquina mefloquine mefloquinum rac--(R)-[2,8-bis(trifluoromethyl)quinolin-4-yl][(2S)-piperidin-2-yl]methanol Misoprostol misoprostol (+-)-methyl (1R,2R,3R)-3-hydroxy-2-((E)-(4RS)-4-hydroxy-4-methyl-1-octenyl)-5-oxocyclopentaneheptanoate (11-alpha,13E)-(+-)-11,16-dihydroxy-16-methyl-9-oxoprost-13-en-1-oic acid methyl ester 42331 A diastereoisomeric mixture composed of approximately equal amounts of a double racemate of four of the sixteen possible diastereoisomers of methyl (13E)-11,16-dihydroxy-16-methyl-9-oxoprost-13-en-1-oate that is racemic prostaglandin E1 which is lacking the hydroxy group at position 15, but which has an additional hydroxy group at position 16. It is a synthetic prostaglandin E1 analogue, used in the treatment of gastric and duodenal ulcers. A weak abortifacient, it is also used for cervical ripening prior to surgical termination of pregnancy. The (11R,16S)-diastereoisomer is the pharmacologically active form. Arthrotec CHEBI:63610 CHEBI:6952 ChemIDplus:59122-46-2 CiteXplore:10945193 CiteXplore:10949752 CiteXplore:11136959 CiteXplore:1417145 CiteXplore:18690850 CiteXplore:19740175 CiteXplore:2109814 CiteXplore:3080288 Cytotec DrugBank:DB00929 KEGG DRUG:59122-46-2 KEGG DRUG:D00419 Methyl (+-)-11-alpha,16-dihydroxy-16-methyl-9-oxoprost-13-en-1-oate Patent:BE827127 Patent:US3965143 Reaxys:4155643 Wikipedia:Misoprostol misoprostol misoprostolum moxifloxacin 1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-((4aS,7aS)-octahydro-6H-pyrrolo(3,4-b)pyridin-6-yl)-4-oxo-3-quinolinecarboxylic acid 1-cyclopropyl-6-fluoro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 139462 A quinolone that consits of 4-oxo-1,4-dihydroquinoline-3-carboxylic acid bearing a cyclopropyl substituent at position 1, a fluoro substitiuent at position 6, a (4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl group at position 7 and a methoxy substituent at position 8. A member of the fluoroquinolone class of antibacterial agents. C21H24FN3O4 CHEBI:63611 CHEBI:7007 ChemIDplus:151096-09-2 DrugBank:DB00218 InChI=1S/C21H24FN3O4/c1-29-20-17-13(19(26)14(21(27)28)9-25(17)12-4-5-12)7-15(22)18(20)24-8-11-3-2-6-23-16(11)10-24/h7,9,11-12,16,23H,2-6,8,10H2,1H3,(H,27,28)/t11-,16+/m0/s1 InChIKey=FABPRXSRWADJSP-MEDUHNTESA-N KEGG COMPOUND:C07663 KEGG DRUG:D08237 Moxifloxacin Patent:EP550903 Reaxys:8365827 Wikipedia:Moxifloxacin [H][C@@]12CCCN[C@]1([H])CN(C2)c1c(F)cc2c(c1OC)n(cc(C(O)=O)c2=O)C1CC1 moxifloxacin Pergolide pergolide (8beta)-8-[(methylsulfanyl)methyl]-6-propylergoline 8047 A diamine that is ergoline in which the beta-hydrogen at position 8 is replaced by a (methylthio)methyl group and the hydrogen attached to the piperidine nitrogen (position 6) is replaced by a propyl group. A dopamine D2 receptor agonist which also has D1 and D2 agonist properties, it is used as the mesylate salt in the management of Parkinson's disease, although it was withdrawn from the U.S. and Canadian markets in 2007 due to an increased risk of cardiac valve dysfunction. C19H26N2S CHEBI:63617 CHEBI:8020 ChemIDplus:66104-22-1 CiteXplore:11852289 CiteXplore:15180134 CiteXplore:16845152 CiteXplore:18071034 CiteXplore:2012117 DrugBank:DB01186 InChI=1S/C19H26N2S/c1-3-7-21-11-13(12-22-2)8-16-15-5-4-6-17-19(15)14(10-20-17)9-18(16)21/h4-6,10,13,16,18,20H,3,7-9,11-12H2,1-2H3/t13-,16-,18-/m1/s1 InChIKey=YEHCICAEULNIGD-MZMPZRCHSA-N KEGG COMPOUND:66104-22-1 KEGG COMPOUND:C07425 KEGG DRUG:D08339 Patent:US4166182 Reaxys:5091461 Wikipedia:Pergolide [H][C@@]12Cc3c[nH]c4cccc(c34)[C@@]1([H])C[C@@H](CSC)CN2CCC pergolida pergolide pergolidum Pravastatin pravastatin (+)-(3R,5R)-3,5-dihydroxy-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-{[(S)-2-methylbutyryl]oxy}-1,2,6,7,8,8a-hexahydro-1-naphthyl]heptanoic acid (3R,5R)-3,5-dihydroxy-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-{[(2S)-2-methylbutanoyl]oxy}-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]heptanoic acid 42463 A carboxylic ester resulting from the formal condensation or (S)-2-methylbutyric acid with the hydroxy group adjacent to the ring junction of (3R,5R)-7-[(1S,2S,6S,8S,8aR)-6,8-dihydroxy-2-methyl-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid. Derived from microbial transformation of mevastatin, pravastatin is a reversible inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA). The sodium salt is used for lowering cholesterol and preventing cardiovascular disease. It is one of the lower potency statins, but has the advantage of fewer side effects compared with lovastatin and simvastatin. C23H36O7 CHEBI:63618 CHEBI:8360 ChemIDplus:81093-37-0 CiteXplore:21749370 CiteXplore:21851379 DrugBank:DB00175 HMDB:HMDB05022 InChI=1S/C23H36O7/c1-4-13(2)23(29)30-20-11-17(25)9-15-6-5-14(3)19(22(15)20)8-7-16(24)10-18(26)12-21(27)28/h5-6,9,13-14,16-20,22,24-26H,4,7-8,10-12H2,1-3H3,(H,27,28)/t13-,14-,16+,17+,18+,19-,20-,22-/m0/s1 InChIKey=TUZYXOIXSAXUGO-PZAWKZKUSA-N KEGG COMPOUND:81093-37-0 KEGG COMPOUND:C01844 KEGG DRUG:D08410 Reaxys:4825538 Wikipedia:Pravastatin [H][C@]12[C@H](C[C@H](O)C=C1C=C[C@H](C)[C@@H]2CC[C@@H](O)C[C@@H](O)CC(O)=O)OC(=O)[C@@H](C)CC pravastatin pravastatin acid pravastatina pravastatine pravastatinum Propafenone propafenone 1-(2-(2-hydroxy-3-(propylamino)propoxy)phenyl)-3-phenyl-1-propanone 1-{2-[2-hydroxy-3-(propylamino)propoxy]phenyl}-3-phenylpropan-1-one 2-(2'-hydroxy-3'-propylaminopropoxy)-omega-phenylpropiophenone 8754 A ketone that is 3-(propylamino)propane-1,2-diol in which the hydrogen of the primary hydroxy group is replaced by a 2-(3-phenylpropanoyl)phenyl group. It is a class 1C antiarrhythmic drug with local anesthetic effects, and is used as the hydrochloride salt in the management of supraventricular and ventricular arrhythmias. C21H27NO3 CCCNCC(O)COc1ccccc1C(=O)CCc1ccccc1 CHEBI:63619 CHEBI:8465 ChemIDplus:54063-53-5 CiteXplore:8777484 DrugBank:DB01182 InChI=1S/C21H27NO3/c1-2-14-22-15-18(23)16-25-21-11-7-6-10-19(21)20(24)13-12-17-8-4-3-5-9-17/h3-11,18,22-23H,2,12-16H2,1H3 InChIKey=JWHAUXFOSRPERK-UHFFFAOYSA-N KEGG COMPOUND:54063-53-5 KEGG COMPOUND:C07381 KEGG DRUG:D08435 Patent:DE2001431 Reaxys:2175182 Wikipedia:Propafenone propafenona propafenone propafenonum Sotalol sotalol 4'-(1-hydroxy-2-(isopropylamino)ethyl)methane sulfonanilide 9947 A sulfonamide that is N-phenylmethanesulfonamide in which the phenyl group is sustituted at position 4 by a 1-hydroxy-2-(isopropylamino)ethyl group. It has both beta-adrenoreceptor blocking (Vaughan Williams Class II) and cardiac action potential duration prolongation (Vaughan Williams Class III) antiarrhythmic properties. It is used (usually as the hydrochloride salt) for the management of ventricular and supraventricular arrhythmias. C12H20N2O3S CC(C)NCC(O)c1ccc(NS(C)(=O)=O)cc1 CHEBI:63622 CHEBI:9206 ChemIDplus:3930-20-9 CiteXplore:20562595 CiteXplore:21553267 CiteXplore:21854895 DrugBank:DB00489 InChI=1S/C12H20N2O3S/c1-9(2)13-8-12(15)10-4-6-11(7-5-10)14-18(3,16)17/h4-7,9,12-15H,8H2,1-3H3 InChIKey=ZBMZVLHSJCTVON-UHFFFAOYSA-N KEGG COMPOUND:3930-20-9 KEGG COMPOUND:C07309 KEGG DRUG:D08525 N-{4-[1-hydroxy-2-(propan-2-ylamino)ethyl]phenyl}methanesulfonamide Reaxys:2380820 Sotalol Wikipedia:Sotalol beta-cardone sotalol sotalolum Tinidazole tinidazole 1-[2-(ethylsulfonyl)ethyl]-2-methyl-5-nitro-1H-imidazole 10612 1H-imidazole substituted at C-1 by a (2-ethylsulfonyl)ethyl group, at C-2 by a methyl group and at C-5 by a nitro group. It is used as an antiprotozoal, antibacterial agent. C8H13N3O4S CCS(=O)(=O)CCn1c(C)ncc1[N+]([O-])=O CHEBI:32227 CHEBI:63627 CiteXplore:5458368 DrugBank:DB00911 InChI=1S/C8H13N3O4S/c1-3-16(14,15)5-4-10-7(2)9-6-8(10)11(12)13/h6H,3-5H2,1-2H3 InChIKey=HJLSLZFTEKNLFI-UHFFFAOYSA-N KEGG DRUG:D01426 Patent:US3376311 Reaxys:618182 Wikipedia:Tinidazole timidazole tipranavir 190548 3'-((1R)-1-((6R)-5,6-Dihydro-4-hydroxy-2-oxo-6-phenethyl-6-propyl-2H-pyran-3-yl)propyl)-5-(trifluoromethyl)-2-pyridinesulfonanilide A pyridine-2-sulfonamide substituted at C-5 by a trifluoromethyl group and at the sulfonamide nitrogen by a dihydropyrone-containing m-tolyl substituent. It is an HIV-1 protease inhibitor. C31H33F3N2O5S CCC[C@@]1(CCc2ccccc2)CC(O)=C([C@H](CC)c2cccc(NS(=O)(=O)c3ccc(cn3)C(F)(F)F)c2)C(=O)O1 CHEBI:63628 ChemIDplus:174484-41-4 CiteXplore:17620375 CiteXplore:20368406 CiteXplore:21041916 CiteXplore:21571982 CiteXplore:21576452 CiteXplore:21825300 CiteXplore:21871444 CiteXplore:22007990 CiteXplore:22096044 CiteXplore:22258921 DrugBank:DB00932 InChI=1S/C31H33F3N2O5S/c1-3-16-30(17-15-21-9-6-5-7-10-21)19-26(37)28(29(38)41-30)25(4-2)22-11-8-12-24(18-22)36-42(39,40)27-14-13-23(20-35-27)31(32,33)34/h5-14,18,20,25,36-37H,3-4,15-17,19H2,1-2H3/t25-,30-/m1/s1 InChIKey=SUJUHGSWHZTSEU-FYBSXPHGSA-N KEGG DRUG:D08605 N-(3-{(1R)-1-[(6R)-4-hydroxy-2-oxo-6-(2-phenylethyl)-6-propyl-5,6-dihydro-2H-pyran-3-yl]propyl}phenyl)-5-(trifluoromethyl)pyridine-2-sulfonamide Reaxys:7698323 tipranavir tizanidine 2,1,3-Benzothiadiazole substituted at C-4 by a Delta(1)-imidazolin-2-ylamino group and at C-4 by a chloro group. It is an agonist at alpha2-adrenergic receptor sites. 5-Chloro-4-(2-imidazolin-2-ylamino)-2,1,3-benzothiadiazole 5-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-2,1,3-benzothiadiazol-4-amine 57258 C9H8ClN5S CHEBI:63629 CHEBI:9608 ChemIDplus:51322-75-9 ChemIDplus:618691 CiteXplore:21317414 CiteXplore:21733633 CiteXplore:21982341 CiteXplore:22196407 CiteXplore:22223284 Clc1ccc2nsnc2c1NC1=NCCN1 DrugBank:DB00697 InChI=1S/C9H8ClN5S/c10-5-1-2-6-8(15-16-14-6)7(5)13-9-11-3-4-12-9/h1-2H,3-4H2,(H2,11,12,13) InChIKey=XFYDIVBRZNQMJC-UHFFFAOYSA-N KEGG COMPOUND:51322-75-9 KEGG COMPOUND:C07452 KEGG DRUG:D08611 Patent:US3843668 Reaxys:618691 Tizanidine Wikipedia:Tizanidine tizanidina tizanidine tizanidinum topiramate 2,3:4,5-bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate 2,3:4,5-di-O-isopropylidene-beta-D-fructopyranose sulfamate 38404 A hexose derivative that is 2,3:4,5-di-O-isopropylidene-beta-D-fructopyranose in which the hydroxy group has been converted to the corresponding sulfamate ester. It blocks voltage-dependent sodium channels and is used as an antiepileptic and for the prevention of migraine. C12H21NO8S CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1 CHEBI:63631 CHEBI:9633 ChemIDplus:97240-79-4 CiteXplore:22233396 CiteXplore:22249827 DrugBank:DB00273 InChI=1S/C12H21NO8S/c1-10(2)18-7-5-16-12(6-17-22(13,14)15)9(8(7)19-10)20-11(3,4)21-12/h7-9H,5-6H2,1-4H3,(H2,13,14,15)/t7-,8-,9+,12+/m1/s1 InChIKey=KJADKKWYZYXHBB-XBWDGYHZSA-N KEGG COMPOUND:97240-79-4 KEGG COMPOUND:C07502 KEGG DRUG:D00537 McN-4853 Patent:US4513006 RWJ-17021 Reaxys:5988957 TPM Topamax Topiramate Wikipedia:Topiramate tipiramate tipiramato topiramate topiramato topiramatum Topotecan topotecan (4S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione 57308 9-[(dimethylamino)methyl]-10-hydroxy-(4S)-camptothecin A pyranoindolizinoquinoline used as an antineoplastic agent. It is a derivative of camptothecin and works by binding to the topoisomerase I-DNA complex and preventing religation of these 328 single strand breaks. C23H23N3O5 CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O CHEBI:63632 CHEBI:9634 ChemIDplus:123948-87-8 CiteXplore:20574789 CiteXplore:21255983 CiteXplore:21352915 CiteXplore:21910214 CiteXplore:22028494 CiteXplore:22075006 CiteXplore:22136714 CiteXplore:22190039 DrugBank:DB01030 InChI=1S/C23H23N3O5/c1-4-23(30)16-8-18-20-12(9-26(18)21(28)15(16)11-31-22(23)29)7-13-14(10-25(2)3)19(27)6-5-17(13)24-20/h5-8,27,30H,4,9-11H2,1-3H3/t23-/m0/s1 InChIKey=UCFGDBYHRUNTLO-QHCPKHFHSA-N KEGG COMPOUND:123948-87-8 KEGG COMPOUND:C11158 KEGG DRUG:D08618 Patent:EP321122 Reaxys:4279441 Topotecan Wikipedia:Topotecan topotecan topotecane topotecanum pyrrolidinopiperidine Any organic heterobicyclic compound containing ortho-fused pyrrolidine and piperidine rings. CHEBI:63697 lansoprazole 17128 2-({[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methyl}sulfinyl)-1H-benzimidazole A sulfoxide that has formula C16H14F3N3O2S. AG 1749 Bamalite Beilstein:4333393 C16H14F3N3O2S CHEBI:6375 Cc1c(OCC(F)(F)F)ccnc1CS(=O)c1nc2ccccc2[nH]1 ChemIDplus:103577-45-3 InChI=1S/C16H14F3N3O2S/c1-10-13(20-7-6-14(10)24-9-16(17,18)19)8-25(23)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22) InChIKey=MJIHNNLFOKEZEW-UHFFFAOYSA-N KEGG DRUG:D00355 Lanzol Lanzopral Lanzul Limpidex Monolitum Ogastro Opiren Patent:EP174726 Patent:US4628098 Prevacid Wikipedia:Lansoprazole lansoprazol lansoprazolum leflunomide 27169 5-Methyl-N-(4-(trifluoromethyl)phenyl)-4-isoxazolecarboxamide 5-Methylisoxazole-4-carboxylic acid (4-trifluoromethyl)anilide 5-methyl-N-[4-(trifluoromethyl)phenyl]-1,2-oxazole-4-carboxamide An isoxazole that has formula C12H9F3N2O2. Arava (TN) Beilstein:4323174 C12H9F3N2O2 CHEBI:6402 Cc1oncc1C(=O)Nc1ccc(cc1)C(F)(F)F ChemIDplus:75706-12-6 InChI=1S/C12H9F3N2O2/c1-7-10(6-16-19-7)11(18)17-9-4-2-8(3-5-9)12(13,14)15/h2-6H,1H3,(H,17,18) InChIKey=VHOGYURTWQBHIL-UHFFFAOYSA-N KEGG COMPOUND:75706-12-6 KEGG COMPOUND:C07905 KEGG DRUG:D00749 Leflunomide Wikipedia:Leflunomide alpha,alpha,alpha-Trifluoro-5-methyl-4-isoxazolecarboxy-p-toluidide Leuprolide leuprolide (D-Leu(6),des-Gly-NH2(10),Pro-ethylamide(9))-gonadotropin-releasing hormone 42375 5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-leucyl-L-leucyl-L-arginyl-N-ethyl-L-prolinamide An oligopeptide comprising pyroglutamyl, histidyl, tryptophyl, seryl, tyrosyl, D-leucyl, leucyl, arginyl, and N-ethylprolinamide residues joined in sequence. It is a synthetic nonapeptide analogue of gonadotropin-releasing hormone, and is used as a subcutaneous hydrogel implant (particularly as the acetate salt) for the treatment of prostate cancer and for the suppression of gonadal sex hormone production in children with central precocious puberty. C59H84N16O12 CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1 CHEBI:6427 ChemIDplus:53714-56-0 DrugBank:DB00007 InChI=1S/C59H84N16O12/c1-6-63-57(86)48-14-10-22-75(48)58(87)41(13-9-21-64-59(60)61)68-51(80)42(23-32(2)3)69-52(81)43(24-33(4)5)70-53(82)44(25-34-15-17-37(77)18-16-34)71-56(85)47(30-76)74-54(83)45(26-35-28-65-39-12-8-7-11-38(35)39)72-55(84)46(27-36-29-62-31-66-36)73-50(79)40-19-20-49(78)67-40/h7-8,11-12,15-18,28-29,31-33,40-48,65,76-77H,6,9-10,13-14,19-27,30H2,1-5H3,(H,62,66)(H,63,86)(H,67,78)(H,68,80)(H,69,81)(H,70,82)(H,71,85)(H,72,84)(H,73,79)(H,74,83)(H4,60,61,64)/t40-,41-,42-,43+,44-,45-,46-,47-,48-/m0/s1 InChIKey=GFIJNRVAKGFPGQ-LIJARHBVSA-N KEGG COMPOUND:53714-56-0 KEGG COMPOUND:C07612 KEGG DRUG:D08113 L-pyroglutamyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-leucyl-L-leucyl-L-arginyl-L-proline ethylamide Leuprorelin Patent:DE2446005 Patent:US4005063 Reaxys:741818 leuprorelina leuproreline leuprorelinum pGlu-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHC2H5 pGlu-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHEt biaryl CHEBI:64459 Losartan losartan (2-butyl-4-chloro-1-{[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl}-1H-imidazol-5-yl)methanol (2-butyl-4-chloro-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazol-5-yl)methanol 2-n-butyl-4-chloro-5-hydroxymethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole 52175 A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position Beilstein:4770867 C22H23ClN6O CCCCc1nc(Cl)c(CO)n1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1 CHEBI:6541 ChemIDplus:114798-26-4 CiteXplore:15703421 DrugBank:DB00678 InChI=1S/C22H23ClN6O/c1-2-3-8-20-24-21(23)19(14-30)29(20)13-15-9-11-16(12-10-15)17-6-4-5-7-18(17)22-25-27-28-26-22/h4-7,9-12,30H,2-3,8,13-14H2,1H3,(H,25,26,27,28) InChIKey=PSIFNNKUMBGKDQ-UHFFFAOYSA-N KEGG COMPOUND:114798-26-4 KEGG COMPOUND:C07072 KEGG DRUG:D08146 Losartan Patent:EP253310 Patent:US5138069 Reaxys:4770867 Wikipedia:Losartan losartan Megestrol megestrol 17-Hydroxy-6-methylpregna-4,6-diene-3,20-dione 17-hydroxypregna-4,6-diene-3,20-dione 6703 A 17alpha-hydroxy steroid that has formula C22H30O3. Beilstein:3164843 C22H30O3 CHEBI:6722 ChemIDplus:3562-63-8 DrugBank:DB00351 InChI=1S/C21H28O3/c1-13(22)21(24)11-8-18-16-5-4-14-12-15(23)6-9-19(14,2)17(16)7-10-20(18,21)3/h4-5,12,16-18,24H,6-11H2,1-3H3/t16-,17+,18+,19+,20+,21+/m1/s1 InChIKey=JBVNBBXAMBZTMQ-CEGNMAFCSA-N KEGG COMPOUND:C07120 KEGG DRUG:D08167 Megestrol [H][C@]12CC[C@@]3(C)[C@@]([H])(CC[C@]3(O)C(C)=O)[C@]1([H])C=CC1=CC(=O)CC[C@]21C megestrol megestrolum mesalamine 3-carboxy-4-hydroxyaniline 5-ASA 5-Aminosalicylic acid 5-amino-2-hydroxybenzoic acid 52582 An aromatic amine comprising salicylic acid having an amino group at the 5-position. Asacol Asacolitin Beilstein:2090421 C7H7NO3 CHEBI:6775 Canasa Claversal DrugBank:DB00244 Fisalamine Iialda InChI=1S/C7H7NO3/c8-4-1-2-6(9)5(3-4)7(10)11/h1-3,9H,8H2,(H,10,11) InChIKey=KBOPZPXVLCULAV-UHFFFAOYSA-N KEGG DRUG:D00377 Lixacol Mesalazina Mesalazine Mesalazinum Mesasal Nc1ccc(O)c(c1)C(O)=O Pentasa Rowasa Salofalk Wikipedia:Mesalamine m-Aminosalicylic acid mesalazine p-Aminosalicylsaeure Metformin metformin 1,1-Dimethylbiguanide 6809 A guanidine that has formula C4H11N5. C4H11N5 CHEBI:6801 CN(C)C(=N)NC(N)=N ChemIDplus:657-24-9 InChI=1S/C4H11N5/c1-9(2)4(7)8-3(5)6/h1-2H3,(H5,5,6,7,8) InChIKey=XZWYZXLIPXDOLR-UHFFFAOYSA-N KEGG COMPOUND:657-24-9 KEGG COMPOUND:C07151 Metformin N,N-dimethylimidodicarbonimidic diamide Wikipedia:Metformin 6alpha-methylprednisolone Methylprednisolone (6alpha,11beta)-11,17,21-trihydroxy-6-methylpregna-1,4-diene-3,20-dione 1-dehydro-6alpha-methylhydrocortisone 11beta,17,21-trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione 6902 6alpha-methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione A 6-methylprednisolone that has formula C22H30O5. Beilstein:2340300 C22H30O5 CHEBI:6888 ChemIDplus:83-43-2 Delta(1)-6alpha-methylhydrocortisone DrugBank:DB00959 InChI=1S/C22H30O5/c1-12-8-14-15-5-7-22(27,18(26)11-23)21(15,3)10-17(25)19(14)20(2)6-4-13(24)9-16(12)20/h4,6,9,12,14-15,17,19,23,25,27H,5,7-8,10-11H2,1-3H3/t12-,14-,15-,17-,19+,20-,21-,22-/m0/s1 InChIKey=VHRSUDSXCMQTMA-PJHHCJLFSA-N KEGG DRUG:D00407 Medrate Medrol Medrone Methylprednisolon NIST Chemistry WebBook:83-43-2 Patent:US2897218 Patent:US3053832 Solomet Urbason Wikipedia:Methylprednisolone [H][C@@]12C[C@H](C)C3=CC(=O)C=C[C@]3(C)[C@@]1([H])[C@@H](O)C[C@@]1(C)[C@@]2([H])CC[C@]1(O)C(=O)CO methylprednisolone methylprednisolonum metilprednisolona Metronidazole metronidazole 1-(beta-Ethylol)-2-methyl-5-nitro-3-azapyrrole 2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethanol 6922 Arilin Beilstein:611683 C6H9N3O3 CHEBI:63636 CHEBI:6909 Cc1ncc(n1CCO)[N+]([O-])=O ChemIDplus:443-48-1 CiteXplore:11906111 CiteXplore:14702395 CiteXplore:15739364 CiteXplore:16901452 CiteXplore:18397330 CiteXplore:19485831 CiteXplore:22226009 CiteXplore:22252819 Clont DrugBank:DB00916 Efloran Elyzol Entizol Flagyl Fossyol Imidazole substituted at C-1, -2 and -5 with 2-hydroxyethyl, nitro and methyl groups respectively. InChI=1S/C6H9N3O3/c1-5-7-4-6(9(11)12)8(5)2-3-10/h4,10H,2-3H2,1H3 InChIKey=VAOCPAMSLUNLGC-UHFFFAOYSA-N KEGG DRUG:D00409 Klion Klont Metrocream Metrogel Metrogel-Vaginal Metrolyl Metrotop NIST Chemistry WebBook:443-48-1 Nalox Nidagel Noritate Novonidazol Patent:US2944061 Protostat Reaxys:611683 Trichex Trichopol Tricowas B Trikacide Trikozol Vagilen Vagimid Vertisal Wikipedia:Metronidazole Zadstat metronidazole Nitrofurantoin nitrofurantoin 7454 CHEBI:7591 Nortriptyline nortriptyline 10,11-dihydro-N-methyl-5H-dibenzo[a,d]cycloheptene-Delta(5,gamma)-propylamine 3-(10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-ylidene)-N-methylpropan-1-amine 3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine 7531 A tricyclic antidepressant that has formula C19H21N. Ateben Avantyl Aventyl C19H21N CHEBI:7640 CNCCC=C1c2ccccc2CCc2ccccc12 ChemIDplus:2216786 ChemIDplus:72-69-5 InChI=1S/C19H21N/c1-20-14-6-11-19-17-9-4-2-7-15(17)12-13-16-8-3-5-10-18(16)19/h2-5,7-11,20H,6,12-14H2,1H3 InChIKey=PHVGLTMQBUFIQQ-UHFFFAOYSA-N KEGG COMPOUND:72-69-5 KEGG COMPOUND:C07274 NIST Chemistry WebBook:72-69-5 Noritren Nortriptyline Psychostyl Sensaval Wikipedia:Nortriptyline demethylamitriptyline desmethylamitriptyline Ofloxacin ofloxacin 7623 8-Fluoro-3-methyl-9-(4-methyl-piperazin-1-yl)-6-oxo-2,3-dihydro-6H-1-oxa-3a-aza-phenalene-5-carboxylic acid 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication. C18H20FN3O4 CC1COc2c(N3CCN(C)CC3)c(F)cc3c2n1cc(C(O)=O)c3=O CHEBI:100146 CHEBI:7731 ChEMBL:100146 CiteXplore:11710934 DrugBank:DB01165 InChI=1S/C18H20FN3O4/c1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21/h7-8,10H,3-6,9H2,1-2H3,(H,24,25) InChIKey=GSDSWSVVBLHKDQ-UHFFFAOYSA-N KEGG COMPOUND:82419-36-1 KEGG COMPOUND:C07321 KEGG DRUG:D00453 OFLX Wikipedia:Ofloxacin ofloxacin Omeprazole omeprazole 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole 7646 A sulfoxide having 3-methoxybenzimidazol-3-yl and 4-methoxy-3,5-dimethylpyridin-2-ylmethyl groups attached to the sulfur. Antra Audazol Beilstein:3628192 Belmazol C17H19N3O3S CHEBI:7772 COc1ccc2[nH]c(nc2c1)S(=O)Cc1ncc(C)c(OC)c1C Ceprandal ChemIDplus:73590-58-6 CiteXplore:11060758 CiteXplore:11208500 CiteXplore:11210716 CiteXplore:11304936 CiteXplore:11321383 CiteXplore:11395292 CiteXplore:11404722 CiteXplore:11459434 CiteXplore:11568514 CiteXplore:11700946 CiteXplore:11774962 CiteXplore:11807212 CiteXplore:11851112 CiteXplore:11903739 CiteXplore:11962536 CiteXplore:12072663 CiteXplore:12135028 CiteXplore:12235248 CiteXplore:12495367 CiteXplore:12683615 CiteXplore:13680386 CiteXplore:14616415 CiteXplore:14708212 CiteXplore:14725575 CiteXplore:15004262 CiteXplore:15125696 CiteXplore:15586641 CiteXplore:15598025 CiteXplore:15684503 CiteXplore:15707461 CiteXplore:15774534 CiteXplore:16080278 CiteXplore:16129922 CiteXplore:16259581 CiteXplore:16276979 CiteXplore:16380990 CiteXplore:16386527 CiteXplore:16397810 CiteXplore:16440530 CiteXplore:16998872 CiteXplore:17049542 CiteXplore:17384694 CiteXplore:17532167 CiteXplore:18294333 CiteXplore:18366242 CiteXplore:18416943 CiteXplore:18448060 CiteXplore:18498918 CiteXplore:18520598 CiteXplore:18571645 CiteXplore:18616070 CiteXplore:18793272 CiteXplore:18818790 CiteXplore:19150046 CiteXplore:19166730 CiteXplore:19176055 CiteXplore:19236757 CiteXplore:19327607 CiteXplore:19383986 CiteXplore:19434360 CiteXplore:19470853 CiteXplore:19517893 CiteXplore:19746659 CiteXplore:19796313 CiteXplore:19801857 CiteXplore:19937171 Danlox Desec DrugBank:DB00338 Elgam Emeproton Gasec Gastrimut InChI=1S/C17H19N3O3S/c1-10-8-18-15(11(2)16(10)23-4)9-24(21)17-19-13-6-5-12(22-3)7-14(13)20-17/h5-8H,9H2,1-4H3,(H,19,20) InChIKey=SUBDBMMJDZJVOS-UHFFFAOYSA-N Indurgan Inhibitron KEGG COMPOUND:C07324 KEGG DRUG:D00455 Losec OMEP OMP OMZ Olit Omapren Omebeta Patent:EP5129 Patent:US4255431 Patent:US5693818 Prazidec Procelac Reaxys:3628192 Sanamidol Ulceral Ulcesep Ultop Wikipedia:Omeprazole omeprazol omeprazole omeprazolum pantoprazole 40790 5-(difluoromethoxy)-2-{[(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole A benzimidazole that has formula C16H15F2N3O4S. Beilstein:5361474 C16H15F2N3O4S CHEBI:7915 COc1ccnc(CS(=O)c2nc3cc(OC(F)F)ccc3[nH]2)c1OC ChemIDplus:102625-70-7 DrugBank:DB00213 InChI=1S/C16H15F2N3O4S/c1-23-13-5-6-19-12(14(13)24-2)8-26(22)16-20-10-4-3-9(25-15(17)18)7-11(10)21-16/h3-7,15H,8H2,1-2H3,(H,20,21) InChIKey=IQPSEEYGBUAQFF-UHFFFAOYSA-N KEGG COMPOUND:C11806 KEGG DRUG:D05353 Patent:EP166287 Patent:US4758579 Wikipedia:Pantoprazole pantoprazol pantoprazole pantoprazolum Paroxetine paroxetine (-)-(3S,4R)-4-(p-fluorophenyl)-3-((3,4-(methylenedioxy)phenoxy)methyl)piperidine (3S,4R)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine (3S-trans)-3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)piperidine 32937 A benzodioxole that consists of piperidine bearing 1,3-benzodioxol-5-yloxy)methyl and 4-fluorophenyl substituents at positions 3 and 4 respectively; the (3S,4R)-diastereomer. Highly potent and selective 5-HT uptake inhibitor that binds with high affinity to the serotonin transporter (Ki = 0.05 nM). Ki values are 1.1, 350 and 1100 nM for inhibition of [3H]-5-HT, [3H]-l-NA and [3H]-DA uptake respectively. Displays minimal affinity for alpha1-, alpha2- or beta-adrenoceptors, 5-HT2A, 5-HT1A, D2 or H1 receptors at concentrations below 1000 nM, however displays weak affinity for muscarinic ACh receptors (Ki = 42 nM). Antidepressant and anxiolytic in vivo. Beilstein:7467879 C19H20FNO3 CHEBI:7936 ChemIDplus:61869-08-7 CiteXplore:11009210 CiteXplore:11169163 CiteXplore:11271409 CiteXplore:11281965 CiteXplore:11324355 CiteXplore:11360029 CiteXplore:11513198 CiteXplore:11563413 CiteXplore:11565622 CiteXplore:11819027 CiteXplore:11893234 CiteXplore:11910269 CiteXplore:12027788 CiteXplore:12088162 CiteXplore:12369443 CiteXplore:12421645 CiteXplore:12818234 CiteXplore:12820211 CiteXplore:12906023 CiteXplore:12920419 CiteXplore:14516531 CiteXplore:14521492 CiteXplore:14566196 CiteXplore:14566200 CiteXplore:14619895 CiteXplore:14624192 CiteXplore:14673053 CiteXplore:14689334 CiteXplore:14978354 CiteXplore:15048901 CiteXplore:15199661 CiteXplore:15241233 CiteXplore:15264994 CiteXplore:15374134 CiteXplore:15376524 CiteXplore:15544025 CiteXplore:15613191 CiteXplore:15845695 CiteXplore:15853570 CiteXplore:15903129 CiteXplore:15963219 CiteXplore:15992089 CiteXplore:16395417 CiteXplore:16397315 CiteXplore:16426087 CiteXplore:16765127 CiteXplore:16822276 CiteXplore:16913391 CiteXplore:17122538 CiteXplore:17162096 CiteXplore:17219219 CiteXplore:17286545 CiteXplore:17452166 CiteXplore:17559097 CiteXplore:17612590 CiteXplore:17652957 CiteXplore:17874333 CiteXplore:18273418 CiteXplore:18345955 CiteXplore:18808757 CiteXplore:18983224 CiteXplore:19687003 CiteXplore:19851065 CiteXplore:21404089 CiteXplore:21452176 CiteXplore:21739267 CiteXplore:21908494 CiteXplore:21909633 CiteXplore:21922171 CiteXplore:21939725 CiteXplore:22153922 CiteXplore:22198456 CiteXplore:22212003 CiteXplore:22240860 CiteXplore:22263916 CiteXplore:22283559 CiteXplore:22353759 CiteXplore:22377745 DrugBank:DB00715 InChI=1S/C19H20FNO3/c20-15-3-1-13(2-4-15)17-7-8-21-10-14(17)11-22-16-5-6-18-19(9-16)24-12-23-18/h1-6,9,14,17,21H,7-8,10-12H2/t14-,17-/m0/s1 InChIKey=AHOUBRCZNHFOSL-YOEHRIQHSA-N KEGG COMPOUND:61869-08-7 KEGG COMPOUND:C07415 KEGG DRUG:D02362 Paroxetine Reaxys:7467879 Wikipedia:Paroxetine [H][C@]1(CCNC[C@H]1COc1ccc2OCOc2c1)c1ccc(F)cc1 paroxetina paroxetinum Phenytoin phenytoin 5,5-Diphenyl-imidazolidine-2,4-dione 5,5-diphenylimidazolidine-2,4-dione 5,5-diphenylimidazolidine-2,4-dione 5,5-diphenyltetrahydro-1H-2,4-imidazoledione 8183 A imidazolidine-2,4-dione that consists of hydantoin bearing two phenyl substituents at position 5. Beilstein:384532 C15H12N2O2 CHEBI:100921 CHEBI:8107 ChEMBL:100921 ChemIDplus:57-41-0 CiteXplore:7602118 DILANTIN DrugBank:DB00252 InChI=1S/C15H12N2O2/c18-13-15(17-14(19)16-13,11-7-3-1-4-8-11)12-9-5-2-6-10-12/h1-10H,(H2,16,17,18,19) InChIKey=CXOFVDLJLONNDW-UHFFFAOYSA-N KEGG COMPOUND:57-41-0 KEGG COMPOUND:C07443 KEGG DRUG:D00512 O=C1NC(=O)C(N1)(c1ccccc1)c1ccccc1 PHENTYTOIN Wikipedia:Phenytoin pioglitazone (+-)-5-((4-(2-(5-ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione 33738 5-{4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl}-1,3-thiazolidine-2,4-dione A thiazolidenedione that has formula C19H20N2O3S. Beilstein:3595485 C19H20N2O3S CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1 CHEBI:8228 ChemIDplus:111025-46-8 DrugBank:DB01132 InChI=1S/C19H20N2O3S/c1-2-13-3-6-15(20-12-13)9-10-24-16-7-4-14(5-8-16)11-17-18(22)21-19(23)25-17/h3-8,12,17H,2,9-11H2,1H3,(H,21,22,23) InChIKey=HYAFETHFCAUJAY-UHFFFAOYSA-N KEGG COMPOUND:111025-46-8 KEGG COMPOUND:C07675 Patent:EP193256 Patent:US4687777 Pioglitazone Wikipedia:Pioglitazone pioglitazona pioglitazone pioglitazonum Pramipexole pramipexole (-)-Pramipexole (6S)-N(6)-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine 2,6-Benzothiazolediamine, 4,5,6,7-tetrahydro-N(sup 6)-propyl-, (S)- 746741 A member of the class of benzothiazoles that is 4,5,6,7-tetrahydro-1,3-benzothiazole in which the hydrogens at the 2 and 6-pro-S-positions are substituted by amino and propylamino groups, respectively. Beilstein:6479326 C10H17N3S CCCN[C@H]1CCc2nc(N)sc2C1 CHEBI:8356 ChemIDplus:104632-26-0 DrugBank:DB00413 InChI=1S/C10H17N3S/c1-2-5-12-7-3-4-8-9(6-7)14-10(11)13-8/h7,12H,2-6H2,1H3,(H2,11,13)/t7-/m0/s1 InChIKey=FASDKYOPVNHBLU-ZETCQYMHSA-N KEGG DRUG:D05575 Patent:EP186087 Patent:US4886812 Wikipedia:Pramipexole pramipexol pramipexole pramipexolum prednisolone (11beta)-11,17,21-trihydroxypregna-1,4-diene-3,20-dione 1,4-pregnadiene-11beta,17alpha,21-triol-3,20-dione 1,4-pregnadiene-3,20-dione-11beta,17alpha,21-triol 11beta,17,21-trihydroxypregna-1,4-diene-3,20-dione 3,20-dioxo-11beta,17alpha,21-trihydroxy-1,4-pregnadiene 8638 A 21-hydroxy steroid that has formula C21H28O5. C21H28O5 CHEBI:8378 ChemIDplus:1354103 ChemIDplus:50-24-8 Delta(1)-dehydrocortisol Delta(1)-dehydrohydrocortisone Delta(1)-hydrocortisone InChI=1S/C21H28O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h5,7,9,14-16,18,22,24,26H,3-4,6,8,10-11H2,1-2H3/t14-,15-,16-,18+,19-,20-,21-/m0/s1 InChIKey=OIGNJSKKLXVSLS-VWUMJDOOSA-N KEGG COMPOUND:50-24-8 KEGG COMPOUND:C07369 Prednisolone Wikipedia:Prednisolone [H][C@@]12CCC3=CC(=O)C=C[C@]3(C)[C@@]1([H])[C@@H](O)C[C@@]1(C)[C@@]2([H])CC[C@]1(O)C(=O)CO hydroretrocortine metacortandralone 6-propyl-2-thiouracil Propylthiouracil 2,3-dihydro-6-propyl-2-thioxo-4(1H)-pyrimidinone 2-Mercapto-6-propyl-4-pyrimidone 2-Mercapto-6-propylpyrimid-4-one 2-Thio-4-oxo-6-propyl-1,3-pyrimidine 2-Thio-6-propyl-1,3-pyrimidin-4-one 4-Propyl-2-thiouracil 4-propyl-2-thiouracil 6-Propyl-2-thio-2,4(1H,3H)pyrimidinedione 6-Propylthiouracil 6-Thio-4-propyluracil 6-propyl-2-sulfanylidene-2,3-dihydropyrimidin-4(1H)-one 6-propyl-2-thiouracil 6-propyl-2-thioxo-2,3-dihydropyrimidin-4(1H)-one 8794 A pyrimidinethione consisting of uracil in which the 2-oxo group is substituted by a thio group and the hydrogen at position 6 is substituted by a propyl group. Beilstein:130039 C7H10N2OS CCCc1cc(=O)[nH]c(=S)[nH]1 CHEBI:8502 ChemIDplus:51-52-5 CiteXplore:11005705 CiteXplore:11036881 CiteXplore:11350963 CiteXplore:11401533 CiteXplore:12135875 CiteXplore:12922945 CiteXplore:14692727 CiteXplore:14745920 CiteXplore:16380675 CiteXplore:16498810 CiteXplore:16880639 CiteXplore:17365943 CiteXplore:17497002 CiteXplore:17878268 CiteXplore:18055877 CiteXplore:18710353 CiteXplore:19530273 CiteXplore:19578601 CiteXplore:20166204 CiteXplore:21749382 CiteXplore:6387489 DrugBank:DB00550 Gmelin:1998546 InChI=1S/C7H10N2OS/c1-2-3-5-4-6(10)9-7(11)8-5/h4H,2-3H2,1H3,(H2,8,9,10,11) InChIKey=KNAHARQHSZJURB-UHFFFAOYSA-N KEGG COMPOUND:51-52-5 KEGG COMPOUND:C07569 KEGG DRUG:D00562 NIST Chemistry WebBook:51-52-5 Propylthiouracil Reaxys:130039 Wikipedia:Propylthiouracil propiltiouracilo propylthiouracil propylthiouracile propylthiouracilum Protriptyline protriptyline 3-(5H-dibenzo[a,d][7]annulen-5-yl)-N-methylpropan-1-amine 3-(5H-dibenzo[a,d]cyclohepten-5-yl)-N-methyl-1-propanamine 5-(3-methylaminopropyl)-5H-dibenzo[a,d]cycloheptene 7-(3-methylaminopropyl)-1,2:5,6-dibenzocycloheptatriene 8886 A tricyclic antidepressant that has formula C19H21N. C19H21N CHEBI:8597 CNCCCC1c2ccccc2C=Cc2ccccc12 ChemIDplus:2217411 ChemIDplus:438-60-8 InChI=1S/C19H21N/c1-20-14-6-11-19-17-9-4-2-7-15(17)12-13-16-8-3-5-10-18(16)19/h2-5,7-10,12-13,19-20H,6,11,14H2,1H3 InChIKey=BWPIARFWQZKAIA-UHFFFAOYSA-N KEGG COMPOUND:438-60-8 KEGG COMPOUND:C07408 N-methyl-5H-dibenzo[a,d]cycloheptene-5-propanamine N-methyl-5H-dibenzo[a,d]cycloheptene-5-propylamine NIST Chemistry WebBook:438-60-8 Protriptyline Wikipedia:Protriptyline amimetilina rabeprazole 114979 2-({[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methyl}sulfinyl)-1H-benzimidazole A sulfoxide that has formula C18H21N3O3S. Beilstein:8159014 C18H21N3O3S CHEBI:8768 COCCCOc1ccnc(CS(=O)c2nc3ccccc3[nH]2)c1C ChemIDplus:117976-89-3 Clofezone DrugBank:DB01129 InChI=1S/C18H21N3O3S/c1-13-16(19-9-8-17(13)24-11-5-10-23-2)12-25(22)18-20-14-6-3-4-7-15(14)21-18/h3-4,6-9H,5,10-12H2,1-2H3,(H,20,21) InChIKey=YREYEVIYCVEVJK-UHFFFAOYSA-N KEGG COMPOUND:117976-89-3 KEGG COMPOUND:C07864 Rabeprazole Wikipedia:Rabeprazole rabeprazole Ramipril ramipril (2S,3aS,6aS)-1-[(2S)-2-{[(1S)-1-ethoxycarbonyl-3-phenylpropyl]amino}propanoyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid (2S-(1(R*(R*)),2alpha,3abeta,6abeta))-1-(2-((1-(Ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydrocyclopenta(b)pyrrole-2-carboxylic acid. 35296 A cyclopentapyrrole that has formula C23H32N2O5. Altace (TN) Beilstein:4214464 C23H32N2O5 CHEBI:8774 ChemIDplus:87333-19-5 InChI=1S/C23H32N2O5/c1-3-30-23(29)18(13-12-16-8-5-4-6-9-16)24-15(2)21(26)25-19-11-7-10-17(19)14-20(25)22(27)28/h4-6,8-9,15,17-20,24H,3,7,10-14H2,1-2H3,(H,27,28)/t15-,17-,18-,19-,20-/m0/s1 InChIKey=HDACQVRGBOVJII-JBDAPHQKSA-N KEGG DRUG:87333-19-5 KEGG DRUG:D00421 Ramipril Tritace Wikipedia:Ramipril [H][C@@]12CCC[C@]1([H])N([C@@H](C2)C(O)=O)C(=O)[C@H](C)N[C@@H](CCc1ccccc1)C(=O)OCC ropinirole 4-[2-(dipropylamino)ethyl]-1,3-dihydro-2H-indol-2-one 72302 An indolone that has formula C16H24N2O. Beilstein:6062222 C16H24N2O CCCN(CCC)CCc1cccc2NC(=O)Cc12 CHEBI:8888 ChemIDplus:91374-21-9 DrugBank:DB00268 InChI=1S/C16H24N2O/c1-3-9-18(10-4-2)11-8-13-6-5-7-15-14(13)12-16(19)17-15/h5-7H,3-4,8-12H2,1-2H3,(H,17,19) InChIKey=UHSKFQJFRQCDBE-UHFFFAOYSA-N KEGG COMPOUND:C07564 Patent:US4452808 Ropinirole Wikipedia:Ropinirole ropinirol ropinirole ropinirolum Simvastatin simvastatin (1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate 2,2-dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one 36567 A fatty acid ester comprising a dihydroxyheptanoic acid unit condensed into a lactone; a partially reduced naphthalene structure; and a 2,2-dimethylbutyric acyl substituent at C17. It is used as a cholesterol-lowering and anti-cardiovascular disease drug. Beilstein:4768037 C25H38O5 CHEBI:45577 CHEBI:9150 ChemIDplus:79902-63-9 DrugBank:DB00641 InChI=1S/C25H38O5/c1-6-25(4,5)24(28)30-21-12-15(2)11-17-8-7-16(3)20(23(17)21)10-9-19-13-18(26)14-22(27)29-19/h7-8,11,15-16,18-21,23,26H,6,9-10,12-14H2,1-5H3/t15-,16-,18+,19+,20-,21-,23-/m0/s1 InChIKey=RYMZZMVNJRMUDD-HGQWONQESA-N KEGG DRUG:79902-63-9 KEGG DRUG:D00434 MK-733 Patent:EP33538 Patent:US4444784 Simvastatin Simvastatina Simvastatine Simvastatinum Wikipedia:Simvastatin Zocor [H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)C(C)(C)CC simvastatin Sulfasalazine sulfasalazine 2-Hydroxy-5-((4-((2-pyridinylamino)sulfonyl)phenyl)azo)benzoic acid 2-Hydroxy-5-[4-(pyridin-2-ylsulfamoyl)-phenylazo]-benzoic acid 2-hydroxy-5-{[4-(pyridin-2-ylsulfamoyl)phenyl]diazenyl}benzoic acid 4-(Pyridyl-2-amidosulfonyl)-3'-carboxy-4'-hydroxyazobenzene 5-((p-(2-Pyridylsulfamoyl)phenyl)azo)salicylic acid 5-(4-(2-Pyridylsulfamoyl)phenylazo)-2-hydroxybenzoic acid 5-(p-(2-Pyridylsulfamyl)phenylazo)salicylic acid 9524 An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position. Azulfidine Beilstein:356241 Beilstein:8132868 C18H14N4O5S CHEBI:101223 CHEBI:9334 ChemIDplus:599-79-1 CiteXplore:2434548 DrugBank:DB00795 Gmelin:2666050 InChI=1S/C18H14N4O5S/c23-16-9-6-13(11-15(16)18(24)25)21-20-12-4-7-14(8-5-12)28(26,27)22-17-3-1-2-10-19-17/h1-11,23H,(H,19,22)(H,24,25)/b21-20+ InChIKey=NCEXYHBECQHGNR-QZQOTICOSA-N KEGG COMPOUND:599-79-1 KEGG COMPOUND:C07316 KEGG DRUG:D00448 OC(=O)c1cc(ccc1O)\N=N\c1ccc(cc1)S(=O)(=O)Nc1ccccn1 Patent:US2396145 Reaxys:8132868 Salazosulfapiridina Salazosulfapyridine Salazosulfapyridinum Salicylazosulfapyridine Sulfasalazina Sulfasalazine Sulfasalazinum sulfasalazine Ticlopidine ticlopidine 10594 5-(2-chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine A thienopyridine that has formula C14H14ClNS. C14H14ClNS CHEBI:9588 ChemIDplus:55142-85-3 Clc1ccccc1CN1CCc2sccc2C1 DrugBank:DB00208 InChI=1S/C14H14ClNS/c15-13-4-2-1-3-11(13)9-16-7-5-14-12(10-16)6-8-17-14/h1-4,6,8H,5,7,9-10H2 InChIKey=PHWBOXQYWZNQIN-UHFFFAOYSA-N KEGG COMPOUND:C07140 Patent:DE2404308 Patent:US4051141 Patent:US4127580 Wikipedia:Ticlopidine ticlopidina ticlopidine ticlopidinum Triamcinolone 10759 CHEBI:9667 Trimipramine trimipramine 10,11-dihydro-N,N,beta-trimethyl-5H-dibenz[b,f]azepine-5-propanamine 10834 3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N,2-trimethylpropan-1-amine 5-(gamma-dimethylamino-beta-methylpropyl)-10,11-dihydro-5H-dibenzo[b,f]azepine 5-[3-(dimethylamino)-2-methylpropyl]-10,11-dihydro-5H-dibenz[b,f]azepine A dibenzoazepine that has formula C20H26N2. C20H26N2 CC(CN(C)C)CN1c2ccccc2CCc2ccccc12 CHEBI:9738 ChemIDplus:1321466 ChemIDplus:739-71-9 InChI=1S/C20H26N2/c1-16(14-21(2)3)15-22-19-10-6-4-8-17(19)12-13-18-9-5-7-11-20(18)22/h4-11,16H,12-15H2,1-3H3 InChIKey=ZSCDBOWYZJWBIY-UHFFFAOYSA-N KEGG DRUG:D00394 NIST Chemistry WebBook:739-71-9 RP-7162 Sapilent Trimeprimine Trimipramine Wikipedia:Trimipramine beta-methylimipramine trimeproprimine venlafaxine 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexanol 39786 A cyclohexanol that has formula C17H27NO2. Beilstein:4234848 C17H27NO2 CHEBI:9943 COc1ccc(cc1)C(CN(C)C)C1(O)CCCCC1 ChemIDplus:93413-69-5 DrugBank:DB00285 Elafax InChI=1S/C17H27NO2/c1-18(2)13-16(17(19)11-5-4-6-12-17)14-7-9-15(20-3)10-8-14/h7-10,16,19H,4-6,11-13H2,1-3H3 InChIKey=PNVNVHUZROJLTJ-UHFFFAOYSA-N KEGG COMPOUND:93413-69-5 KEGG COMPOUND:C07187 Venlafaxine Wikipedia:Venlafaxine venlafaxina venlafaxine venlafaxinum cell A material entity of anatomical origin (part of or deriving from an organism) that has as its parts a maximally connected cell compartment surrounded by a plasma membrane. CALOHA:TS-2035 CL:0000000 FMA:68646 GO:0005623 KUPO:0000002 The definition of cell is intended to represent all cells, and thus a cell is defined as a material entity and not an anatomical structure, which implies that it is part of an organism (or the entirety of one). VHOG:0001533 WBbt:0004017 XAO:0003012 cell native cell A cell that is found in a natural setting, which includes multicellular organism cells 'in vivo' (i.e. part of an organism), and unicellular organisms 'in environment' (i.e. part of a natural environment). CARO:0000013 CL:0000003 To accommodate unicellular organisms better, 'cell in vivo' has been re-labeled 'native cell' to better represent its intended meaning - that is, that it is a cell in the context of a multicellular organism or in a natural environment. 'Native' is intended to contrast with 'in vitro', which refers to cells or other biological entities that have been intentionally placed in a controlled, non-natural setting for the purpose of study or manipulation. (MAH 1.12.12). cell cell in vivo neuronal receptor cell CL:0000006 cell neuronal receptor cell (sensu Animalia) neuroblast A cell that will develop into a neuron often after a migration phase. BTO:0000930 CL:0000031 FBbt:00005146 FMA:70563 cell stem cell A relatively undifferentiated cell that retains the ability to divide and proliferate throughout life to provide progenitor cells that can differentiate into specialized cells. CALOHA:TS-2086 CL:0000034 FMA:63368 cell neuronal stem cell BTO:0002881 CALOHA:TS-2360 CL:0000047 FMA:86684 NSC Neural stem cell is characterized as an undifferentiated cell that originates from the neuroectoderm and has the capacity both to perpetually self-renew without differentiating and to generate multiple types of lineage-restricted progenitors. cell neural stem cell multi fate stem cell A stem cell that can give rise to multiple lineages of cells. CL:0000048 FMA:84789 cell multi-fate stem cell multifate stem cell multipotent cell multipotent stem cell totipotent stem cell A stem cell from which all cells of the body can form. CL:0000052 FMA:84790 cell totipotential stem cell non-terminally differentiated cell A precursor cell with a limited number of potential fates. BTO:0000125 CL:0000055 FMA:84782 blast cell cell define using PATO mulit-potent or oligopotent? sensory neuron Any neuron having a sensory function; an afferent neuron conveying sensory impulses. BTO:0001037 CL:0000101 FBbt:00005124 FMA:84649 WBbt:0005759 cell neurectodermal cell CL:0000133 Ectoderm destined to be nervous tissue. cell neurectoderm cell pigment cell A pigment cell is a cell that contains pigment granules. CL:0000147 VHOG:0001678 cell chromatocyte chromatophore visual pigment cell CL:0000149 cell pigment cell receptor cell CL:0000197 cell photoreceptor cell A cell specialized to detect and transduce light. BTO:0001060 CALOHA:TS-0868 CL:0000210 FBbt:00004211 FMA:86740 cell electrically active cell A cell whose function is determined by the generation or the reception of an electric signal. CL:0000211 cell ectodermal cell A cell of the outer of the three germ layers of the embryo. CL:0000221 FMA:72549 cell ectoderm cell eukaryotic cell CL:0000255 cell stuff accumulating cell A cell that is specialised to accumulate a particular substance(s). CL:0000325 cell epiblast cell A cell of the outer layer of a blastula that gives rise to the ectoderm after gastrulation. CL:0000352 cell electrically responsive cell A cell whose function is determined by its response to an electric signal. CL:0000393 cell electrically signaling cell A cell that initiates an electrical signal and passes that signal to another cell. CL:0000404 cell afferent neuron A neuron which conveys sensory information centrally from the periphery. CL:0000526 FMA:87653 cell input neuron neuron BTO:0000938 CALOHA:TS-0683 CL:0000540 FBbt:00005106 FMA:54527 The basic cellular unit of nervous tissue. Each neuron consists of a body, an axon, and dendrites. Their purpose is to receive, conduct, and transmit impulses in the nervous system. These cells are also reportedly CD4-negative and CD200-positive. They are also capable of producing CD40L and IFN-gamma. VHOG:0001483 WBbt:0003679 cell nerve cell animal cell CL:0000548 cell somatic stem cell A stem cell that can give rise to cell types of the body other than those of the germ-line. CALOHA:TS-2086 CL:0000723 FMA:63368 cell neural cell 2010-09-15T01:34:57Z A cell that is part of the nervous system. CALOHA:TS-2040 CL:0002319 FMA:70333 cell tmeehan embryonic cell 2010-09-15T03:39:21Z A cell of the embryo. CALOHA:TS-0263 CL:0002321 FMA:82840 FMA:82841 WBbt:0007028 cell tmeehan somatic cell 2010-09-24T09:44:42Z A cell of an organism that does not pass on its genetic material to the organism's offspring (i.e. a non-germ line cell). BTO:0001268 CL:0002371 FMA:72300 WBbt:0008378 cell tmeehan clinical drug role William Hogan William Hogan the role of a material entity to prevent, diagnose, treat, or study disease and/or its effects drug product William Hogan William Hogan a material entity (1) containing at least one scattered molecular aggregate as part (the active ingredient) and (2) that is the bearer of a clinical drug role Altretamine 5296 capecitabine 194000 Cerivastatin sodium 221072 NDF-RT: N0000022124 RxNORM: RXNORM/221072 Delavirdine 83816 NDF-RT: N0000022056 RxNORM: RXNORM/83816 lomefloxacin 28872 olsalazine 32385 Penicillamine 7975 Procarbazine 8702 Succimer 3446 tolcapone 72937 Tolmetin 10636 fluvastatin 41127 infliximab 191831 NDF-RT: N0000148580 RxNORM: RXNORM/191831 Vigabatrin 14851 Aldesleukin 70223 Teniposide 10362 basiliximab 196102 RxNORM: RXNORM/196102 NDF-RT: N0000148568 trastuzumab 224905 linezolid 190376 arsenic trioxide 18330 rituximab 121191 Auranofin 1227 Acitretin 16818 Sirolimus 35302 Carmustine 2105 cevimeline 44281 NDF-RT: N0000148658 RxNORM: RXNORM/44281 Insulin, Protamine Zinc, Human 236646 eletriptan 231049 RxNORM: RXNORM/231049 NDF-RT: N0000148791 mycophenolate mofetil 68149 bexarotene 233272 Zalcitabine 3363 alosetron 85248 enfuvirtide 139896 RxNORM: RXNORM/139896 NDF-RT: N0000148793 zolmitriptan 135775 gemifloxacin 138099 RxNORM: RXNORM/138099 NDF-RT: N0000148804 Daptomycin 22299 RxNORM: RXNORM/22299 NDF-RT: N0000148828 pemetrexed 68446 Probenecid 8698 Chlorambucil 2346 NDF-RT: N0000147072 RxNORM: RXNORM/2346 rofecoxib 232158 Sulfamethizole 10179 Thalidomide 10432 Metolazone 6916 Saquinavir 83395 Flecainide 4441 histrelin 50975 rasagiline 134748 gatifloxacin 228476 Phenazopyridine 8120 rivastigmine 183379 Iopamidol 5966 peginterferon alfa-2b 253453 Triptorelin 38782 fludarabine 24698 efavirenz 195085 pregabalin 187832 Lamivudine 68244 Memantine 6719 gabapentin 25480 Nevirapine 53654 doxorubicin liposome 214525 NDF-RT: N0000147829 RxNORM: RXNORM/3639 fluticasone 41126 sildenafil 136411 almotriptan 279645 NDF-RT: N0000148709 RxNORM: RXNORM/279645 valdecoxib 278567 Miglustat 402316 Atazanavir 343047 RxNORM: RXNORM/343047 NDF-RT: N0000022320 bortezomib 358258 tadalafil 358263 aprepitant 358255 NDF-RT: N0000148809 RxNORM: RXNORM/358255 imatinib 282388 erlotinib 337525 NDF-RT: N0000148872 RxNORM: RXNORM/337525 Eszopiclone 461016 RxNORM: RXNORM/461016 NDF-RT: N0000023088 sorafenib 495881 lenalidomide 342369 NDF-RT: N0000171749 RxNORM: RXNORM/342369 nelarabine 274771 Nalidixate 618425 dasatinib 475342 NDF-RT: N0000176043 RxNORM: RXNORM/475342 posaconazole 282446 maraviroc 620216 NDF-RT: N0000176115 RxNORM: RXNORM/620216 ixabepilone 337523 NDF-RT: N0000176119 RxNORM: RXNORM/337523 nilotinib 662281 etravirine 475969 NDF-RT: N0000176133 RxNORM: RXNORM/475969 Fosaprepitant dimeglumine 754763 RxNORM: RXNORM/754763 NDF-RT: N0000176136 golimumab 819300 NDF-RT: N0000178413 RxNORM: RXNORM/819300 certolizumab pegol 709271 valganciclovir 275891 levoleucovorin 877015 NDF-RT: N0000177954 RxNORM: RXNORM/877015 telbivudine 474128 tocilizumab 612865 Cytarabine liposome 968804 NDF-RT: N0000146419 RxNORM: RXNORM/3041 cabazitaxel 996051 NDF-RT: N0000181529 RxNORM: RXNORM/996051 tesamorelin 1044584 eribulin 1045453 RxNORM: RXNORM/1045453 NDF-RT: N0000182260 ipilimumab 1094833 NDF-RT: N0000182641 RxNORM: RXNORM/1094833 Vemurafenib 1147220 crizotinib 1148495 NDF-RT: N0000183253 RxNORM: RXNORM/1148495 avanafil 1291301 carfilzomib 1302966 emtricitabine 276237 tenofovir disoproxil 300195 teriflunomide 1310520 non-activating competitive beta-adrenergic receptor binding disposition function-inhibiting hydrogen/potassium adenosine triphosphatase enzyme (H+/K+ ATPase) binding disposition function-inhibiting L-type voltage-gated calcium channel binding disposition Triamcinolone Oral Tablet 96819 RxNORM: RXNORM/10759 NDF-RT: N0000145980 Dexamethasone Ophthalmic Ointment 103217 NDF-RT: N0000146273 RxNORM: RXNORM/3264 Hydrocortisone Ophthalmic Ointment 108133 Colchicine / Probenecid Oral Tablet 239053 RxNORM: RXNORM/2683 NDF-RT: N0000145804 fluticasone Inhalant Powder 361834 Carmustine Injectable Solution 370496 NDF-RT: N0000146473 RxNORM: RXNORM/2105 Acitretin Oral Capsule 370533 NDF-RT: N0000148524 RxNORM: RXNORM/16818 Allopurinol Oral Tablet 370547 RxNORM: RXNORM/519 NDF-RT: N0000146247 Amantadine Oral Tablet 370559 NDF-RT: N0000147697 RxNORM: RXNORM/620 Amiodarone Oral Tablet 370568 NDF-RT: N0000147701 RxNORM: RXNORM/203114 RxNORM: RXNORM/703 NDF-RT: N0000146406 Amitriptyline Oral Tablet 370570 NDF-RT: N0000023131 RxNORM: RXNORM/203168 Amlodipine Oral Tablet 370573 NDF-RT: N0000148333 RxNORM: RXNORM/17767 anastrozole Oral Tablet 370588 NDF-RT: N0000148427 RxNORM: RXNORM/84857 Aspirin Oral Tablet 370611 atorvastatin Oral Tablet 370621 NDF-RT: N0000022046 RxNORM: RXNORM/83367 hydroxyurea Oral Tablet 370657 NDF-RT: N0000146101 RxNORM: RXNORM/5552 Imipramine Oral Tablet 370679 NDF-RT: N0000147875 NDF-RT: N0000146215 RxNORM: RXNORM/5691 RxNORM: RXNORM/150816 Imipramine Oral Capsule 370680 NDF-RT: N0000146216 RxNORM: RXNORM/91118 Indomethacin Oral Suspension 370686 NDF-RT: N0000146243 RxNORM: RXNORM/5781 Iopamidol Injectable Solution 370700 NDF-RT: N0000146122 RxNORM: RXNORM/5966 isoniazid Oral Tablet 370716 NDF-RT: N0000145890 RxNORM: RXNORM/6038 Itraconazole Oral Capsule 370725 NDF-RT: N0000148264 RxNORM: RXNORM/28031 Altretamine Oral Tablet 370819 RxNORM: RXNORM/5296 NDF-RT: N0000147673 Auranofin Oral Tablet 370967 RxNORM: RXNORM/1227 NDF-RT: N0000146358 Betaxolol Oral Tablet 371065 NDF-RT: N0000147726 RxNORM: RXNORM/1520 bicalutamide Oral Tablet 371070 RxNORM: RXNORM/83008 NDF-RT: N0000148428 Bromocriptine Oral Capsule 371127 Buspirone Oral Tablet 371164 Caffeine Oral Tablet 371181 capecitabine Oral Tablet 371250 RxNORM: RXNORM/996051 NDF-RT: N0000148555 Capsaicin Topical Solution 371251 RxNORM: RXNORM/1992 NDF-RT: N0000147626 Ciprofloxacin Oral Capsule 371523 NDF-RT: N0000147503 RxNORM: RXNORM/2551 Ciprofloxacin Oral Tablet 371525 RxNORM: RXNORM/81981 NDF-RT: N0000147502 Clomipramine Oral Capsule 371572 RxNORM: RXNORM/2597 NDF-RT: N0000147779 Codeine Oral Tablet 371613 cyclobenzaprine Oral Tablet 371661 RxNORM: RXNORM/21949 NDF-RT: N0000147791 Cyclosporine Oral Capsule 371666 NDF-RT: N0000147064 RxNORM: RXNORM/3008 Dapsone Oral Tablet 371689 RxNORM: RXNORM/3108 NDF-RT: N0000147467 Desipramine Oral Tablet 371709 NDF-RT: N0000147800 RxNORM: RXNORM/3247 Didanosine Chewable Tablet 371819 RxNORM: RXNORM/3364 NDF-RT: N0000148104 Diltiazem Oral Tablet 371856 NDF-RT: N0000147814 RxNORM: RXNORM/3443 Disulfiram Oral Tablet 371940 NDF-RT: N0000146816 RxNORM: RXNORM/3554 efavirenz Oral Capsule 372003 NDF-RT: N0000148587 RxNORM: RXNORM/195085 Enalapril Oral Tablet 372007 Ethambutol Oral Tablet 372091 NDF-RT: N0000147838 NDF-RT: N0000146263 RxNORM: RXNORM/142435 RxNORM: RXNORM/4110 Etidronate Oral Tablet 372120 RxNORM: RXNORM/42682 NDF-RT: N0000147844 Etoposide Oral Capsule 372132 NDF-RT: N0000146478 RxNORM: RXNORM/4179 Fentanyl Injectable Solution 372160 RxNORM: RXNORM/4337 NDF-RT: N0000147049 Fluconazole Oral Capsule 372208 RxNORM: RXNORM/4450 NDF-RT: N0000147613 Flucytosine Oral Capsule 372211 NDF-RT: N0000146153 RxNORM: RXNORM/4451 Fluorouracil Oral Capsule 372227 RxNORM: RXNORM/4492 NDF-RT: N0000146166 Fluoxetine Oral Capsule 372231 fluvastatin Oral Capsule 372255 NDF-RT: N0000021914 RxNORM: RXNORM/41127 Fluvoxamine Oral Tablet 372256 RxNORM: RXNORM/203143 NDF-RT: N0000148386 Ganciclovir Oral Capsule 372292 NDF-RT: N0000147855 RxNORM: RXNORM/4678 Gentamicin Sulfate (USP) Injectable Solution 372302 Haloperidol Oral Solution 372376 RxNORM: RXNORM/5093 NDF-RT: N0000146461 Lamivudine Oral Tablet 372563 RxNORM: RXNORM/68244 NDF-RT: N0000148418 leflunomide Oral Tablet 372570 RxNORM: RXNORM/27169 NDF-RT: N0000148586 Leuprolide Injectable Solution 372576 Levodopa Oral Tablet 372586 Levofloxacin Oral Tablet 372588 NDF-RT: N0000148474 RxNORM: RXNORM/82122 Lisinopril Oral Tablet 372614 RxNORM: RXNORM/29046 NDF-RT: N0000147537 lomefloxacin Oral Tablet 372630 NDF-RT: N0000148144 RxNORM: RXNORM/235762 NDF-RT: N0000148250 RxNORM: RXNORM/28872 Losartan Oral Tablet 372651 RxNORM: RXNORM/203160 NDF-RT: N0000148401 RxNORM: RXNORM/52175 NDF-RT: N0000148405 Lovastatin Oral Tablet 372652 RxNORM: RXNORM/6472 NDF-RT: N0000147602 Mefloquine Oral Tablet 372745 NDF-RT: N0000147900 RxNORM: RXNORM/6694 Megestrol Oral Suspension 372747 RxNORM: RXNORM/6703 NDF-RT: N0000020211 Memantine Oral Tablet 372757 mesalamine Extended Release Capsule 372783 RxNORM: RXNORM/52582 NDF-RT: N0000147614 Metformin Oral Tablet 372803 Methimazole Oral Tablet 372827 RxNORM: RXNORM/6835 NDF-RT: N0000145822 Methotrexate Injectable Solution 372835 NDF-RT: N0000147916 RxNORM: RXNORM/6851 Methylprednisolone Topical Ointment 372863 RxNORM: RXNORM/52582 NDF-RT: N0000146409 Methylprednisolone Injectable Suspension 372866 RxNORM: RXNORM/155323 NDF-RT: N0000146411 Metolazone Oral Tablet 372888 RxNORM: RXNORM/6916 NDF-RT: N0000146498 Metronidazole Oral Suspension 372893 RxNORM: RXNORM/6922 NDF-RT: N0000146194 Misoprostol Oral Tablet 372941 NDF-RT: N0000147506 RxNORM: RXNORM/42331 Nevirapine Oral Tablet 373046 RxNORM: RXNORM/53654 NDF-RT: N0000148461 Nitrofurantoin Oral Tablet 373101 RxNORM: RXNORM/7454 NDF-RT: N0000147151 Norfloxacin Oral Tablet 373120 RxNORM: RXNORM/7517 NDF-RT: N0000147623 Nortriptyline Oral Tablet 373126 NDF-RT: N0000147946 RxNORM: RXNORM/7531 Ofloxacin Oral Tablet 373141 RxNORM: RXNORM/7623 NDF-RT: N0000147667 olsalazine Oral Tablet 373144 NDF-RT: N0000147671 RxNORM: RXNORM/104123 pantoprazole Enteric Coated Tablet 373222 RxNORM: RXNORM/40790 NDF-RT: N0000148654 Penicillamine Oral Tablet 373258 NDF-RT: N0000146290 RxNORM: RXNORM/7975 Penicillin G Oral Solution 373263 Penicillin V Oral Tablet 373266 RxNORM: RXNORM/203195 NDF-RT: N0000145824 Pergolide Oral Tablet 373291 RxNORM: RXNORM/8047 NDF-RT: N0000147968 Phenazopyridine Oral Tablet 373303 Phenytoin Oral Tablet 373432 RxNORM: RXNORM/8183 NDF-RT: N0000146211 Pravastatin Oral Tablet 373560 RxNORM: RXNORM/42463 NDF-RT: N0000148255 prednisolone Oral Tablet 373578 Procarbazine Oral Capsule 373602 Propafenone Oral Tablet 373637 Propylthiouracil Oral Tablet 373658 NDF-RT: N0000145820 RxNORM: RXNORM/8794 Protriptyline Oral Tablet 373665 RxNORM: RXNORM/8886 NDF-RT: N0000148003 Ramipril Oral Tablet 373749 RxNORM: RXNORM/35296 NDF-RT: N0000147662 Ribavirin Oral Tablet 373774 rivastigmine Oral Capsule 373797 RxNORM: RXNORM/183379 NDF-RT: N0000148665 ropinirole Oral Tablet 373800 NDF-RT: N0000022086 RxNORM: RXNORM/72302 Selegiline Oral Tablet 373842 NDF-RT: N0000148014 RxNORM: RXNORM/9639 sildenafil Oral Tablet 373871 NDF-RT: N0000022115 RxNORM: RXNORM/136411 Simvastatin Oral Tablet 373888 NDF-RT: N0000148200 RxNORM: RXNORM/36567 Sotalol Oral Tablet 373937 NDF-RT: N0000148322 RxNORM: RXNORM/7008 RxNORM: RXNORM/9947 NDF-RT: N0000148334 Stavudine Oral Capsule 373959 RxNORM: RXNORM/59763 NDF-RT: N0000148369 Succimer Oral Capsule 373964 RxNORM: RXNORM/3446 NDF-RT: N0000147417 Sulfamethizole Oral Tablet 373981 NDF-RT: N0000146815 Sulfasalazine Oral Tablet 373991 NDF-RT: N0000146249 RxNORM: RXNORM/9524 Sumatriptan Oral Tablet 374012 Tamoxifen Oral Tablet 374020 NDF-RT: N0000148024 RxNORM: RXNORM/10324 Ticlopidine Oral Tablet 374131 NDF-RT: N0000148235 RxNORM: RXNORM/10594 Tinidazole Oral Tablet 374138 RxNORM: RXNORM/10612 NDF-RT: N0000148851 tizanidine Oral Tablet 374146 NDF-RT: N0000148492 RxNORM: RXNORM/57258 Tobramycin Injectable Solution 374147 tolcapone Oral Tablet 374153 RxNORM: RXNORM/72937 NDF-RT: N0000148551 Tolmetin Oral Tablet 374157 RxNORM: RXNORM/10636 NDF-RT: N0000148037 topiramate Oral Tablet 374166 NDF-RT: N0000148493 RxNORM: RXNORM/38404 Trimipramine Oral Tablet 374239 NDF-RT: N0000148047 RxNORM: RXNORM/10834 venlafaxine Oral Tablet 374285 NDF-RT: N0000021906 RxNORM: RXNORM/39786 Vigabatrin Oral Tablet 374291 RxNORM: RXNORM/14851 NDF-RT: N0000171807 zafirlukast Oral Tablet 374330 RxNORM: RXNORM/114970 NDF-RT: N0000148457 Zidovudine Oral Tablet 374332 NDF-RT: N0000147622 RxNORM: RXNORM/11413 zolmitriptan Oral Tablet 374363 RxNORM: RXNORM/135775 NDF-RT: N0000148550 zolpidem Oral Tablet 374364 NDF-RT: N0000021601 RxNORM: RXNORM/39993 clopidogrel Oral Tablet 374583 pioglitazone Oral Tablet 374606 zaleplon Oral Capsule 374609 NDF-RT: N0000148625 RxNORM: RXNORM/74667 moxifloxacin Oral Tablet 374619 RxNORM: RXNORM/139462 NDF-RT: N0000148632 gatifloxacin Oral Tablet 374621 linezolid Oral Tablet 374626 RxNORM: RXNORM/190376 NDF-RT: N0000148664 ziprasidone Oral Capsule 374649 RxNORM: RXNORM/115698 NDF-RT: N0000148690 valganciclovir Oral Tablet 374656 RxNORM: RXNORM/275891 NDF-RT: N0000148704 mycophenolate mofetil Oral Tablet 374667 peginterferon alfa-2b Injectable Solution 374678 RxNORM: RXNORM/253453 NDF-RT: N0000148697 exemestane Oral Tablet 375061 NDF-RT: N0000148637 RxNORM: RXNORM/258494 Mitoxantrone Injectable Solution 375173 RxNORM: RXNORM/203129 RxNORM: RXNORM/7005 NDF-RT: N0000147641 NDF-RT: N0000147929 Pentamidine Injectable Solution 375205 NDF-RT: N0000147966 RxNORM: RXNORM/7994 rabeprazole Enteric Coated Tablet 375256 zonisamide Oral Tablet 375369 NDF-RT: N0000148668 RxNORM: RXNORM/39998 cefepime Injectable Solution 375794 NDF-RT: N0000022054 RxNORM: RXNORM/20481 Aurothiomalate Injectable Solution 376337 RxNORM: RXNORM/4981 NDF-RT: N0000146340 Deferoxamine Injectable Solution 376374 NDF-RT: N0000147797 RxNORM: RXNORM/3131 rofecoxib Oral Tablet 376431 NDF-RT: N0000148611 RxNORM: RXNORM/232158 Cisplatin Injectable Solution 376433 NDF-RT: N0000146476 RxNORM: RXNORM/2555 Foscarnet Injectable Solution 376842 RxNORM: RXNORM/33562 NDF-RT: N0000148246 gemcitabine Injectable Solution 376887 RxNORM: RXNORM/12574 NDF-RT: N0000022036 docetaxel Injectable Solution 376888 NDF-RT: N0000148441 RxNORM: RXNORM/72962 Aldesleukin Injectable Solution 377091 RxNORM: RXNORM/70223 NDF-RT: N0000148066 Paclitaxel Injectable Solution 377111 RxNORM: RXNORM/56946 NDF-RT: N0000148314 vinorelbine Injectable Solution 377125 RxNORM: RXNORM/39541 NDF-RT: N0000021986 Ifosfamide Injectable Solution 377128 RxNORM: RXNORM/5657 NDF-RT: N0000147596 Teniposide Injectable Solution 377130 RxNORM: RXNORM/10362 NDF-RT: N0000148273 Cladribine Injectable Solution 377175 NDF-RT: N0000148293 RxNORM: RXNORM/44157 oxaliplatin Injectable Solution 377209 RxNORM: RXNORM/32592 NDF-RT: N0000148774 trastuzumab Injectable Solution 377216 NDF-RT: N0000148593 RxNORM: RXNORM/224905 rituximab Injectable Solution 377259 NDF-RT: N0000148560 RxNORM: RXNORM/121191 Propofol Injectable Suspension 377483 RxNORM: RXNORM/8782 NDF-RT: N0000147620 bexarotene Topical Gel 378079 RxNORM: RXNORM/233272 NDF-RT: N0000148643 gabapentin Oral Tablet 378099 NDF-RT: N0000148345 RxNORM: RXNORM/25480 Bupropion Oral Tablet 378233 NDF-RT: N0000147738 RxNORM: RXNORM/42347 Sirolimus Oral Tablet 378277 ropivacaine Injectable Solution 378318 RxNORM: RXNORM/35780 NDF-RT: N0000022060 Carboplatin Injectable Solution 378363 NDF-RT: N0000147598 RxNORM: RXNORM/40048 histrelin Injectable Solution 378634 RxNORM: RXNORM/50975 NDF-RT: N0000176176 montelukast Oral Tablet 378682 RxNORM: RXNORM/88249 NDF-RT: N0000022122 valdecoxib Oral Tablet 378686 NDF-RT: N0000148721 RxNORM: RXNORM/278567 vardenafil Oral Tablet 378688 RxNORM: RXNORM/306674 NDF-RT: N0000148820 voriconazole Oral Tablet 378691 NDF-RT: N0000148767 RxNORM: RXNORM/121243 Paroxetine Oral Tablet 378925 NDF-RT: N0000148335 RxNORM: RXNORM/32937 Insulin, Protamine Zinc, Human Injectable Suspension 379009 Zalcitabine Oral Tablet 379127 RxNORM: RXNORM/3363 NDF-RT: N0000021287 Triptorelin Injectable Suspension 379232 NDF-RT: N0000148818 RxNORM: RXNORM/38782 fludarabine Oral Tablet 393413 NDF-RT: N0000148244 RxNORM: RXNORM/24698 RxNORM: RXNORM/25102 NDF-RT: N0000148119 Omeprazole Oral Tablet 393435 RxNORM: RXNORM/7646 NDF-RT: N0000147569 fluticasone Nasal Suspension 393446 RxNORM: RXNORM/41126 NDF-RT: N0000148245 Miglustat Oral Capsule 402347 RxNORM: RXNORM/402316 NDF-RT: N0000148822 bortezomib Injectable Solution 402394 RxNORM: RXNORM/358258 NDF-RT: N0000148811 tadalafil Oral Tablet 402452 NDF-RT: N0000148829 RxNORM: RXNORM/358263 imatinib Oral Tablet 406050 NDF-RT: N0000148698 RxNORM: RXNORM/282388 pemetrexed Injectable Solution 406178 RxNORM: RXNORM/68446 NDF-RT: N0000148831 butalbital Oral Tablet 435471 Tacrolimus Oral Tablet 451875 RxNORM: RXNORM/42316 NDF-RT: N0000148372 Streptomycin Oral Capsule 451949 NDF-RT: N0000148018 RxNORM: RXNORM/10109 Thalidomide Oral Tablet 452059 RxNORM: RXNORM/10432 NDF-RT: N0000148588 pregabalin Oral Capsule 483437 NDF-RT: N0000023107 RxNORM: RXNORM/187832 Saquinavir Oral Tablet 485467 NDF-RT: N0000148419 RxNORM: RXNORM/83395 Flecainide Oral Tablet 498897 RxNORM: RXNORM/4441 NDF-RT: N0000147848 Nitrofurantoin Oral Capsule 498905 RxNORM: RXNORM/221129 NDF-RT: N0000147151 RxNORM: RXNORM/7454 NDF-RT: N0000163521 tipranavir Oral Capsule 577211 NDF-RT: N0000023100 RxNORM: RXNORM/190548 lansoprazole Oral Capsule 596836 NDF-RT: N0000148407 RxNORM: RXNORM/17128 sorafenib Oral Tablet 597746 NDF-RT: N0000171742 RxNORM: RXNORM/495881 nelarabine Injectable Solution 603565 NDF-RT: N0000171753 RxNORM: RXNORM/274771 rasagiline Oral Tablet 608327 RxNORM: RXNORM/134748 NDF-RT: N0000171790 Nalidixate Oral Tablet 618427 tenofovir disoproxil Oral Tablet 632025 RxNORM: RXNORM/117466 NDF-RT: N0000148716 emtricitabine Oral Tablet 639882 RxNORM: RXNORM/276237 NDF-RT: N0000148813 posaconazole Oral Suspension 665018 telbivudine Oral Tablet 665121 RxNORM: RXNORM/474128 NDF-RT: N0000176071 Triamcinolone Prefilled Syringe 727885 Pramipexole Oral Tablet 745021 NDF-RT: N0000022076 RxNORM: RXNORM/746741 nilotinib Oral Capsule 746605 NDF-RT: N0000176124 RxNORM: RXNORM/662281 fluticasone Dry Powder Inhaler 746765 Topotecan Oral Capsule 747192 NDF-RT: N0000022037 RxNORM: RXNORM/57308 certolizumab pegol Injectable Solution 795080 certolizumab pegol Prefilled Syringe 849596 NDF-RT: N0000178499 RxNORM: RXNORM/709271 tocilizumab Injectable Solution 895759 Ritonavir Oral Tablet 900574 NDF-RT: N0000148436 RxNORM: RXNORM/85762 tesamorelin Injectable Solution 1044586 RxNORM: RXNORM/1044584 NDF-RT: N0000182253 Vemurafenib Oral Tablet 1147222 NDF-RT: N0000183250 RxNORM: RXNORM/1147220 avanafil Oral Tablet 1291305 RxNORM: RXNORM/1291301 carfilzomib Injectable Solution 1302969 RxNORM: RXNORM/1302966 NDF-RT: N0000185509 teriflunomide Oral Tablet 1310524 NDF-RT: N0000185727 RxNORM: RXNORM/1310520 penicillin G benzathine 115 MG/ML Oral Solution 102692 NDF-RT: N0000145827 RxNORM: RXNORM/7982 Procarbazine 50 MG Oral Capsule 314167 pioglitazone 15 MG Oral Tablet 317573 Leuprolide Acetate 5 MG/ML Injectable Solution 545835 NDF-RT: N0000147256 RxNORM: RXNORM/203217 0.1 ML Triamcinolone Acetonide 80 MG/ML Prefilled Syringe 833449 Enalapril Maleate 2.5 MG Oral Tablet 858804 RxNORM: RXNORM/203123 NDF-RT: N0000146304 Insulin, Protamine Zinc, Human 40 UNT/ML Injectable Suspension 966903 Procarbazine 50 MG Oral Capsule [Matulane] 207588 RxNORM: RXNORM/8702 NDF-RT: N0000147991 pioglitazone 15 MG Oral Tablet [Actos] 261266 0.1 ML Triamcinolone Acetonide 80 MG/ML Prefilled Syringe [Trivaris] 835559 Insulin, Protamine Zinc, Human 40 UNT/ML Injectable Suspension [ProZinc] 966907 NDF-RT: N0000147876 RxNORM: RXNORM/5856 negative regulation of transcription from RNA polymerase II promoter Any process that stops, prevents, or reduces the frequency, rate or extent of transcription from an RNA polymerase II promoter. GO:0000122 GO:0010553 GO:0045816 biological_process down regulation of global transcription from RNA polymerase II promoter down regulation of transcription from RNA polymerase II promoter down-regulation of global transcription from RNA polymerase II promoter down-regulation of transcription from RNA polymerase II promoter downregulation of global transcription from RNA polymerase II promoter downregulation of transcription from RNA polymerase II promoter inhibition of global transcription from RNA polymerase II promoter inhibition of transcription from RNA polymerase II promoter negative regulation of gene-specific transcription from RNA polymerase II promoter negative regulation of global transcription from Pol II promoter negative regulation of transcription from Pol II promoter negative regulation of transcription from RNA polymerase II promoter, global embryonic epithelial tube formation neural tube formation regulation of cytokine-mediated signaling pathway Any process that modulates the frequency, rate or extent of the cytokine mediated signaling pathway. GO:0001959 biological_process regulation of cytokine and chemokine mediated signaling pathway regulation of cytokine mediated signaling pathway regulation of cytokine mediated signalling pathway negative regulation of cytokine-mediated signaling pathway Any process that stops, prevents, or reduces the frequency, rate or extent of the cytokine mediated signaling pathway. GO:0001960 biological_process down regulation of cytokine mediated signaling pathway down-regulation of cytokine mediated signaling pathway downregulation of cytokine mediated signaling pathway inhibition of cytokine mediated signaling pathway negative regulation of cytokine and chemokine mediated signaling pathway negative regulation of cytokine mediated signaling pathway negative regulation of cytokine mediated signalling pathway morphogenesis of an epithelium system process cellular_component cell regulation of transcription, DNA-templated Any process that modulates the frequency, rate or extent of cellular DNA-templated transcription. GO:0006355 GO:0032583 GO:0045449 GO:0061019 biological_process regulation of cellular transcription, DNA-dependent regulation of gene-specific transcription regulation of transcription, DNA-dependent transcriptional control regulation of transcription from RNA polymerase II promoter Any process that modulates the frequency, rate or extent of transcription from an RNA polymerase II promoter. GO:0006357 GO:0006358 GO:0010551 biological_process global transcription regulation from Pol II promoter regulation of gene-specific transcription from RNA polymerase II promoter regulation of global transcription from Pol II promoter regulation of transcription from Pol II promoter regulation of transcription from RNA polymerase II promoter, global multicellular organismal development gastrulation nervous system development sensory perception visual perception biological_process Any process specifically pertinent to the functioning of integrated living units: cells, tissues, organs, and organisms. A process is a collection of molecular events with a defined beginning and end. GO:0000004 GO:0007582 GO:0008150 Note that, in addition to forming the root of the biological process ontology, this term is recommended for use for the annotation of gene products whose biological process is unknown. Note that when this term is used for annotation, it indicates that no information was available about the biological process of the gene product annotated as of the date the annotation was made; the evidence code ND, no data, is used to indicate this. Wikipedia:Biological_process biological process biological_process physiological process regulation of G-protein coupled receptor protein signaling pathway Any process that modulates the frequency, rate or extent of G-protein coupled receptor protein signaling pathway activity. GO:0008277 biological_process regulation of G protein coupled receptor protein signaling pathway regulation of G protein coupled receptor protein signalling pathway regulation of G-protein coupled receptor protein signalling pathway regulation of G-protein-coupled receptor protein signaling pathway regulation of G-protein-coupled receptor protein signalling pathway regulation of GPCR protein signaling pathway regulation of GPCR protein signalling pathway response to radiation response to light stimulus detection of external stimulus detection of abiotic stimulus detection of light stimulus detection of visible light response to external stimulus response to abiotic stimulus anatomical structure morphogenesis embryo development post-embryonic development embryo development ending in birth or egg hatching tissue development regulation of biosynthetic process Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of substances. GO:0009889 biological_process regulation of anabolism regulation of biosynthesis regulation of formation regulation of synthesis negative regulation of biosynthetic process Any process that stops, prevents, or reduces the rate of the chemical reactions and pathways resulting in the formation of substances. GO:0009890 biological_process down regulation of biosynthetic process down-regulation of biosynthetic process downregulation of biosynthetic process inhibition of biosynthetic process negative regulation of anabolism negative regulation of biosynthesis negative regulation of formation negative regulation of synthesis negative regulation of metabolic process Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways within a cell or an organism. GO:0009892 biological_process down regulation of metabolic process down-regulation of metabolic process downregulation of metabolic process inhibition of metabolic process negative regulation of metabolism regulation of signal transduction Any process that modulates the frequency, rate or extent of signal transduction. GO:0009966 GO:0035466 biological_process regulation of signaling pathway regulation of signalling pathway positive regulation of signal transduction Any process that activates or increases the frequency, rate or extent of signal transduction. GO:0009967 GO:0035468 Reactome:REACT_6227 activation of signal transduction biological_process positive regulation of signaling pathway positive regulation of signalling pathway stimulation of signal transduction up regulation of signal transduction up-regulation of signal transduction upregulation of signal transduction negative regulation of signal transduction Any process that stops, prevents, or reduces the frequency, rate or extent of signal transduction. GO:0009968 GO:0035467 Reactome:REACT_6334 biological_process down regulation of signal transduction down-regulation of signal transduction downregulation of signal transduction inhibition of signal transduction negative regulation of signaling pathway negative regulation of signalling pathway cellular process regulation of gene expression Any process that modulates the frequency, rate or extent of gene expression. Gene expression is the process in which a gene's coding sequence is converted into a mature gene product or products (proteins or RNA). This includes the production of an RNA transcript as well as any processing to produce a mature RNA product or an mRNA (for protein-coding genes) and the translation of that mRNA into protein. Some protein processing events may be included when they are required to form an active form of a product from an inactive precursor form. GO:0010468 Wikipedia:Regulation_of_gene_expression biological_process regulation of gene product expression regulation of protein expression regulation of receptor activity Any process that modulates the frequency, rate or extent of receptor activity. Receptor activity is when a molecule combines with an extracellular or intracellular messenger to initiate a change in cell activity. GO:0010469 biological_process regulation of macromolecule biosynthetic process Any process that modulates the rate, frequency or extent of the chemical reactions and pathways resulting in the formation of a macromolecule, any molecule of high relative molecular mass, the structure of which essentially comprises the multiple repetition of units derived, actually or conceptually, from molecules of low relative molecular mass. GO:0010556 biological_process negative regulation of macromolecule biosynthetic process Any process that decreases the rate, frequency or extent of the chemical reactions and pathways resulting in the formation of a macromolecule, any molecule of high relative molecular mass, the structure of which essentially comprises the multiple repetition of units derived, actually or conceptually, from molecules of low relative molecular mass. GO:0010558 biological_process negative regulation of macromolecule metabolic process Any process that decreases the frequency, rate or extent of the chemical reactions and pathways involving macromolecules, any molecule of high relative molecular mass, the structure of which essentially comprises the multiple repetition of units derived, actually or conceptually, from molecules of low relative molecular mass. GO:0010605 biological_process negative regulation of gene expression Any process that decreases the frequency, rate or extent of gene expression. Gene expression is the process in which a gene's coding sequence is converted into a mature gene product or products (proteins or RNA). This includes the production of an RNA transcript as well as any processing to produce a mature RNA product or an mRNA (for protein-coding genes) and the translation of that mRNA into protein. Some protein processing events may be included when they are required to form an active form of a product from an inactive precursor form. GO:0010629 biological_process regulation of cell communication Any process that modulates the frequency, rate or extent of cell communication. Cell communication is the process that mediates interactions between a cell and its surroundings. Encompasses interactions such as signaling or attachment between one cell and another cell, between a cell and an extracellular matrix, or between a cell and any other aspect of its environment. GO:0010646 biological_process positive regulation of cell communication Any process that increases the frequency, rate or extent of cell communication. Cell communication is the process that mediates interactions between a cell and its surroundings. Encompasses interactions such as signaling or attachment between one cell and another cell, between a cell and an extracellular matrix, or between a cell and any other aspect of its environment. GO:0010647 biological_process negative regulation of cell communication Any process that decreases the frequency, rate or extent of cell communication. Cell communication is the process that mediates interactions between a cell and its surroundings. Encompasses interactions such as signaling or attachment between one cell and another cell, between a cell and an extracellular matrix, or between a cell and any other aspect of its environment. GO:0010648 biological_process negative regulation of tumor necrosis factor-mediated signaling pathway Any process that decreases the rate or extent of the tumor necrosis factor-mediated signaling pathway. The tumor necrosis factor-mediated signaling pathway is the series of molecular signals generated as a consequence of tumor necrosis factor binding to a cell surface receptor. GO:0010804 biological_process negative regulation of TNF signaling negative regulation of TNF-mediated signaling pathway negative regulation of tumor necrosis factor-mediated signalling pathway regulation of dopamine secretion Any process that modulates the frequency, rate or extent of the regulated release of dopamine. GO:0014059 biological_process death morphogenesis of embryonic epithelium regulation of lipid metabolic process Any process that modulates the frequency, rate or extent of the chemical reactions and pathways involving lipids. GO:0019216 biological_process regulation of lipid metabolism regulation of nucleobase-containing compound metabolic process Any cellular process that modulates the frequency, rate or extent of the chemical reactions and pathways involving nucleobases, nucleosides, nucleotides and nucleic acids. GO:0019219 biological_process regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolic process regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolism regulation of metabolic process Any process that modulates the frequency, rate or extent of the chemical reactions and pathways within a cell or an organism. GO:0019222 biological_process regulation of metabolism neural tube development regulation of signaling 2010-02-16T09:30:50Z Any process that modulates the frequency, rate or extent of a signaling process. GO:0023051 biological_process regulation of signaling process regulation of signalling process positive regulation of signaling 2010-02-16T09:30:50Z Any process that activates, maintains or increases the frequency, rate or extent of a signaling process. GO:0023056 biological_process positive regulation of signaling process positive regulation of signalling process negative regulation of signaling 2010-02-16T09:30:50Z Any process that stops, prevents, or reduces the frequency, rate or extent of a signaling process. GO:0023057 biological_process negative regulation of signaling process negative regulation of signalling process extracellular matrix regulation of cellular metabolic process Any process that modulates the frequency, rate or extent of the chemical reactions and pathways by which individual cells transform chemical substances. GO:0031323 biological_process regulation of cellular metabolism negative regulation of cellular metabolic process Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways by which individual cells transform chemical substances. GO:0031324 biological_process down regulation of cellular metabolic process down-regulation of cellular metabolic process downregulation of cellular metabolic process inhibition of cellular metabolic process negative regulation of cellular metabolism regulation of cellular biosynthetic process Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of substances, carried out by individual cells. GO:0031326 biological_process regulation of cellular anabolism regulation of cellular biosynthesis regulation of cellular formation regulation of cellular synthesis negative regulation of cellular biosynthetic process Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of substances, carried out by individual cells. GO:0031327 biological_process down regulation of cellular biosynthetic process down-regulation of cellular biosynthetic process downregulation of cellular biosynthetic process inhibition of cellular biosynthetic process negative regulation of cellular anabolism negative regulation of cellular biosynthesis negative regulation of cellular formation negative regulation of cellular synthesis regulation of synaptic transmission, dopaminergic Any process that modulates the frequency, rate or extent of dopaminergic synaptic transmission, the process of communication from a neuron to another neuron across a synapse using the neurotransmitter dopamine. GO:0032225 biological_process negative regulation of synaptic transmission, dopaminergic Any process that stops, prevents, or reduces the frequency, rate or extent of dopaminergic synaptic transmission, the process of communication from a neuron to another neuron across a synapse using the neurotransmitter dopamine. GO:0032227 biological_process down regulation of synaptic transmission, dopaminergic down-regulation of synaptic transmission, dopaminergic downregulation of synaptic transmission, dopaminergic inhibition of synaptic transmission, dopaminergic multicellular organismal process developmental process negative regulation of ATPase activity Any process that stops or reduces the rate of ATP hydrolysis by an ATPase. GO:0032780 biological_process down regulation of ATPase activity down-regulation of ATPase activity downregulation of ATPase activity inhibition of ATPase activity negative regulation of adenosinetriphosphatase activity regulation of localization Any process that modulates the frequency, rate or extent of any process in which a cell, a substance, or a cellular entity is transported to, or maintained in, a specific location. GO:0032879 biological_process regulation of localisation regulation of intracellular steroid hormone receptor signaling pathway Any process that modulates the frequency, rate or extent of the activity of any intracellular steroid hormone receptor signaling pathway. GO:0033143 biological_process regulation of steroid hormone receptor signaling pathway regulation of steroid hormone receptor signalling pathway negative regulation of intracellular steroid hormone receptor signaling pathway Any process that stops, prevents, or reduces the frequency, rate or extent of the activity of any intracellular steroid hormone receptor signaling pathway. GO:0033144 biological_process negative regulation of steroid hormone receptor signaling pathway negative regulation of steroid hormone receptor signalling pathway negative regulation of dopamine secretion Any process that stops, prevents, or reduces the frequency, rate or extent of the regulated release of dopamine. GO:0033602 biological_process down regulation of dopamine secretion down-regulation of dopamine secretion downregulation of dopamine secretion inhibition of dopamine secretion negative regulation of catecholamine secretion Any process that stops, prevents, or reduces the frequency, rate or extent of the regulated release of a catecholamine. GO:0033604 biological_process down regulation of catecholamine secretion down-regulation of catecholamine secretion downregulation of catecholamine secretion inhibition of catecholamine secretion regulation of cellular amide metabolic process Any process that modulates the frequency, rate or extent of the chemical reactions and pathways involving amides. GO:0034248 biological_process regulation of amide metabolism negative regulation of cellular amide metabolic process Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways involving amides. GO:0034249 biological_process negative regulation of amide metabolism tube formation tube morphogenesis tube development embryonic cleavage chordate embryonic development negative regulation of catalytic activity Any process that stops or reduces the activity of an enzyme. GO:0043086 biological_process down regulation of enzyme activity down-regulation of enzyme activity downregulation of enzyme activity inhibition of enzyme activity negative regulation of enzyme activity regulation of ion transport Any process that modulates the frequency, rate or extent of the directed movement of charged atoms or small charged molecules into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. GO:0043269 biological_process negative regulation of ion transport Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of charged atoms or small charged molecules into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. GO:0043271 biological_process down regulation of ion transport down-regulation of ion transport downregulation of ion transport inhibition of ion transport negative regulation of sequence-specific DNA binding transcription factor activity Any process that stops, prevents, or reduces the frequency, rate or extent of the activity of a transcription factor, any factor involved in the initiation or regulation of transcription. GO:0043433 biological_process down regulation of transcription factor activity down-regulation of transcription factor activity downregulation of transcription factor activity inhibition of transcription factor activity negative regulation of transcription factor activity regulation of ATPase activity Any process that modulates the rate of ATP hydrolysis by an ATPase. GO:0043462 biological_process regulation of adenosinetriphosphatase activity regulation of anion transport Any process that modulates the frequency, rate or extent of the directed movement of anions, atoms or small molecules with a net negative charge into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. GO:0044070 biological_process negative regulation of molecular function 2009-04-21T04:07:27Z Any process that stops or reduces the rate or extent of a molecular function, an elemental biological activity occurring at the molecular level, such as catalysis or binding. GO:0044092 biological_process jane single-organism process single-multicellular organism process single-organism cellular process single-organism developmental process positive regulation of G-protein coupled receptor protein signaling pathway Any process that activates or increases the frequency, rate or extent of G-protein coupled receptor protein signaling pathway activity. GO:0045745 activation of G-protein coupled receptor protein signaling pathway biological_process positive regulation of G protein coupled receptor protein signaling pathway positive regulation of G protein coupled receptor protein signalling pathway positive regulation of G-protein coupled receptor protein signalling pathway positive regulation of G-protein-coupled receptor protein signaling pathway positive regulation of G-protein-coupled receptor protein signalling pathway positive regulation of GPCR protein signaling pathway positive regulation of GPCR protein signalling pathway stimulation of G-protein coupled receptor protein signaling pathway up regulation of G-protein coupled receptor protein signaling pathway up-regulation of G-protein coupled receptor protein signaling pathway upregulation of G-protein coupled receptor protein signaling pathway negative regulation of lipid metabolic process Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways involving lipids. GO:0045833 biological_process down regulation of lipid metabolic process down-regulation of lipid metabolic process downregulation of lipid metabolic process inhibition of lipid metabolic process negative regulation of lipid metabolism negative regulation of transcription, DNA-templated Any process that stops, prevents, or reduces the frequency, rate or extent of cellular DNA-templated transcription. GO:0016481 GO:0032582 GO:0045892 GO:0061021 biological_process down regulation of gene-specific transcription down regulation of transcription, DNA-dependent down-regulation of gene-specific transcription down-regulation of transcription, DNA-dependent downregulation of gene-specific transcription downregulation of transcription, DNA-dependent inhibition of gene-specific transcription inhibition of transcription, DNA-dependent negative regulation of cellular transcription, DNA-dependent negative regulation of gene-specific transcription negative regulation of transcription, DNA-dependent transcription repressor activity negative regulation of nucleobase-containing compound metabolic process Any cellular process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways involving nucleobases, nucleosides, nucleotides and nucleic acids. GO:0045934 biological_process down regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolic process down-regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolic process downregulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolic process inhibition of nucleobase, nucleoside, nucleotide and nucleic acid metabolic process negative regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolic process negative regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolism negative regulation of glucosylceramide biosynthetic process Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of glucosylceramide. GO:0046318 biological_process down regulation of glucosylceramide biosynthetic process down-regulation of glucosylceramide biosynthetic process downregulation of glucosylceramide biosynthetic process inhibition of glucosylceramide biosynthetic process negative regulation of glucosylceramide anabolism negative regulation of glucosylceramide biosynthesis negative regulation of glucosylceramide formation negative regulation of glucosylceramide synthesis regulation of lipid biosynthetic process Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of lipids. GO:0046890 biological_process regulation of lipid anabolism regulation of lipid biosynthesis regulation of lipid formation regulation of lipid synthesis regulation of lipogenesis organ development positive regulation of biological process Any process that activates or increases the frequency, rate or extent of a biological process. Biological processes are regulated by many means; examples include the control of gene expression, protein modification or interaction with a protein or substrate molecule. GO:0043119 GO:0048518 activation of biological process biological_process positive regulation of physiological process stimulation of biological process up regulation of biological process up-regulation of biological process upregulation of biological process negative regulation of biological process Any process that stops, prevents, or reduces the frequency, rate or extent of a biological process. Biological processes are regulated by many means; examples include the control of gene expression, protein modification or interaction with a protein or substrate molecule. GO:0043118 GO:0048519 biological_process down regulation of biological process down-regulation of biological process downregulation of biological process inhibition of biological process negative regulation of physiological process positive regulation of cellular process Any process that activates or increases the frequency, rate or extent of a cellular process, any of those that are carried out at the cellular level, but are not necessarily restricted to a single cell. For example, cell communication occurs among more than one cell, but occurs at the cellular level. GO:0048522 GO:0051242 activation of cellular process biological_process positive regulation of cellular physiological process stimulation of cellular process up regulation of cellular process up-regulation of cellular process upregulation of cellular process negative regulation of cellular process Any process that stops, prevents, or reduces the frequency, rate or extent of a cellular process, any of those that are carried out at the cellular level, but are not necessarily restricted to a single cell. For example, cell communication occurs among more than one cell, but occurs at the cellular level. GO:0048523 GO:0051243 biological_process down regulation of cellular process down-regulation of cellular process downregulation of cellular process inhibition of cellular process negative regulation of cellular physiological process regulation of response to stimulus Any process that modulates the frequency, rate or extent of a response to a stimulus. Response to stimulus is a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus. GO:0048583 Note that this term is in the subset of terms that should not be used for direct gene product annotation. Instead, select a child term or, if no appropriate child term exists, please request a new term. Direct annotations to this term may be amended during annotation QC. biological_process positive regulation of response to stimulus Any process that activates, maintains or increases the rate of a response to a stimulus. Response to stimulus is a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus. GO:0048584 Note that this term is in the subset of terms that should not be used for direct gene product annotation. Instead, select a child term or, if no appropriate child term exists, please request a new term. Direct annotations to this term may be amended during annotation QC. activation of response to stimulus biological_process stimulation of response to stimulus up regulation of response to stimulus up-regulation of response to stimulus upregulation of response to stimulus negative regulation of response to stimulus Any process that stops, prevents, or reduces the frequency, rate or extent of a response to a stimulus. Response to stimulus is a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus. GO:0048585 Note that this term is in the subset of terms that should not be used for direct gene product annotation. Instead, select a child term or, if no appropriate child term exists, please request a new term. Direct annotations to this term may be amended during annotation QC. biological_process down regulation of response to stimulus down-regulation of response to stimulus downregulation of response to stimulus inhibition of response to stimulus embryonic morphogenesis anatomical structure formation involved in morphogenesis tissue morphogenesis system development anatomical structure development regulation of catecholamine secretion Any process that modulates the frequency, rate or extent of the regulated release of catecholamines. GO:0050433 biological_process regulation of biological process Any process that modulates the frequency, rate or extent of a biological process. Biological processes are regulated by many means; examples include the control of gene expression, protein modification or interaction with a protein or substrate molecule. GO:0050789 GO:0050791 biological_process regulation of physiological process regulation of catalytic activity Any process that modulates the activity of an enzyme. GO:0050790 biological_process regulation of enzyme activity regulation of cellular process Any process that modulates the frequency, rate or extent of a cellular process, any of those that are carried out at the cellular level, but are not necessarily restricted to a single cell. For example, cell communication occurs among more than one cell, but occurs at the cellular level. GO:0050794 GO:0051244 biological_process regulation of cellular physiological process regulation of synaptic transmission Any process that modulates the frequency or rate of synaptic transmission, the process of communication from a neuron to a target (neuron, muscle, or secretory cell) across a synapse. GO:0050804 biological_process negative regulation of synaptic transmission Any process that stops, prevents, or reduces the frequency, rate or extent of synaptic transmission, the process of communication from a neuron to a target (neuron, muscle, or secretory cell) across a synapse. GO:0050805 biological_process down regulation of synaptic transmission down-regulation of synaptic transmission downregulation of synaptic transmission inhibition of synaptic transmission neurological system process response to stimulus detection of stimulus involved in sensory perception sensory perception of light stimulus regulation of secretion Any process that modulates the frequency, rate or extent of the controlled release of a substance from a cell or a tissue. GO:0051046 biological_process negative regulation of secretion Any process that stops, prevents, or reduces the frequency, rate or extent of the controlled release of a substance from a cell or a tissue. GO:0051048 biological_process down regulation of secretion down-regulation of secretion downregulation of secretion inhibition of secretion regulation of transport Any process that modulates the frequency, rate or extent of the directed movement of substances (such as macromolecules, small molecules, ions) into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. GO:0051049 biological_process negative regulation of transport Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of substances (such as macromolecules, small molecules, ions) into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. GO:0051051 biological_process down regulation of transport down-regulation of transport downregulation of transport inhibition of transport negative regulation of lipid biosynthetic process Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of lipids. GO:0051055 biological_process down regulation of lipid biosynthetic process down-regulation of lipid biosynthetic process downregulation of lipid biosynthetic process inhibition of lipid biosynthetic process negative regulation of lipid anabolism negative regulation of lipid biosynthesis negative regulation of lipid formation negative regulation of lipid synthesis negative regulation of lipogenesis regulation of sequence-specific DNA binding transcription factor activity Any process that modulates the frequency, rate or extent of the activity of a transcription factor, any factor involved in the initiation or regulation of transcription. GO:0051090 Reactome:REACT_104536 Reactome:REACT_107559 Reactome:REACT_109535 Reactome:REACT_110257 Reactome:REACT_110693 Reactome:REACT_21326 Reactome:REACT_82719 Reactome:REACT_83365 Reactome:REACT_90659 Reactome:REACT_92725 Reactome:REACT_96476 Reactome:REACT_99415 biological_process regulation of transcription factor activity regulation of nitrogen compound metabolic process Any process that modulates the frequency, rate or extent of the chemical reactions and pathways involving nitrogen or nitrogenous compounds. GO:0051171 biological_process regulation of nitrogen metabolic process regulation of nitrogen metabolism negative regulation of nitrogen compound metabolic process Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways involving nitrogen or nitrogenous compounds. GO:0051172 biological_process down regulation of nitrogen metabolic process down-regulation of nitrogen metabolic process downregulation of nitrogen metabolic process inhibition of nitrogen metabolic process negative regulation of nitrogen metabolic process negative regulation of nitrogen metabolism regulation of RNA metabolic process Any process that modulates the frequency, rate or extent of the chemical reactions and pathways involving RNA. GO:0051252 biological_process regulation of RNA metabolism negative regulation of RNA metabolic process Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways involving RNA. GO:0051253 biological_process down regulation of RNA metabolic process down-regulation of RNA metabolic process downregulation of RNA metabolic process inhibition of RNA metabolic process negative regulation of RNA metabolism cell division regulation of hydrolase activity Any process that modulates the frequency, rate or extent of hydrolase activity, the catalysis of the hydrolysis of various bonds, e.g. C-O, C-N, C-C, phosphoric anhydride bonds, etc. Hydrolase is the systematic name for any enzyme of EC class 3. GO:0051336 biological_process hydrolase regulator regulation of oxidoreductase activity Any process that modulates the frequency, rate or extent of oxidoreductase activity, the catalysis of an oxidation-reduction (redox) reaction, a reversible chemical reaction in which the oxidation state of an atom or atoms within a molecule is altered. One substrate acts as a hydrogen or electron donor and becomes oxidized, while the other acts as hydrogen or electron acceptor and becomes reduced. GO:0051341 biological_process oxidoreductase regulator negative regulation of cyclic-nucleotide phosphodiesterase activity 3',5' cyclic nucleotide phosphodiesterase inhibitor 3',5'-cyclic-AMP phosphodiesterase inhibitor Any process that stops or reduces the rate of cyclic nucleotide phosphodiesterase activity, the catalysis of the reaction: nucleotide 3',5'-cyclic phosphate + H2O = nucleotide 5'-phosphate. GO:0051344 biological_process cAMP phosphodiesterase inhibitor down regulation of cyclic nucleotide phosphodiesterase activity down-regulation of cyclic nucleotide phosphodiesterase activity downregulation of cyclic nucleotide phosphodiesterase activity inhibition of cyclic nucleotide phosphodiesterase activity negative regulation of 3',5' cyclic nucleotide phosphodiesterase activity negative regulation of 3',5'-cyclic-AMP phosphodiesterase activity negative regulation of cAMP phosphodiesterase activity negative regulation of cGMP phosphodiesterase activity negative regulation of cyclic nucleotide phosphodiesterase activity phosphodiesterase inhibitor negative regulation of hydrolase activity Any process that stops or reduces the rate of hydrolase activity, the catalysis of the hydrolysis of various bonds. GO:0051346 biological_process down regulation of hydrolase activity down-regulation of hydrolase activity downregulation of hydrolase activity hydrolase inhibitor inhibition of hydrolase activity negative regulation of oxidoreductase activity Any process that stops or reduces the rate of oxidoreductase activity, the catalysis of an oxidation-reduction (redox) reaction, a reversible chemical reaction in which the oxidation state of an atom or atoms within a molecule is altered. GO:0051354 biological_process down regulation of oxidoreductase activity down-regulation of oxidoreductase activity downregulation of oxidoreductase activity inhibition of oxidoreductase activity oxidoreductase inhibitor regulation of neurotransmitter uptake Any process that modulates the frequency, rate or extent of the directed movement of a neurotransmitter into a neuron or glial cell. GO:0051580 biological_process regulation of neurotransmitter import regulation of neurotransmitter reuptake negative regulation of neurotransmitter uptake Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of a neurotransmitter into a neuron or glial cell. GO:0051581 biological_process down regulation of neurotransmitter uptake down-regulation of neurotransmitter uptake downregulation of neurotransmitter uptake negative regulation of neurotransmitter import regulation of dopamine uptake involved in synaptic transmission Any process that modulates the frequency, rate or extent of the directed movement of the catecholamine neurotransmitter dopamine into a cell. GO:0051584 biological_process regulation of dopamine import involved in synaptic transmission negative regulation of dopamine uptake involved in synaptic transmission Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of dopamine into a presynaptic neuron or glial cell. GO:0051585 biological_process down regulation of dopamine uptake involved in synaptic transmission down-regulation of dopamine uptake involved in synaptic transmission downregulation of dopamine uptake involved in synaptic transmission negative regulation of dopamine import involved in synaptic transmission regulation of neurotransmitter transport Any process that modulates the frequency, rate or extent of the directed movement of a neurotransmitter into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. GO:0051588 biological_process negative regulation of neurotransmitter transport Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of a neurotransmitter into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. GO:0051589 biological_process down regulation of neurotransmitter transport down-regulation of neurotransmitter transport downregulation of neurotransmitter transport inhibition of neurotransmitter transport detection of stimulus regulation of serotonin uptake Any process that modulates the frequency, rate or extent of the directed movement of the monoamine neurotransmitter serotonin into a cell. GO:0051611 biological_process regulation of 5-HT uptake regulation of 5-hydroxytryptamine uptake regulation of 5HT uptake regulation of serotonin import negative regulation of serotonin uptake Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of serotonin into a cell. GO:0051612 biological_process down regulation of serotonin uptake down-regulation of serotonin uptake downregulation of serotonin uptake negative regulation of 5-HT uptake negative regulation of 5-hydroxytryptamine uptake negative regulation of 5HT uptake negative regulation of serotonin import negative regulation of norepinephrine uptake Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of norepinephrine into a cell. GO:0051622 biological_process down regulation of norepinephrine uptake down-regulation of norepinephrine uptake downregulation of norepinephrine uptake negative regulation of levarterenol uptake negative regulation of noradrenaline uptake negative regulation of norepinephrine import inhibition of norepinephrine uptake Any process that prevents the activation of the directed movement of norepinephrine into a cell. GO:0051624 biological_process inhibition of levarterenol uptake inhibition of noradrenaline uptake inhibition of norepinephrine import negative regulation of calcium ion transport Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of calcium ions into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. GO:0051926 biological_process down regulation of calcium ion transport down-regulation of calcium ion transport downregulation of calcium ion transport inhibition of calcium ion transport negative regulation of calcium transport regulation of catecholamine uptake involved in synaptic transmission Any process that modulates the frequency, rate or extent of the directed movement of catecholamine neurotransmitters into a neuron or glial cell. GO:0051940 biological_process regulation of catecholamine neurotransmitter reuptake regulation of catecholamine neurotransmitter uptake regulation of catecholamine uptake during transmission of nerve impulse negative regulation of catecholamine uptake involved in synaptic transmission Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of catecholamine neurotransmitters into a neuron or glial cell. GO:0051945 biological_process down regulation of catecholamine uptake during transmission of nerve impulse down-regulation of catecholamine uptake during transmission of nerve impulse downregulation of catecholamine uptake during transmission of nerve impulse inhibition of catecholamine uptake during transmission of nerve impulse negative regulation of catecholamine neurotransmitter reuptake negative regulation of catecholamine neurotransmitter uptake negative regulation of catecholamine uptake during transmission of nerve impulse regulation of amine transport Any process that modulates the frequency, rate or extent of the directed movement of amines into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. GO:0051952 biological_process negative regulation of amine transport Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of amines into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. GO:0051953 biological_process down regulation of amine transport down-regulation of amine transport downregulation of amine transport inhibition of amine transport regulation of macromolecule metabolic process Any process that modulates the frequency, rate or extent of the chemical reactions and pathways involving macromolecules, any molecule of high relative molecular mass, the structure of which essentially comprises the multiple repetition of units derived, actually or conceptually, from molecules of low relative molecular mass. GO:0060255 biological_process regulation of cellular localization Any process that modulates the frequency, rate or extent of a process in which a cell, a substance, or a cellular entity is transported to, or maintained in a specific location within or in the membrane of a cell. GO:0060341 biological_process regulation of cellular localisation epithelium development epithelial tube morphogenesis regulation of response to cytokine stimulus 2009-06-22T02:56:12Z Any process that modulates the rate, frequency, or extent of a response to cytokine stimulus. GO:0060759 biological_process dph negative regulation of response to cytokine stimulus 2009-06-22T02:59:57Z Any process that decreases the rate, frequency, or extent of a response to cytokine stimulus. GO:0060761 biological_process dph regulation of androgen receptor signaling pathway 2009-07-06T11:07:38Z Any process that modulates the rate, frequency, or extent of the androgen receptor signaling pathway. GO:0060765 biological_process dph regulation of androgen receptor signalling pathway negative regulation of androgen receptor signaling pathway 2009-07-06T11:09:36Z Any process that decreases the rate, frequency, or extent of the androgen receptor signaling pathway. GO:0060766 biological_process dph negative regulation of androgen receptor signalling pathway biological regulation Any process that modulates a measurable attribute of any biological process, quality or function. GO:0065007 biological_process regulation regulation of molecular function Any process that modulates the frequency, rate or extent of a molecular function, an elemental biological activity occurring at the molecular level, such as catalysis or binding. GO:0065009 biological_process regulation of a molecular function epithelial tube formation regulation of primary metabolic process 2009-04-22T04:30:52Z Any process that modulates the frequency, rate or extent of the chemical reactions and pathways within a cell or an organism involving those compounds formed as a part of the normal anabolic and catabolic processes. These processes take place in most, if not all, cells of the organism. GO:0080090 biological_process donghui regulation of sphingolipid biosynthetic process 2009-12-08T03:25:49Z Any process that modulates the rate, frequency or extent of sphingolipid biosynthesis. Sphingolipid biosynthesis is the chemical reactions and pathways resulting in the formation of sphingolipids, any of a class of lipids containing the long-chain amine diol sphingosine or a closely related base (a sphingoid). GO:0090153 biological_process tanyaberardini negative regulation of sphingolipid biosynthetic process 2009-12-08T03:33:39Z Any process that decreases the rate, frequency or extent of sphingolipid biosynthesis. Sphingolipid biosynthesis is the chemical reactions and pathways resulting in the formation of sphingolipids, any of a class of lipids containing the long-chain amine diol sphingosine or a closely related base (a sphingoid). GO:0090155 biological_process tanyaberardini negative regulation of ceramide biosynthetic process 2012-01-25T03:18:07Z Any process that stops, prevents or reduces the frequency, rate or extent of a ceramide biosynthetic process. GO:1900060 biological_process down regulation of ceramide anabolism down regulation of ceramide biosynthesis down regulation of ceramide biosynthetic process down regulation of ceramide formation down regulation of ceramide synthesis down-regulation of ceramide anabolism down-regulation of ceramide biosynthesis down-regulation of ceramide biosynthetic process down-regulation of ceramide formation down-regulation of ceramide synthesis downregulation of ceramide anabolism downregulation of ceramide biosynthesis downregulation of ceramide biosynthetic process downregulation of ceramide formation downregulation of ceramide synthesis dph inhibition of ceramide anabolism inhibition of ceramide biosynthesis inhibition of ceramide biosynthetic process inhibition of ceramide formation inhibition of ceramide synthesis negative regulation of ceramide anabolism negative regulation of ceramide biosynthesis negative regulation of ceramide formation negative regulation of ceramide synthesis regulation of cellular response to insulin stimulus 2012-01-31T11:22:22Z Any process that modulates the frequency, rate or extent of cellular response to insulin stimulus. GO:1900076 biological_process yaf positive regulation of cellular response to insulin stimulus 2012-01-31T11:24:30Z Any process that activates or increases the frequency, rate or extent of cellular response to insulin stimulus. GO:1900078 activation of cellular response to insulin stimulus biological_process up regulation of cellular response to insulin stimulus up-regulation of cellular response to insulin stimulus upregulation of cellular response to insulin stimulus yaf negative regulation of RNA biosynthetic process 2014-02-05T16:32:01Z Any process that stops, prevents or reduces the frequency, rate or extent of RNA biosynthetic process. GO:1902679 biological_process down regulation of RNA anabolism down regulation of RNA biosynthesis down regulation of RNA biosynthetic process down regulation of RNA formation down regulation of RNA synthesis down-regulation of RNA anabolism down-regulation of RNA biosynthesis down-regulation of RNA biosynthetic process down-regulation of RNA formation down-regulation of RNA synthesis downregulation of RNA anabolism downregulation of RNA biosynthesis downregulation of RNA biosynthetic process downregulation of RNA formation downregulation of RNA synthesis inhibition of RNA anabolism inhibition of RNA biosynthesis inhibition of RNA biosynthetic process inhibition of RNA formation inhibition of RNA synthesis jl negative regulation of RNA anabolism negative regulation of RNA biosynthesis negative regulation of RNA formation negative regulation of RNA synthesis regulation of nucleic acid-templated transcription 2014-10-01T14:44:47Z Any process that modulates the frequency, rate or extent of nucleic acid-templated transcription. GO:1903506 biological_process pr negative regulation of nucleic acid-templated transcription 2014-10-01T14:44:56Z Any process that stops, prevents or reduces the frequency, rate or extent of nucleic acid-templated transcription. GO:1903507 biological_process down regulation of nucleic acid-templated transcription down-regulation of nucleic acid-templated transcription downregulation of nucleic acid-templated transcription inhibition of nucleic acid-templated transcription pr regulation of secretion by cell 2014-10-08T13:24:59Z Any process that modulates the frequency, rate or extent of secretion by cell. GO:1903530 biological_process pm regulation of cellular secretion negative regulation of secretion by cell 2014-10-08T13:25:08Z Any process that stops, prevents or reduces the frequency, rate or extent of secretion by cell. GO:1903531 biological_process down regulation of cellular secretion down regulation of secretion by cell down-regulation of cellular secretion down-regulation of secretion by cell downregulation of cellular secretion downregulation of secretion by cell inhibition of cellular secretion inhibition of secretion by cell negative regulation of cellular secretion pm negative regulation of anion transport 2015-01-12T21:50:20Z Any process that stops, prevents or reduces the frequency, rate or extent of anion transport. GO:1903792 biological_process down regulation of anion transport down-regulation of anion transport downregulation of anion transport inhibition of anion transport sl regulation of cellular macromolecule biosynthetic process 2010-09-15T08:55:45Z Any process that modulates the frequency, rate or extent of cellular macromolecule biosynthetic process. GO:2000112 biological_process regulation of cellular biopolymer biosynthetic process regulation of cellular macromolecule anabolism regulation of cellular macromolecule biosynthesis regulation of cellular macromolecule formation regulation of cellular macromolecule synthesis tanyaberardini negative regulation of cellular macromolecule biosynthetic process 2010-09-15T08:55:48Z Any process that stops, prevents, or reduces the frequency, rate or extent of cellular macromolecule biosynthetic process. GO:2000113 biological_process negative regulation of cellular biopolymer biosynthetic process negative regulation of cellular macromolecule anabolism negative regulation of cellular macromolecule biosynthesis negative regulation of cellular macromolecule formation negative regulation of cellular macromolecule synthesis tanyaberardini negative regulation of receptor activity 2010-12-02T09:28:47Z Any process that stops, prevents or reduces the frequency, rate or extent of receptor activity. GO:2000272 biological_process rfoulger regulation of ceramide biosynthetic process 2011-01-04T02:37:12Z Any process that modulates the frequency, rate or extent of a ceramide biosynthetic process. GO:2000303 biological_process dph regulation of ceramide anabolism regulation of ceramide biosynthesis regulation of ceramide formation regulation of ceramide synthesis regulation of DNA topoisomerase (ATP-hydrolyzing) activity 2011-02-09T02:35:27Z Any process that modulates the frequency, rate or extent of DNA topoisomerase (ATP-hydrolyzing) activity. GO:2000371 biological_process midori regulation of DNA gyrase activity regulation of DNA topoisomerase (ATP-hydrolysing) regulation of DNA topoisomerase II regulation of DNA topoisomerase IV activity regulation of DNA topoisomerase type II activity regulation of DNA-gyrase activity regulation of deoxyribonucleate topoisomerase regulation of deoxyribonucleic topoisomerase activity regulation of topoisomerase regulation of topoisomerase II regulation of type II DNA topoisomerase activity negative regulation of DNA topoisomerase (ATP-hydrolyzing) activity 2011-02-09T02:35:36Z Any process that stops, prevents or reduces the frequency, rate or extent of DNA topoisomerase (ATP-hydrolyzing) activity. GO:2000372 biological_process midori negative regulation of DNA gyrase activity negative regulation of DNA topoisomerase (ATP-hydrolysing) negative regulation of DNA topoisomerase II negative regulation of DNA topoisomerase IV activity negative regulation of DNA topoisomerase type II activity negative regulation of DNA-gyrase activity negative regulation of deoxyribonucleate topoisomerase negative regulation of deoxyribonucleic topoisomerase activity negative regulation of topoisomerase negative regulation of topoisomerase II negative regulation of type II DNA topoisomerase activity positive regulation of opioid receptor signaling pathway 2011-03-09T09:41:35Z Any process that activates or increases the frequency, rate or extent of opioid receptor signaling pathway. GO:2000476 biological_process positive regulation of opioid receptor signalling pathway rfoulger regulation of androgen receptor activity 2011-07-15T10:56:08Z Any process that modulates the frequency, rate or extent of androgen receptor activity. GO:2000823 biological_process yaf negative regulation of androgen receptor activity 2011-07-15T10:56:12Z Any process that stops, prevents or reduces the frequency, rate or extent of androgen receptor activity. GO:2000824 biological_process yaf regulation of RNA biosynthetic process 2011-10-17T11:36:25Z Any process that modulates the frequency, rate or extent of RNA biosynthetic process. GO:2001141 biological_process dph regulation of RNA anabolism regulation of RNA biosynthesis regulation of RNA formation regulation of RNA synthesis negative regulation of hydroxymethylglutaryl-CoA reductase (NADPH) activity 2011-11-16T11:34:17Z Any process that stops, prevents or reduces the frequency, rate or extent of hydroxymethylglutaryl-CoA reductase (NADPH) activity. GO:2001216 biological_process negative regulation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase activity negative regulation of HMG-CoA reductase activity rfoulger data item information content entity curation status specification Better to represent curation as a process with parts and then relate labels to that process (in IAO meeting) GROUP:OBI:<http://purl.obolibrary.org/obo/obi> OBI_0000266 PERSON:Bill Bug The curation status of the term. The allowed values come from an enumerated list of predefined terms. See the specification of these instances for more detailed definitions of each enumerated value. curation status specification data about an ontology part Person:Alan Ruttenberg data about an ontology part is a data item about a part of an ontology, for example a term Eukaryota Opisthokonta Metazoa Bilateria Eumetazoa adverse event Melanie Courtot and YH: More work is needed on how to restrict the scope of a term to be an 'adverse event', notably regarding temporal association. When is an appropirate time interval between a medical intervention and an adverse event observed? One week, one month, one year, or a lifetime? For some well-studied medical interventions (e.g., administration of many vaccines or drugs), we probably have a general idea. For many new interventions, we don't know much. In OAE, this issue is associated with defining the 'adverse event incubation time'. AE YH: There has been discussion regarding whether the term 'side effect' is an alternative term for 'adverse event'. In AERO, the term 'AERO:adverse event' represents a subset of those adverse events for which causality has been established. In OAE, an adverse event for which causality has been established is called 'causal adverse event'. a pathological bodily process that occurs after a medical intervention. An adverse event is likely caused by the medical intervention; however, such a causal association is not required to be an adverse event. YH: The main scope of OAE includes: (1) represent terms and relations in the area of adverse events, (2) assess possible associations between an adverse event and a medical intervention, particularly, identify any causal effect of a medical intervention to an adverse event; and (2) understand the mechanism (including molecular mechanisms) of causal adverse events. WEB: http://www.ncbi.nlm.nih.gov/pubmed/25093068 The OAE official website is: http://www.oae-ontology.org/. WEB: http://www.fda.gov/Safety/MedWatch/HowToReport/ucm053087.htm adverse reaction YH: An adverse event is a process that has specified output of some adverse medical outcome (e.g., symptom, sign or accident) after a medical intervention (or process) (e.g., administration of drug or vaccine). The medical intervention can be an administration of a drug, a vaccine (i.e., vaccination), or a special nutritional product (for example, dietary supplement, infant formula, medical food), surgery, or usage of a medical device. WEB: http://en.wikipedia.org/wiki/Adverse_event YH: An adverse event is possibly induced by the medical intervention. It can be caused by the medical intervention, or may not be caused by the medical intervention. One ultimate goal (or the goal in clinics) of study adverse events is to assess if the adverse event outcome is due to the medical intervention. Yongqun He medical intervention medical intervention is a planned process that has the goal of diagnosing, preventing or relieving illness or injury. YH WEB: http://wiki.answers.com/Q/What_is_medical_intervention drug administration a medical intervention where a patient is administered with a drug YH sensory neuropathy AE a peripheral neuropathy AE which has an outcome of sensory neuropathy that involves damage to nerves of the peripheral nervous system. sensory neuropathy AE YH, AG motor neuropathy AE a peripheral neuropathy AE which is caused by a damage to motor neurons AG, YH polyneuropathy AE WEB: http://www.merckmanuals.com/home/brain_spinal_cord_and_nerve_disorders/peripheral_nerve_disorders/polyneuropathy.html AG, YH, RR SIDER: C0152025 A peripheral neuropathy AE which is characterized by damage to more than one nerve HPO: HP_0001271 MedDRA ID: 10036105 peripheral neuropathy AE MedDRA: 10029331 an neuropathy AE that results in a damage to the peripheral nervous system (PNS, outside the brain and spinal cord), the vast communication network that transmits information from the brain and the spinal cord (the central nervous system) to every other part of the body. neuropathy peripheral AE WEB: http://www.ninds.nih.gov/disorders/peripheralneuropathy/detail_peripheralneuropathy.htm SS, YH WEB: http://en.wikipedia.org/wiki/Peripheral_neuropathy paresthesia AE YH a sensory neuropathy AE that shows a sensation of tingling, pricking, or numbness of a person's skin with no apparent long-term physical effect. WEB: http://en.wikipedia.org/wiki/Paraesthesia MedDRA: 10033775 Paresthesia is more generally known as the feeling of "pins and needles" or of a limb being "asleep" (although this is not directly related to the phenomenon of sleep). The manifestation of paresthesia may be transient or chronic. neuropathy AE WEB: http://www.neuropathy.org/ SIDER: C0442874 a nervous system AE that shows a damage to or disease affecting the nerves. WEB: http://www.emedicinehealth.com/neuropathy/article_em.htm WEB: http://www.medicalnewstoday.com/articles/147963.php HPO: HP_0007141 YH, RR nervous system AE an AE that occurs in nervous system. MP: MP_0003633 YH neuritis AE MP: MP_0006082 MedDRA ID: 10029240 a peripheral neuropathy AE which has an outcome of neuritis, the local accumulation of fluid, plasma proteins, and leukocytes in the brain and/or spinal cord neurotoxicity AE WEB: http://en.wikipedia.org/wiki/Neurotoxicity a nervous system AE that alters the normal activity of the nervous system due to exposure to neurotoxins, causes damage to nervous tissue SZ, SS, YH MedDRA: 10029350 peripheral sensorimotor neuropathy AE MedDRA: 10056673 Neuropathy can affect nerves that provide feeling (sensory neuropathy) or cause movement (motor neuropathy). It can also affect both, in which case it is called a sensorimotor neuropathy. SZ, SS, YH a peripheral sensory neuropathy AE that results in the patient losing the ability to move or feel. WEB: http://www.nlm.nih.gov/medlineplus/ency/article/000750.htm peripheral sensory neuropathy AE MedDRA: 10034620 SZ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/Peripheral+sensory+neuropathy SIDER: C0151313 a sensory neuropathy AE that has an outcome of damaged nerves outside the brain and spinal cord HPO: HP_0000763 carpal tunnel syndrome AE Carpal tunnel syndrome AE is a peripheral neuropathy AE that is a median entrapment neuropathy that causes paresthesia, pain, numbness, and other symptoms in the distribution of the median nerve due to its compression at the wrist in the carpal tunnel. WEB: http://en.wikipedia.org/wiki/Carpal_tunnel_syndrome MedDRA: 10007697 JX, LW, YH WEB: http://emedicine.medscape.com/article/1141168-clinical#showall 腕管综合征 median nerve neuropathy AE ischemic optic neuropathy AE optic ischemic neuropathy AE WEB: http://www.merckmanuals.com/professional/eye_disorders/optic_nerve_disorders/ischemic_optic_neuropathy.html WEB: http://www.geteyesmart.org/eyesmart/diseases/ischemic-optic-neuropathy/ RR an optic neuropahty AE which shows an infarction of the optic disk which presents as painless vision loss MedDRA: 10030924 optic neuropathy AE a peripheral neuropathy AE which shows an damage or abnormality to the nerves in the eyes. RR, YH MedDRA: 10061323 WEB: http://www.allaboutvision.com/conditions/optic-neuritis.htm neuroretinitis AE MedDRA: 10060701 an optic neuropathy AE characterized by optic disc swelling, peripapillary and macular hard exudates, and vitreous cells. WEB: http://www.ncbi.nlm.nih.gov/pubmed/6466175 RR, YH anterior ischemic optic neuropathy AE MedDRA: 10068250 WEB: http://emedicine.medscape.com/article/1216891-overview WEB: http://www.geteyesmart.org/eyesmart/diseases/ischemic-optic-neuropathy/ RR, YH AION an optic neuropathy AE characterized by vision loss, optic disc swelling, flame hemorrhages, and cotton-wool exudates. It occurs when blood flow is interrupted to the front (anterior) part of the optic nerve (also called optic nerve head). non-arteritic anterior ischemic optic neuropathy AE MedDRA: 10068249 WEB: http://emedicine.medscape.com/article/1216891-clinical#a0217 RR, YH a type of anterior ischemic optic neuropathy AE that presents primarily with vision loss, especially upon wakening, and sectorial disc edema. mixed neuropathy AE WEB: http://www.aafp.org/afp/2010/0401/p887.html RR, YH a peripheral neuropathy AE that shows a combination of axonal and demyelinating neuropathy. sensory peripheral polyneuropathy AE WEB: http://www.merckmanuals.com/home/brain_spinal_cord_and_nerve_disorders/peripheral_nerve_disorders/polyneuropathy.html RR, YH a peripheral sensory neuropathy AE that shows neuropathy in many sensory nerves at one time peripheral demyelinating polyneuropathy AE RR, YH a peripheral neuropathy AE that results from the loss of the myelin sheath on peripheral nerves roughly evenly distributed on both sides of the body diabetic neuropathy AE a neuropathy AE that shows nerve damage and occurs in a patient with diabetes WEB: http://www.mayoclinic.org/diseases-conditions/diabetic-neuropathy/basics/definition/con-20033336 RR, YH MedDRA: 10012680 neurological deficit AE RR, YH a nervous system AE that is an umbrella term referring to conditions relating to the nervous system, including loss of sensation and paralysis WEB: http://en.wikipedia.org/wiki/Functional_neurological_deficit planned process A processual entity that realizes a plan which is the concretization of a plan specification. processed material http://purl.obolibrary.org/obo/obi.owl Examples include gel matrices, filter paper, parafilm and buffer solutions, mass spectrometer, tissue samples Is a material entity that is created or changed during material processing. PERSON: Alan Ruttenberg processed material scattered molecular aggregate scattered molecular aggregate the sodium and chloride ions in a glass of salt water A scattered molecular aggregate is a material entity that consists of all the molecules of a specific type that are located in some bounded region and which is part of a more massive material entity that has parts that are other such aggregates Collective Discussion in Karslruhe with, among others, Alan Rector, Stefan Schulz, Marijke Keet, Melanie Courtot, and Alan Ruttenberg. With inspiration from the paper Granularity, scale and collectivity: When size does and does not matter, Alan Recto, Jeremy Rogers, Thomas Bittner, Journal of Biomedical Informatics 39 (2006) 333-349 PERSON: Alan Ruttenberg a material entity that consists of all the molecules of a specific type that are located in some bounded region and which is part of a more massive material entity that has parts that are other such aggregates scattered molecular aggregate organism 10/21/09: This is a placeholder term, that should ideally be imported from the NCBI taxonomy, but the high level hierarchy there does not suit our needs (includes plasmids and 'other organisms') GROUP: OBI Biomaterial Branch A material entity that is an individual living system, such as animal, plant, bacteria or virus, that is capable of replicating or reproducing, growth and maintenance in the right environment. An organism may be unicellular or made up, like humans, of many billions of cells divided into specialized tissues and organs. WEB: http://en.wikipedia.org/wiki/Organism animal fungus organism plant virus drug-associated neuropathy AE YH, RR a neuropathy adverse event that is associated with a drug. role in cellular and molecular interactions RR, YH drug-associated mixed neuropathy AE RR, YH drug-associated peripheral neuropathy adverse event RR, YH drug-associated motor neuropathy AE RR, YH drug-associated neuritis neuropathy AE RR, YH drug-associated optic neuropathy AE RR, YH drug-associated diabetic neuropathy AE RR, YH drug-associated neuroretinitis neuropathy AE RR, YH drug-associated polyneuropathy AE RR, YH drug-associated sensory neuropathy AE RR, YH drug-associated neurotoxicity neuropathy AE RR, YH drug-associated peripheral sensory neuropathy AE RR, YH drug-associated sensory peripheral polyneuropathy AE RR, YH drug-associated peripheral sensorimotor neuropathy AE RR, YH drug-associated peripheral demyelinating polyneuropathy AE RR, YH drug-associated anterior ischemic optic neuropathy AE RR, YH drug-associated non-arteritic anterior ischemic optic neuropathy AE RR, YH drug-associated carpal tunnel syndrome AE RR, YH drug-associated neurological deficit AE RR, YH drug-associated paresthesia AE RR, YH ciprofloxacin hydrochloride (Ciloxan, Cipro, Cetraxal)-associated peripheral neuropathy AE WEB: http://www.fda.gov/downloads/Drugs/EmergencyPreparedness/BioterrorismandDrugPreparedness/UCM130802.pdf RR, AG, YH cefepime (Maxipime)-associated neurotoxicity AE RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050679s036lbl.pdf penicillin G benzathine (Bicillin L-A)-associated neuropathy AE RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050141s231lbl.pdf fosaprepitant dimeglumine (Emend)-associated sensory neuropathy AE RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021549s021lbl.pdf emtricitabine (Emtriva)-associated neuropathy AE WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021500s019lbl.pdf RR, AG, YH emtricitabine (Emtriva)-associated peripheral neuritis AE WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021500s019lbl.pdf RR, AG, YH ropivacaine (Naropin)-associated neuropathy AE RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020533s028lbl.pdf omeprazole (Prilosec)-associated anterior ischemic optic neuropathy AE WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019810s095,022056s011lbl.pdf RR, AG, YH hydroxyurea (Droxia, Hydrea)-associated peripheral neuropathy AE RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/016295s041s042lbl.pdf vemurafenib (Zelboraf)-associated peripheral neuropathy AE RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202429s000lbl.pdf ipilimumab (Yervoy)-associated neuropathy AE WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/125377s0000lbl.pdf RR, AG, YH golimumab (Simponi)-associated peripheral demylinating polyneuropathy AE WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/125289s0038lbl.pdf RR, AG, YH peginterferon alfa-2b (Peg Intron, Sylatron)-associated peripheral neuropathy AE RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/103949s5217s5222lbl.pdf infliximab (Remicade)-associated neuropathy AE RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/103772s5301lbl.pdf tacrolimus (Astagraf XL, Hecoria, Prograf, Protopic)-associated neuropathy AE WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/050708s036s037,050709s028s030lbl.pdf RR, AG, YH tacrolimus (Astagraf XL, Hecoria, Prograf, Protopic)-associated neurotoxicity AE RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/050708s036s037,050709s028s030lbl.pdf tesamorelin (Egrifta)-associated peripheral neuropathy AE WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022505s001s003lbl.pdf RR, AG, YH docetaxel (Taxotere, Docefrez)-associated neuropathy AE WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022234s000lbl.pdf RR, AG, YH etravirine (Intelence)-associated peripheral neuropathy AE RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022187s008lbl.pdf maraviroc (Selzentry)-associated peripheral neuropathy AE RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022128s007lbl.pdf bupropion (Aplezin, Wellbutrin, Zyban, Budeprion SR, Buproban, Forfivo XL)-associated neuropathy AE WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022108s005s006lbl.pdf RR, AG, YH nilotinib (Tasigna)-associated peripheral neuropathy AE RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022068s008s009lbl.pdf ixabepilone (Ixempra)-associated peripheral neuropathy AE WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022065s006lbl.pdf RR, AG, YH telbivudine (Tyzeka)-associated peripheral neuropathy AE RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022011S012,022154S009lbl.pdf dasatinib (Sprycel)-associated neuropathy AE RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021986s009s010lbl.pdf sorafenib (NexAVAR)-associated sensory neuropathy AE RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021923s012lbl.pdf lenalidomide (Revlimid)-associated neuropathy AE RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021880s023lbl.pdf tipranavir (Aptivus)-associated peripheral neuropathy AE RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021814s011lbl.pdf metronidazole (Flagyl, Metrocream, Metrogel, Metrolotion, Noritate)-associated peripheral neuropathy AE WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021806s003lbl.pdf RR, AG, YH histrelin (Vantas, Supprelin LA)-associated neuropathy AE RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021732s007s010s012lbl.pdf bortezomib (Velcade)-associated peripheral neuropathy AE RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021602s029s030lbl.pdf imatinib (Gleevec)-associated peripheral neuropathy AE WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021588s030s031lbl.pdf RR, AG, YH daptomycin (Cubicin)-associated peripheral neuropathy AE RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021572s038lbl.pdf atazanavir (Reyataz)-associated peripheral neurologic symptoms AE RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021567s026lbl.pdf enfuvirtide (Fuzeon)-associated peripheral neuropathy AE RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021481s020lbl.pdf pemetrexed (Alimta)-associated motor neuropathy AE WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021462s029s030s032lbl.pdf RR, AG, YH pemetrexed (Alimta)-associated sensory neuropathy AE WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021462s029s030s032lbl.pdf RR, AG, YH vardenafil (Levitra, Staxyn)-associated non-arteritic anterior ischemic optic neuropathy AE WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021400s013lbl.pdf RR, AG, YH tenofovir (Viread)-associated peripheral neuropathy AE RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021356s041lbl.pdf voriconazole (Vfend)-associated neuropathy AE WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021266s035,021267s040,021630s026lbl.pdf RR, AG, YH gemifloxacin (Factive)-associated peripheral neuropathy AE RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021158s021lbl.pdf moxifloxacin (Avelox, Vigamox, Moxeza)-associated peripheral neuropathy AE RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021085s050s053,021277s046s050lbl.pdf bexarotene (Targretin)-associated neuropathy AE WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021055s006lbl.pdf RR, AG, YH cytarabine (Cytosar-U, Tarabine PFS)-associated peripheral neuropathy AE RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021041s023lbl.pdf eletriptan (Relpax)-associated neuropathy AE WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021016s018lbl.pdf RR, AG, YH efavirenz (Sustiva)-associated neuropathy AE WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020972s040lbl.pdf RR, AG, YH leflunomide (Arava)-associated peripheral neuropathy AE WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020905s022lbl.pdf RR, AG, YH capecitabine (Xeloda)-associated peripheral sensory neuropathy AE RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020896s026lbl.pdf sildenafil (Revatio, Viagra)-associated neuropathy AE WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020895s036lbl.pdf RR, AG, YH montelukast (Singulair)-associated neuropathy AE RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020829s060,020830s062,021409s037lbl.pdf exemestane (Aromasin)-associated neuropathy AE WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020753s009s011s012lbl.pdf RR, AG, YH triptorelin (Trelstar)-associated neuropathy AE RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020715s025,021288s022,022437s003lbl.pdf pramipexole (Mirapex)-associated neuropathy AE RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020667s025lbl.pdf ritonavir (Norvir)-associated neuropathy AE WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020659s055,022417s006lbl.pdf RR, AG, YH nevirapine (Viramune)-associated paresthesia AE RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020636s039_020933s030lbl.pdf levofloxacin (Levaquin, Quixin, Iquix)-associated peripheral neuropathy AE WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020634s062s064,020635s068s070,021721s029s031lbl.pdf RR, AG, YH lamivudine (Epivir)-associated neuropathy AE RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020564s031,020596s030lbl.pdf zafirlukast (Accolate)-associated neuropathy AE WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020547s031lbl.pdf RR, AG, YH gemcitabine (Gemzar)-associated neuropathy AE RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020509s069lbl.pdf topiramate (Topamax, Topiragen, Trokendi XR, Qudexy XR)-associated neuropathy AE WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020505s042,020844s036lbl.pdf RR, AG, YH vigabatrin (Sabril)-associated peripheral neuropathy AE WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020427s002lbl.pdf RR, AG, YH stavudine (Zerit)-associated peripheral neuropathy AE WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020412s038,020413s030lbl.pdf RR, AG, YH losartan (Cozaar)-associated peripheral neuropathy AE RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020386s056lbl.pdf fluvastatin (Lescol)-associated peripheral neuropathy AE RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020261s042,021192s016lbl.pdf desipramine (Norpramin)-associated peripheral neuropathy AE RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020156s048lbl.pdf levoleucovorin (Fusilev)-associated neuropathy AE RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020140s002lbl.pdf diltiazem (Dilacor, Cardizem, Cartia XT, Tiazac, Dilt-CD, Dilt-XR, Diltia XT)-associated neuropathy AE WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020092s017lbl.pdf RR, AG, YH paroxetine (Paxil, Pexeva, Brisdelle)-associated neuropathy AE RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020031s058s066,020710s022s030lbl.pdf leuprolide acetate (Lupron, Eligard, Viadur)-associated peripheral neuropathy AE WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019943s032,020011s039lbl.pdf RR, AG, YH ramipril (Altace)-associated neuropathy AE RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019901s058lbl.pdf pravastatin (Pravachol)-associated neuropathy AE WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019898s061lbl.pdf RR, AG, YH sotalol (Betapace, Sorine, Sotylize)-associated peripheral neuropathy AE RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019865s020lbl.pdf acitretin (Soriatane)-associated peripheral neuropathy AE WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019821s018lbl.pdf RR, AG, YH amlodipine (Norvasc)-associated neuropathy peripheral AE RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019787s052lbl.pdf simvastatin (Zocor)-associated peripheral neuropathy AE RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019766s083lbl.pdf ifosfamide (Ifex)-associated polyneuropathy AE RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019763s016lbl.pdf ofloxacin (Floxin, Ocuflox)-associated peripheral neuropathy AE RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019735s061lbl.pdf zidovudine (Retrovir)-associated neuropathy AE RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019655s052,019910s039,020518s022lbl.pdf lisinopril (Prinivil, Zestril)-associated peripheral neuropathy AE WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019558s054lbl.pdf RR, AG, YH ciprofloxacin (Cipro, Ciloxan, Cetraxal)-associated peripheral neuropathy AE WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019537s074,020780s032lbl.pdf RR, AG, YH betaxolol (Kerlone, Betoptic S)-associated neuropathy AE WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019507s008lbl.pdf RR, AG, YH norfloxacin (Noroxin)-associated peripheral neuropathy AE WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019384s060lbl.pdf RR, AG, YH amiodarone (Cordarone, Pacerone)-associated peripheral neuropathy AE WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018972s044lbl.pdf RR, AG, YH cisplatin (Platinol)-associated peripheral neuropathy AE WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018057s081lbl.pdf RR, AG, YH carmustine (Bicnu, Gliadel)-associated neuroretinitis AE RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/017422s042lbl.pdf deferoxamine (Desferal)-associated mixed neuropathy AE RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/016267s050lbl.pdf chlorambucil (Leukeran)-associated peripheral neuropathy AE RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/010669s032lbl.pdf propylthiouracil-associated neuropathy AE RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/006188s021s022lbl.pdf eribulin (Halaven)-associated peripheral neuropathy AE RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/201532lbl.pdf cabazitaxel (Jevtana)-associated peripheral neuropathy AE WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/201023lbl.pdf RR, AG, YH certolizumab pegol (Cimzia)-associated peripheral neuropathy AE WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/125160s111lbl.pdf RR, AG, YH erlotinib (Tarceva)-associated neuropathy AE WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021743s14s16lbl.pdf RR, AG, YH aprepitant (Emend)-associated sensory neuropathy AE WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021549s017lbl.pdf RR, AG, YH miglustat (Zavesca)-associated peripheral neuropathy AE WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021348s008lbl.pdf RR, AG, YH valganciclovir (Valcyte)-associated peripheral neuropathy AE RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021304s008,022257s003lbl.pdf linezolid (Zyvox)-associated optic neuropathy AE WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021130s022lbl.pdf RR, AG, YH ziprasidone (Geodon)-associated neuropathy AE WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020825s038,020919s025,021483s005lbl.pdf RR, AG, YH topotecan (Hycamtin)-associated neuropathy AE WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020671s016s017lbl.pdf RR, AG, YH bicalutamide (Casodex)-associated neuropathy AE RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020498s022lbl.pdf venlafaxine (Effexor)-associated neuropathy AE RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020151s056s057lbl.pdf itraconazole (Onmel, Sporanox)-associated neuropathy AE RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020083s046lbl.pdf fludarabine (Fludara)-associated peripheral neuropathy AE WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020038s033lbl.pdf RR, AG, YH zolpidem (Zolpimist, Ambien, Edluar, Intermezzo)-associated neuropathy AE RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/019908s029lbl.pdf triamcinolone (Aristocort, Azmacort, Cinolar, Kenalog, Nasacort, Clinacort, Triam-Forte, Triamcot, Aristospan)-associated neuropathy AE WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/012802s031lbl.pdf RR, AG, YH metronidazole (Flagyl, Metrocream, Metrogel, Metrolotion, Noritate)-associated optic neuropathy AE RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/012623s061lbl.pdf oxaliplatin (Eloxatin)-associated neuropathy AE RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/078810s000lbl.pdf cyclosporine (Gengraf, Neoral, Sandimmune, Restasis)-associated neuropathy AE WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/050715s028,050716s029lbl.pdf RR, AG, YH capsaicin (Zostrix, Capsagel, Capsagesic HP, Capsin, Trixaicin, Pain Enz, Rid-A-Pain, Sportsmed)-associated peripheral sensory neuropathy AE RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022395lbl.pdf nelarabine (Arranon)-associated peripheral neuropathy AE WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021877s001lbl.pdf RR, AG, YH dapsone (Aczone)-associated peripheral neuropathy AE RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021794s006lbl.pdf rasagiline (Azilect)-associated neuropathy AE WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021641s002s003s004s005s007s008s010lbl.pdf RR, AG, YH eszopiclone (Lunesta)-associated neuropathy AE WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021476s012lbl.pdf RR, AG, YH almotriptan (Axert)-associated neuropathy AE WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021001s010s011lbl.pdf RR, AG, YH atorvastatin (Lipitor)-associated peripheral neuropathy AE WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020702s056lbl.pdf RR, AG, YH tolcapone (Tasmar)-associated neuropathy AE WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020697s013s015lbl.pdf RR, AG, YH nitrofurantoin (Furadantin)-associated peripheral neuropathy AE RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020064s019lbl.pdf olsalazine sodium (Dipentum)-associated peripheral neuropathy AE RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019715s027lbl.pdf mefloquine (Lariam)-associated sensory neuropathy AE WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019591s026s028lbl.pdf RR, AG, YH mefloquine (Lariam)-associated motor neuropathy AE RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019591s026s028lbl.pdf misoprostol (Cytotec)-associated neuropathy AE WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019268s041lbl.pdf RR, AG, YH indomethacin (Indocin, Tivorbex)-associated peripheral neuropathy AE RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018332s032lbl.pdf etidronate (Didronel)-associated peripheral neuropathy AE WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/017831s055lbl.pdf RR, AG, YH sulfasalazine (Azulfidine, Sulfazine)-associated peripheral neuropathy AE WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/007073s124lbl.pdf RR, AG, YH doxorubicin (Doxil, Adriamycin)-associated peripheral neuropathy AE RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050718s033lbl.pdf mesalamine (Canasa, Pentasa, Rowasa, Lialda, Apriso, Asacol HD, sfRowasa, Delzicol)-associated peripheral neuropathy AE WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022301lbl.pdf RR, AG, YH selegiline (Emsam, Eldepryl, Zelapar)-associated neuropathy AE RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021479s003s004lbl.pdf ropinirole (Requip)-associated peripheral neuropathy AE RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020658s018s020s021lbl.pdf enalapril maleate (Vasotec, Epaned)-associated peripheral neuropathy AE RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/018998s071lbl.pdf cyclobenzaprine (Flexeril, Amrix, Fexmid, FusePaq Tabradol)-associated peripheral neuropathy AE RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021777lbl.pdf tinidazole (Tindamax)-associated neuropathy AE WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021618s003lbl.pdf RR, AG, YH zaleplon (Sonata)-associated neuropathy AE RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/020859s011lbl.pdf foscarnet (Foscavir)-associated neuropathy AE RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/020068s017lbl.pdf succimer (Chemet)-associated sensorimotor neuropathy AE RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019998s013lbl.pdf clomipramine (Anafranil)-associated neuropathy AE RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019906s34lbl.pdf nortriptyline (Aventyl, Pamelor)-associated peripheral neuropathy AE WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018013s58lbl.pdf RR, AG, YH trimipramine (Surmontil)-associated peripheral neuropathy AE RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/016792s025lbl.pdf thalidomide (Thalomid)-associated peripheral neuropathy AE RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021430s000,020785s031lbl.pdf cevimeline (Evoxac)-associated neuropathy AE WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/020989s008lbl.pdf RR, AG, YH tizanidine (Zanaflex)-associated neuropathy AE RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/020397s021,021447s002lbl.pdf didanosine (Videx)-associated peripheral neuropathy AE WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/020154s50,20155s39,20156s40,21183s16lbl.pdf RR, AG, YH ganciclovir (Cytovene, Vitrasert, Zirgan)-associated neuropathy AE RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/019661s030lbl.pdf flucytosine (Ancobon)-associated peripheral neuropathy AE WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/017001s027lbl.pdf RR, AG, YH lomefloxacin (Maxaquin)-associated peripheral neuropathy AE WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/20013s015lbl.pdf RR, AG, YH saquinavir (Invirase)-associated peripheral neuropathy AE WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021785s001,002,020828s019,020,020628s022,023lbl.pdf RR, AG, YH valdecoxib (Bextra)-associated neuropathy AE RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21341lbl.pdf lovastatin (Altoprev, Mevacor)-associated peripheral neuropathy AE RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21316s010lbl.pdf fluticasone (Flonase, Cutivate, Flovent)-associated neuropathy AE WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/20549slr016,20548slr020,20121slr030_flonase_lbl.pdf RR, AG, YH penicillamine (Cuprimine, Depen)-associated peripheral neuropathy AE RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/19853s012,014lbl.pdf dexamethasone (Decadron, DexPak, Maxidex, Dekpak 13 day Taperpak, Baycadron Elixer, Ozurdex)-associated neuropathy AE WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/11664slr062_decadron_lbl.pdf RR, AG, YH rofecoxib-associated median nerve neuropathy AE RR, AG, YH This drug has been withdrawn from the US market. WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/021052s026_021042s019lbl.pdf basiliximab (Simulect)-associated neuropathy AE WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/basnov010203LB.htm RR, AG, YH pergolide (Permax)-associated neuropathy AE This drug has been withdrawn from the US market. WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/19385slr030,031,035_permax_lbl.pdf RR, AG, YH vinorelbine (Navelbine)-associated neuropathy AE WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20388S014lbl.pdf RR, AG, YH zalcitabine-associated peripheral neuropathy AE WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20199s16lbl.pdf RR, AG, YH This drug has been discontinued from the US market. cerivastatin (Baycol)-associated peripheral neuropathy AE WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2001/20740S19lbl.pdf RR, AG, YH This drug has been withdrawn from the US market. delavirdine (Rescriptor)-associated neuropathy AE RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2001/20705S8lbl.pdf amiodarone hydrochloride (Cordarone, Pacerone)-associated optic neuropathy AE RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/anda/98/74-739_Amiodarone_prntlbl.pdf paclitaxel (Taxol, Onxol, Nov-Onxol, Paclitaxel Novaplus)-associated peripheral neuropathy AE WEB: http://www.accessdata.fda.gov/drugsatfda_docs/anda/2002/75184_Paclitaxel_Prntlbl.pdf RR, AG, YH tadalafil (Cialis, Adcirca)-associated non-arteritic anterior ischemic optic neuropathy AE RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ff61b237-be8e-461b-8114-78c52a8ad0ae#nlm34084-4 rivastigmine (Exelon)-associated peripheral neuropathy AE WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fead084a-a376-4d57-bdf0-aa7ed3655505#nlm34084-4 RR, AG, YH mitoxantrone hydrochloride (Novantrone)-associated neurological deficit AE RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fcb8ef8a-f770-4416-8fc5-fa01d98c8eee#nlm34084-4 zonisamide (Zonegran)-associated neuropathy AE RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f94b2ba4-024f-4068-8759-da6c8d31c546#nlm34084-4 sotalol hydrochloride (Betapace, Sorine, Sotylize)-associated peripheral neuropathy AE RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f16f9ae6-d29f-4b31-a240-c7ebb0d7d36a#nlm34084-4 propofol (Diprivan, Fresenious Propoven)-associated neuropathy AE RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e3105799-a4b6-f3f4-e6e2-b2b29bbdb538#nlm34084-4 pentamidine (Nebupent, Pentam)-associated neuropathy AE WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e2ad9d3c-b6c3-4f70-87e0-722a8ff94ccb#nlm34084-4 RR, AG, YH procarbazine 50 MG oral capsule [Matulane]-associated neuropathy AE RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=de1c8271-64d8-4ea5-85e8-871faa4d7632#nlm34084-4 penicillin V potassium (Veetids, Truxcillin VK)-associated neuropathy AE RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d6918541-6285-48ea-8255-23212f9a3ad7#nlm34084-4 Imipramine pamoate (Tofranil-PM)-associated peripheral neuropathy AE RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d1dde497-1889-4424-af18-da7ca6459cf3#nlm34084-4 methylprednisolone acetate (Depo-Medrol)-associated neuropathy AE WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ccb4d123-7b12-4aef-8ef0-f8d68c1a6547#nlm34084-4 RR, AG, YH sulfamethizole-associated neuropathy AE RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=be27854a-a805-4300-9729-accd1b7f226f#nlm34084-4 This drug has been discontinued from the US market. zolmitriptan (Zomig)-associated neuropathy AE WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bac91e37-91ce-4bbf-77bc-ef5f242589f8#nlm34084-4 RR, AG, YH ethambutol (Myambutol)-associated peripheral neuritis AE WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b2f95b0b-9de3-4c0b-a46e-a7eee6428b4b#nlm34084-4 RR, AG, YH ethambutol hydrochloride (Myambutol)-associated optic neuropathy AE RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b2f95b0b-9de3-4c0b-a46e-a7eee6428b4b#nlm34084-4 rituximab (Rituxan)-associated peripheral sensory neuropathy AE WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b172773b-3905-4a1c-ad95-bab4b6126563#nlm34084-4 RR, AG, YH amitriptyline hydrochloride (Elavil, Vanatrip)-associated peripheral neuropathy AE RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=acd53964-52dc-4534-b20f-14a7561b8a6c#nlm34084-4 gabapentin (Gabarone, Neurontin, Gralise, FusePaq Fanatrex)-associated neuropathy AE WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=aa2e353f-860b-4d10-9a62-aad1c533b8aa#nlm34084-4 RR, AG, YH tolmetin (Tolectin)-associated optic neuropathy AE WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a6c72634-4613-4d21-bc9a-09dad17eb137#nlm34084-4 RR, AG, YH megestrol (Megace)-associated neuropathy AE RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=65b28775-ee59-88cf-e4d8-372c6c79ad14#nlm34084-4 pregabalin (Lyrica)-associated neuropathy AE RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=60185c88-ecfd-46f9-adb9-b97c6b00a553#nlm34084-4 imipramine (Tofranil, Tofranil-PM)-associated peripheral neuropathy AE WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=55311747-710c-43c4-821d-76323ff2520e#nlm34084-4 RR, AG, YH methylprednisolone (Medrol, Methylpred-DP)-associated neuropathy AE RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=532f0c6c-cd76-44d1-27b7-581cee86bc34#nlm34084-4 fluvoxamine maleate (Luvox)-associated neuropathy AE RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4d80812c-dfc1-456c-9368-697267630c2c#nlm34084-4 mitoxantrone (Novantrone)-associated neuropathy AE WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4d0f0f1a-31af-40fa-9c64-e90891fa6ce4#nlm34084-4 RR, AG, YH pantoprazole (Protonix)-associated neuropathy AE RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4b4edc09-bbfd-471f-ac16-6118937a6e7e#nlm34084-4 phenytoin (Dilantin, Phenytek)-associated sensory peripheral polyneuropathy AE WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4a4c577d-9267-40eb-9ed9-09ceb6377026#nlm34084-4 RR, AG, YH trastuzumab (Herceptin)-associated motor neuropathy AE RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=492dbdb2-077e-4064-bff3-372d6af0a7a2#nlm34084-4 trastuzumab (Herceptin)-associated sensory neuropathy AE WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=492dbdb2-077e-4064-bff3-372d6af0a7a2#nlm34084-4 RR, AG, YH losartan potassium (Cozaar)-associated peripheral neuropathy AE RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3f60ac2e-031a-48fa-ab47-4e3aec49cb83#nlm34084-4 metolazone (Mykrox, Zaroxolyn)-associated neuropathy AE WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=34868f95-78d0-4089-8cbd-bec1cb730eda#nlm34084-4 RR, AG, YH haloperidol (Haldol)-associated neurotoxicity AE RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=27cfe684-7d11-4f37-9c8b-b2bdd6b5348e#nlm34084-4 lomefloxacin hydrochloride (Maxaquin)-associated peripheral neuropathy AE RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=173018f5-fd76-4480-90f8-4b7efe328444#nlm34084-4 ticlopidine (Ticlid)-associated peripheral neuropathy AE RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=13d85420-75e2-46e7-93eb-dcd10675cd03#nlm34084-4 disulfiram (Antabuse)-associated peripheral neuropathy AE WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=12850de3-c97c-42c1-b8d3-55dc6fd05750#nlm34084-4 RR, AG, YH nitrofurantoin macrocrystals (Macrodantin)-associated peripheral neuropathy AE WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=013433a1-c27c-4712-a03b-0949b2969fbb#nlm34084-4 RR, AG, YH nitrofurantoin, monohydrate (Macrobid)-associated peripheral neuropathy AE RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=013433a1-c27c-4712-a03b-0949b2969fbb#nlm34084-4 fluconazole (Diflucan)-associated paresthesia AE WEB: http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f694c617-3383-416c-91b6-b94fda371204&type=display RR, AG, YH fludarabine phosphate-associated peripheral neuropathy AE RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f1ffd18c-9f6b-4479-94b9-6890bc730ecc&type=display fentanyl (Actiq, Duragesic, Subsys, Fentora, Abstral)-associated neuropathy AE WEB: http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=90b94524-f913-48b3-3771-7b2fcffd888a&type=display RR, AG, YH insulin, protamine zinc, human 40 UNT/ML injectable suspension [ProZinc]-associated diabetic neuropathy AE WEB: http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8dbc0e47-8df9-4484-903b-70fdd26f7998&type=display RR, AG, YH fluorouracil (Carac, Efudex, Fluoroplex, Adrucil)-associated neurotoxicity AE WEB: http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8379f1db-4255-4285-abd3-8ecdcaf03372&type=display RR, AG, YH carboplatin (Paraplatin)-associated peripheral neuropathy AE RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=806736d3-215a-4df5-8187-97f2161e5a53&type=display isoniazid (Nydrazid)-associated peripheral neuropathy AE RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=77795c31-1cdf-4a20-b4a1-cd15f5b310f1&type=display methotrexate (Rheumatrex, Trexall, Otrexup, Rasuvo)-associated neurotoxicity AE WEB: http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=6cf2e15a-6286-41f7-aa7d-3968d735c864&type=display RR, AG, YH imipramine hydrochloride (Tofranil)-associated peripheral neuropathy AE WEB: http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=2f7d5e7f-79aa-4f3a-b9a6-758d9f3ce74d&type=display RR, AG, YH tamoxifen (Nolvadex, Soltamox)-associated neurotoxicity AE WEB: http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=063fa789-4570-4715-c3bd-1bad0449fb26&type=display RR, AG, YH colchicine (Colcrys, Mitigare)-associated sensory motor neuropathy AE WEB: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee1583ac-c308-4beb-b602-9ecac4977026#section-6 RR, AG, YH crizotinib (Xalkori)-associated neuropathy AE WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202570s003lbl.pdf RR, AG, YH allopurinol (Zyloprim, Aloprim)-associated peripheral neuropathy AE RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=73cd79c1-6bab-4d7b-ae8b-0176efbaf5b9#nlm34084-4 aldesleukin (Proleukin)-associated neuropathy AE WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/103293s5130lbl.pdf RR, AG, YH altretamine (Hexalen)-associated peripheral neuropathy AE RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8456a8db-a7f6-4bc0-86be-e9c8c374140b&type=display amantadine (Symmetrel)-associated paresthesia AE RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fc78c074-3ca8-4e29-9c18-8fab97558fc2&type=display anastrozole (Arimidex)-associated paresthesia AE RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=03586c40-eb32-45c5-beb7-6762a6b78790&type=display auranofin (Ridaura)-associated peripheral neuropathy AE WEB: http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=05c34ddf-a0f7-4267-83f5-d02be3defc37&type=display RR, AG, YH avanafil (Stendra)-associated non-arteritic anterior ischemic optic neuropathy AE RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202276s001lbl.pdf carfilzomib (Kyprolis)-associated peripheral neuropathy AE RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202714lbl.pdf cladribine (Leustatin)-associated peripheral sensory neuropathy AE WEB: http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a2592a9b-bca6-4a5a-89c2-855a0634d5fe&type=display RR, AG, YH cladribine (Leustatin)-associated motor neuropathy AE RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a2592a9b-bca6-4a5a-89c2-855a0634d5fe&type=display cladribine (Leustatin)-associated polyneuropathy AE WEB: http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a2592a9b-bca6-4a5a-89c2-855a0634d5fe&type=display RR, AG, YH etoposide (Vepesid, Etopophos)-associated peripheral neurotoxicity AE RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=e28c05f0-081f-406d-8bfb-9160a6908307&type=display flecainide (Tambocor)-associated neuropathy AE WEB: http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fa68b35e-9f50-408b-9e70-e84cecf3fd6e&type=display RR, AG, YH gold sodium thiomalate (Myochrysine)-associated peripheral neuropathy AE WEB: http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a29045b5-ba4f-407a-a0fd-3ef7e1ce64ee&type=display RR, AG, YH iopamidol (Isovue)-associated paresthesia AE WEB: http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=416ab996-a2e8-4fe1-a9c9-f10b86df3bb5&type=display RR, AG, YH lansoprazole (Prevacid)-associated paresthesia AE RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=924c5a35-4804-4e14-a2fc-2b84d186d257&type=display methimazole (Tapazole)-associated paresthesia AE WEB: http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=dc92f45f-8d27-4dcb-b72d-6b8b04c6f0ce&type=display RR, AG, YH protriptyline (Vivactil)-associated peripheral neuropathy AE WEB: http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=700abc58-9362-4ef5-9d7a-dd3c4d364d0a&type=display RR, AG, YH streptomycin-associated paresthesia AE RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=abd1f64e-4283-4370-aae8-3666316aa36e&type=display teniposide (Vumon)-associated neurotoxicity AE WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020119s010s011lbl.pdf RR, AG, YH teriflunomide (Aubagio)-associated peripheral neuropathy AE WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202992s000lbl.pdf RR, AG, YH bodily process Albert Goldfain creation date: 2009-06-23T11:53:49Z pathological bodily process Albert Goldfain http://ontology.buffalo.edu/medo/Disease_and_Diagnosis.pdf A bodily process that is clinically abnormal. creation date: 2009-06-23T11:54:29Z age A time quality inhering in a bearer by virtue of how long the bearer has existed. PATO:0000011 time A quality in which events occur in sequence. PATO:0000165 physical quality A quality of a physical entity that exists through action of continuants at the physical level of organisation in relation to other entities. PATO:0001018 PATO:0002079 Wikipedia:Physical_property relational physical quality physical object quality A quality which inheres in a continuant. PATO:0001237 PATO:0001238 PATO:0001241 Relational qualities are qualities that hold between multiple entities. Normal (monadic) qualities such as the shape of a eyeball exist purely as a quality of that eyeball. A relational quality such as sensitivity to light is a quality of that eyeball (and connecting nervous system) as it relates to incoming light waves/particles. monadic quality of a continuant monadic quality of an object monadic quality of continuant multiply inhering quality of a physical entity quality of a continuant quality of a single physical entity quality of an object quality of continuant snap:Quality cellularity multicellular organismal quality peripheral nervous system (...) specific vertebrate traits within the chordate phylum such as skeletal tissues, PNS, and spectacular head and brain development, are linked to the NC (neural crest) and its derivatives.[well established][VHOG] A major division of the nervous system that contains nerves which connect the central nervous system (CNS) with sensory organs, other organs, muscles, blood vessels and glands. AAO:0000429 BAMS:PNS BILA:0000081 BTO:0001028 CALOHA:TS-0808 EFO:0000891 EHDAA2:0001445 EHDAA:2893 EMAPA:16665 EMAPA:18370 EV:0100335 FBbt:00005098 FMA:9903 GAID:715 MA:0000218 MAT:0000338 MESH:A08.800 MIAA:0000338 Nervous structures including ganglia outside of the central nervous system. Kimmel et al, 1995.[TAO] PNS Part of nervous system in which nerves extend throughout the body outside of the brain and spinal cord.[AAO] TAO:0000142 The peripheral nervous system (PNS) is the part of the nervous system connected to the CNS which contains cranial nerves III - XII, spinal, peripheral and autonomic nerves. (CUMBO) UBERON:0000010 UMLS:C0206417 UMLS:C1305921 VHOG:0000399 XAO:0000178 ZFA:0000142 http://braininfo.rprc.washington.edu/centraldirectory.aspx?ID=247 lateral part of the basal amygdalar nucleus lateral part of the basolateral nucleus nucleus amygdalae basalis, pars lateralis nucleus amygdaloideus basalis, pars lateralis magnocellularis nucleus basalis lateralis amygdalae pars peripherica; systema nervosum periphericum uberon sense organ AEO:0000094 An organ that is capable of detection of chemical stimulus involved in sensory perception of smell. BSA:0000121 BTO:0000202 CALOHA:TS-2043 EHDAA2:0001824 EHDAA:500 EMAPA:16192 EMAPA:35955 FBbt:00005155 GAID:63 HAO:0000930 MA:0000017 MESH:A09 Sinnesorgan UBERON:0000020 UMLS:C0935626 VHOG:0001407 WBbt:0006929 organ of sense organ system organ of sensory organ system organ of sensory system sense organ system organ sensillum sensor sensory organ sensory organ system organ sensory system organ uberon anatomical structure AAO:0010825 AEO:0000003 BILA:0000003 CARO:0000003 EHDAA2:0003003 EMAPA:0 FBbt:00007001 FMA:67135 GAID:781 HAO:0000003 MA:0003000 MESH:A13 Material anatomical entity that has inherent 3D shape and is generated by coordinated expression of the organism's own genome. TAO:0000037 TGMA:0001823 UBERON:0000061 VHOG:0001759 WBbt:0000100 XAO:0003000 ZFA:0000037 biological structure uberon organ Anatomical structure that performs a specific function or group of functions [WP]. CARO does not include a generic 'organ' class, only simple and compound organ EFO:0000634 EMAPA:35949 ENVO:01000162 FMA:67498 MA:0003001 OpenCyc:Mx4rv5XMb5wpEbGdrcN5Y29ycA OpenCyc:Mx4rwP3iWpwpEbGdrcN5Y29ycA Organs are commonly observed as visibly distinct structures, but may also exist as loosely associated clusters of cells that work together to perform a specific function or functions. UBERON:0000062 UMLS:C0178784 WBbt:0003760 anatomical unit body organ element uberon fully formed stage BTO:0001043 BilaDO:0000004 EFO:0001272 FBdv:00005369 The stage of development at which the animal is fully formed, including immaturity and maturity. Includes both sexually immature stage, and adult stage. UBERON:0000066 WBls:0000041 XtroDO:0000084 adult stage fully formed animal stage juvenile-adult stage uberon embryo stage part A stage that is part of the embryo stage. UBERON:0000067 embryonic stage part uberon embryo stage A life cycle stage that starts with fertilization and ends with the fully formed embryo. BilaDO:0000002 EV:0300001 FBdv:00005289 HsapDv:0000002 MmusDv:0000002 OGES:000000 OGES:000022 UBERON:0000068 WBls:0000003 WBls:0000092 WBls:0000102 XAO:1000012 embryogenesis embryonic stage uberon death stage End of the life of an organism. UBERON:0000071 XAO:0000437 XtroDO:0000085 death ncit:Death is an outcome uberon post-embryonic stage BilaDO:0000003 In birds, the postnatal stage begins when the beak penetrates the shell (i.e., external pipping) (Brown et al. 1997) OGES:000010 OGES:000014 OGES:000024 UBERON:0000092 WBls:0000022 WBls:0000093 WBls:0000103 post-hatching stage postembryonic postembryonic stage stage succeeding embryo, including mature structure uberon life cycle An entire span of an organism's life, commencing with the zygote stage and ending in the death of the organism. FBdv:00000000 HsapDv:0000001 MmusDv:0000001 OGES:000011 UBERON:0000104 life lifespan uberon life cycle stage A spatiotemporal region encompassing some part of the life cycle of an organism. BILS:0000105 EFO:0000399 FBdv:00007012 HsapDv:0000000 MmusDv:0000000 OlatDv:0000010 PdumDv:0000090 UBERON:0000105 WBls:0000002 XAO:1000000 ZFS:0000000 ZFS:0100000 developmental stage stage uberon we map the ZFS unknown stage here as it is logically equivalent to saying *some* life cycle stage zygote stage 1-cell stage A stage at which the organism is a single cell produced by means of sexual reproduction. As in all metazoans, eumetazoan development begins with a fertilized egg, or zygote.[well established][VHOG] BILS:0000106 BilaDO:0000005 EFO:0001322 EHDAA:27 EMAPA:16033 FBdv:00005288 PdumDv:0000100 UBERON:0000106 VHOG:0000745 XAO:1000001 ZFS:0000001 fertilized egg stage fertilized egg stage one cell stage one-cell stage uberon zygote zygotum cleavage stage BILS:0000107 BilaDO:0000006 EFO:0001290 FBdv:00000054 MESH:A16.254.270 MmusDv:0000004 OGES:000015 OGES:000020 PdumDv:0000200 The first few specialized divisions of an activated animal egg; Stage consisting of division of cells in the early embryo. The zygotes of many species undergo rapid cell cycles with no significant growth, producing a cluster of cells the same size as the original zygote. The different cells derived from cleavage are called blastomeres and form a compact mass called the morula. Cleavage ends with the formation of the blastula. UBERON:0000107 XAO:1000004 ZFS:0000046 uberon blastula stage An early stage of embryonic development in animals. It is produced by cleavage of a fertilized ovum and consists of a spherical layer of around 128 cells surrounding a central fluid-filled cavity called the blastocoel. The blastula follows the morula and precedes the gastrula in the developmental sequence. BILS:0000108 BilaDO:0000007 EFO:0001282 HsapDv:0000006 MmusDv:0000007 OGES:000003 OGES:000016 OGES:000021 OpenCyc:Mx4rEetFnKP2EdqAAAACs4vPlg UBERON:0000108 WBls:0000005 XAO:1000003 ZFS:0000045 consider adding a preceding stage 'morula stage' as part of cleavage uberon gastrula stage A stage defined by complex and coordinated series of cellular movements that occurs at the end of cleavage during embryonic development of most animals. The details of gastrulation vary from species to species, but usually result in the formation of the three primary germ layers, ectoderm, mesoderm and endoderm. BILS:0000109 BilaDO:0000008 EFO:0001296 FBdv:00005317 HsapDv:0000010 MmusDv:0000013 OGES:000004 OGES:000019 UBERON:0000109 WBls:0000010 XAO:1000005 ZFS:0000047 blastocystis trilaminaris stage trilaminar blastocyst stage trilaminar blastoderm stage trilaminar disk stage trilaminar germ stage trilaminar stage uberon neurula stage BILS:0000110 BilaDO:0000009 HsapDv:0000012 MmusDv:0000017 Staged defined by the formation of a tube from the flat layer of ectodermal cells known as the neural plate. This will give rise to the central nervous system. UBERON:0000110 XAO:1000006 uberon organogenesis stage A stage at which the ectoderm, endoderm, and mesoderm develop into the internal organs of the organism. BILS:0000111 BilaDO:0000010 HsapDv:0000015 MmusDv:0000018 OGES:000005 OGES:000032 UBERON:0000111 segmentation stage uberon blastula BILA:0000059 BTO:0000128 GAID:1294 MESH:A16.254.270.274 OGEM:000006 OpenCyc:Mx4rEetFnKP2EdqAAAACs4vPlg Organism at the blastula stage - an early stage of embryonic development in animals. It is produced by cleavage of a fertilized ovum and consists of a spherical layer of around 128 cells surrounding a central fluid-filled cavity called the blastocoel. The blastula follows the morula and precedes the gastrula in the developmental sequence. TODO - check relationship with epiblast. Note in FMA this is not a subclass of embryo, but in uberon embryo is the whole organism from zygote onwards and thus includes the blastula UBERON:0000307 UBERON:0007011 blastosphere blastula embryo uberon material anatomical entity AAO:0010264 AEO:0000006 Anatomical entity that has mass. BILA:0000006 CARO:0000006 EHDAA2:0003006 FBbt:00007016 FMA:67165 HAO:0000006 TAO:0001836 TGMA:0001826 UBERON:0000465 VHOG:0001721 uberon immaterial anatomical entity AAO:0010265 AEO:0000007 Anatomical entity that has no mass. BILA:0000007 CARO:0000007 EHDAA2:0003007 FBbt:00007015 FMA:67112 HAO:0000007 TAO:0001835 TGMA:0001827 UBERON:0000466 VHOG:0001727 immaterial physical anatomical entity uberon anatomical system AAO:0000007 AEO:0000011 Anatomical group that is has as its parts distinct anatomical structures interconnected by anatomical structures at a lower level of granularity[CARO]. A group of organs that work together to perform a certain task [Wikipedia]. BILA:0000011 BSA:0000049 CALOHA:TS-2088 CARO:0000011 EHDAA2:0003011 EHDAA:392 EMAPA:16103 EV:0100000 FBbt:00004856 FMA:7149 HAO:0000011 MA:0000003 OpenCyc:Mx4rCWM0QCtDEdyAAADggVbxzQ TAO:0001439 TGMA:0001831 UBERON:0000467 UMLS:C0460002 VHOG:0001725 WBbt:0005746 WBbt:0005763 XAO:0003002 ZFA:0001439 body system galen:AnatomicalSystem organ system system uberon multi-cellular organism AAO:0010026 AEO:0000191 Anatomical structure that is an individual member of a species and consists of more than one cell. BILA:0000012 BSA:0000038 BTO:0000042 CARO:0000012 EFO:0002906 EHDAA2:0003103 EHDAA2:0003191 EHDAA:1 EHDAA:9178 EMAPA:25765 EV:0100016 FBbt:00000001 FMA:256135 HAO:0000012 Koerper TADS:0000001 TAO:0001094 TGMA:0001832 TODO - split body and mc organism? body continues after death stage UBERON:0000468 VHOG:0000671 WBbt:0007833 XAO:0003004 ZFA:0001094 animal body galen:Organism organism organismal uberon whole body whole organism anatomical cluster AAO:0010009 AEO:0000041 Anatomical group that has its parts adjacent to one another. BILA:0000041 CARO:0000041 EHDAA2:0003041 FBbt:00007277 FMA:49443 HAO:0000041 TADS:0000605 TAO:0001478 TGMA:0001842 UBERON:0000477 VHOG:0001737 XAO:0003160 ZFA:0001478 uberon tissue AAO:0000607 AAO:0010054 AEO:0000043 BILA:0000043 CALOHA:TS-2090 CARO:0000043 EHDAA2:0003043 EMAPA:35868 FBbt:00007003 FMA:9637 HAO:0000043 MA:0003002 MESH:A10 Multicellular anatomical structure that consists of many cells of one or a few types, arranged in an extracellular matrix such that their long-range organisation is at least partly a repetition of their short-range organisation. TAO:0001477 TGMA:0001844 UBERON:0000479 UMLS:C0040300 VHOG:0001757 WBbt:0005729 XAO:0003040 ZFA:0001477 changed label and definition to reflect CARO2 galen:Tissue portion of tissue simple tissue tissue portion uberon anatomical group AAO:0010008 AEO:0000054 Anatomical structure consisting of at least two non-overlapping organs, multi-tissue aggregates or portion of tissues or cells of different types that does not constitute an organism, organ, multi-tissue aggregate, or portion of tissue. BILA:0000054 CARO:0000054 EHDAA2:0003054 HAO:0000054 TAO:0001512 TGMA:0001846 UBERON:0000480 VHOG:0001724 XAO:0003001 ZFA:0001512 uberon embryo AAO:0011035 AEO:0000169 Anatomical entity that comprises the organism in the early stages of growth and differentiation that are characterized by cleavage, the laying down of fundamental tissues, and the formation of primitive organs and organ systems. For example, for mammals, the process would begin with zygote formation and end with birth. For insects, the process would begin at zygote formation and end with larval hatching. For plant zygotic embryos, this would be from zygote formation to the end of seed dormancy. For plant vegetative embryos, this would be from the initial determination of the cell or group of cells to form an embryo until the point when the embryo becomes independent of the parent plant. BILA:0000056 BSA:0000039 BTO:0000379 CALOHA:TS-0229 EFO:0001367 EHDAA2:0000002 EHDAA2_RETIRED:0003236 EHDAA:38 EMAPA:16039 FBbt:00000052 FMA:69068 GAID:963 MAT:0000226 MESH:A16.254 MIAA:0000019 OGEM:000001 Obsoleted in ZFA. Note that embryo is not classified as an embryonic structure - an embryonic structure is only the parts of an embryo OpenCyc:Mx4rwP1ceZwpEbGdrcN5Y29ycA UBERON:0000922 UMLS:C0013935 VHOG:0001766 XAO:0000113 ZFA:0000103 developing organism developmental tissue embryonic embryonic organism uberon germ layer A layer of cells produced during the process of gastrulation during the early development of the animal embryo, which is distinct from other such layers of cells, as an early step of cell differentiation. The three types of germ layers are the endoderm, ectoderm, and mesoderm. AAO:0000480 BILA:0000035 BTO:0000556 Classically the germ layers are ectoderm, mesoderm and endoderm. Alternatively: primary = ectoderm, endoderm; secondary=mesoderm; tertiary=dorsal mesoderm, NC[UBERONREF:0000002] FBbt:00000110 FMA:69069 GAID:1303 MESH:A16.254.425 TAO:0001122 The Bilateria are triploblastic (with true endoderm, mesoderm, and ectoderm) (...).[well established][VHOG] UBERON:0000923 UMLS:C0920502 UMLS:C1708239 VHOG:0001223 XAO:0003011 ZFA:0001122 embryonic germ layer embryonic germ layers embryonic tissue germinal layer primary germ layer uberon ectoderm AAO:0000137 BILA:0000036 BTO:0000315 CALOHA:TS-0216 EFO:0000414 EHDAA2:0000428 EMAPA:16069 EV:0100003 FBbt:00000111 FMA:69070 GAID:1304 MAT:0000155 MAT:0000173 MESH:A16.254.425.273 MIAA:0000173 Primary germ layer that is the outer of the embryo's three germ layers and gives rise to epidermis and neural tissue. Primary germ layer that is the outer of the embryonic germ layers and gives rise to epidermis and neural tissue.[AAO] TAO:0000016 The Bilateria are triploblastic (with true endoderm, mesoderm, and ectoderm) (...).[well established][VHOG] UBERON:0000924 UMLS:C0013574 VHOG:0000153 XAO:0000001 ZFA:0000016 ectodermal embryonic ectoderm uberon eye An organ that detects light. BILA:0000017 BTO:0000439 CALOHA:TS-0309 EFO:0000827 EV:0100336 FBbt:00005162 GAID:69 MAT:0000140 MESH:A01.456.505.420 MIAA:0000140 Note that whilst this is classified as an organ, it is in fact more of a unit composed of different structures: in Drosophila, it includes the interommatidial bristle as a part; we consider here the vertebrate eye to include the eyeball/eye proper as a part, with the eye having as parts (when present): eyelids, conjuctiva, OpenCyc:Mx4rvViTvpwpEbGdrcN5Y29ycA This class encompasses a variety of light-detecting structures from different phyla with no implication of homology, from the compound insect eye to the vertebrate camera-type eye (distinct classes are provided for each) UBERON:0000970 light-detecting organ ocular optic uberon visual apparatus nervous system A regulatory system of the body that consists of neurons and neuroglial cells. The nervous system is divided into two parts, the central nervous system (CNS) and the peripheral nervous system (PNS). (Source: BioGlossary, www.Biology-Text.com)[TAO] AAO:0000324 Anatomical system consisting of nerve bodies and nerve fibers which regulate the response of the body to external and internal stimuli.[AAO] BILA:0000079 BTO:0001484 CALOHA:TS-1313 EFO:0000802 EHDAA2:0001246 EHDAA:826 EMAPA:16469 EV:0100162 FBbt:00005093 FMA:7157 GAID:466 MA:0000016 MAT:0000026 MESH:A08 MIAA:0000026 Nervensystem Nervous systems evolved in the ancestor of Eumetazoa.[well established][VHOG] OpenCyc:Mx4rvViT_pwpEbGdrcN5Y29ycA TAO:0000396 The nervous system is an organ system containing predominantly neuron and glial cells. In bilaterally symmetrical organism, it is arranged in a network of tree-like structures connected to a central body. The main functions of the nervous system are to regulate and control body functions, and to receive sensory input, process this information, and generate behavior [CUMBO]. UBERON:0001016 UMLS:C0027763 VHOG:0000402 WBbt:0005735 XAO:0000177 ZFA:0000396 nerve net nervous neural relationship type change: differentiates_from ectoderm (AAO:0000137) CHANGED TO: develops_from ectoderm (UBERON:0000924)[AAO] systema nervosum uberon central nervous system (...) at some stage of its development, every chordate exhibits five uniquely derived characters or synapomorphies of the group: (...) (4) a single, tubular nerve cord that is located dorsal to the notochord (...) (reference 1); The neural tube is destined to differentiate into the brain and spinal cord (the central nervous system) (reference 2); Taken together, our data make a very strong case that the complex molecular mediolateral architecture of the developing trunk CNS (central nervous system), as shared between Platynereis and vertebrates, was already present in their last common ancestor, Urbilateria. The concept of bilaterian nervous system centralization implies that neuron types concentrate on one side of the trunk, as is the case in vertebrates and many invertebrates including Platynereis, where they segregate and become spatially organized (as opposed to a diffuse nerve net). Our data reveal that a large part of the spatial organization of the annelid and vertebrate CNS was already present in their last common ancestor, which implies that Urbilateria had already possessed a CNS (reference 3).[well established][VHOG] AAO:0000090 BAMS:CNS BILA:0000080 BTO:0000227 CALOHA:TS-0150 CNS EFO:0000908 EHDAA2:0000225 EHDAA:828 EMAPA:16470 EMAPA:16754 EV:0100163 FBbt:00005094 FMA:55675 GAID:570 MA:0000167 MAT:0000457 MESH:A08.186 OpenCyc:Mx4rvzYt3pwpEbGdrcN5Y29ycA Part of the nervous system which includes the brain and spinal cord.[AAO] TAO:0000012 The brain and spinal cord. Kimmel et al, 1995.[TAO] The central nervous system (CNS) is the part of the nervous system which includes the brain, spinal cord, and nerve cell layer of the retina (CUMBO). The central nervous system is the core nervous system that serves an integrating and coordinating function. In vertebrates it consists of the brain, spinal cord and spinal nerves. In those invertebrates with a central nervous system it typically consists of a brain, cerebral ganglia and a nerve cord[GO]. UBERON:0001017 UMLS:C0927232 VHOG:0000293 XAO:0000215 ZFA:0000012 basal nucleus of the amygdala basolateral nucleus of amygdala basolateral nucleus of the amygdala cerebrospinal axis http://braininfo.rprc.washington.edu/centraldirectory.aspx?ID=246 neuraxis nucleus amygdalae basalis nucleus amygdaloideus basalis nucleus amygdaloideus basolateralis nucleus basalis amygdalae systema nervosum centrale uberon sensory system AAO:0000555 An early step in the evolution of neural crest, therefore, may have been the origin of a specific dorsal neural cell population contributing to sensory processing; this would predate the divergence of the amphioxus and vertebrate lineages.[well established][VHOG] Anatomical system that overlaps the nervous system and is responsible for receiving and processing sensory information. BAMS:SEN BILA:0000099 EFO:0000805 EHDAA2:0003094 EMAPA:16192 FBbt:00005827 FMA:75259 MA:0002442 MAT:0000031 MIAA:0000031 TAO:0000282 UBERON:0001032 VHOG:0001674 XAO:0003194 ZFA:0000282 note the distinct between entire sensory system and individual system. this reconciles is_a and part_of distinctions between ssAOs organa sensuum organa sensuum sense organ subsystem sense organs sense organs set sensory organ system sensory subsystem sensory systems set of sense organs uberon anatomical entity AAO:0010841 AEO:0000000 BILA:0000000 Biological entity that is either an individual member of a biological species or constitutes the structural organization of an individual member of a biological species. CARO:0000000 EHDAA2:0002229 FBbt:10000000 FBbt_root:00000000 FMA:62955 HAO:0000000 MA:0000001 TAO:0100000 TGMA:0001822 UBERON:0001062 UMLS:C1515976 XAO:0000000 ZFA:0100000 uberon embryonic structure AAO:0000138 Anatomical structure that is part of an embryo. Anatomical structure that is part of the embryo and is comprised of portions of tissue or cells.[AAO] Anatomical structure that is part of the embryo and is comprised of portions of tissue or cells.[TAO] Anatomical structure that is part of the embryo and is comprised of portions of tissue or cells.[VSAO] BILA:0000034 BTO:0000174 CALOHA:TS-2110 EFO:0000461 FBbt:00004208 FMA:69067 GAID:407 MESH:A16 RETIRED_EHDAA2:0003169 TAO:0001105 UBERON:0002050 UMLS:C0013948 VSAO:0000178 XAO:0003042 ZFA:0001105 developing embryonic structure developing structure embryonale Struktur embryonic anatomical structure in FMA embryo is_a embryonic structure uberon visual system AAO:0000632 BILA:0000140 FMA:7191 MA:0002444 OpenCyc:Mx4rvViCtpwpEbGdrcN5Y29ycA TAO:0001127 The sensory system subserving the sense of vision. The sensory system used for sight.[AAO] This class was created automatically from a combination of ontologies UBERON:0002104 UBERON:0007036 UMLS:C0587900 XAO:0003198 ZFA:0001127 photosensory system uberon visual organ system vestibulo-auditory system AAO:0000631 FMA:78500 Sensory system responsible for the perception of spatial orientation and auditory stimuli. TAO:0001138 The sensory system used for balance and hearing.[AAO] UBERON:0002105 XAO:0003195 ZFA:0001138 auditory organ system auditory system auditory/vestibular system uberon vestibuloauditory system vestibuloauditory system epiblast (generic) BTO:0004593 In amniote animal embryology, the epiblast is a tissue type derived either from the inner cell mass in mammals or the blastodisc in birds and reptiles. It lies above the hypoblast. In mammalian embryogenesis, the columnar cells of the epiblast are adjacent to the trophoblast, while the cuboidal cells of the hypoblast are closer to the blastocoele. The epiblast, whilst referred to as the primary ectoderm, differentiates to form all three layers of the trilaminar germ disc in a process called gastrulation[WP]. The outer of the two layers of the blastoderm that form during gastrulation, corresponding to primitive ectoderm during gastrulation and to the definitive ectoderm after gastrulation[ZFA] In pregastrula zebrafish embryos, the epiblast is an inverted cup of cells that sits on top of a large yolk cell. (...) In amniote embryos (mammals and birds), gastrulation initiates in an epithelial layer called the epiblast. Cells in the epiblast undergo an epithelial to mesenchymal transition (EMT), migrate through the primitive streak (PS), and incorporate in the middle (mesoderm) or outer (endoderm) layer. The presumptive definitive endoderm (DE) cells invade and displace an outer layer of extraembryonic tissue cells, the hypoblast in chick and the visceral endoderm (VE) in mouse, which form supporting structures such as the yolk sac.[uncertain][VHOG] MAT:0000067 MIAA:0000067 MP says - tissue that gives rise to the ectoderm, endoderm and mesoderm of the embryo proper. In HOG, epiblast is part of primitive streak/blastpore, which is inconsistent with the MP definition of primitive streak as a ridge of the epiblast. Note that these terms, epiblast and hypoblast, are also used to describe layers of the avian embryonic blastoderm, but the layers so-named seem to be altogether different in these two kinds of vertebrate embryos(CVS). Consider obsoleting this as a grouping class UBERON:0002532 VHOG:0000243 blastocyst ectoblast epiblast epiblastus primitive ectoderm uberon ectoderm-derived structure An anatomical structure that develops (entirely or partially) from the ectoderm. Grouping term for query purposes UBERON:0004121 uberon entire sense organ system FMA:78499 Sum of all sensory systems in an organism. UBERON:0004456 note the distinct between entire sensory system and individual system. this reconciles is_a and part_of distinctions between ssAOs sense organ system uberon embryonic tissue A portion of tissue that is part of an embryo. CALOHA:TS-2100 UBERON:0005291 developing tissue portion of embryonic tissue uberon developing anatomical structure AEO:0000125 CALOHA:TS-2122 EHDAA2:0003125 FBbt:00007006 MIAA:0000019 UBERON:0005423 developing structure developmental structure developmental tissue uberon presumptive structure AAO:0000479 TAO:0001116 UBERON:0006598 ZFA:0001116 presumptive structures uberon presumptive ectoderm AAO:0000470 EFO:0003466 Presumptive structure of the blastula that will develop into ectoderm. TAO:0001376 UBERON:0006601 XAO:0004132 ZFA:0001376 presumptive epidermis uberon anatomical surface AAO:0010270 BILA:0000010 CARO:0000010 EHDAA2:0003192 FMA:24137 ID:0000000 Non-material anatomical entity of two dimensions, that is demarcated by anatomical lines or points on the external or internal surfaces of anatomical structures. UBERON:0006984 UMLS:C1515977 ZFA:0005594 uberon cleaving embryo BILA:0000058 Organism at the cleavage stage. UBERON:0007010 uberon multicellular anatomical structure An anatomical structure that has more than one cell as a part. CARO:0010000 FBbt:00100313 UBERON:0010000 multicellular structure uberon germ layer / neural crest UBERON:0010316 uberon organ system subdivision Anatomical structure, which consists of a specific set of the members of (predominantly) one organ or organ part subclass interconnected by zones of continuity or body substances; is demarcated from other subdivisions of the same organ system by one or more zones of continuity or anatomical lines; together with other subdivisions of the same organ system, it constitutes an organ system. Examples: rib cage, facial skeleton, portal system, central nervous system, upper respiratory tract, muscle group of back. FBbt:00007330 FMA:67509 UBERON:0011216 uberon future central nervous system Primordium that develops into the central nervous system UBERON:0016879 UBERON:3000469 future CNS presumptive central nervous system uberon future nervous system AAO:0000477 Primordium that develops into the nervous system UBERON:0016880 UBERON:3000477 presumptive nervous system uberon example to be eventually removed metadata complete Class has all its metadata, but is either not guaranteed to be in its final location in the asserted IS_A hierarchy or refers to another class that is not complete. organizational term term created to ease viewing/sort terms for development purpose, and will not be included in a release ready for release Class has undergone final review, is ready for use, and will be included in the next release. Any class lacking "ready_for_release" should be considered likely to change place in hierarchy, have its definition refined, or be obsoleted in the next release. Those classes deemed "ready_for_release" will also derived from a chain of ancestor classes that are also "ready_for_release." metadata incomplete Class is being worked on; however, the metadata (including definition) are not complete or sufficiently clear to the branch editors. uncurated Nothing done yet beyond assigning a unique class ID and proposing a preferred term. pending final vetting All definitions, placement in the asserted IS_A hierarchy and required minimal metadata are complete. The class is awaiting a final review by someone other than the definition editor. to be replaced with external ontology term Alan Ruttenberg Terms with this status should eventually replaced with a term from another ontology. group:OBI requires discussion A term that is metadata complete, has been reviewed, and problems have been identified that require discussion before release. Such a term requires editor note(s) to identify the outstanding issues. Alan Ruttenberg group:OBI axiom holds for all times is_bearer_of bearer of at some time is bearer of http://purl.obolibrary.org/obo/omrse.owl Alan Ruttenberg: This is a binary version of a ternary time-indexed, instance level, relation. The BFO reading of the binary relation 'bearer of at some time@en' is: exists t, exists_at(x,t) & exists_at(y,t) & 'bearer of@en'(x,y,t) BFO2 Reference: independent continuant that is not a spatial region bearerOfAt (iff (bearerOfAt a b t) (and (specificallyDependsOnAt b a t) (IndependentContinuant a) (not (SpatialRegion a)) (existsAt b t))) // axiom label in BFO2 CLIF: [053-004] bearer-of_st BFO2 Reference: specifically dependent continuant b bearer_of c at t =Def. c s-depends_on b at t & b is an independent continuant that is not a spatial region. (axiom label in BFO2 Reference: [053-004]) bearer of bearer_of Synonym C136 Display_Name C264 UMLS_CUI C140 RxNorm_CUI C818 MeSH_DUI C134 NUI C10490107818172 MeSH_Name C287 1 AHC0